






Successive Ring Expansion Reactions 
 







Doctor of Philosophy  
 
 











ii | P a g e  
 
Abstract 
This thesis describes the development of a series of methods for performing ring expansion 
reactions consecutively, either using successive reactions (explored in Chapters 2–4) or cascade 
sequences (explored in Chapters 5 and 6). 
In Chapter two, β-ketoester ring expansion methodology (that has been developed in the 
Unsworth group) has been extended by incorporating both amino acids and β-hydroxy acids into 
a range of previously inaccessible cyclic starting materials. The molecular properties of the 
compounds were then examined to assess their ‘lead-likeliness’. In Chapter three, the simple 
lactam motif was utilised to incorporate α-/β-amino acids to produce macrocyclic 
peptidiomimetics directly, with a range of natural α-amino acids incorporated. In Chapter four, 
lactams were then ring enlarged with hydroxy acids forming a diverse array of functionalised 
macrocyclic lactones. In Chapter five, a cyclisation/expansion cascade was collaboratively 
explored forming medium-sized bi-aryl lactones/lactams with excellent atroposelectivity. 
Chapter six describes the preliminary results obtained, for a similar cyclisation/expansion 
cascade (towards the synthesis of polyamine macrocycles), whereby consecutive acyl transfer 
reactions must occur. 
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Chapter One: Introduction 
1.1 The Utility of Macrocycles 
Macrocycles (≥12-membered rings) are a unique class of molecule with broad utility, finding 
application in many scientific fields; for example, they are ubiquitous in mechanically inter-
locked catenane/rotaxane systems,1 can be used as chiral shift reagents,2 and have many uses 
in the fields of nanotechnology,3 catalysis,4 and medicinal chemistry.5 With such interdisciplinary 
function, there is unsurprisingly increasing interest in macrocyclic scaffolds and their synthesis, 
especially in regards to the generation of compound libraries for lead identification in medicinal 
chemistry6 where historically macrocycles have been poorly represented. 
Macrocycles often possess distinct molecular shapes and sizes7 which can enable improved 
affinity binding to target receptors than their linear analogues.8 This is rationalised by the 
decreased entropic penalty upon binding (compared to  linear molecules) known as the 
macrocyclic effect, whilst still offering some degree of flexibility (due to multiple low energy 
conformations) to accommodate alternative binding modes if required.  This can allow 
macrocycles to be both potent and selective drugs, for example natural products such as 
erythromycin, vancomycin, and epothilone C (figure 1.1). 
 
Figure 1.1: Structure of natural products erythromycin, vancomycin and epothilone C. 
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Macrocyclisation is recognised as a strategy to enhance the druggability of peptides by 
restricting their conformation, reducing polarity and increasing proteolytic stability and 
membrane permeability.9–12 Macrocyclic peptides can serve as structure mimics of large peptidic 
fragments, for example, in the inhibition of protein-protein interactions (PPIs), but they 
generally have lower molecular weight than standard peptide-based PPI inhibitors.13 
Macrocycles are also not limited to peptide fragments and can include macrocyclic 
carbohydrates 4, calixarenes 5, and porphyrins 6 (seen in figure 1.2 respectively). 
 
Figure 1.2: Macrocyclic scaffolds: bivalent cyclodextrins, calixarenes and porphyrins. 
Structurally diverse macrocycles have been prepared14 with ‘drug-like’ physio-chemical 
properties as defined by Lipinski’s rule-of-five,15 with prominent examples being the macrocyclic 
libraries developed by the Spring group.16,17 Although used ubiquitously by medicinal chemists 
to predict druggability, Lipinski’s rules were initially intended to predict the absorption of orally 
administered compounds. Recent reviews18–20 have shown that the widespread application of 
Lipinski’s rules has led to, on average, poorer pharmacokinetics than those predicted, often due 
to poor selectivity, metabolism and absorption. It is now being suggested that such protocols 
have led to medicinally potent compounds being lost, including macrocyclic compounds which 
may have missed one criterium.21,22 
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Despite the potential to create medicinally potent compounds, macrocycles have been 
traditionally under-explored in medicinal chemistry23 and are still poorly represented in most 
contemporary screening libraries.24 One significant factor which has contributed to this, is the 
difficulty of their synthesis,25,26 which is pivotal during the drug-discovery process. 
1.2 Synthesis of Macrocycles and Medium-Sized Rings 
Macrocycles (≥12-membered rings) and medium-sized (8–11 membered) rings both have 
difficulties associated with their synthesis, which makes these cyclic systems significantly 
tougher to synthesise than their five- and six-membered counterparts. 
1.2.1 Medium-Sized Ring Synthetic Problems 
Medium-sized rings often have significant ring strain which is comprised of Baeyer (bond angle 
distortion), Pitzer (torsional-eclipsing) and Prelog (transannular) strain. For medium-sized rings, 
Prelog strain is often the major contributing factor to its overall ring strain, where substituents 
on opposite sides of the ring come in close proximity to each other, resulting in unfavourable 
steric repulsion. Commonly, this cannot be avoided without significant Baeyer and Pitzer strain 
being imposed. The ring strain of simple cycloalkanes can be seen in figure 1.3 (derived from the 
enthalpy of combustion and normalised to their linear counterparts),27 illustrating the amount 
of strain that can be present in these ringed systems. A similar study was completed by Illuminati 
et al.28 on the kinetics of cyclisation reactions. Some methods exist to reduce the amount of 
strain that exists in medium-sized rings, that include (but are not limited to): changing 
hybridisation of atoms to reduce Baeyer strain and introducing a methylene bridge to reduce 
transannular interactions. 
 
























Empirically derived ring strain of cycloalkanes as a 
function of ring size 
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Despite the aforementioned methods known to reduce the strain associated with medium-sized 
rings, their synthesis remains a significant synthetic challenge. This can be made more difficult 
when functionality and chirality must be incorporated into these already challenging targets. 
Side-reactions, from robust organic transformations, are also known to occur in the context of 
medium-sized rings such as the epoxidation/ring opening of Z-octene 7 (shown in scheme 1.1). 
In this example, epoxidation of the alkene proceeds onto the convex face, using mCPBA, 
however under acidic aqueous conditions (which would normally deliver a 1,2-diol) migration 
occurs to deliver the 1,5-diol 11. This can be explained when considering the direction and 
position of the C-O σ* anti-bonding orbital of the epoxide. The anti-bonding orbital has a large 
proportion of a C-H σ bond (on the opposite side of the ring) occupying it. The proximity of 
substituents (across the ring) normally results in an unfavourable repulsion and overall increase 
in energy (increase in strain), however here it is the root of this remarkable reactivity. Although 
drawn stepwise for clarity, via a stabilised tertiary carbenium, it has been shown that the 
migration occurs in a concerted associative mechanism to deliver diol 11. This shows how 
seemingly trivial transformations on these systems can be unexpectedly more challenging. 
 
Scheme 1.1: Formation of 1,5-diol from Z-octene via epoxidation, migration, aqueous quench 
sequence. 
1.2.2 Macrocycle Synthetic Problems 
Macrocyclisation reactions are often encumbered by unfavourable entropic and enthalpic 
effects, associated with bringing the two reactive ends together, which can make it hard to avoid 
unwanted side reactions. These thermodynamic penalties arise from accessing higher energy 
‘folded’ conformations which are unlikely to be the lowest energy conformations due to losing 
degrees of freedom and electronic/steric effects. As a result of these thermodynamic penalties, 
it is common that dimerisation/oligomerisation or unwanted transannular side reactions occur 
and sometimes outcompete the desired cyclisation pathway. This is a well-documented problem 
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and a number of strategies have been developed, trying to minimise or completely stop these 
unwanted side reactions. 
1.2.3 Macrocyclisation Strategies 
One of these strategies is to bias the conformation of the substrate, in such a way as to bring 
together the two reactive ends, thus aiding cyclisation. This can be achieved by inserting sp2 
hybridised centres in the linear precursor to limit flexibility and engineer the conformation such 
that the reactive ends move closer in proximity. This is known as pre-organisation and can 
produce a more efficient cyclisation, as there is a higher probability of reactive conformations 
being occupied. Z-Alkenes are commonly used for this reason, however the incorporation of 
these into the desired linear sequence often produce substrates sensitive to small changes. This 
is linked to the Thorpe-Ingold effect29 which has been exploited on numerous medium-sized ring 
cyclisations, such as a key step in the total synthesis of dactylol reported by Fürstner30 (seen in 
scheme 1.2). Diene 12, undergoes ring closing metathesis to give fused ring system 13, with the 
geminal-dimethyl substituent increasing both the rate and yield of this cyclisation. 
 
Scheme 1.2: Dactylol synthesis using the Thorpe-Ingold effect in a ring closing metathesis reaction. 
Another example of pre-organisation can be demonstrated in the context of cyclic oligopeptides 
or cyclic peptide mimetics. Although linear peptides can be made expeditiously via solution 
phase or solid supported synthesis, their cyclisation is typically encumbered due to 
conformational rigidity from the amide bonds. Linear amides typically adopt a Z-geometry due 
to reduced steric interactions which often does not lead to a reactive conformer for cyclisation. 
Shipman and co-workers31 have demonstrated that an oxetane unit can be used in place of an 
amide as a turn inducing moiety. The amino oxetane fragment mimics an amino acid, and can 
be introduced using two separate strategies with orthogonal deprotection conditions. They then 
showed that the oxetane fragment can be introduced at varying points through the linear 
peptide and enhance cyclisation rates and yields. Multiple oxetane-containing macrocycles in 
challenging ring sizes were made (tetra-, penta- and hexapeptides) with similar IC50 values as 
those of the parent cyclic peptide (scheme 1.3). 
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Scheme 1.3: Synthesis of cyclic peptide mimetics via head-to-tail cyclisation using oxetane modified 
substrates. The yields of the unmodified parent systems are shown in parentheses. 
Alternatively, metals can be used to chelate and pre-organise a linear substrate into a reactive 
conformation, facilitating macrocyclisation.32 This is typically referred to as ‘templated 
synthesis’ and benefits from kinetic and thermodynamic effects which can favour cyclisation 
over dimerisation.33 One example, by Beck and co-workers,34 shows that initial coordination of 
two amino acid derivatives 20, can help them to undergo templated cyclisation without the 
requirement to use an activating additive such as DMAP. Upon acidic work up, the metal can be 
removed alongside the desired macrocyclic tetrapeptide 24 (scheme 1.4). Coordinating groups 
are essential and therefore a limitation is that templated synthesis can only produce classes of 
macrocycles, with these motifs present. 
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Scheme 1.4: Templated synthesis of cyclic tetrapeptides using palladium, nickel and copper 
complexes. 
Whether or not pre-organisation of a substrate is possible, high dilution or pseudo-high dilution 
conditions are commonly used as methods to increase the yields of macrocyclisation reactions. 
Running the reaction at high-dilution decreases the probability of intermolecular reactions 
occurring and therefore reduces dimerisation/oligomerisation pathways. However, high dilution 
is usually impractical and not easily scalable. Pseudo-high dilution can also be used as an 
alternative, for example, where the linear reagent is added very slowly to create a high dilution 
environment under reaction conditions. This is more effective for some classes of cyclisation 
reactions (e.g. many examples of amidation or esterifications are reported), however, can be 
less successful on other cyclisation reactions, such a Stille or Sonagashira reaction due to the 
catalytic cycle being interrupted/halted.35 In these cases, higher catalyst loadings or additives 
are commonly employed in addition to dilution. As an example of the reaction dependence on 
different macrocyclisation protocols, linear analogue 25 was cyclised via a fairly low yielding SNAr 
reaction, using pseudo high dilution conditions. However, if the linear precursor is modified to 
26, then a macrolactamisation can be performed at a greatly improved 83% yield. These two 
strategies appear equally viable on paper, and the large difference in yield highlights the 
difficulty of predicting macrocyclisation efficiency even using high dilution conditions (scheme 
1.5). 
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Scheme 1.5: Cyclisation via two separate strategies under high dilution conditions. 
1.2.4 Macrocyclisation Reaction Types 
In theory, many retrosynthetic disconnections can be made from a macrocyclic product, which 
gives rise to many macrocyclisation reaction classes. A few of the most common cyclisation 
strategies are explained below, although this is by no means a comprehensive list. 
1.2.4.1 Macrolactamisation Reaction 
Lactamisation reactions have been a staple in cyclic peptide/oligomer synthesis, helped by the 
advancement in Solid Phase Peptide Synthesis (SPPS). In SPPS, the nascent peptide is covalently 
bonded to a polymer resin and excess reagents can be washed away, thus avoiding time-
consuming purification after each iteration. Therefore, peptides and oligomers can be rapidly 
made using SPPS, and a single discrete cyclisation can afford the desired cyclic product.  
Macrolactamisations can also be utilised to synthesis natural products such as quebrachamine 
34. Using iodinated indole 28, a Sonagashira coupling was performed with alkyne 29 (itself 
synthesised using a Seyferth–Gilbert homologation). Subsequent deprotection and 
hydrogenation afforded the Z-olefin 31, which was amenable to macrolactamisation using 
coupling reagent HBTU. Final hydrogenation to alkane 33 and amide reduction afforded the 
natural product quebrachamine.  
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Scheme 1.6: Total synthesis of quebrachamine via macrolactamisation. 
1.2.4.2 Macrolactonisation Reaction 
Macrolactonisation has been used extensively in multiple total syntheses due to its broad 
applicability, functional group tolerance and compatibility with high dilution/templating effects. 
Many different reagents/named reactions/modifications exist which all offer slightly different 
reactivity; amongst the most notable are Yamaguchi, Steglich and Mukaiyama–Corey–Nicolaou 
esterifications.36 These all operate via initial activation of the carboxylic acid, through an 
anhydride species, followed by lactonisation via the tethered alcohol. These methods were 
developed to overcome the harsh acidic conditions of Fischer esterification, which would not be 
applicable in a highly functionalised late stage setting.  
One example is in the total synthesis of (−)-amphidinolide E, 44 where a Kita–Trost 
macrolactonisation is utilised (scheme 1.7). Sulfone 35 was deprotonated using KHMDS and 
subjected to aldehyde 36 in a Julia–Kocienski olefination, to afford solely the E-olefin 37. 
Palladium-catalysed Suzuki–Molander coupled trifluoroborate fragment 38 in excellent yield 
with no olefin isomerisation. Deprotection of the TBDPS using TBAF was performed at room 
temperature and afforded alcohol 40. Oxidation of the alcohol to the corresponding carboxylic 
acid was non-trivial, with Jones oxidation resulting in removal of the acid labile protecting groups 
and olefin scrambling. Consequently, a two-stage oxidation using Dess–Martin periodinane (to 
generate the aldehyde) followed by a Pinnick oxidation formed carboxylic acid 41 in 91% over 
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both steps. Removal of the TBDPS at the highly hindered C-17 position required TBAF at elevated 
temperatures for extended time to afford alcohol 42 in modest yield, with the starting material 
recoverable. The key macrocyclisation step was initially tested with a Yamaguchi lactonisation 
and was completely unsuccessful. As a result, alternative lactonisations were tested with the 
Kita–Trost reaction delivering the highest yield, most reliably, through an ethoxyvinyl ester (not 
shown). Finally, global deprotection was performed using HCl, producing (−)-amphidinolide E in 
77% yield. 
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Scheme 1.7: Total synthesis of (−)-amphidinolide E using macrolactonisation. R1 = TBDPS 
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1.2.4.3 Mitsunobu Macrocyclisation 
An alternative disconnection approach that can be used to produce macrocyclic lactones is the 
Mitsunobu cyclisation. The Mitsunobu reaction operates by activating the alcohol using a 
combination of a phosphine reagent (commonly triphenylphosphine) and an azo coupling 
partner (commonly DIAD or DEAD). Many nucleophiles can be now be used with recent 
modifications,37 although they typically must be related to acidic pro-nucleophiles, such as 
carboxylic acids, phenols, thioethers, and imides. The reaction proceeds with complete, clean 
inversion of stereochemistry at the alcohol and is usually very reliable, which is useful in 
stereoselective and total synthesis.  
An interesting example was reported in the synthesis of peloruside A, 49 (scheme 1.8). Aldehyde 
45 was reacted with the corresponding boron enolate of ketone 46, in a highly stereoselective 
aldol addition. Meerwein’s salt was then used to methylate this newly formed secondary alcohol 
in excellent yield and with remarkable selectivity. Enone 47 was reduced using a Corey–Bakshi–
Shibata (CBS) reduction, and subsequent ester hydrolysis yielded carboxylic acid 48. High 
dilution Mitsunobu cyclisation afforded the macrocyclic lactone in modest yield with some loss 
of yield, presumably due to side reactions with other unprotected alcohols, although not 
disclosed in the report. Global acidic deprotection generated peloruside A, 49 in 65% yield. 
 
Scheme 1.8: Total synthesis of peloruside A using a Mitsunobu cyclisation. 
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1.2.4.4 Palladium Catalysed Macrocyclisation 
With ever-increasing understanding of palladium coupling catalytic cycles, alongside the design 
and development of new and improved catalysts, palladium-catalysed cross coupling has drawn 
significant attention for the macrocyclisation of complex targets. Owing to its orthogonal 
reactivity, palladium coupling reactions have broad functional group and substrate applicability 
and therefore multiple disconnections approaches can be envisaged. Suzuki, Heck, Negishi and 
Stille couplings38–41 have all been used to generate macrocyclic natural 
products/pharmaceuticals, sometimes when other macrocyclisation methods were not 
applicable or successful. 
One example is found in the synthesis of highly unsaturated macrocycle isocembrene, 57 
(scheme 1.9).42 Lithium halogen exchange of iodide 50 was followed by SN2 with fragment 51. 
Deprotection of the alcohol and acetal, with TBAF and acid respectively, afforded alcohol 53. 
Swern oxidation to generate aldehyde 54, was followed by Takai-type olefination which 
proceeded with very high E-selectivity, to generate vinyl tin species 55. Conversion of the ketone 
to the corresponding enol triflate 56, was completed with NaHMDS and phenyl triflimide. Stille 
macrocyclisation was completed with Pd(PPh3)4 at reflux in THF, under high dilution conditions 
(1 mM) to access the natural product in 76%. The triflate is used in this context as a pseudo-
halide, with oxidative addition into the C-OTf bond being comparable with that of C-Br. 
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Scheme 1.9: Total synthesis of isocembrene using Stille coupling. 
1.2.4.5 Ring-Closing Metathesis 
Since its conception by Didier Villemin and co-workers43 within the synthesis of an Exaltolide 
precursor in 1980, and later popularised by Grubbs and Schrock, ring closing metathesis (RCM) 
has become a powerful tool when targeting difficult ring systems.44 The RCM method has been 
used in many total syntheses to produce both medium-sized rings and macrocycles such as 
floresolide B (Nicolaou, 2005),45 (−)-balanol (Fürstner, 2000)46 and (+)-migrastatin (Danishefsky, 
2003)46 to highlight a few. It has become a powerful synthetic tool, due to its broad substrate 
scope and the by-product (olefin) being volatile and therefore easily removable. Ruthenium, 
molybdenum and tungsten are the most common metals used at the core of the Grubbs and 
Schrock catalysts, with the mechanism proceeding through a series of formal [2+2] 
cycloadditions and reversions via metallocyclobutane intermediates. The geometry of the 
produced olefin has historically been problematic, with mixtures of both Z- and E-olefins being 
Chapter One: Introduction 
 
15 | P a g e  
 
produced in large ring sizes. Typically, the reaction is under thermodynamic control with the 
more stable E-olefin generally being the major product. However, in 2013 Grubbs showed that 
using a ruthenium NHC catalyst excellent E-selectivity was achieved, and when using a chelating 
ruthenium catalyst, the corresponding Z-olefin product was formed.47 Since then, Z-selective 
RCM catalysts have been developed which create a sterically demanding transition state, which 
give rise to the change in selectivity.48  
One example of this Z-selectivity can be seen within the total synthesis of (−)-nakadomarin A, 67 
(scheme 1.10).48 1,3-Dicarbonyl 58 was treated with cinchona alkaloid 59 to induce highly 
stereoselective Michael addition into furan 60, producing a single observable diastereomer. A 
Mannich-type reaction with formaldehyde and amine 62 was used to form spirocyclic lactam 63, 
which required a further 6 steps to produce tetracyclic diene 64, which was ready for the key 
RCM step. Using a tungsten alkydene catalyst, under vacuum to remove olefin by-products, 
macrocycle 66 was produced in excellent yield with outstanding (97:3) Z-/E-selectivity. Further 
manipulation of this core was completed to afford the natural product. 
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Scheme 1.10: Synthesis of (−)-nakadomarin A using Z-selective RCM catalyst. 
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1.2.4.6 Alkyne Metathesis 
This reaction is very closely related to alkene RCM, but works on the principle of rearranging 
alkyne bonds to produce a cyclic alkyne and a volatile biproduct (commonly ethyne or butyne), 
which provides an entropic driving force for the reaction. Molybdenum-based catalysts are 
commonly used, and substrate scope is comparable if not more tolerant than with alkene 
metathesis.49,50 One significant advantage, due to sp-hybridisation, is that Z-/E-isomerism is not 
a concern. Once the cyclic alkyne is generated, hydrogenation can be performed using Lindlar’s 
catalyst to generate Z-olefins and dissolving metal reduction (similar to Birch reduction) can be 
used to access E-olefins. Although two distinct reactions are required to access a desired cyclic 
olefin via this approach, complete control of geometry can be achieved.  
One example of alkyne ring closing metathesis which showcases its advantages, is seen during 
the synthesis of rhizoxin D, 80 (scheme 1.11).51 In this synthesis, ketone 68 undergoes a 
stereoselective aldol reaction with aldehyde 69 mediated by chiral Lewis acid (+)-DIPCl. Using 
substrate control, reduction of ketone 70 to diol 71 is possible using weak reducing agent ATAB. 
Protection of the secondary alcohol followed by esterification affords phosphonate 73 in 
excellent yield. Horner–Wadsworth–Emmons olefination coupled the phosphonate 73 with 
aldehyde 74, exclusively observed as the E-isomer. Di-alkyne 75 is then subjected to ring closing 
alkyne metathesis with molybdenum catalyst in good overall yield. Reduction of the newly 
formed cyclic alkyne 77 was achieved using in situ reductive decomplexation of a cobalt complex 
with EPHP, with satisfactory E:Z selectivity. This alkyne reduction was surprisingly found to be 
extremely challenging with all attempts of transition metal catalysed hydrogenation, 
hydroborylation and hydrostannylation being unsuccessful. The Z-,E-diene 78 was then radically 
flipped to the corresponding E-,E-diene. Stille coupling with diene 79 finishes the total synthesis 
of rhizoxin D in 68% yield.  
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Scheme 1.11: Total synthesis of rhizoxin D via ring closing alkyne metathesis. 
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1.2.4.7 Cycloaddition of Alkyne and Azide 
Huisgen 1,3-dipolar cycloaddition reactions between an azide and alkyne are able to selectively 
generate 1,2,3-triazoles, often without the requirement to use chromatography to remove by-
products. Based on this, the reactions fulfil the pre-requisites of a ‘Click’ reaction, a concept 
introduced by Sharpless in 200151 to describe reactions which are “high yielding, wide in scope, 
create only by-products that can be removed without chromatography, stereospecific, 
operationally simple and can be performed in benign or easily removed solvents.” However, 
thermal 1,3-dipolar cycloadditions usually give a mixture of regioisomers when using 
unsymmetrical alkynes, and therefore arguably should not be classified as a click reaction in 
these cases. As a result, a copper-catalysed variation was reported which benefits from greater 
control of regiochemistry, and operates via a different mechanism, with the reaction completed 
at room temperature in aqueous conditions. This quickly became incredibly popular due to the 
huge rate acceleration, broad pH and functional group tolerability and simple isolation of 
products via filtration.52 In particular the bio-conjugation of enzymes/peptides, the synthesis of 
supramolecular structures (such as catenannes and rotaxannes) and the synthesis of 
pharmaceuticals/natural products use this reaction frequently.  
A clever use of this chemistry can be seen within the synthesis of cyclic peptide mimetics. Lokey 
and co-workers53 identified that a 1,2,3-triazole can mimic an amide and be constructed regio-
selectively through the use of the copper catalysed cycloaddition. Using SPPS, alkyne amino acid 
81 was coupled with leucine fragment 82 and repeated twice more to generate tetramer 84. 
Azido-leucine 85 was coupled using HOAT and DCC to afforded azido alkyne 86. Copper catalysed 
cycloaddition forming macrocycle 87, was performed whilst the peptide was still attached to the 
resin, because the acidic conditions required for cleavage would have degraded the azide. 
Subsequent removal from the resin was completed with 1% TFA, affording the cyclic peptide 
mimetic, 88, in 25% overall yield. 
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Scheme 1.12: Copper catalysed azide-alkyne cycloaddition towards the synthesis of cyclic peptide 
mimetics. 
1.2.4.8 Diels–Alder Cycloaddition 
Another example of a concerted pericyclic reaction that has been used for macrocyclisation is 
the Diels–Alder reaction. The Diels-Alder reaction is a [4+2] cycloaddition between a diene and 
dienophile, which results in the formation of an unsaturated six-membered ring. Regioselectivity 
is dictated by orbital overlap and the electronics of both diene and dienophile. 
Diastereoselectivity can also be controlled, for example, if a cyclic diene is used, and when 
operating under kinetic control, the endo product can be preferentially formed if a secondary 
orbital overlap with a carbonyl is present (this can be seen in scheme 1.13).  
Although not commonly utilised in macrocyclisation, an example can be seen within the 
synthesis of abyssomicin C 97.54 First, ketone 89 was kinetically deprotonated using LDA, and 
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reacted with aldehyde 90 to yield the corresponding alcohol, which was trapped with TBSOTf to 
generate silyl ether 91. Swern oxidation conditions were sufficient to deprotect and oxidise 
primary silyl ether 91 to analogous aldehyde 92. Deprotonation and subsequent nucleophilic 
attack of cyclic vinyl ester 93 to aldehyde 92 was followed with Dess–Martin periodinane 
oxidation to generate 1,3-dicarbonyl 94. With the use of lanthanum(III) triflate, a Diels–Alder 
reaction (proceeding via 94a), afforded macrocycle 95 in modest yield. Epoxidation and enol 
ether hydrolysis afforded macrocycle 96 which was treated with p-TSA to induce ring opening 
of the activated epoxide with pendant alcohol to generate the natural product 97 in 50% yield. 
 
 
Scheme 1.13: Diels–Alder macrocyclisation within the total synthesis of 97. 
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1.2.4.9 Horner–Wadsworth–Emmons/Wittig Olefination  
The Horner–Wadsworth–Emmons was successfully employed as a macrocyclisation strategy in 
the synthesis of riccardin B, 105 (scheme 1.14).55,56 Initially, an Ullman coupling between phenol 
98 and aryl bromide 99 generated the equivalent di-aryl. Acetal protection of the aldehyde was 
followed with lithium aluminium hydride reduction of the methyl ester to form primary alcohol 
100. Conversion into the alkyl bromide was completed with thionyl bromide (which clumsily 
deprotected the acetal), which was then subjected to an Arbuzov reaction to generate the 
phosphonate ester. Protection of the aldehyde was required to generate 101. Potassium tert-
butoxide was used to deprotonate the phosphonate ester which was then coupled with bi-aryl 
aldehyde 102 in the first Horner–Wadsworth–Emmons reaction which proceeded in excellent 
yield and with complete regio-selectivity. Olefin hydrogenation, ester reduction, acetal 
deprotection, bromination and Arbuzov reactions were telescoped, generating phosphonate 
ester 104. A second Horner–Wadsworth–Emmons reaction was performed which formed the 
macrocycle, under high dilution, in an excellent 89% yield. Hydrogenation of the produced olefin 
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1.2.5 Ring Expansion Reactions 
An alternative strategy to the direct cyclisation of a linear precursor is to use ring expansion to 
enlarge an existing cyclic scaffold. This means that the often-difficult cyclisation step can be 
entirely avoided, and has been used as an effective tool in total synthesis for many years. The 
powerful cyclisation reactions outlined thus far have been used in conjunction with at least one 
macrocyclisation strategy (e.g. high dilution) that minimises the damage of the difficult end-to-
end cyclisation. However, utilising a suitable ring expansion can allow access to ringed systems 
that are traditionally difficult to synthesise (such as 8–11 membered rings or macrocycles), 
without the requirement of substrate bias or high dilution. This is most effective when a 
cyclisation step is required, then it is based on the formation of easily accessible cyclic transition 
states (i.e. 5- ,6- and 7-membered rings). This results in procedures that tend to be more 
predictable, operationally simple, and importantly scalable, without the competing 
dimerisation/oligomerisation pathways. 
Most published ring expansion processes fall within four categories: fragmentation, pericyclic 
rearrangements, radical ring expansion and side-chain insertion with the following sub-sections 
split accordingly. This section of the introduction summarises an enormous body of literature 
and is not designed to be a comprehensive cover of the topic. For an excellent review of the 
area, the author highlights the subsequent paper.57 In addition, the following sections will only 
cover ring expansions based on greater than or equal to 3-atom insertions, unless otherwise 
stated, as these are generally the most synthetically useful in the synthesis of medium-sized 
rings and macrocycles.58–61 This is not done to diminish the importance of 1- and 2- atom ring 
expansions, however due to the large number of synthetic transformations, a review of this area 
would be too extensive. 
1.2.5.1 Elimination Reactions (Grob/Wharton-type Fragmentation) 
Arguably the most direct ring expansion approach, fragmentation involves breaking the bridge 
in a fused ring structure. Providing that the bicyclic system can be expeditiously prepared, a 
single fragmentation process is then required. Amongst the most widely used of these is the 
Grob fragmentation.62 This elimination reaction profits from its irreversibility and has 
subsequently been applied to countless examples. Although too many to mention them all, 
three examples have been selected to illustrate this fragmentation approach. First, in the 
synthesis of jatrophatrione by Paquette and co-workers,63,64 1,3-diol 106 is treated with mesyl 
chloride which acts upon the less hindered secondary alcohol. Deprotonation causes 
fragmentation through intermediate 107, affording the jatrophatrione natural product 108 in 
excellent yield (scheme 1.15a). Second, tricyclic core 109 was treated with potassium carbonate, 
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causing reversible deprotonation of both alcohols. A Grob fragmentation occurs generating 
ketone 111 with the expulsion of carbon dioxide driving the reaction via a large, favourable 
entropic change. Two separate transannular ring contractions then occur between the alkoxides 
and ketones to yield the eleutherobin core in a 68% yield.65 It can be proposed that the first ring 
contraction occurs to relieve the strain associated with the medium-sized ring, as well as placing 
the alkoxide and ketone in close proximity in order for the second ring contraction to occur 
(scheme 1.15b). Finally, in the vinigrol synthesis by Baran,66 mesylation of secondary alcohol 114 
was achieved by an intriguing oxidation-reduction-trapping procedure. Deprotonation of 
tertiary alcohol with KHMDS initially generates an intermediate alkoxide 116, and subsequent 
Grob fragmentation generates vinigrol core 117 in excellent yield, exclusively as the Z-olefin due 
to the geometry required for the elimination (scheme 1.15c). 
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Scheme 1.15: Grob fragmentation reactions in total syntheses. 
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1.2.5.2 Pericyclic Rearrangements 
Characterised by the concerted movement of electrons within a cyclic transition state, pericyclic 
rearrangements are a popular approach for the synthesis of complex targets.67 Heterocyclic 
scaffolds are dominated by this approach due to their efficiency as well as their tuneable regio- 
and enantioselectivity.68 This chemistry offers creative and sometimes disguised disconnections, 
which would otherwise be difficult to perform in a small number of steps. Significant investment 
has been placed into developing new, broad and interesting pericyclic chemistry with numerous 
named reactions operating via different reaction modes.  
The three most common classes of pericyclic rearrangements are: electrocyclisation, 
cycloaddition and sigmatropic rearrangements. Each of these reaction classes have broad utility 
and have been used to create highly functionalised cyclic compounds. One example of a 
cycloaddition reaction, namely a Diels–Alder macrocyclisation, performed within the total 
synthesis of abyssomicin C, 97, has already been described (see section 1.2.4). However, 
sigmatropic rearrangements are probably the most common class used for ring expansion. This 
molecular rearrangement involves the formation of a new σ-bond between two atoms not 
previously directly bonded, with the breaking of an existing σ-bond as defined by IUPAC.69 [3,3]-
Sigmatropic rearrangements have become the most widely used, being involved in many named 
reactions such as the Claisen, Cope, Carroll and Overman rearrangements. This class of 
sigmatropic rearrangement often proceeds through a chair-like transition state, which can result 
in predictable stereocontrol in the product. In addition, the formation of a carbonyl from an 
alcohol is often utilised as a strong thermodynamic driving force, to push the reaction to 
completion and avoid any unwanted equilibrium side products. 
One example of a [3,3]-sigmatropic rearrangement can be seen in the synthesis of (±)-
preisocalamendiol 124 by Still and co-workers.70 Starting from the monoterpene, 
isopiperitenone (118), 1,2-addition using vinyl lithium reagent 119 afforded diene 120. Using the 
anionic oxy-Cope rearrangement, developed by Evans,71 (which has a substantial rate 
acceleration, being approximately 1017 times faster compared to the neutral oxy-Cope) yielded 
ketone 122. Kinetic enolate protonation72 resulted in deconjugation of the olefin, to produce 
the natural product in 76% yield.  
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Scheme 1.16: Anionic oxy–Cope rearrangement employed by Still in the synthesis of the germacrene 
class of natural products. 
 
1.2.5.3 Radical Ring Expansion 
Owing to the short-lived, high-energy nature of radical intermediates in reactions, a plethora of 
chemistry can be observed ranging from functional group interconversions to highly complex 
cascade processes.73 Radical transformations can be performed through many methods such as 
photochemistry, electrosynthesis and thermal decomposition. C- , O- and N-centred radicals are 
all possible and open up many different pathways, which can be seen in the ensuing section. 
Arguably, the most widely implemented strategy is the Dowd-Beckwith reaction, alongside its 
variations. Radical generation (from the thermal decomposition of AIBN) has commonly been 
utilised to produce a primary radical 126 which can cyclise onto a carbonyl moiety (commonly a 
ketone) and induce a ring expansion via a high-energy O-centred radical 127. The typical alkyl 
variation is shown in scheme 1.17, however an aminyl radical can also take place in the same 
reaction sequence if an azide precursor is used. 
 
Scheme 1.17: Classical Dowd–Beckwith ring expansion reaction with primary iodide. 
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Radical reactions are not limited to variations of carbonyl addition chemistry and sites of radical 
attack can vary dramatically. An excellent example highlighting this comes from Harrowven et 
al., who reported an intriguing ipso-substitution in the synthesis of atropisomeric bi-aryl medium 
sized rings (Scheme 1.18).74 The reaction proceeds via conventional thermal initiation of tributyl 
tin hydride using AIBN, and the stannyl radical abstracting iodide from the aryl iodide 129. The 
resulting aryl radical 130 has the option of attacking into the carbonyl, but opts to attack the 
adjacent aryl ring. This results in the formation of a more stabilised tertiary allylic radical 131, 
which is followed by concerted aromatisation/ring expansion, to generate electrophilic 
stabilised radical 132. Tributyltin hydride propagates this radical chain reaction, generating the 
neutral product 133. It is noted that the reaction works more effectively with indanone systems 
than the corresponding tetralones, which undergo unwanted ortho-substitution. 
 
Scheme 1.18: Radical ring expansion towards the synthesis of atropisomeric bi-aryl medium sized rings. 
1.2.5.4 Side Chain Insertion Reaction 
As well as being a radical reaction, the Dowd–Beckwith reaction can also be classified as a side 
chain insertion reaction. Side chain insertion is best defined by the division into its stages: i) 
addition of a linear fragment to an already existing cyclic molecule, ii) the formation of a fused 
bicyclic system, iii) fragmentation of the bridging bond in an elimination type reaction, resulting 
in an overall ring expansion. Typically, a linear fragment is utilised with both an electrophilic and 
nucleophilic site to combine the processes into one cascade. Moreover, this can be achieved via 
both one and two electron processes, and consequently radical ring expansion reactions can 
also be placed into this category (as seen previously with the Dowd–Beckwith reaction). 
Commonly, this ring expansion class often proceeds under thermodynamic control, and as a 
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result the reaction must be carefully designed such that there is a clear propensity for expansion. 
When looking at ring size, functional group conversion or entropy in isolation, some insertion 
reactions may appear unfavourable, however all thermodynamic aspects must be considered 
together.  
C- , O- , and N-nucleophiles can all be appended onto the cyclic starting material, which creates 
a further three sub-divisions of this ring expansion class. It is common that a protecting group 
strategy is used, to avoid any uncontrolled ring expansion or polymerisation of the linear 
fragment. 
1.2.5.4.1 C-C Bond Forming Side Chain Insertion Ring Expansion 
Carbon-carbon bond forming ring expansions are amongst the most valuable ring expansion 
processes synthetically, as well as being one of the most challenging to achieve through two-
electron processes. However, commercially important macrocycles such as the perfume 
ingredient muscone necessitates a viable and scalable synthesis towards these all carbon 
macrocyclic scaffolds, and this has led to much interest in the development of such ring 
expansion approaches. The radical Dowd-Beckwith expansion can be utilised, however this can 
be problematic with highly functionalised intermediates. 
Within the synthesis of muscone, Trost et al.75 reported an astute condensative expansion under 
mild conditions and excellent selectivity. An initial alkylation of β-keto sulfone 134 with mesylate 
135, assisted via an in-situ Finkelstein reaction, generates ketone 136. Treatment with TBAF is 
sufficient to initiate ring expansion followed by olefin migration to the thermodynamically stable 
tri-substituted internal conjugated system 138. A final hydrogenation affords the natural 
product muscone 139. 
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Scheme 1.19: C-C bond forming side chain insertion within the synthesis of muscone. 
This methodology is not limited to organosilicon or radical chemistry; through the use of a 
suitably strong base, similar transformations can be performed with organometallics. Serious 
consideration of the acidity and electrophilicity of reactants and products must be taken when 
handling these reactive intermediates to avoid side reactions, however, with judicious selection 
of protecting groups and functional groups, transformations which would otherwise be 
incredibly difficult to perform can be achieved. Exemplifying this reactivity, a host of medium-
sized rings have been accessed through a proposed associative concerted mechanism reported 
by Clayden and co-workers (scheme 1.20).76 The proposed mechanism proceeds through initial 
lithiation of cyclic urea 140 at the benzylic position, adjacent to the urea, with hindered base 
LDA and DMPU used to encumber a 1,2-acyl shift pathway. The benzylic anion 141 undergoes 
ipso-substitution, which results in an overall ring expansion. An associative concerted 
mechanism (rather than an SNAr mechanism) is proposed because electron donating groups on 
the arene, which would destabilise the Meisenheimer complex in a standard SNAr process, often 
progress with higher yields (144). Exquisite enantioselectivities/diastereoselectivities (143 and 
145) highlight the influence that lithiated derivatives can have in ring expansion.  
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Scheme 1.20: Synthesis of benzodiazepines through organometallic migration of cyclic ureas by 
Clayden and co-workers. 
1.2.5.4.2 C-O Bond Forming Side Chain Insertion Ring Expansion 
Since the development of Yamaguchi lactonisation,77 many more macrocyclic lactonic natural 
products (such as macrolide antibiotics) have been synthesised. This resulted in significant 
academic interest in developing streamlined synthetic routes to these valuable targets. Ring 
expansion was identified as an alternative strategy, which had the potential to access 
functionalised macrocyclic lactones with continued research. It was quickly understood that 
basic conditions were commonly required to promote C-O bond forming ring expansion, 
however some examples have been reported to operate through acid-catalysed mechanisms.78  
Ring expansion reactions based on transesterifications have been described,79 however with no 
change in the functional group composition during such reactions, the driving force for ring 
expansion must arise from only ring size stability. Corey and co-workers80 illustrated the 
challenges associated with medium-sized ring synthesis via a transesterification approach. 
Treating lactones of the type 146 with p-TSA, activated the lactone carbonyl by increasing its 
reactivity through an oxonium intermediate. At room temperature, an equilibrium between 147 
and 148 was achieved, with the position of equilibrium dependant on ring size. Those ring sizes 
with higher Prelog strain, produced no or very little ring enlarged products under the reaction 
conditions. However, once the ring size had become significantly large and flexible to reduce the 
unfavourable transannular interactions, yields of product increased dramatically to near 
quantitative for macrocyclic lactone 151. These results highlight the difficulty in synthesising 
medium-sized rings, however also demonstrate that they can often undergo facile ring 
expansion to macrocycles, due to the release of ring strain.  
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Scheme 1.21: Transesterification of medium-sized rings by Corey and co-workers. 
1.2.5.4.3 C-N Bond Forming Side Chain Insertion Ring Expansion 
With the prevalence of nitrogen containing heterocycles in Nature and pharmaceuticals, ring 
expansion methods that incorporate this desirable heteroatom have clear benefits. In addition 
to the importance/usability of the products, using an amine as a pendant nucleophile has many 
synthetic advantages. Amine protecting groups have been extensively examined and developed, 
offering orthogonal stability/lability with regards to other functional groups and reaction 
conditions. Therefore, a suitable protecting group can often be found, with the amine only 
revealed when needed, avoiding unwanted side reactions such as dimerisation or transannular 
interactions. The revealed amine is also usually a good nucleophile and has the ability to partake 
in a whole host of chemistry such as: carbonyl addition, Michael addition, nucleophilic 
substitution and Buchwald-Hartwig coupling to name a few. 
One example, reported by Buchwald and co-workers, uses a telescoped one-pot approach to 
access benzoazocines.81 Initially, a copper-catalysed Ullmann-type coupling is performed 
between aryl halide 152 and azetidinone 153, forming amine 154. Although not required in 
every case, DMEDA was added to ligate the copper catalyst, which increased the reaction yields. 
Under the coupling conditions used, the amine 154 undergoes transamidation to relieve ring 
strain of the β-lactam moiety. In some instances, catalytic acetic acid was required for ring 
expansion to be successful. The real advantage with this chemistry arises from the diversity and 
ease in which these complex heterocycles can be constructed. Azetidinone 153 and many 
derivatives are commercially available and benzyl amines 152 can be simply made on large scale 
in a single step with two further points of modification. 
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Scheme 1.22: Synthesis of benzoazocines via a domino C-N coupling/ring expansion cascade by 
Buchwald and co-workers. 
 
A non-catalytic C-N bond forming ring expansion reaction is the amino acid acyl incorporation 
(AAI). This involves the incorporation of an amino acid fragment into a cyclic amide, generating 
a cyclic dipeptide. Despite the power of this reaction, this intriguing intramolecular ring 
expansion has surprisingly received little attention,82 with only a few advancements being 
reported by Shemyakin and co-workers83–86 until the work reported in this thesis, along with a 
recent report (published at the same time as the work completed in Chapter three) by Yudin and 
co-workers.87  
A generic early example88 takes tripeptide, synthesised by SPPS, and activated the C-terminus 
via p-nitrophenol ester 156 (scheme 1.23). Assisted by the turn-inducing amino acid proline, 
present in the sequence, cyclisation to diketopiperazine intermediate (157 → 158) under 
extremely mild conditions was possible. If a more activated pentafluorophenol ester is utilised, 
intermolecular dimerisation/oligomerisation occurs resulting in no observed cyclised product. 
The diketopiperazine intermediate 158, was then proposed to undergo spontaneous ring 
expansion, under neutral conditions, generating 9-membered tripeptide 159 in high yield for 
sterically unencumbering Pro-Ala-Pro tripeptide. Medium-sized cyclic tripeptides similar to 159 
are usually extremely difficult to synthesise via the head-to-tail cyclisation of a linear peptide so 
this reaction is not viable. The mechanism proposed is supported by a control experiment in 
which removing the internal nucleophilic amide, resulted in incredibly poor yields (<5%) of the 
cyclised tripeptide (160 → 161). 
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Scheme 1.23: Synthesis of tripeptide medium-sized rings through AAI reaction. 
However, more recent work by Yudin et al.87 sheds significant doubt on the mechanism 
proposed in scheme 1.23.  An extensive study (supported by computational calculations) on 
direct amino acyl incorporation to produce 8- , 9- , 10- and 11-membered peptides was 
performed, which contradicted the results obtained by Rothe et al.. They found that whilst β-
amino acids could undergo ring expansion with lactams of varying ring size, α-amino acids would 
stop at a tetrahedral intermediate 165 (scheme 1.24), named a cyclol. For 6-membered lactams, 
including diketopiperazines, the cyclol or open amine form was found to be thermodynamically 
most stable, rather than the desired ring expanded product 164. Although the same reaction 
(156 → 159) was not completed, this work opposes a two-step mechanism in the synthesis of 
cyclic tripeptides, and suggests that direct 9-membered lactamisation aided by a favourable 
conformation may have been the true mechanism in the study conducted by Rothe et al. 
(scheme 1.23).  
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Scheme 1.24: Synthesis of medium-sized rings, examining the key cyclol intermediate by Yudin and co-
workers. 
1.2.5.5 Consecutive Ring Expansions 
In all the preceding sections, interesting cyclic compounds have been accessed in good to 
excellent yields that are typically difficult to synthesise via end-to-end cyclisation. Particular 
emphasis has been placed on the synthesis of medium-sized rings, as their precursors are often 
commercially available or easy to make, typically with excellent control of regio- and 
stereochemistry. However, to ensure ring expansion is efficient it is common that reactions 
proceed via fused 5- ,6- and 7-membered ring intermediates/transition states before expansion, 
and this can limit the number of atoms (3–5) that can be efficiently added to the ring size during 
a single ring expansion. This in turn significantly limits the number of molecules that ring 
expansion methods can access. 
One strategy that has emerged to combat this limitation, is the use of consecutive ring 
expansions. There are far fewer examples of this approach being used, however those 
developed clearly show the potential of this approach. When done well, individual ring 
expansion can be utilised to incorporate specific functionality, allowing macrocycles to be 
‘grown’ in a programmable and predictable method. We have recently published a full review 
on this area of ring expansion, which can be consulted for a more detailed account of this topic.89 
Selected highlights are described in this section, with these sequential ring expansion types 
separated into the same sub-divisions as used previously: pericyclic rearrangements, elimination 
reactions and insertion reactions. 
1.2.5.5.1 Pericyclic Rearrangements 
There has been significant interest in this area, with most publications utilising charged 
intermediates (often acting as a thermodynamic driving force) within sigmatropic 
rearrangements. Heteroatoms are also commonly employed which can facilitate starting 
material preparation.  
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Sulfur can be used to mediate pericyclic rearrangements as sulfonium cations and ylides can be 
generated with ease, which in turn can result in a facile rearrangement. Sulfur can also be 
subjected to well-known chemistry to perform functional group interconversion, however the 
incorporation of sulfur can be advantageous, e.g. the sulfone group is often included in 
medicinal chemistry to act as a hydrogen bond acceptor.90 The total synthesis of cytochalasan D 
171 (scheme 1.25) by Vedejs and Reid91 utilises these advantages of sulfur mediation, 
eliminating the heteroatom in a mild fashion at the end of the synthesis. Thus, iodide 166 was 
heated in acetonitrile/potassium carbonate to produce ylide 167. Under the reaction conditions 
used to generate the ylide, spontaneous [2,3]-sigmatropic rearrangement occurred producing 
9-membered sulfide 168 in an overall good yield. Methylation with Meerwein’s salt afforded 
sulfonium 169, which was amenable to zinc/acidic C-S bond cleavage delivering 11-membered 
sulfide 170. Oxidation and following elimination formed unconjugated olefin, with TBAF 
mediated elimination of the silyl group generating the natural product. 
 
 
Scheme 1.25: Sulfur mediated consecutive ring expansions within the total synthesis of cytochalasan 
D. 
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Vedejs and co-workers also pioneered the development of successive [2,3]-sigmatropic 
rearrangements in order to build ring enlarged products.92 With only a small number of 
transformations between each ring expansion iteration, this method illustrates the power of 
these iterative sigmatropic rearrangements. Starting from allyl sulfide 172, perchloric acid 
assisted nucleophilic substitution of diazocarbonyl 173 delivered sulfonium 174. Treatment with 
base generated sulfur ylide 175 which efficiently underwent [2,3]-sigmatropic rearrangement in 
excellent yield to ring enlarged sulfide 176. Wittig olefination afforded new allyl sulfide 177, 
which contained the required functionality for a further iteration. For the second [2,3]-
sigmatropic rearrangement, an alternative diazo-compound is utilised however the reaction 
proceeds in the same fashion. Copper-catalysed coupling of sulfide 177 and diazomalonate 178, 
generated 11-membered sulfide 180 in a single step, presumably through the same steps as 
described previously. Unfortunately, the yields of the final two steps was not disclosed in the 
report. However, further studies on sulfur mediated [2,3]-sigmatropic rearrangements were 
completed by Vedejs and co-workers93–96 as well as Schmid and co-workers,97 which streamlined 
this process to an allylation/[2,3]-sigmatropic rearrangement sequence, which could be iterated 
3 times, generating a 14-membered highly unsaturated macrocyclic from the same sulfide 172.  
   
Scheme 1.26: Iterative synthesis of ringed compounds via sequential [2,3]-sigmatropic 
rearrangements by Vedejs and co-workers. 
Nitrogen can also be utilised within sigmatropic rearrangements to mediate consecutive ring 
expansions. Similar to the sulfur mediated rearrangements, charged intermediates are often 
utilised, in aza-variations of the carbon rearrangements. One example of this, is the use of two 
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consecutive [3,3]-sigmatropic rearrangements reported by Back and co-workers.98 Thus, 2-
vinylpyrollidine 181 underwent conjugate addition into acetylenic sulfone 182 generating 
transient zwitterion 183, which underwent a [3,3]-sigmatropic rearrangement in situ in excellent 
yield. Hydrogenation of isolated olefin 184 was successful with quantitative yield generating 
cyclic amine 185. Treatment with triflic acid formed the corresponding iminium intermediate 
which was immediately quenched with a vinyl-Grignard reagent. This regenerated the α-vinyl 
moiety, and therefore, this compound could be re-subjected to the same reactions conditions 
as the initial ring expansion. Using a different acetylenic sulfone 188, conjugate addition was 
performed and once again in situ [3,3]-sigmatropic rearrangement was performed generating 
doubly ring expanded product 190. Additional modifications were required to access the natural 
product motuporamine A, however the main backbone was introduced using this sequential 
aza-Cope rearrangement protocol. 
 
Scheme 1.27: Total synthesis of natural product motuporamine A using two sequential aza-Cope 
rearrangements reported by Back and co-workers. Ar = p-Cl-Ph. 
Another intriguing example comes from Suh and co-workers99 which requires somewhat harsher 
conditions with the use of a strong hindered base and heat, however, excellent yields and 
diastereomeric control were nonetheless achieved (scheme 1.28). The stereocontrol arises from 
a 6-membered transition state, demonstrating that these rearrangements can transfer 
stereochemical information, without the need for chiral reagents or ligands. Thus, α-vinyl lactam 
192, synthesised by use of Evans asymmetric alkylation/stereoselective vinylation, was treated 
with LHMDS and heated at 110 °C to induce the desired aza-claisen rearrangement (ACR), 
producing ring enlarged ten-membered lactam 194. Hydrogenation of the isolated olefin 
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proceeded in excellent yield to generate saturated lactam 195. Protection of the amide was 
required and thus completed in excellent yield using n-BuLi and Boc2O to afford 196. Reduction 
of the amide to the corresponding hemi-aminal, followed by trapping with TMSOTf generates 
the silyl ether 197, which was amenable to highly selective amidoalkylation producing 198. 
Unfortunately, the Lewis acidic BF3 catalyst used in this step led to unwanted Boc cleavage, and 
therefore reprotection was required, this time with a base labile Fmoc protecting group. 
Lemieux–Johnson oxidation was performed generating the aldehyde which was transformed 
into silyl enol ether 200. Amidation was achieved using mild in-situ coupling conditions with E-
pentenoic acid producing a newly formed α-vinyl amide 201. Treatment with LHMDS at 110 °C 
(identical conditions to those applied previously) generated macrocyclic amide 203 in excellent 
yield and diastereoselectivity. It was noted that the second ACR exhibited a greatly improved 
rate compared to that of the first, which was proposed to be as a result of the silyl enol ether.100 
Follow up studies focusing on this were completed shortly afterwards, which confirmed this 
statement and produced natural product fluvirucinin A2.101 
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Scheme 1.28: Synthesis of macrocyclic amides via sequential aza-claisen rearrangements by Suh and 
co-workers. 
 
1.2.5.5.2 Elimination Reactions 
These powerful reactions can be used to deliver many different ring sizes, and often benefit from 
being irreversible reactions. Elimination reactions can be designed to undergo fragmentation 
only at a specific point within a reaction sequence, when the leaving group is revealed in the 
required position. 
Dowd and Zhang102 utilised the advantages of a radical expansion/Grob fragmentation sequence 
in the synthesis of macrocyclic and medium-sized ring ketones. Starting from silyl enol ether 
204, a [2+2]-cycloaddition with ketene 205 was performed generating highly functionalised 
cyclobutanone 206. Varying cryogenic temperatures were tested, achieving excellent 
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diastereoselectivity when −78 °C was utilised, however a significant decrease in the yield was 
obtained. Classical formation of primary alkyl radical 207 using AIBN and Bu3SnH was used, 
promoting a cascade ring expansion/de-chlorination producing fused bicycle 211. Multiple 
equivalents of tributyltin hydride were utilised to achieve this transformation in a modest yield, 
with no mention of whether the chlorine was intentionally removed or alternatively 
incorporated to improve the preceding cycloaddition. Reduction of the ketone and mesylation 
of the resulting alcohol formed bicycle 212, which was then set to undergo Grob fragmentation. 
However, upon addition of TBAF and cleavage of silyl protecting group, Grob fragmentation did 
not spontaneously occur and formed alcohol 213. Only upon addition of strong hindered base, 
forming the more reactive alkoxide, did fragmentation occur forming 11-membered ketone 214 
in excellent yield and Z-olefin geometry. Larger ring sizes (e.g. ketone 216) were produced with 
an appearance of E-olefin geometry, as the ring size can accommodate this motif without 
significant increase in ring strain. 
 
Scheme 1.29: Radical ring expansion/Grob fragmentation protocol employed by Dowd and Zhang. 
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Thommen and co-workers103 utilised a strategy of employing two sequential Grob 
fragmentations to produce macrocyclic ketone 223. Starting from tricyclic ketone 217, 
stereoselective reduction with Red-Al® generated triol 218. Other more traditional reducing 
agents were tested (such as LiAlH4 and NaBH4), with poorer selectivity or yields obtained. The 
newly formed secondary alcohol was transformed into tosylate 219 using butyllithium/tosyl 
chloride trap. When t-BuOK was used, a mixture of isomers was formed with either of the 
tertiary alcohols undergoing the functional group conversion, despite the increased steric 
interaction. The first Grob fragmentation was performed in modest yield, and was followed by 
a spontaneous olefin migration, presumably due to minimise transannular interactions, to form 
ketone 220. Reduction of the ketone with lithium aluminium hydride afforded alcohol 221 as a 
mixture of diastereomers, which was quickly subjected to slightly modified tosylation conditions 
generating 222. The second Grob fragmentation occurred with excellent yield and complete 
control of olefin geometry, forming macrocyclic ketone 223.  
 
 
Scheme 1.30: Synthesis of macrocyclic ketones via sequential Grob fragmentation by Thommen and 
co-workers. 
Clayden and co-workers104 developed an insertion/fragmentation method to access a medium-
sized ringed urea, with the insertion reaction described previously in section 1.2.5.4, whereby a 
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lithium base mediated insertion reaction is used to form 8-membered urea 227. Then, simply 
using p-TSA and microwave heating, acidic fragmentation occurs from oxonium 228 to stabilised 
benzylic carbenium 229. This fragmentation occurs as the resulting carbenium intermediate is 
thermodynamically more stable with respect to ring size and cation stability. Elimination then 
occurs to form enlarged ring product 230, thus ending the sequence. 
 
Scheme 1.31: Successive insertion/fragmentation in the synthesis of medium-sized cyclic ureas by 
Clayden and co-workers. 
1.2.5.5.3 Insertion Reactions 
Similar to elimination reactions, this sub-division of ring expansion has a very broad definition 
and therefore many transformations can be included into this classification. It is common that 
during a sequence with multiple ring expansions, that one step will include the addition of two 
compounds and thus is an insertion reaction. This is the area with the largest number of 
examples where multiple ring expansions have been completed, with publications dating back 
to 1970.105 Despite the longevity of this reaction class, transformations remain fairly simple with 
most reports describing lactamisation/lactonisations until the recent resurgence in the area. 
Hesse (one of the most important contributors within the topic of ring expansion) and co-
workers106–109 established a series of transamidation reactions coined as ‘zip reactions’, which 
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enabled many different polyamine macrocycles to be accessed in a one-pot cascade procedure. 
Numerous communications were published from Hesse’s group, in both developing the 
methodology and in natural product synthesis.110 One early example from this body of work 
highlights the efficiency of these ‘zip reactions’ and the synthetic ease in making the starting 
materials from commercially available building blocks. Deprotonated lactam 231 was alkylated 
with acrylonitrile and the resulting olefin hydrogenated, without purification, to produce amine 
232. The same reaction conditions were repeated to build diamine 233 in a similarly high yield. 
Transamidation was accomplished under strong basic conditions (using KAPA = potassium 3-
aminopropylamide), and was proposed to proceed through ring enlarged amide 234 (proceeding 
through 6-membered intermediate) instead of direct transamidation (proceeding through 10-
membered intermediate) with the primary amine. This was further supported by the synthesis 
of 17-membered lactam 234 and subjecting it to the same ring expansion conditions. This 
resulted in the same 21-membered macrocyclic product 235, in a similar yield that was obtained 
for the cascade double-ring expansion. This chemistry was not limited to two-consecutive ring 
expansions, and was shown to create many large macrocycles in a single step, often in higher 
yields than the discrete cyclisation of a linear precursor. This is exemplified by the impressive 
construction of 33- and 54-membered macrocyclic polyamines (236 and 237 respectively) shown 
in scheme 1.32.  
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Scheme 1.32: Typical 'zip reaction' forming polyamine macrocyclic lactams via cascade transamidation 
reactions by Hesse and co-workers. 
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Another example of the ‘zip reaction’ which proceeds under acidic conditions rather than the 
strongly basic conditions already established, features in the synthesis of desoxo-indandenine 
(which is part of the spermidine family of alkaloids).110 Starting from ketone 238, α-nitration was 
accomplished via initial formation of an enol acetate (not shown), to generate ketone 239. 
Conjugate addition of α-nitro ketone 239 in acrylaldehyde was performed in excellent yield, in 
the presence of PPh3, forming aldehyde 240. Reductive amination was then performed with the 
weak reducing agent sodium cyanoborohydride and triamine 241, forming ketone 242. An in-
situ ring expansion insertion reaction was then observed, with weakly basic conditions being 
used to improve yield of amide 243, resulting in isolation of the amide in 55% yield. Hydrolysis 
and reductive Nef reaction were performed to remove the nitro group, via ketone 244, followed 
by electrolysis of the tosyl groups forming diamine 246 in excellent yield. Treatment of the newly 
formed diamine with p-TSA, under reflux, formed a 1:1 equilibrium mixture of ring enlarged 
amide 247 and diamine starting material 246. This highlights the importance of there being a 
strong thermodynamic driving force to promote ring expansion, otherwise equilibrium mixtures 
can be obtained. The acyl transfer reaction between diamine 246 and ring expanded product 
247 has no overall change in functional groups, and both macrocyclic ringed systems should 
have very little ring strain and therefore both compounds should be very similar in energy, 
resulting in the observed equilibrium. In this case, once cooled and neutralised, the two 
compounds were separable and a modest yield of the 21-membered macrocycle was achieved, 
however this could not be generalised for all insertion reactions. 
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Scheme 1.33: Acidic 'zip reaction' of 21-membered macrocycle towards the synthesis of desoxo-
indandenine by Hesse and co-workers. 
Although they have less precedent than transamidation reactions, transesterifications reactions 
can be used sequentially towards the synthesis of macrocycles. This might be explained by the 
relative scarcity of polylactonic macrocycles found in Nature, compared to commonly found 
polyamide (peptidyl) macrocycles. Nevertheless, Corey and Nicolaou80 reported the use of 
sequential reversible transesterification reactions in the synthesis of macrocyclic lactone 256, 
with the thermodynamic driving force arising from the release of ring strain. Thus, acid 248 was 
coupled with pyridyl sulfide 249 to form thioester 250, followed by Grignard addition of aliphatic 
fragment 251, forming ketone 252 in excellent yield over the telescoped steps. Sodium 
borohydride reduction of the newly formed ketone, followed by silyl ether deprotection with 
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TBAF generated diol 254. Despite the potential release of ring strain, transesterification did not 
take place spontaneously and required stoichiometric p-TSA to promote the double insertion 
ring expansion (through 13-membered lactone 255) to form 15-membered diol 256.  
 
Scheme 1.34: Synthesis of macrocyclic lactone using sequential translactonisation reactions by Corey 
and Nicoloau. 
Seyden-Penne, Rousseau and Fouque111 have developed an iterative process to make ring 
enlarged lactones from commercially available smaller lactones. This work represents one of the 
first reports which is aimed at developing a multiple ring expansion route towards the synthesis 
of medium-sized rings and macrocycles. Hence, 7-membered lactone 257, was converted into 
labile trimethylsilyl enol ether 258 using an LDA/TMSCl protocol. Preformed carbenoid (from 
trichloroethane 259 and butyllithium) was engaged in cyclopropanation with the silyl enol ether 
258 to form fused bicyclic acetal 260. Upon heating, de-silylation occurred, instigating carbonyl 
formation and ring expansion. Release of ring strain and elimination of chloride as a stable 
leaving group act as both enthalpic and entropic driving forces, for the ring expansion reaction. 
α,β-Unsaturated ester 261 was formed in 81% yield over the telescoped two steps, which was 
followed by hydrogenation to form the ring enlarged lactone 262. The 5-step procedure can be 
iterated, to produce further ring enlarged lactones. This was demonstrated by two further ring 
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expansion iterations, which employed two different carbenoids, to form 9- and 10-membered 
medium-sized rings, 264 and 265 respectively. 
 
Scheme 1.35: Iterative ring expansion of lactones via cyclopropanation/expansion sequence by 
Seyden-Penne and co-workers. 
Prior to my arrival, the Unsworth group reported a proof-of-concept idea that utilises 
commercially available building blocks to construct macrocycles in a programmable and 
predictable fashion.112 This was based on the Successive Ring Expansion (SuRE) of β-ketoesters, 
using amino/hydroxy acid fragments to undergo a 3- or 4-atom insertion. The elegant two step 
procedure was telescoped, with no requirement to purify and isolate the intermediates and with 
no further functional group manipulation or modification required to complete the next ring 
enlargement iteration. Each step was synthetically facile and could be completed without 
cryogenic temperature control, inert atmosphere, elevated temperature/reflux conditions, 
Schlenk tubes or precious metal catalysts. Therefore, a wide variety of starting materials and 
linear fragments could be introduced and tolerated, with enantiomerically enriched macrocycles 
also being accessed.  
A representative example of this chemistry can be seen in scheme 1.36, where a triple ring 
expansion sequence was performed. Starting from 12-membered β-ketoester 266, which was 
itself made via a base mediated α-esterification of the 12-membered ketone, C-acylation with 
amino acid chloride 267 was achieved in excellent yield. The use of magnesium chloride was 
imperative in coordinating the two carbonyls present in the starting material to inhibit 
unproductive competing O-acylation. The tri-carbonyl species 268 was then subjected to basic 
conditions, cleaving the carbamate protecting group, forming primary amine 269 (although it 
was never previously observed). It was proposed that spontaneous cyclisation of the amine 
formed fused bi-cyclic species 270, which could then undergo subsequent ring expansion to β-
ketoester 271. Although all three species could exist in equilibria, only the desired ring expanded 
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product was observed and obtained in excellent isolated yield. The thermodynamic driving force 
for the reaction originates from the formation of a strong amide bond and conjugated β-
ketoester. The design of the reaction results in the regeneration of the key β-ketoester motif 
after each ring expansion iteration, and therefore in theory can be repeated indefinitely to 
generate macrocycles of any size. To prove this concept, the 16-membered ring enlarged β-
ketoester 271, was subjected to the same acylation with amino acid chloride/ring expansion 
procedure, forming 20-membered macrocycle 272 in 70% yield over both steps. This was 
repeated once again, to form 24-membered macrocycle tri-amide 273 from 20-membered 272 
in good yield. Importantly, all of these reactions do not require high dilution (each was 
performed at 0.1 M) and therefore are amenable to large scale synthesis, with 266 to 271 
performed on 20 mmol scale (approximately 5 g) with no considerable drop in yield.    
 
Scheme 1.36: An example of Successive Ring Expansion (SuRE) of β-ketoesters to form macrocyclic 
products by Unsworth and co-workers. 
Having established the concept, attention turned towards testing the range of ring sizes that 
could be accessed and the linear fragments that could be inserted, and it was found that this 
methodology works well on a range of systems, and despite the well-known difficulties of 
medium-sized ring synthesis, ring sizes of 9–16 members could be made in generally good yield. 
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N-Methylated linear fragments were tolerated well, forming 11-membered β-ketoester 278 in 
high yield, which should encourage the use of this methodology in the synthesis of N-methylated 
peptides, that can benefit from the so-called “magic methyl” effect.113 However, increasing the 
steric bulk of the N-substituent was noticed to lower the yield of the ring expanded product, as 
can be seen with benzylated-variant 281, despite none of the other equilibrium species being 
observed. Substituents can be introduced onto the backbone of linear fragment, with varying 
yields obtained, seen in 282 and 283. In addition to 4-atom insertion, α-amino acid derived linear 
fragments can also be introduced using this method in comparable yields. Alanine was shown 
to undergo insertion to make 10-membered ring 279, with a significant [α]D value showing that 
racemisation has not occurred. Using a similar strategy, an ester was produced (280) when 
benzyl protected hydroxy acid was utilised. Hydrogenolysis was performed to remove the benzyl 
group and induce spontaneous ring expansion. Although the exchange of one heteroatom for 
another may seem trivial, this example is important in providing access to macrocyclic lactones 
and may be one of the first examples of C-O bond forming insertion reaction that does not 
proceed via transesterification. Both C-N and C-O bond forming methodologies operate via 
similar key intermediates, and were shown to be compatible with each other (see proceeding 
section), therefore mixed lactone/lactam macrocyclic systems could be produced with this work.   
 
Scheme 1.37: Substrate scope for ring size and linear fragment within SuRE methodology. 
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A range of macrocycles were also synthesised in which two and three successive ring expansions 
were completed (seen in scheme 1.38). A series of ring sizes were made with different linear 
fragments inserted, including both α- and β-amino acids as well as examples with hydroxy acids. 
Yields for these examples dropped slightly, typically achieving 40–70% using the standard, 
unoptimised conditions. The loss in yield is accounted for during the acylation step, with some 
cyclic β-ketoester starting materials acylating slowly/inefficiently. It was proposed that the 
starting materials exist as less reactive conformers, hence slower acylation is observed. 
However, the starting material was recoverable, and therefore if desired could be re-subjected 
to the same reaction conditions to improve the corresponding yield. 
 
Scheme 1.38: Successive ring expansion methodology forming a diverse array of macrocycles. 
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1.3 Project Outline 
First, our aim was to extend the β-ketoester methodology by incorporating more α-amino acids 
into normal and medium-sized rings, which would produce more functionalised examples. The 
products molecular properties would then be analysed with respect to their medicinal interest, 
and manipulation of in-vivo labile functional groups would be performed. It was planned that 
hydroxy acid incorporation would be examined, making this new methodology compatible with 
varying ring size and linear fragment size. 
Second, we planned to study the viability of a simple lactam motif, as the regenerating 
functionality in the successive ring expansion reactions. Optimisation of both acylation and 
deprotection steps would be completed, to produce a small library of peptidiomimetic 
macrocycles and medium-sized rings. Significant interest was placed on making these peptide 
mimetics medicinally interesting, with the intention to incorporate a wider range of α-amino 
acids than has been achieved previously. 
Finally, an examination of whether hydroxy acids were compatible with the lactam motif, which 
would produce a range of mixed lactam/lactone systems, was planned. Some natural products 
(i.e. cyclodepsipeptides) were identified which contain both ester and amide functionalities, and 


















Chapter Two: Extension of β-Ketoester Methodology 
 
55 | P a g e  
 
Chapter Two: Extension of β-Ketoester Methodology 
2.1 Previous work on β-ketoester methodology 
Upon arriving in York, I joined a project close to the end of completion, with the target of 
synthesising medicinally interesting medium-sized ringed lactams with the β-ketoester motif 
(scheme 2.1). From previous studies in the group, it was found that β-amino acids (296, m = 2) 
worked well with many different ring sizes and substitution patterns. However, when the natural 
α-amino acids were utilised (296, m = 1), the reactions often produced poorer yields or failed to 
acylate at all. My first task was to address the gaps in the substrate scope with respect to the 
amino acid partner. 
 
Scheme 2.1: General scheme for β-ketoester successive ring expansion with amino acid chlorides. 
2.2 Oxazolone/Oxazinone Formation 
Within peptide chemistry, synthesising the sequence of amino acids often proceeds through a 
two-step addition/deprotection sequence (commonly on a solid support using SPPS – see 
section 1.2.4). One such strategy activates the C-terminus of the nascent peptide, which is then 
reacted with an amino acid derivative in an amidation reaction. When an acid chloride 299 is 
utilised, base-mediated intramolecular cyclisation can occur and form an undesired oxazolone 
intermediate 300.114 This is a major disadvantage, as it is a non-productive pathway and can lead 
to racemisation (300 → 302) of the peptide chain. We believed that this pathway may have been 
occurring with the carbamate protected α-amino acid chlorides 296, as the same pathway was 
shown to exist in N-acyl α-amino acid chlorides, and hence leading to unwanted consumption 
of the acid chloride.115 Oxazolone 300 was never isolated to prove this, however the 
corresponding 6-membered heterocycle (oxazinone) 305 was isolated in high yield, 
demonstrating that this type of process is viable. 
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Scheme 2.2: Oxazolone formation/racemisation pathway in peptide chemistry and 6-membered 
lactone isolated. 
2.3 Ring Expansion of β-Ketoester to form medium-sized rings and macrocycles 
In an attempt to combat this problem, three additional equivalents of acid chloride were utilised 
in ring expansion reactions, where poor acylation of the β-ketoester had been observed. This 
improvement, led to an additional 4 examples of ring expanded products being formed that 
were previously unsuccessful. Branched β-amino acid examples 310–312 were obtained in 
modest yields (50–65%). All examples were synthesised using racemic building blocks (with 
exception to the achiral glycine derivative 309), however previous work has shown that 
enantioenriched examples can be produced. 
 
Scheme 2.3: Ring expanded products formed by the insertion of amino acids into cyclic β-ketoesters. 
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Most of the ring expansion reactions on these cyclic β-ketoesters, proceeded as planned with 
no observable side-products and only minor/no alterations to the standard conditions. 
However, two examples differed from the desired reaction pathway, producing two separate 
side-products. First, 7-membered β-ketoester 313, was C-acylated under the normal reactions 
conditions with leucine derived amino acid chloride 314 to form tri-carbonyl species (not 
shown). However, upon piperidine induced cleavage of the Fmoc protecting group (which 
should spontaneously undergo cyclisation/ring expansion) only small amounts of ring expanded 
product 315 were isolated. Instead, bi-cyclic imine 316 was isolated and found to be stable 
towards both acidic and basic hydrolysis. We proposed that the transition state/product must 
experience significant transannular steric repulsion with the large iso-butyl group, increasing the 
relative energy, therefore rendering this pathway less favourable. Second, 6-membered N-
benzylpiperidine β-ketoester 317 was C-acylated with amino acid chloride 267 forming the 
corresponding tri-carbonyl species. Again, upon Fmoc cleavage conditions, the desired ring 
expanded product was not produced. Ring expansion did occur, however a condensation 
reaction took place between piperidine and the newly formed ketone, to form enamine 319 (this 
work was completed by Morgan Manning). 
 
Scheme 2.4: Uncommon examples of side-product formed during ring expansion. 
2.3.1 Synthesis of Cyclic β-Ketoester Starting Materials 
Whilst 5–7-membered cyclic β-ketoester starting materials were easily available from 
commercial sources, 8-membered cyclic β-ketoesters (and higher) are not, hence a reliable and 
scalable route to prepare these starting materials was needed. Therefore, starting from the 
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corresponding ketone 320 two different literature procedures were found to access cyclic β-
ketoesters, which could be utilised in successive ring expansion. In one of these methods, 
deprotonation of a cyclic ketone 320 using sodium hydride formed sodium-enolate 321 and was 
followed by diethyl carbonate addition, generating the product in typical yields of ≥90% on 
multigram scale.112 An alternative homologation approach was also found,116 which increased 
the ring size by a single carbon atom and incorporated the ester in one transformation; thus, 
Lewis acid catalysed addition of ethyl diazoacetate 322 into a cyclic ketone 320, formed 
tetrahedral intermediate 323 and through a migration/elimination formed ring-enlarged β-
ketoester product 324 (scheme 2.5).  
 
Scheme 2.5: Synthesis of cyclic β-ketoesters via two separate methods. 
We realised that the medium-sized ring β-ketoesters in which the required cyclic ketones were 
not commercially available could be synthesised using the ethyl diazoacetate homologation 
pathway. Starting with cyclooctanone 325, homologation to 9-membered β-ketoester 326 
proceeded in high yield even on multigram scale (up to 9.8 g was made and purified in a single 
batch). Using reagent grade DMSO (which contains a small amount of water), ester hydrolysis 
and subsequent decarboxylation was completed in a single pot to form the 9-membered ketone 
327 in excellent yield. This two-step procedure was iterated to form the 10-membered ketone 
(329 – ketones were also used in Beckmann rearrangements described later in section 3.5) as 
well as the corresponding β-ketoesters 328 and 330 in good/excellent yield. 
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Scheme 2.6: Synthesis of medium-sized cyclic β-ketoester starting materials from 
homologation/hydrolysis pathway. 
2.3.2 Synthesis of Macrocyclic β-Ketoesters with Medium-Sized Rings  
Having gained accessed to the medium-sized ring starting materials, we then wanted to utilise 
these in ring expansion reactions to produce novel macrocyclic products. Therefore, using 
standard conditions, C-acylation of cyclic β-ketoesters, similar to 331, formed tri-carbonyl 
species 332 followed by protecting group cleavage/ring expansion delivering macrocyclic 
products 333. Pleasingly, 13- , 14- and 15-membered macrocyclic β-ketoesters were indeed 
formed 334–336 in 52–74% yields with β-amino acid derivative 267, with no appreciable side-
product formation.      
 
Scheme 2.7: Synthesis of macrocyclic ring expanded β-ketoesters from non-commercial medium-sized 
rings. 
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At this point, it is noteworthy to state that while all the ring-expanded products were pure 
compounds, they commonly existed in CDCl3 as an equilibrating mixture of both keto- and enol 
tautomers, as well as being rotameric about the amide bond at room temperature. Therefore, 
up to four isomers (336a–336d) can be seen in the 1H and 13C NMR spectra for each ring 
expanded product. The observed mixture of isomers is temperature, solvent and concentration 
dependant, and thus it is common that only the major constituent is fully characterised with 
diagnostic resonances in both 1H and 13C NMR spectra highlighting the presence of any of the 
isomers. Typically, secondary amides did not exhibit rotameric conformations and in the 
medium-sized rings, but keto-enol tautomerisation was more prominent (presumably to reduce 
ring strain).   
 
Scheme 2.8: Rotamers and keto/enol tautomers shown for a single ring expanded example. 
 
With a small library of medium-sized rings having been prepared (30 compounds), the 
physiochemical and spatial properties were analysed using an open-access computational tool 
called LLAMA.117 This program judges the ‘lead-likeliness’ of molecules based on: lipophilicity, 
functional groups, heavy atoms, the presence of aromatic rings and molecular weight. This is 
commonly in accordance to Lipinski’s rules118 (which has been previously discussed in section 
1.1). LLAMA is also able to predict the three-dimensional spatial properties of molecules using 
the principal moments of inertia method (PMI).119 All the ring expanded products contained the 
metabolically labile β-ketoester moiety and therefore were unlikely to be medicinally applicable 
in their own right. However, these compounds could be useful within the context of fragment-
based drug discovery, in which additional synthetic steps could be completed to afford a suitable 
lead compound. Therefore, starting from ring expanded product 337, ester hydrolysis followed 
Chapter Two: Extension of β-Ketoester Methodology 
 
61 | P a g e  
 
by decarboxylation afforded ketone 338 in excellent yield. The ketone undergoes facile 
reductive amination to form secondary amines 339 and 340 which were amenable to 
sulfonylation, acetylation and amide alkylation producing medicinally interesting compounds 
341, 342 and 343 (scheme 2.9, these reactions were completed by Laetitia Baud and Morgan 
Manning). Therefore, a hydrolysis/decarboxylation procedure was completed virtually on the 
entire library, and allowing a single transformation from the ketones produced, a virtual library 
of 402 compounds was generated. Of the virtual library, 200 compounds were found to lie within 
‘lead-like’ space, with favourable molecular properties. 
   
Scheme 2.9: Further synthetic modifications used in virtual library enumerations. 
2.3.3 Synthesis of Lactones using Ring Expansion of β-Ketoesters 
Next, we turned our attention to the C-O bond forming variant of this ring expansion, which had 
been previously reported with only two examples. The approach is based on acylation with a 
benzyl protected hydroxy acid chloride 344, under otherwise identical acylation conditions to 
those used for the amino acid reactions, to form a tri-carbonyl species 345. Under 
hydrogenolysis conditions, which we predicted could be optimised and improved, cleavage of 
the benzyl group would occur unveiling the primary alcohol. A systematic study could then probe 
the effects of ring size upon the position of equilibrium between the three isomeric species 346, 
347 and 348.   
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Scheme 2.10: Hydroxy acid methodology, showing three isomers that could be in solution. 
To complete this study, a large-scale synthesis of the corresponding hydroxy acid 351 was 
required. Using literature procedure,120 β-propiolactone 349 was reacted with benzyl alcohol 
350 under neat conditions, affording the desired product in excellent yield directly in a single 
step. 
 
Scheme 2.11: Synthesis of benzyl protected β-hydroxy acid. 
With the desired starting materials in-hand, C-acylation was completed to produce tri-carbonyl 
species 345 with various ring sizes. Table 2.1 shows the results obtained from brief optimisation 
of the hydrogenolysis conditions. Entry 1 was a repeat of the example reported previously and 
resulted in an identical yield. However, when these conditions were used on the 5-membered 
β-ketoester (entry 2), no diagnostic 1H NMR resonances were observed for any of the three 
isomers. Changing the palladium catalyst (entry 3), had no effect on product formation. This led 
us to change the solvent, and implement a shorter reaction time to achieve our optimised 
conditions (entry 5). However, these conditions still led to the formation of all three isomeric 
forms and it was desirable that only the ring expanded product was produced. Pleasingly, a 
solvent switch to chloroform and the addition of triethylamine as a base was sufficient to drive 
the equilibrium to form only ring expanded product 348. Although this did add a further step, 
the shorter hydrogenolysis time, higher yields and production of a single product (in the same 
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Entry Ring Size Hydrogenolysis conditions Yield 
1 7 → 11 Pd(OH)2/C, MeOH, r.t., 16 h 59% 
2 5 → 9 Pd(OH)2/C, MeOH, r.t., 16 h 0% 
3 5 → 9 Pd/C, MeOH, r.t., 16 h 0% 
4 5 → 9 Pd/C, EtOAc, r.t., 16 h trace 
5 5 → 9 Pd/C, EtOAc, r.t., 4 h 90% 
Table 2.1: Optimisation of hydrogenolysis conditions within ring expansion of β-ketoesters. Yields 
based on analysis by 1H NMR and comparison with signals for 1,3,5-trimethoxybenzene that was used 
as an internal standard.  
Having established reliable conditions, testing the viability of this methodology on different ring 
sizes was performed. Therefore 5-membered to 8-membered β-ketoesters were subjected to 
the three-step procedure with the results shown in scheme 2.12. All examples proceeded to 
exclusively form the ring expanded products, with the yield determined from the success of the 
acylation step. These results are more significant when considering the ring strain of the 
medium-sized rings products (352, 353 and 280), which demonstrates that the systems have a 
large thermodynamic driving force for ring expansion. We propose that the favourable 
thermodynamic driving force for these challenging transformations originates from the 
formation of a new lactone, and entropic drive from the loss of toluene in the hydrogenolysis 
step. For each example, all three isomers were observed after hydrogenolysis in the 1H NMR 
spectra (via diagnostic resonances) although accurate ratios were not possible to calculate due 
to similar chemical shifts resulting in overlapping resonances. Interestingly, these intermediates 
were never identified when inserting amino acids, as spontaneous ring expansion occurred.  
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Scheme 2.12: Synthesis of ring expanded lactone products using C-O forming SuRE process. 
 
2.4 Chapter Summary 
Previously inaccessible cyclic β-ketoesters have been prepared, which could then be ring 
expanded using the developed SuRE methodology to make novel medium-sized rings and 
macrocycles. Other challenging α- and β-amino acid derivatives have been incorporated into 
cyclic β-ketoesters, in an attempt to make the ring enlarged products more medicinally 
interesting. Hydroxy acid derivatives have also been investigated, improving the ring size scope 
by modifying the hydrogenolysis conditions used previously, hence generating novel lactone 
containing ring expanded products.  
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Chapter Three: Successive Ring Expansion of Lactams 
3.1 Lactam SuRE Concept 
Taking inspiration from the β-ketoester work and some aspects of the amino acid incorporation 
(AAI) reaction (of which a large contribution was made by Shemyakin and co-workers84,87), we 
wanted to change the functionality which was regenerated after each ring expansion. We felt 
that although there was a clear thermodynamic driving force for ring expansion in the cyclic β-
ketoester methodology, which was clearly borne out in the experimental results, the final 
products were not directly medicinally relevant due to the metabolic instability of the key β-
ketoester motif; as seen in section 2.3, additional synthetic steps were required to modify the 
products to achieve appropriate molecular properties for medicinally relevant compounds.  
Therefore, we endeavoured to develop a new SuRE procedure that generates medicinally 
relevant ring expanded products directly. We believed that by starting with a simple lactam, this 
could be achieved, to produce cyclic peptide mimetics following amino acid incorporation. Thus, 
if a cyclic lactam 355 could be N-acylated with amino acid chloride 356, then an imide 
intermediate 357 would be produced and following deprotection, we hoped that spontaneous 
ring expansion (358 → 360) would occur. The integral NH lactam motif would be regenerated 
upon ring expansion, and therefore we would be able to apply multiple successive ring 
expansions on these simple compounds. 
 
Scheme 3.1: Concept of the synthesis of di-peptides when using lactam as cyclic starting unit. 
3.2 Preliminary Results and Optimisation 
Starting from 13-membered lactam 361 N-acylation was achieved, with modified conditions 
based on the earlier β-ketoester work (importantly the addition of DMAP), forming imide 362 in 
excellent yield. This imide is stable to column chromatography, however we found that 
improved yields were obtained if the acylation and deprotection/ring expansion steps were 
telescoped. Therefore, crude imide 362 was reacted with piperidine to induce Fmoc cleavage, 
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which was followed by spontaneous ring expansion to afford the desired lactam product 365 in 
excellent yield (scheme 3.2), proving that lactams can be used in these type of ring expansion 
reactions. 
 
Scheme 3.2: Proof-of-concept ring expansion of 13-membered lactam with an amino acid chloride. 
In order to develop a system whereby predictable multiple ring expansions can take place 
sequentially, it was preferable that only a single secondary lactam be present in the molecule. 
In the 17-membered ring expanded lactam 365 (scheme 3.2), there are two NH lactam motifs, 
which was predicted to be a problem in subsequent N-acylation reactions. This problem can be 
circumvented by using a secondary protected amine which would result in the formation of a 
new tertiary amide which can therefore not acylate.  
Thus, if amino acid chlorides, of type 356 (scheme 3.3), were utilised then new ring expanded 
products, 367, would be produced which are better suited for further ring expansion iterations. 
Using a methylated variant, the ring expanded product 368 was formed in excellent yield, 
however extending this to the benzyl variant was surprisingly poor yielding, with only obtaining 
5% of the desired macrocyclic product 369 being isolated. We felt that the benzyl variant was 
more interesting, as once the ring expansion sequence had been completed, hydrogenolysis of 
the benzyl groups would be possible. We therefore felt that this problem must be overcome, 
and reasoned that the loss in yield may be due to the deprotection/ring expansion step, based 
on the isolation of degradation products.  
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Scheme 3.3: Ring expansion of 13-membered lactam with secondary protected amino acid chlorides. 
A piperidine induced imide cleavage appeared to be a competing side reaction, whereby after 
initial Fmoc deprotection, piperidine attacks the exocyclic carbonyl of the imide. This pathway 
was confirmed by the isolation and characterisation of the 13-membered lactam 361 by 1H NMR, 
despite starting with purified imide precursor. Presumably, this cleavage only becomes 
prevalent when the cyclisation/ring expansion of the secondary amine is slow. When the N-
methyl variant was utilised, presumably the cyclisation/expansion kinetics are more similar to a 
primary amine example, in which an excellent yield was obtained. 
 
Scheme 3.4: Piperidine induced imide cleavage mechanism. 
Piperidine is used very commonly for Fmoc cleavage within peptide coupling reactions and, in 
this context, its nucleophilicity is often an advantage. Piperidine is typically used in large excess 
during Fmoc deprotection of the N-terminus. As seen in scheme 3.5, piperidine initially 
deprotonates the ‘acidic’ proton from the Fmoc protecting group (which can form an anionic 
aromatic species in polar aprotic solvent such as DMF, not shown) which then causes elimination 
and decarboxylation to form the desired amine 373 in addition to the dibenzofulvene (DBF) side 
product 374. If additional equivalents of piperdine are present, then a conjugate addition can 
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take place and form piperidine adduct 375 (pathway 2), which can be then be removed. 
However, if all the piperidine is consumed (or a tertiary or non-nucleophilic base is employed) 
in the deprotection step, then the liberated amine can itself undergo conjugate addition with 
the DBF (pathway 1) in an unproductive pathway forming amine adduct 376. In SPPS, this DBF 
side product is then washed away.   
 
Scheme 3.5: Fmoc deprotection and Michael addition into dibenzofulvene mechanism. 
In our work, the liberated amine is consumed within a ring expansion reaction and therefore it 
may be that alternative non-nucleophilic bases could be utilised which would not normally be 
suitable in peptide coupling. Therefore, optimisation of the base and solvent for 
deprotection/ring expansion step were undertaken from a purified sample of the acylated 
intermediate 377. Similar to the β-ketoester work, we did not observe either 370 or 378 isomers 
by 1H NMR and therefore proceeded to optimise through isolated yield of the desired 
macrocycle 369. These optimisations are summarised in table 3.1, which shows that the use of 
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Entry Conditions Yield of 369 
1 Piperidine (10 equiv), CH2Cl2, 4 h, 30 °C 0% 
2 20% Piperidine in DMF (v/v), 18 h, r.t. 6% 
3 20% NEt3 in DMF (v/v), 5 h, r.t. 0% 
4 TBAF (0.1 M), DMF, 4 h, r.t. 0% 
5 DBU (10 equiv), DMF, 5 h, r.t. 46% 
6 DBU (10 equiv), CH2Cl2, 18 h, r.t. 91% 
Table 3.1: Optimisation results for deprotection/ring expansion step using N,N-Bn,Fmoc-β-alanine 
amino acid chloride. 
With optimised conditions in hand, the N,N-Bn,Fmoc-β-alanine amino acid 381 was produced 
on gram scale using the following two step procedure from a literature procedure122 (scheme 
3.6). Starting from commercially available amino ester 379, hydrolysis using lithium hydroxide 
formed amino acid as lithium carboxylate 380. Without purification, Fmoc protection was 
achieved under Schotten-Baumann conditions to produce the desired protected amino acid 381 
in excellent yield on multi-gram scale. 
 
Scheme 3.6: Synthesis of N,N-Bn,Fmoc-B-alanine amino acid starting material. 
3.3 Protecting Group Scope 
Having achieved optimised conditions for the telescoped acyation/deprotection sequence using 
an Fmoc protecting group, other orthogonal protecting groups were investigated. We proposed 
that Cbz would work well with our chemistry, with deprotection occurring under hydrogenolysis 
conditions. Therefore, the Cbz-β-amino acids (383 and 385, scheme 3.7) were synthesised on 
gram scale in excellent yield.   
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Scheme 3.7: Synthesis of Cbz-protected β-amino acids for protecting group scope testing. 
With the Cbz-protected amino acid starting materials 383 and 385 in-hand, they were tested 
within the standard acylation conditions and pleasingly the corresponding imide was formed in 
quantitative conversion. In order to remove the Cbz protecting group, hydrogenolysis with Pd/C 
in ethyl acetate was performed, using similar conditions to those used in the β-ketoester 
methodology (see Chapter 2). We found that when benzyl β-amino acid chloride 386 was used, 
two ring expanded products were formed (365 and 369, scheme 3.8) with significant amounts 
of amide debenzylation occurring. Although in this case, this was an undesired pathway, this 
result supported our previous hypothesis that if benzyl amides were synthesised, they could be 
removed if required using hydrogenolysis. When the similar methyl β-amino acid chloride 387 
was utilised, the 17-membered lactam 368 was exclusively formed in excellent yield, proving 
that the Cbz protecting group can be utilised successfully.  
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Scheme 3.8: Formation of ring expanded macrocycles using Cbz protecting group. 
3.4 Successive Ring Expansion Proof-Of-Concept 
With two separate protecting group strategies, we went on to test if the reactions could be 
performed successively with the regenerating lactam motif. Although Cbz protection worked 
well, it was decided to prioritise the previous Fmoc protecting group strategy as it was higher 
yielding and allowed the use of N-benzyl amino acids, meaning that after ring expansion, the 
amides would be amenable to hydrogenolysis.  
First, 17-membered lactam 369 was produced using the standard conditions in excellent overall 
yield (scheme 3.9). As the product contains only a single secondary amide, it could then be re-
subjected to our ring expansion sequence with expectation of a selective N-acylation reaction, 
and pleasingly the 21-membered macrocycle 389 was isolated in excellent yield over the 
telescoped two step protocol. This example proved our design concept is viable, and further, we 
were able to complete a third ring expansion, producing 25-membered macrocycle 390 in 77% 
yield over the two steps. This methodology should be useful in the synthesis of medium-sized 
rings and macrocycles, with a large amount of complexity being introduced to the 25-membered 
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macrocycle 390 in only three iterations of our ring expansion procedure, from the commercially 
available 13-membered lactam 361. 
 
Scheme 3.9: Proof-Of-Concept Successive Ring Expansion examples forming 17- , 21- and 25-
membered macrocycles. 
3.5 Ring Size Scope 
3.5.1 Synthesis of Starting Materials 
Having successfully established this new SuRE reaction system, it was important to demonstrate 
that different ring sizes could be produced using the methodology. Therefore, we set about 
examining the effect of ring size on the chemistry, and whether medium-sized rings could be 
synthesised using this methodology. However, despite their simplicity, 9–12-membered lactams 
394–397 are not commercially available and therefore a route to access them was designed. 
Fortunately, from the previous β-ketoester methodology (see Chapter 2), the corresponding 
Chapter Three: Successive Ring Expansion of Lactams 
 
73 | P a g e  
 
ketones had already been prepared on gram scale and thus could be transformed into lactams 
using a Beckmann rearrangement. Thus, using a single step, ketones 391 were condensed with 
hydroxylamine-O-sulfonic acid 392 (HOSA), and treated with formic acid under reflux conditions 
to afford the desired lactam, via a Beckmann rearrangement (scheme 3.10). All lactams 394–
397 were produced in high to excellent yield, following purification by a series of aqueous work 
ups and column chromatography. 
 
Scheme 3.10: Synthesis of medium-sized ringed lactams using Beckmann rearrangements. 
3.5.2 Ring Expansion  
With the required lactam starting materials in hand, an examination of how ring size effects the 
ring expansion reaction was conducted. Using β-amino acid chloride 388, 6–13-membered 
lactams were acylated and ring expanded successfully. All ring expanded products were formed 
clearly, with no observation of other isomers or unwanted side-products. Medium-sized rings 
400 and 401 were slightly lower in yield, which we believe is simply as a result of their high 
polarity making the products more difficult to purify.  
The rings 400–402 also displayed very interesting 1H NMR spectra with diastereotopic protons 
throughout the ring system (figure 3.2). A crystal structure of the 10-membered ring enlarged 
compound 400 was taken (see figure 3.1) which shows a Z-,E-diamide configuration which 
causes a twisting in the ring, which might be causing this inequivalence in the proton 
environments. However, another explanation arises from the conformation of the ring.  As the 
ring is strained (due to transannular strain in medium-sized rings), a single conformation which 
is significantly more thermodynamically stable than others, may exist which orientates its 
protons into non-equivalent axial and equatorial environments. Variable temperature NMR was 
performed in deuterated d6-DMSO up to 140 °C, and at elevated temperature the 
diastereotopicity was resolved, however only broad resonances were obtained (see figure 3.3). 
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14-membered macrocycle 404 was also synthesised on gram scale with no appreciable loss of 
yield, highlighting the scalability of this reaction.  
 
Scheme 3.11: Ring size scope of ring expansion producing 10- to 17-membered rings. 
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Figure 3.2: 1H NMR of 10-membered ring expanded product 400 at room temperature in CDCl3, which 
exists as a mixture of rotamers. 






























































































































































































































































































































































Figure 3.3: 1H NMR of 10-membered ring expanded product 400 at 100° C in d6-DMSO. 
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3.5.3 Four and Five Membered Lactam Examples 
The ring size scope was extended to the smaller four- and five-membered lactams, however we 
encountered difficulties in determining the reaction outcome. The 4-membered lactam (β-
lactam) was successfully N-acylated, however, when performing the deprotection/ring 
expansion step, we believe that the 8-membered enlarged product was formed based on 
diagnostic resonances in the 1H NMR (in comparison with the product formed later), but was 
too polar to separate from the excess DBU via column chromatography. The 5-membered 
lactam was also studied with successful acylation producing the corresponding imide, however 
upon deprotection no product was observed.  
To address this, we decided to use the Cbz protecting group instead, as this would allow us to 
better understand where the reaction was halting, because column chromatography is not 
usually required. Therefore both lactams were acylated with N,N-Me,Cbz-β-alanine 387, which 
produced their corresponding imides 409 and 412 (scheme 3.12). These imides were purified 
using a silica plug to remove the excess pyridine and amino acid residues. It was important that 
these amine-based residues were removed from the crude mixture, as they would likely have a 
high affinity for the palladium catalyst used in the hydrogenolysis step, and could therefore 
poison the catalyst. The 4-membered imide 409 successfully produced the 8-membered ring 
enlarged medium-sized ring 410 in a good overall yield of 61%. However, the 5-membered imide 
412 did not produce the corresponding ring expanded product, and instead produced fused 
bicyclic N,N-acetal 413 in excellent yield. This was a new reaction pathway which had not been 
previously observed, and surprisingly this relatively simple compounds were novel.  
 
Scheme 3.12: Using a Cbz protecting group strategy to synthesis medium-sized rings previously unsuccessful 
when Fmoc was used. 
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We wanted to understand the mechanism in which this N,N-acetal 413 was being formed. We 
propose the following reaction pathway, seen in scheme 3.13. Initially hydrogenolysis of the Cbz 
protecting group occurs producing amine 414. The liberated amine spontaneously cyclises onto 
the endocyclic carbonyl forming the fused hemi-aminal 415. This can be followed by dehydration 
to form iminium ion 416. This iminium ion is stabilised as another resonance form can be drawn 
as an N-acyl iminium 417. The iminium is then reduced to the N,N-acetal 413 as the reaction is 
still under reducing conditions.  
 
Scheme 3.13: Formation of N,N-acetal 413 from 5-membered lactam using a Cbz protection strategy. 
3.5.4 Benzannulated Ring Size Scope 
In order to increase the diversity and structural complexity of the products, different sized 
benzannulated lactams were also tested. The focus was on producing more medicinally 
interesting ring expanded products, which may have more favourable molecular properties than 
those produced previously. Introducing the benzannulated motif in the backbone also reduced 
the polarity of the products which also aided in the purification of these compounds. Thus, 5- , 
6- and 7-membered benzannulated systems were tested with the results shown in scheme 3.14. 
All examples acylated (with varying amounts of conversion), however both 419 and 423 were 
not successfully produced. However pleasingly, 10- and 11-membered products 420 and 421 
produced the ring expanded products in useable and high yields. The poorer yielding 10-
membered example suffered from poor acylation, with a significant amount of starting material 
being recovered and therefore with small reaction optimisation, we are confident that this yield 
could be improved significantly.     
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Scheme 3.14: Synthesis of various sized benzannulated ring expanded products. 
3.6 Amino Acid Scope 
With the ring size scope extensively studied, we turned our attention to varying the linear 
fragment that is introduced during the ring expansion. Two points of diversification were 
highlighted: the addition of a group onto the α-carbon of an amino acid and substitution onto 
the nitrogen of the amino acid. Initially, we examined placing substituents onto the nitrogen, 
which would create cyclic peptoid mimetics upon ring expansion. Peptoids are a class of 
peptidiomimetics, in which the amino acid side chain is transposed onto the nitrogen, and can 
have increased binding affinity compared to the analogous peptides, hence currently there is 
significant interest in installing peptoid fragments into large ring systems.123,124 
3.6.1 Peptoid-Based Amino Acids 
First, we made the peptoid amino acids via a three-step sequence, inspired by how peptoids are 
made on solid support.125 Ethyl bromoacetate 424 was treated with excess equivalents of a 
commercially available primary amine to form an amino ester. Ester hydrolysis was then 
completed using lithium hydroxide to form the lithium carboxylate 425. Schotten-Baumann 
reaction conditions126 for Fmoc protection produced the desired protected amino acid linear 
fragments 426. This sequence could be performed on gram scale if required. The analogous 
proteinogenic amino acid three letter code is given in brackets underneath the corresponding 
compound (synthesis of these amino acid starting materials was completed by Dr. Mahendar 
Lodi).    
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Scheme 3.15: Synthesis of peptoid amino acid linear fragments via three step procedure. 
With the desired linear fragments in-hand, their use within the ring expansion chemistry was 
tested. All linear fragments were successfully acylated and ring expanded using the standard 
conditions with no modification to the procedure. All examples produced the cyclic peptoids 
433–436 in excellent yields with no variation in yields, despite some sterically demanding groups 
being introduced (such as iso-propyl and iso-butyl groups). There has been significantly more 
work (by another PhD student in the group) based on producing these cyclic peptidiomimetic 
compounds, introducing far more complexity and different functional groups which these 
aliphatic side chains do not possess.121 
 
Scheme 3.16: Synthesis of cyclic peptidiomimetic macrocycles using standard ring expansion 
conditions. 
3.6.2 Amino acids 
With the success of incorporating the simple peptoid amino acids, we believed that introducing 
the linear fragment based on proteinogenic amino acids would also be equally viable. There was 
literature procedure to synthesise N,N-Bn,Boc amino acids from the parent unprotected amino 
acid,127 and we believed that this could be easily modified to incorporate the Fmoc protecting 
group instead. Therefore, the amino acid 437 was initially treated with benzaldehyde to form 
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the imine, which was then reduced using sodium borohydride to form the secondary amine 441. 
Due to the zwitterionic nature of the starting material and product, the reaction had to be 
completed in a bi-phasic mixture of THF and water, which did produce some reproducibility 
problems (only in this reductive amination step) when scaling this reaction. On account of the 
reaction being conducted via portionwise addition of reagents, a side product where reductive 
amination occurred twice produced dibenzyl amino acid 439 (scheme 3.17). As a result, the 
commercially available Fmoc amino acid 440, was also observed and isolated. We believe that 
this was because of inefficient mixing of the organic and aqueous phases, which was not a 
problem with the smaller volumes conducted previously. The desired protected amino acid 438 
was purified and the ratio of 438:439:440 was not calculated. 
 
Scheme 3.17: Side-products in the large scale synthesis of N,N-Bn,Fmoc amino acids, during the 
reductive amination step. 
With the amino acid derivative 441 (scheme 3.18) from the reductive amination step, Schotten 
Baumann conditions were utilised for Fmoc protection and was very reliable procedure at this 
point. Amino acids with aliphatic/lipophilic side chains were successfully produced in good 
yields, with glycine (442), alanine (443), phenylalanine (444) and leucine (445) all being produced 
with little problem. The methionine derivative 446 was also synthesised and we extended this 
methodology to create a tryptophan example (447). The synthetic steps used to produce these 
protected amino acids should not epimerise the stereogenic centre, which allowed us to make 
enantioenriched amino acid linear fragments, when we utilised the enantioenriched amino acid 
starting materials (depending on commercial availability of the parent amino acid). The [α]D 
value measured was always significantly large, illustrating that a racemic sample was not 
produced. 
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Scheme 3.18: Synthesis of N,N-Bn,Fmoc amino acids using reductive amination/protection sequence. 
Having successfully made the derivatised amino acids (and obtaining some commercially 
available suitable amino acids), we then investigated the viability of these starting materials in 
the ring expansion chemistry. All amino acids that had been synthesised were successfully 
incorporated into the lactam starting material, producing a range of cyclic peptide-based 
medium-sized rings and macrocycles. As a general note, the yields are usually determined by 
the efficiency of the N-acylation step and when acid sensitive functionality such as indole 
(tryptophan - 447) and sulfide (methionine - 446) were incorporated, a significant drop in yield 
was observed. Although a few yields were modest, the production of these macrocyclic 
compounds via a head-to-tail cyclisation of the corresponding linear precursor would likely be 
difficult. There appeared to be some more dependence of the yield obtained and the size of the 
side-chain of the amino acid. When small side chains such as alanine (450), phenylalanine (451 
and 452) or the unnatural straight-chained norleucine (453) were used, good yields were 
obtained. However, when the steric demand was increased such as leucine (454) the yield 
decreased fairly significantly. We believe that this is again due to a slower acylation and that 
deviation from using the standard conditions may offer improvements in the future. Pleasingly, 
a series of examples (456–458) were produced which incorporated proline as the linear 
fragment. Both medium-sized ringed and macrocyclic compounds were created in excellent 
yield, showing good generality. 
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Scheme 3.19: The synthesis of medium-sized and macrocyclic compounds via ring expansion. 
3.7 Successive Ring Expansion 
Attention then turned towards making macrocycles based on successive ring expansions. We 
aimed to make macrocycles of varying ring size, by incorporating different linear fragments in 
various orders. Initially, there was little success with multiple examples failing to acylate, 
presumably due to unreactive conformations, arising from rotamers, being the lowest in energy. 
However, a general trend developed, that ‘smaller’ sized rings (ranging from 10- to 14-
membered) typically did acylate well, under the standard conditions previously optimised. This 
led to successful examples (389–469, scheme 3.20) introducing both natural and unnatural 
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amino acids, with varying ring sizes, all with high to excellent yields. Larger ring sizes, such as the 
21-membered macrocycle 468, were accessed, however the yield was lower than hoped.  
Therefore, the reactions were carefully monitored by TLC and if required, additional equivalents 
of the acid chlorides were used to help improve the yields obtained, as the yields are almost 
exclusively determined by the conversion during the acylation step. We found that this 
significantly bolstered the yields obtained, with very similar 21-membered macrocycle 389 being 
obtained in a much improved 81% yield. 
The methodology was then extended to perform three ring expansion reactions in succession, 
to form 25-membered peptide trimer 390. An excellent yield was obtained over the same 
telescoped two-step procedure, and importantly no degradation of the starting materials was 
observed. Thus, fairly complex macrocycles, which would be difficult to synthesise via a 
traditional end-to-end cyclisation of a linear precursor, can be made reliably via the successive 
ring expansion strategy. Although the same amino acid was utilised in each ring expansion step, 
this was a controlled series of ring expansions, opposed to an uncontrolled polymerisation-type 
ring expansion reaction. We believe that different amino acids could be used, and therefore a 
diverse array of macrocycles can be accessed using this methodology. This work has led to 
further projects in the group, incorporating more medicinally relevant amino acids and peptoid 
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Scheme 3.20: Synthesis of peptidiomimetic macrocycles by the use of successive ring expansions with 
amino acid fragments. *Additional equivalents of the corresponding amino acid chloride were utilised 
in the N-acylation step. Conditions A: a) Pyridine, DMAP, CH2Cl2, 50 °C, 18 h. b) DBU, CH2Cl2, r.t., 18 h. 
3.8 Chapter Summary 
The successive ring expansion of simple, commercially available lactams with amino acid 
derivatives has been developed. A wide range of ring sizes has been prepared, with many 
different linear fragments successfully incorporated, typically in high yields. Enantioenriched α-
amino acid derivatives have been synthesised, and then introduced into lactams to prepare 
enantioenriched macrocyclic products. Seven examples have been produced, whereby 
successive ring expansions have taken place, with varying substitution and functionality. 
The work described in this Chapter is the subject of one publication.128  
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Chapter Four: Lactone Forming Successive Ring Expansion 
4.1 Lactone SuRE Concept 
Using a similar approach to the previously described C-N bond forming ring expansion (see 
Chapter three), we reasoned that a lactone forming reaction would also be possible. There are 
numerous macrocyclic lactones found in nature, including in cyclic siderophores, and natural 
products like the epothilones, vancomycin and macrolide antibiotics such as erythromycin. 
Therefore, a new pathway that can access these targets (as well as analogues) could be 
incredibly valuable.   
Using a two-step procedure, we proposed that N-acylation of lactam 355 with a protected 
hydroxy acid chloride 470 could deliver the corresponding imide 471. With the use of a suitable 
protecting group, mild deprotection conditions could then be employed to liberate the pendant 
alcohol. We proposed that an equilibrium would be established between three isomers (472–
474), with the expectation that the ring expanded product would be the most favourable 
thermodynamically in most cases (scheme 4.1). Importantly, the NH lactam motif is regenerated 
upon ring expansion and therefore the ring expansion sequence can be performed successively. 
 
Scheme 4.1: Lactone forming successive ring expansion concept. 
4.2 Hydroxy Acid Preparation 
A benzyl protecting group was chosen because of its mild cleavage conditions (via 
hydrogenolysis) with the toluene by-product being volatile, whilst the protecting group being 
stable to the strong acidic conditions of acid chloride formation. The simple α- and β-hydroxy 
acids, which were required to test our hypotheses, are not commercially available, therefore, 
using two separate literature procedures were used to make both compounds in excellent yields 
on gram scale. The procedure to make the β-benzyl protected hydroxy acid 351 from β-
propiolactone 349 was discussed previously (see Chapter 2). For the α-hydroxy acid, sodium 
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metal was used to form the benzyl alkoxide 475, which was added (in excess) to chloroacetic 
acid 476, forming the desired hydroxy acid 477.  
 
Scheme 4.2: Preparation of benzyl protected hydroxy acid starting materials. 
4.3 Reaction Optimisation 
With the starting materials in-hand, the ring expansion sequence with hydroxy acid chlorides 
was investigated. Initially, 13-membered lactam 361 was utilised to avoid the added 
complication of preparing strained medium-sized rings. Using identical conditions to those used 
with amino acid chlorides (see section 4.3), successful acylation with β-hydroxy acid chloride 344 
was achieved and the imide 478 was purified and characterised (scheme 4.3). Using the 
optimised conditions, previously obtained from the previous β-ketoester methodology (see 
Chapter 2), debenzylation occurred delivering a mixture of all three isomers 479–481, which was 
observed in CDCl3 (NB: an approximate ratio of 10:2:1 was observed, however resonance 
overlapping in the 1H NMR spectra makes this ratio inaccurate for further analysis). A solvent 
switch was then performed to chloroform, and triethylamine added to promote cyclisation and 
ring expansion. After 18 hours, full conversion to the desired ring expanded product was 
achieved, and upon purification by column chromatography the product 481 was isolated 
exclusively with no observation of conversion back to either of the previous isomers 480 or 479.  
When α-hydroxy acid chloride 482 was utilised, imide 483 was prepared via N-acylation, and 
using the same hydrogenolysis conditions, a similar mixture of isomers was obtained. Following 
a solvent switch to chloroform, with the addition of triethylamine, successfully achieved the 16-
membered macrocyclic product 484 in excellent yield.  
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Scheme 4.3: Reaction optimisation for the incorporation of hydroxy acid chloride fragments into 13-
membered lactam 361. 
4.4 Ring Size Scope 
4.4.1 β-Hydroxy Acid Series 
After the successful incorporation of linear fragments into the 13-membered lactam, we decided 
to complete a systematic study of the effects of ring size in this reaction series. Initially, the 
effect of ring size on product formation was performed using β-hydroxy acid fragment 344. Using 
ring sizes from 4- to 13-membered, lactams were N-acylated (using the standard reaction 
conditions), and the imide products 487–495 (scheme 4.4) were isolated by column 
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chromatography and characterised. As some of the starting lactams were not commercially 
available, these were made via Beckmann rearrangements of the ketones in the same manner 
as used previously (see Chapter 3). 
 
Scheme 4.4: Acylation of lactams of varying sizes using β-hydroxy acid chloride forming the 
corresponding imides. 
Using the standard hydrogenolysis conditions previously developed, the alcohol groups of all 
imides 487–495 were deprotected and after passing through a Celite® plug (to remove palladium 
catalyst), the reaction mixtures were dissolved in chloroform, triethylamine was added and 
stirred for 18 h at room temperature. The results obtained were interesting and showed a clear 
trend. All examples underwent hydrogenolysis successfully however, isomerisation to the 
desired ring expanded product was not achieved for all ring sizes. For example, 4- and 5-
membered lactams formed exclusively the primary alcohols 499 and 500 respectively. These 
products were heated, treated with acid and base (individually) and multiple different solvents 
were used in attempt to promote ring expansion. However, ring expansion was not observed 
and the primary alcohols degraded to the original lactams, presumably via hydrolysis of the 
imides. Considering the change in ring size required for these transformations, perhaps these 
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results were unsurprising, as the ring enlarged products would be the highly strained medium-
sized rings (8- and 9-membered) and therefore the most difficult to make. This effect was also 
observed when incorporating amino acids into these small ring sizes. We propose that the ring 
expanded product is not the lowest energy isomer, and therefore cannot be accessed through 
this method assuming that the reactions are under thermodynamic control (computational 
analysis of these reactions will be discussed later).  
Pleasingly, 10- to 16-membered products (501–508) were formed in excellent yields without 
observation of the other isomers. Most examples existed as rotameric mixtures of the desired 
ring expanded products (in CDCl3), due to the slow rotation of the C-N bond of the secondary 
amide. This resulted in different environments for most atoms, being observed in both their 1H 
and 13C NMR spectra. 
 
Scheme 4.5: Ring size scope for β-hydroxy acids making ring expanded products 10- to 17-membered 
products. 
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4.4.2 α-Hydroxy Acid Series 
Following the success of the ring size study on the β-hydroxy acid series, we then examined the 
analogous α-hydroxy acid series and the effect of ring size on product formation. Similarly, we 
decided to separate the acylation and ring expansion steps so that we could examine each step, 
in isolation. Therefore, 4- to 13-membered lactams were acylated with the α-hydroxy acid 
chloride 482 to produce the corresponding imides 510–518 in good to excellent yields (scheme 
4.6). For 11- and 12-membered derivatives 517 and 518, the two steps were telescoped as the 
N-acylation proceeded to full conversion.  
 
Scheme 4.6: Acylation of 4- to 12-membered lactams with α-hydroxy acid chloride 482. 
Next, we turned our attention towards the deprotection/ring expansion of the different sized 
imides. However, using the previously employed hydrogenolysis conditions (catalysed by 
palladium on carbon in ethyl acetate), N,O-acetals (520–523, scheme 4.7) were synthesised 
rather than the ring expanded products.  
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Scheme 4.7: Synthesis of N,O-acetals from a-hydroxy acid imides. 
Although this is an interesting pathway to the synthesis of these compounds, it is not desirable 
when considering the designed ring expansion concept. A similar side-product was also created 
when using a Cbz protecting group strategy (see Chapter 3), and a similar mechanism is 
proposed. Thus, upon debenzylation of the imide 509, the primary alcohol is formed which 
cyclises to form fused bicycle 525. Dehydration then occurs to form N-acyl iminium 526, which 
is reduced again to form the N,O-acetal 519.  
 
Scheme 4.8: Proposed mechanism of over-reduction to form N,O-acetals via N-acyl iminium 
intermediate. 
We reasoned that if we could trap the proposed N-acyl iminium 526, this would stop the 
formation of these reduced products. We therefore proposed that judicious choice of 
hydrogenolysis solvent could form an adduct, hindering the formation of the N,O-acetal. Thus, 
methanol was chosen as a hydrogenolysis solvent and an acetal adduct (529) was formed in 
excellent yield. Acid mediated cleavage of the acetal adduct was attempted, which would deliver 
a fused bicyclic isomer 530, however all attempts were unsuccessful with heating causing 
degradation of the material.  
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Scheme 4.9: Hydrogenolysis of 8-membered imide using methanol as a solvent to form a hemi-acetal 
type product 528. 
Although changing the solvent to methanol did not achieve ring expanded product, the results 
highlighted that the proposed N-acyl iminium intermediate 526 could be trapped with the 
hydrogenolysis solvent/reagent in-situ. Therefore, we used a mixture of THF and water in a bi-
phasic system as the hydrogenolysis solvent, with the aim that water would act as the trapping 
agent and thus form bicyclic fused isomer 530, which would be amenable to ring expansion. 
Using these altered conditions on the 8-membered imide 528, a mixture of primary alcohol 531 
and bicycle 530 was obtained after the hydrogenolysis step. This mixture was then dissolved in 
chloroform and reacted with triethylamine at room temperature, to exclusively form the 11-
membered ring expanded product 532 in excellent yield (scheme 4.10).  
 
Scheme 4.10: Synthesis of 11-membered ring expanded product using THF/H2O as hydrogenolysis 
solvent system. 
Happy that the reaction pathway was well understood, and that the new optimised conditions 
were suitable for successive ring expansions, the hydrogenolysis/ring expansion conditions were 
then applied to 4- to 13-membered imides 510–518 (scheme 4.6). Similar to the previous ring 
size study, not all imides underwent ring expansion. First, 4- and 5-membered examples formed 
the primary alcohols 534 and 535; as in the β-hydroxy acid series, these were subjected to high 
temperatures and both acidic and basic conditions, but still did not ring expand. In contrast, 6- 
and 7-membered examples were formed as an inseparable mixture of all three isomers, with 
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the major component being the fused bicycles 536 and 537 respectively. Via TLC, both of these 
mixtures appeared as a single spot under many different solvent systems, with attempts to 
purify the mixtures under different conditions being unsuccessful. This led us to believe that the 
three isomers exist in equilibrium. This was supported when the ratios of each isomer changed 
when different deuterated solvent were used. Perhaps it is unsurprising that these examples did 
not ring expand, as the ring enlarged products would be the challenging medium-sized rings, 
which have well-known difficulties of formation (which have been previously discussed). 
However, pleasingly all examples starting from ring sizes 8-membered or larger were 
successfully ring expanded, forming the desired lactones 532–542 in consistently excellent 
yields. From these results we concluded that as long as the change in ring size is 
thermodynamically favourable, then ring expansion works well. 
 
Scheme 4.11: Ring size scope using a-hydroxy acids on 4- to 13-membered lactams. 
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4.4.3 Computational Chemistry 
Based on the experimental findings, we believed that we were obtaining the thermodynamic 
product(s) in the ring expansion reactions, and proposed that a lack of thermodynamic driving 
force for ring expansion to occur was responsible for the unsuccessful examples. To support this, 
a postdoctoral researcher in the group (Dr Aggie Lawer), completed a relatively simple 
computational study using Density Functional Theory (DFT) at the B3LYP/6-31G* level of theory, 
based on a related study by Yudin and co-workers.87 Thus, the relative Gibbs free energies of 
each isomer 544, 545 and 546 were calculated for the 5–8-membered examples and these 
results are summarised in table 4.1. These calculations supported the results obtained 
experimentally. For the α-hydroxy acid series, the 5-membered imide form 544 was shown to 
be significantly lower in energy than the corresponding bicyclic 545 or ring expanded 546 forms. 
However, starting from the 8-membered imide, the ring expanded form 546 was significantly 
lower in energy than the alternate imide 544 or bicyclic 545 forms. The calculations also 
supported the synthetic results for the β-hydroxy acid series, where the ring expansion became 
favourable for ring of 6-members or higher, when the relative energy of the ring expanded form 
546 was calculated to be lower than the other possible isomers 544 and 545. The DFT 
calculations also predicted that the 5-membered imide form would be lower in energy than the 
ring expanded product 546. The calculations were done at a relatively modest level of theory, 
and therefore we believe that the DFT calculations should not be used to make firm conclusions 
about bond angles, length, conformations because of the relative simplicity of the method. 
However, as a tool to estimate the probability of a ring expansion proceeding, we feel that this 
method has value, in advance of committing time and effort into new experiments. 
 
n m Ring Sizes 
544 545 546 
ΔG°rel (kcal/mol) 
2 1 5 → 8 0.0 13.4 10.3 
5 1 8 → 11 6.3 8.9 0.0 
2 2 5 → 9 0.0 11.7 4.1 
3 2 6 → 10 2.4 8.1 0.0 
Table 4.1: Results of computational calculations showing the relative Gibbs free energies of each 
isomers with varying ring size and linear fragment length. 
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4.5 Functionalised Examples 
With better understanding of which examples would be likely to ring expand based on ring size, 
we turned our attention towards more complex and medicinally interesting products. Initially, 
the backbone of the lactam was functionalised to introduce a fused aromatic ring, which would 
increase the rigidity of the system. Thus, benzannulated lactam 547 was acylated with β-hydroxy 
acid chloride 344 using the standard conditions, and then hydrogenolysis and subsequent ring 
expansion formed 11-membered product 549 in high yield. However, when the same 
benzannulated lactam was treated with phenolic acid chloride 550, no ring expansion was 
observed, with phenol isomer 552 isolated in good yield. We propose that increasing the rigidity 
of both lactam and linear fragment does not permit for a kinetically favourable geometry within 
the transition state, and therefore was not thermally accessible under the reaction conditions 
imposed. An alternative could be that the reaction was slow due to the decreased nucleophilicity 
of the phenol, and prolonged reaction conditions would deliver the ring enlarged product, 
however this was not tested. Using more flexible 8-membered lactam 553, the phenol acid 
chloride 550 was incorporated into the cyclic system in excellent yield, with only the ring 
enlarged product being observed.  
We also extended the methodology past ring expansion, with linear amide 556 successfully 
being N-acylated with β-hydroxy acid chloride 344 and under the standard conditions, 
hydrogenolysis led to the β-hydroxy acid fragment being inserted into the middle of this linear 
amide system. Importantly, the insertion operates via an intramolecular cyclisation/extension 
sequence and therefore the linear amide is not broken into two molecules. Thus, it may be 
possible to incorporate hydroxy acid fragments into the middle of more complex linear amides, 
and in the future, there may be potential for this methodology to also be used to modify linear 
peptides. 
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Scheme 4.12: Synthesis of functionalised examples via ring expansion/incorporation. 
Changes to the linear fragment were examined next, with three different hydroxy acid chlorides 
already proven to be successfully introduced using this method. Incorporating a larger degree 
of steric hindrance to the linear fragment was desirable, as this would allow for the 
derivatisation of the relatively simple hydroxy acid chlorides used so far. Therefore, two 
different hydroxy acid chlorides were utilised to investigate the reaction tolerability. Methyl and 
phenyl substituted α-hydroxy acid chlorides 559 and 562 were used to acylate the 13-membered 
lactam 361; the N-acylation using phenyl substituted hydroxy acid chloride 562 did not proceed 
to full completion, with the yield in the final isolated product reflecting this. Both imides 560 
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and 563 were reacted under the standard hydrogenolysis conditions and ring expanded to 
generate 16-membered ring enlarged products 561 and 564 in good and excellent yields. With 
both examples, no over-reduction or side products were observed, with the yields largely 
reflecting the degree of conversion during the N-acylation step.  
 
Scheme 4.13: Synthesis of ring expanded macrocycles incorporating more sterically encumbering 
hydroxy acid chlorides. 
4.6 Successive Ring Expansion 
4.6.1 Double Ring Expansion Expansions 
Having developed what appeared to be a robust and general protocol that had been used across 
a broad range of substrates, we attempted to expand our products for a second time. The 
success of this stage of the project was crucial, as multiple ring expansions would massively 
increase the number of diverse macrocycles that could be accessed via this method. Pleasingly, 
the acylation of these ring enlarged lactones was far more successful that the lactam 
counterparts (discussed in more detail in Chapter 6) and 12 macrocycles were synthesised with 
typical yields of 80% (seen in scheme 4.14). Many different macrocyclic ring sizes (14- to 21-
members) were formed using the standard method with no difficulty, which was expected as all 
examples proceed through fused 5- or 6-membered transition states and intermediates. Many 
different linear fragments were utilised, with amino acids also being introduced in either order. 
Being able to introduce both amino acids and hydroxy acids into macrocycles in sequence was a 
major achievement, with the number of accessible macrocycles being greatly increased. We also 
realized that with these compatible procedures, cyclodepsipeptides (a class of natural product 
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which contain both a lactam and lactone in the molecule) were accessible, which are currently 
receiving medicinal interest.129,130 
Natural and non-natural amino acids have been incorporated in conjunction with hydroxy acids 
to produce mixed lactone/lactam systems in high to excellent yields (568–572). All the 
proteinogenic amino acids derivatives, which contain a stereogenic centre were used as 
enantioenriched starting materials and all the products had a significant non-zero [α]D value, 
proving that full racemisation did not occur; we cannot rule out partial epimerisation, although 
we believe it to be unlikely based on the reaction conditions employed. Lactonic systems were 
also prepared whereby two hydroxy acids were inserted in succession (573–579). Different 
hydroxy acids were commonly used in different orders to show controlled sequential ring 
expansion rather than a polymerisation type pathway. Linear fragments have also been inserted 
into more functionalised examples such as benzannulated system 577, and ether linked 
examples 578 and 579. Macrocycle 575 was completed on larger scale (10 mmol) with no 
appreciable loss in yield. Example 572 was isolated in a lower than expected yield due to 
debenzylation from the amide resulting in side product 581 (scheme 4.15). This was surprising, 
as the rate of debenzylation from an oxygen is usually much faster than from a nitrogen (due to 
electronegativity difference), however in this example the two rates were much closer.  
We believe that the macrocycles produced demonstrate that this new technique is compatible 
with a wide array of starting materials, not limited to those which we have tested.  
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Scheme 4.14: Successive Ring Expansion examples of inserting both hydroxy acids and amino acids. 
*Examples made by Dr. Aggie Lawer. Deprotection conditions: (A) i) H2, Pd/C in THF/H2O, 2-4 h, r.t. 
then ii) CHCl3, NEt3, 18 h, r.t. (for X2PG = OBn, p = 1); (B) i) H2, Pd/C in EtOAc, 4 h, r.t. then ii) CHCl3, 
NEt3, 18 h, r.t. (for X2PG = OBn, p = 2); (C) DBU, CH2Cl2, 18 h, r.t. (for X2PG = NFmoc). 
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Scheme 4.15: Debenzylation side reaction during successive ring expansion of 572. 
4.6.2 Triple Ring Expansion Examples 
With the success of making so many macrocycles by performing two consecutive ring 
expansions, we wanted to extend the methodology further to complete three sequential ring 
expansion reactions. Once again, it was crucial that different ring sizes were produced and many 
different linear fragments were utilised to demonstrate the applicability of the method. To our 
delight, 5 macrocyclic examples were prepared with typical yields of 70%, with no side product 
formation (see scheme 4.16). 
Similar to the previous section, we were able to incorporate both amino acids and hydroxy acids 
into the same molecule as the methods are compatible. Thus, mixed lactam/lactone systems 
were produced in good yields (584 and 585), with the unnatural β-amino acid being incorporated 
in both molecules. Both simple, linear α- and β-hydroxy acids were used in varying orders, in all 
of these examples, showing that these linear fragments can really be ‘chopped and changed’ at 
will. Ring expansions using only hydroxy acid chlorides have also been completed making tri-
lactone systems in equally high yields (586 and 587). The reactions to make 586 and 584 were 
also repeated on ≥5 mmol scale (with no significant loss in yield) to demonstrate the scalability 
of these reactions. Finally, highly oxygenated macrocycle 588 was produced (by Dr Aggie Lawer), 
demonstrating that heteroatoms can be introduced into the backbone and the methodology still 
works (albeit with a dramatically reduced yield). In general, the N-acylation step in these third 
ring expansion reactions was more difficult, probably owing to less reactive conformations being 
adoptable, and therefore additional equivalents of the acid chloride were added to improve 
conversion. This highly oxygenated example (588) showed a severely retarded rate of acylation, 
with an extra 4.5 equivalents still only leading to a 36% yield overall.  
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Scheme 4.16: Synthesis of macrocycles by three successive ring expansions with both amino and 
hydroxy acids. Deprotection conditions: (A) i) H2, Pd/C in THF/H2O, 2-4 h, r.t. then ii) CHCl3, NEt3, 18 h, 
r.t. (for X3PG = OBn, q = 1); (B) i) H2, Pd/C in EtOAc, 4 h, r.t. then ii) CHCl3, NEt3, 18 h, r.t. (for X3PG = 
OBn, q = 2). aAn additional 1.5 equivalents of acid chloride was used. bAn additional 4.5 equivalents of 
acid chloride were used.   
4.6.3 Iterative Assembly Line Synthesis 
With all the examples which have been previously described, each expanded ring has been 
isolated after a single operation. Therefore, when completing three successive ring expansions 
three purifications (by column chromatography) were completed to identify and characterise 
the individual products. As this can be time consuming, we decided to test whether we could 
perform multiple ring expansions in sequence. As the chemistry is relatively simple, we thought 
that we could highlight this practicality in an iterative assembly line type synthesis. Starting from 
commercially available 8-membered lactam 553, the standard telescoped ring expansion 
procedure was performed with β-hydroxy acid chloride 344. After the first ring expansion 
iteration, an acidic work up was completed to remove excess triethylamine and hydroxy acid 
residues. A second and third iteration were then completed with β-hydroxy acid chloride 344 to 
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form the 20-membered macrocyclic tri-lactone 586. A single purification was performed after 
all iterations were complete, to isolate the ring enlarged product in an overall 48% yield. This 
unoptimised process significantly expedited the synthesis of this macrocycle, and we believe 
that the freedom to rapidly install precise sequences could have important consequences as an 
enabling technology in the design of new macrocyclic pharmaceuticals. 
 
Scheme 4.17: Synthesis of 20-membered tri-lactone 586 via an iterative assembly line. 
 
4.7 Chapter Summary 
Successive ring expansion reactions have been completed, whereby hydroxy acid derivatives 
have been incorporated into lactams, typically in high to excellent yield. Both 3- and 4-atom 
linear fragments have been introduced using a benzyl protecting group, with a novel route to 
N,O-acetals also being discovered. Functionalised examples have been examined, producing a 
diverse array of macrocycles, with amino acid incorporation (described in Chapter three) being 
compatible with this lactone forming variant. 
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Chapter Five: Nitrogen-Induced Cyclisation/Expansion Cascade 
5.1 Cyclisation/Expansion Cascade Concept 
Medium-sized rings have recently received a resurgence in medicinal interest,132,133 however can 
be difficult to prepare via the cyclisation of a linear precursor (589 → 590, scheme 5.1a). 
Destabilising transannular strain (Prelog) in addition to the loss of entropy during cyclisation, 
usually impede the formation of the product. Owing to the difficulties of the synthesis of this 
class of molecule (see Chapter one), forcing conditions are typically required,134 hence there is 
a requirement for alternative milder approaches to the synthesis of medium-sized rings.  
All of the ring expansion methods that have been described previously have started from a cyclic 
starting material, however, in this chapter, a cyclisation/ring expansion cascade is described in 
which functionalised medium-sized rings can be accessed directly from a linear precursor. The 
key design feature when starting this project was to avoid kinetically unfavourable medium-
sized ring cyclic transition states/intermediates, by performing a cyclisation followed by a ring 
expansion with both steps proceeding through 5- , 6- or 7-membered rings. We proposed that 
by incorporating a nucleophilic motif into the linear starting material (591, scheme 5.1b), a 
slow/difficult cyclisation process could be improved by breaking it down into two easier parts. 
To do this, a pyridine-based motif was designed to facilitate the lactonisation/lactamisation of a 
linear precursor (594, scheme 5.1c) via a proposed N-acyl pyridinium intermediate 595, with the 
pyridine effectively acting as an internal nucleophilic catalyst.   
 
Scheme 5.1: a) Direct synthesis of medium-sized ring. b) Cyclisation/ring expansion cascade sequence 
using an internal nucleophilic motif. c) Pyridine induced cyclisation/expansion cascade. 
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5.2 Preliminary Work and Optimisation Results 
Work completed in the Unsworth lab by Dr Aggie Lawer established a synthetic route to the 
hydroxy acid starting material (597, scheme 5.2) via a six-step procedure. Retrosynthetic analysis 
of the starting material first required functional group interconversion of the carboxylic acid to 
ester 598. Then, alcohol 598 could be formed via reduction of ketone 599, which in turn can be 
synthesised via Suzuki-Miyaura coupling of both aryl sub-units 600 and 602. The pyridine unit 
was synthesised via a lithiation, followed by trapping with the corresponding Weinreb amide 
delivering the ketone motif. The aryl boronic ester was made via palladium-catalysed borylation 
of the aryl bromide 603 and finally conversion to the carboxylic acid 604, which was a cheap and 
commercially available building block.   
 
Scheme 5.2: Retrosynthetic analysis of linear starting material 597 via six-step sequence completed by 
Dr. Aggie Lawer. 
Next, the cyclisation/expansion cascade was optimised and it was found that T3P 
(propanephosphonic acid anhydride) in chloroform with diethylpropylamine (DIPEA) achieved 
the highest yield of the desired 10-membered lactone 606, with the added benefit that all the 
by-products could be removed by aqueous work up. Serendipitously, the product was formed 
as a single diastereomer, with the relative stereochemistry supported by an X-ray crystal 
structure (seen in scheme 5.3). An acute angle between the two aryl units can be seen, 
presumably due to restricted C-C bond rotation, which results in an axis of chirality, making the 
mirror images non-superimposable. This is called atropisomerism, and is more commonly seen 
on substituted bi-aryls such as BINOL. This means that, there are two elements of chirality in the 
10-membered lactone 606 (the axial chirality and the point stereogenic centre) and therefore 
two diastereomers can be produced. However, only a single diastereomer was observed and 
Chapter Five: Nitrogen-Induced Cyclisation/Expansion Cascade 
 
105 | P a g e  
 
therefore we reasoned that the relative stereochemistry must be controlled during the cascade 
reaction. 
 
Scheme 5.3: Synthesis of 10-membered bi-aryl lactone 606 in excellent yield via cyclisation/expansion 
cascade by Dr. Aggie Lawer. 
5.3 Origin of Diastereoselectivity 
It was proposed that the key to the diastereoselectivity was the point stereogenic centre α- to 
the alcohol. After formation of the N-acyl pyridinium intermediate 605, a pseudo boat-boat 
conformation can be drawn for the tetrahedral intermediate (scheme 5.4) which via Si-face 
attack, places the methyl group in what we propose to be a relatively favourable pseudo-
equatorial position 607. However, for Re-face attack to occur, the methyl group would be 
positioned in a pseudo-axial position (608), which we predict to be higher in energy, thus 
increasing the relative energy of this intermediate and encumbering the formation of this 
diastereomer.  
An alternative explanation for the diastereoselectivity observed, could originate from a 
thermodynamic model. This would require the strained 10-membered lactone product to be 
reversibly formed and a significant difference in Gibbs energy between the two possible 
diastereomers resulting in the observed high selectivity. Owing to the mild conditions and short 
reaction time of this transformation, we postulate that a kinetic model is more likely to be 
operating in the examples described, however we cannot currently exclude a thermodynamic 
explanation. 
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Scheme 5.4: Proposed origin of diastereoselectivity through key transannular interactions in 
tetrahedral intermediate. 
5.4 Examining Diastereoselectivity 
After proposing a model for the diastereoselectivity, a series of chiral tertiary alcohols were 
investigated with varying substituent sizes to better probe the stereoselectivity. We postulated 
that when both substituents are of similar size, the diastereoselectivity would be lower as the 
key steric interaction would be very similar between both Si- and Re-faces. Thus, via lithiation 
and trapping with acetophenone (601 → 610), pyridine 610 was synthesised in excellent yield. 
From this building block, linear precursor 612 was synthesised in a similar fashion to those 
presented previously.  
 
Scheme 5.5: Synthesis of tertiary alcohol linear precursor 612. 
Direct addition of the metallated pyridine intermediate (not shown) into ketones and aldehydes, 
had been previously unsuccessful for other Unsworth groups members. Therefore, to make 
tertiary alcohols, ketone 600 (scheme 5.6, synthesised using a Weinreb amide) was reacted with 
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an organometallic reagent to furnish the desired alcohol. The allyl variant 614 was synthesised 
via this route however, it was not possible to make the t-butyl variant 616 using this method. 
We believed that direct addition into pinacolone 615, would be plausible, and pleasingly we 
obtained the desired tertiary alcohol, in excellent yield, which was previously inaccessible. 
 
Scheme 5.6: Synthesis of tertiary alcohol from the corresponding pyridine. a) Two step organometallic 
addition method used previously. b) One step direct addition into ketones/aldehydes. 
With tertiary alcohols in-hand, the linear precursors were synthesised and the key 
cyclisation/expansion cascade reaction was completed (scheme 5.7). Three tertiary alcohols 
617, 612 and 620 were tested and pleasingly all examples furnished the desired medium-sized 
rings in high to excellent yields. The diastereoselectivity results were also interesting, with 
varying amounts of selectivity observed. Allyl product 618 was isolated in a 1.1:1 diastereomeric 
ratio, suggesting that the methyl and allyl substituents are relatively similar in size/steric 
hindrance which is supported by having similar A-values. A small increase to a 3:2 diastereomeric 
ratio was observed for the phenyl product 619, with a difference in A-value of 1.3. Only upon 
increasing the size of one substituent to a t-butyl group (621), was complete diastereoselectivity 
returned and a single diastereomer obtained, with a difference in A-value of 3.2. These results 
clearly show that the relative size of substitution at this position directly influences the 
diastereoselectivity. 
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Scheme 5.7: Cyclisation/expansion cascade of tertiary alcohol linear starting materials to examine the 
diastereoselectivity. 
In order to support this hypothesis further, we examined the effect of moving the stereogenic 
centre to the other two aliphatic positions in the ring. To do this, we required primary alcohol 
622, however, attempted lithiation of 601 and trapping with paraformaldehyde was 
unsuccessful and delivered only starting material (scheme 5.8). We realised that DMF could be 
used as the electrophile, delivering aldehyde 623 upon acidic work up which could be reduced 
to the primary alcohol. However, upon repeated attempts (using dried DMF) an enamine was 
believed to be produced, which degraded upon acidic workup when trying to isolate the desired 
aldehyde 623. Finally, use of ethyl chloroformate successfully produced the ester 624; in this 
example, the acidic proton between the ester and pyridine functionalities in the product is 
removed by the organometallic reagent (lithiated pyridine) forming an enolate, which prevents 
a second addition. Consequently, multiple equivalents of the organometallic reagent are 
required as it acts as both nucleophile and base, however can be easily recovered if desired. 
Conversion of the ester 624 to primary alcohol 622 was completed, in excellent yield, using 
DIBAL at 0 °C. 
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Scheme 5.8: Different synthetic methods attempted to make the primary alcohol 622. 
After accessing the primary alcohol 622, a boronic ester fragment 626 was required to perform 
a Suzuki-Miyaura cross coupling with the desired stereogenic centre incorporated. Despite its 
relative simplicity, the boronic ester was not commercially available and therefore was 
synthesised by the following procedure (scheme 5.9). Thus, bromo ester 603 was treated with 
methyl iodide using a modified literature procedure135 to form methylated bromo ester 625. 
During this reaction, O-methylation was also observed to provide an unwanted side product, 
which was removed by column chromatography. Palladium-catalysed borylation was then 
performed to deliver the pinacol boronic ester 626. Bringing together both fragments, Suzuki-
Miyaura cross coupling (with previously optimised conditions by Dr. Aggie Lawer) delivered the 
hydroxy ester 627. Finally, hydrolysis was performed to produce carboxylic acid precursor 628.    
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Scheme 5.9: Synthesis of linear fragment with stereogenic centre moved to the α-position of the 
carboxylic acid. 
Introducing the stereogenic centre in the other position (α- to the pyridine) was synthetically 
simpler with few steps required to make the linear precursor (scheme 5.10). Starting with 
methylation of the pyridine ester 624 using the conditions stated above. DIBAL reduction formed 
primary alcohol 630 with the stereogenic centre in the desired position. Suzuki-Miyaura cross 
coupling and subsequent hydrolysis delivered the linear precursor 633. 
  
 
Scheme 5.10: Synthesis of linear fragment moving the stereogenic centre to the a-position of the 
pyridine. 
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With both linear precursors in-hand, the key cyclisation/expansion cascade was tested. 
Pleasingly, we found that both examples furnished the desired 10-membered rings (634 and 
635, scheme 5.11) in excellent yields. However, diastereoselectivity was low, with 
diastereomeric ratios of 1:1 and 3:2 respectively. This supported our idea that the 
diastereoselectivity is determined by a key 1,5-steric interaction through a pseudo axial position. 
Without this key interaction, both pathways are very similar in energy and therefore poor/no 
selectivity is observed, which is seen through these examples.  
 
Scheme 5.11: Cyclisation/expansion of linear precursors where the stereogenic centre has been 
moved. 
5.5 Heteroaromatic Scope 
We moved onto expanding the scope of the pyridine fragment and tested other aromatic 
systems. The key design principle of the cascade requires a nucleophilic motif instigating a 
cyclisation event, which can also induce a ring expansion. With the success of the pyridine motif, 
we envisaged other nitrogen containing heteroaromatics being equally viable. We quickly 
understood that problems arose from the synthesis of the linear precursor, rather than testing 
the key cascade reaction. For example, the lithiation/trapping of nitro-substituted pyridine (636, 
scheme 5.12) was unsuccessful with multiple electrophiles, despite the aromatic being electron 
deficient which should promote the deprotonation. Deprotonation of the thiazole 638 and 
pyrimidine 640 starting materials were also unsuccessful, delivering only unreacted starting 
materials with different electrophiles utilised. 
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Scheme 5.12: Lithiation/trapping procedure tested on other heteroaromatics. 
Pyrazines were then investigated, and pleasingly pyrazine 642 formed ketone 643 in excellent 
yield, using Weinreb amide 614. Sodium borohydride reduction formed the corresponding 
alcohol 644 and Suzuki-Miyaura cross coupling delivered the bi-aryl hydroxy ester 645. 
Hydrolysis produced the carboxylic acid which successfully formed the 10-membered ring 647 
in excellent yield, showing that this heteroaromatic could also be tolerated. Another pyrazine 
linear precursor 648 was also synthesised, via a similar pathway, and successfully underwent the 
cascade reaction to form the 10-membered ring 649 in excellent yield, also as a single 
diastereomer. 
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Scheme 5.13: a) Pyrazine reaction pathway to linear substrate and successful key cascade reaction. b) 
Successful cyclisation/expansion reaction of catechol pyrazine substrate. 
DMAP is commonly used as a nucleophilic catalyst in lactamisation/lactonisation reactions, 
operating mechanistically in a similar fashion to the cyclisation/expansion cascade. Therefore, 
we believed that incorporation of a dimethylaminopyridine unit as the key nucleophilic motif 
would likely work well to produce the desired medium-sized ring. Thus, amino pyridine 650 was 
methylated with a modified literature procedure,136 forming dimethyl pyridine 651. 
Lithium/halogen exchange was utilised to introduce methyl substitution, forming 652 in good 
yield. Importantly, lithium/halogen exchange occurred only once with no di-methylated side 
product being observed. Lithium/trapping with hindered non-nucleophilic base LDA and 
Weinreb amide 614 produced ketone 653, which was then reduced to the alcohol 654 in 
excellent yields. Suzuki-Miyaura cross coupling with anisole boronic ester 655 was performed, 
forming electron rich bi-aryl ester 656. Hydrolysis of the ester produced carboxylic acid 
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precursor 657, which as predicted successfully formed the 10-membered ring 658 in excellent 
yield. 
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5.6 Lactamisation Cyclisation/Expansion Cascade 
Having proved that medium-sized ring lactones can be synthesised by this cascade reaction, we 
turned our attention to a lactamisation variant. The reaction mechanism should proceed in an 
identical fashion, with the only difference being the terminal nucleophile. Therefore, an amine 
linear precursor was synthesised by the following procedure (scheme 5.15). Initially, 
lithiation/trapping was completed with imine 659 forming secondary amine 660. Protection of 
the amine with Boc was completed, in excellent yield, before the Suzuki–Miyaura cross coupling 
was performed to deliver ester 662 (protection of the amine was required beforehand, 
otherwise a Buchwald–Hartwig coupling was possible). Deprotection of the amine with HCl in 
dioxane afforded secondary amine 663, which was subjected to ester hydrolysis to furnish the 
amino acid precursor 664. The key cyclisation/expansion cascade reaction was initially 
performed under the standard conditions and a modest yield was obtained for the 10-
membered lactam 665. We propose that the increased nucleophilicity of the amine results in 
competing intermolecular amide-bond formation; this is supported by the fact that when the 
reaction was repeated under higher dilution, an increased yield was obtained from 50% to 78%. 
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Scheme 5.15: Synthesis of secondary amino acid linear precursor and cyclisation/expansion to form 
tertiary lactam. High dilution was also tested due to significantly reduced yield using standard 
conditions for lactonisation. 
5.7 Asymmetric Synthesis of Linear Precursor 
5.7.1 Asymmetric Synthesis of Alcohol Precursor 
In the atroposelective examples, the relative stereochemistry was controlled by the point 
stereogenic centre. However, all the products (thus far) utilised racemic building 
blocks/transformations and therefore, the products are also racemic. As racemisation of the 
products once formed was deemed unlikely, we realised that enantiomerically enriched 
medium-sized rings should be accessible by using enantioenriched starting materials. Initially 
examining the lactonisation cascade reaction, we identified that asymmetric reduction of the 
ketone 600 (scheme 5.16) would provide an enantioenriched alcohol. Synthesising the racemic 
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alcohol 666 was simple, and using chiral HPLC, conditions by which the two enantiomers could 
be separated were established (see Supporting Information for further details).     
 
Scheme 5.16: Synthesis of racemic alcohol through reduction of ketone. 
Having produced the racemic alcohol 666, asymmetric reduction of the corresponding ketone 
600 was attempted with the results summarised in table 5.1. Using a literature procedure,137 
Jacobsen’s catalyst was used but this was low yielding and formed the product 667 in a 
disappointing 22% ee (entry 1). The procedure was repeated at a lower temperature (−78 °C), in 
an attempt to improve the enantiomeric excess, but no conversion was achieved. An alternative 
approach was utilised where the chiral ligand menthol was used with lithium aluminium 
hydride.138 An initial ‘ligand exchange’ between a menthol and hydride should occur, therefore 
making a chiral reducing agent in-situ. However, chiral induction was not achieved with a 
racemic product formed. Finally, Corey-Bakshi-Shibata reduction was attempted with borane 
using literature conditions,139 however no product formation was observed.  
 
Entry Conditions Yield Enantiomeric Excess 
1 Jacobsen’s catalyst (4 mol%), EtOH, 
NaBH4, CHCl3, −40 °C, 18 h 
19% 22% 
2 Jacobsen’s catalyst (4 mol%), EtOH, 
NaBH4, CHCl3, −78 °C, 18 h 
0% - 
3 Menthol, LiAlH4, THF, EtOH, −20 °C  82% 0% 
4 CBS catalyst, BH3, THF, 0 °C 0% - 
Table 5.1: Summarising the results of the asymmetric reduction of the ketone. 
5.7.2 Asymmetric Synthesis of Amine Precursor 
With the difficulties associated with forming the desired enantioenriched alcohol, we turned our 
attention to produce an enantioenriched amine precursor. We considered using the well-known 
Ellman’s auxiliary that has been used extensively in the synthesis of chiral amines. The chiral 
auxiliary acts as a robust directing group for various reactions involving metalation and trapping 
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with an electrophile, usually providing products with high diastereoselectivity. The auxiliary can 
then be removed with mild acidic conditions to furnish the amines in high yield and often high 
enantiomeric excess. Initially, the racemic amine substrate was synthesised by the following 
linear procedure (scheme 5.17). Pyridine 601 was lithiated and trapped with benzaldehyde to 
form alcohol 668 in high yield. Suzuki-Miyaura cross coupling was performed which then 
delivered hydroxy ester 669. An Appel reaction was used to convert the alcohol to alkyl bromide 
670, which was subsequently substituted to form azide 671. Conversion to the corresponding 
amine 672 was performed by either hydrogenolysis or Staudinger reduction. Hydrolysis to the 
amino acid was followed by the key cyclisation/expansion cascade, forming the 10-membered 
lactam 674 in modest yield under high dilution conditions. The lactam was formed as a single 
diastereomer, however is observed in solution as two rotamers, where the ratio was dependant 
on both solvent and temperature. HPLC analysis of the compound was performed, with only 
partial separation of the enantiomers achieved (see Supporting Information).    
 
Scheme 5.17: Synthesis of racemic primary amine and cyclisation/expansion cascade to form medium-
sized ring 674 using high dilution. 
Then, an asymmetric variant of this route was attempted by the following procedure (scheme 
5.18). Pyridine 601 was lithiated and asymmetrically trapped using Ellman’s auxiliary (tert-butyl 
sulfinyl imine 675) to form sulfinamide 676 in a 6:1 diastereomeric ratio in good yield. Suzuki-
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Miyaura cross coupling furnished the bi-aryl ester 677, with a similar mixture of diastereomers 
observed. The auxiliary was removed using acidic conditions, providing amine 678 in presumably 
71% ee (matching the diastereomeric ratio in the compounds made beforehand). Ester 
hydrolysis to the corresponding carboxylic acid 679 was telescoped with the 
cyclisation/expansion cascade to produce the desired lactam 680 in good yield, with no erosion 
of the enantiomeric excess. 
 
Scheme 5.18: Synthesis of enantiomerically enriched primary amine using Ellman's auxiliary and the 
successful cyclisation/expansion cascade. 
5.8 Chapter Summary 
An atroposelective cyclisation/ring expansion cascade reaction has been developed, enabling 
the formation of 10-membered rings via either lactonisation or lactamisation variations. The 
origin of the diastereoselectivity has been probed, using tertiary alcohols and by moving the 
point stereogenic centre. Alternative heteroaromatics have been examined, forming the desired 
10-membered rings, typically in excellent yields, as single diastereomers. An enantioenriched 
medium-sized lactam was also prepared using Ellman’s auxillary. 
This work was completed collaboratively with Dr Aggie Lawer (where stated), and was published 
alongside related examples. Those examples which I have not participated towards, have not 
been included in this Chapter, however are reported in the publication.140 
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Chapter Six: N-Acyl Transfer Cascade - Current and Future Work 
6.1 N-Acyl Transfer Cascade Concept 
The nitrogen induced cyclisation/expansion cascade described in Chapter five, enables 
functionalised medium-sized lactams and lactones to be prepared atroposelectivity. This mild 
cascade reaction exhibits exquisite stereoselectivity, and we envisaged that macrocyclic 
scaffolds could also be synthesised by a related cascade. The simplified concept can be seen in 
scheme 6.1, where a nucleophilic motif performs a cyclisation (681 → 682), which can reversibly 
undergo a ring expansion (682 → 683), which is quickly trapped in a subsequent irreversible 
step (683 → 684). This would deliver functionalised macrocycles in a pre-determined and 
programmable fashion, similar to the successive ring expansion chemistry discussed already, 
however in a single cascade from a linear precursor. 
 
Scheme 6.1: Multiple ring expansion cascade concept. 
We highlighted that the first ring expansion step (682 → 683) would be the most challenging, as 
there appears to be no clear thermodynamic driving force. However, we proposed that if an 
overall lactonisation is performed (similar to Chapter five), even if this N-acyl transfer reaction 
is reversible, the reaction may be driven forward by irreversible lactonisation. Therefore, we 
imagined starting from substrates similar to carboxylic acid 685 (scheme 6.2) and performing an 
in-situ activation to form N-acyl pyridinium intermediate 686. An equilibrium could be 
established whereby a 10-membered N-acyl ammonium intermediate 687 is produced via an 
acyl transfer reaction. This equilibrium would lie heavily towards the 6-membered intermediate, 
due to the transannular strain associated with medium-sized ring formation; however, when the 
10-membered ammonium species is formed in small quantities, the fast and irreversible 
lactonisation ring expansion reaction would form the desired product 688. We hoped that the 
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lactonisation step will be sufficiently fast to remove the 10-membered ammonium species 687 
from solution, hence we can utilise Le Chatelier’s principle to drive the reaction to completion.      
 
Scheme 6.2: Multi-ring expansion cascade forming lactone 688 using pyridinium/ammonium 
intermediates. 
6.2 Synthesis of Linear Precursors and Cyclisation/Expansion Cascade 
Initially, we wanted to test completely aliphatic linear precursors with this new cascade reaction, 
because the synthesis was simple and they have been shown to undergo the cascade described 
in Chapter five. Thus, starting from alkyl ester 689 (scheme 6.3), an SN2 reaction was performed 
with amino alcohol 690. Transformation of the alcohol to the alkyl bromide 692 was performed 
using an Appel reaction with excellent yield. A second SN2 reaction was then completed, 
furnishing ester 693. Finally, ester hydrolysis was performed to deliver the linear carboxylic acid 
precursor 694.  
Unfortunately, using the optimised conditions from the nitrogen induced cascade reaction only 
starting material was observed, with no product formation. Alternative coupling reagents were 
used, such as HATU and CDI, however only starting material was observed in each case.  
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Scheme 6.3: Synthesis of aliphatic linear precursor via successive SN2 reactions and unsuccessful 
cyclisation/expansion cascade reaction. 
Undeterred, we amended the linear precursor to incorporate sp2 hybridised centres to replicate 
the more successful systems from the previous cascade sequence. However, with these 
modifications, the chemistry becomes somewhat long and more laborious, which is shown in 
scheme 6.4. Thus, bromo pyridine 601 was converted to stannane 696 using lithium halogen 
exchange and the resultant organometallic trapped with tributyltin chloride. Initially, a literature 
procedure was utilised to make this stannane,141 however unidentifiable tin residues plagued 
the subsequent steps, despite several purifications,142 and therefore modifications were made. 
The stannane 696 and dibromo pyridine 697 were then combined using a Stille coupling.143 
Although some tri-pyridine side product (not shown) was observed where Stille coupling had 
occurred on both bromines, the major product was the mono-coupled product 698. 
Deprotonation/trapping with Weinreb amide 614 furnished ketone 699, which was 
consequently reduced to the alcohol 700 with sodium borohydride. Suzuki-Miyaura cross 
coupling with boronic ester 631, made ester 701 in excellent yield. Hydrolysis to the acid 702 
was completed and excess base removed via a silica plug, however due to the polarity of the 
compound, purification of the compound was not possible. Therefore, the key cascade 
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expansion reaction utilised the crude product, however was not successful and only the linear 
carboxylic acid was recovered.   
 
Scheme 6.4: Synthesis of linear precursor with sp2 hybridised centres, with unsuccessful 
cyclisation/expansion cascade. 
Although the key cyclisation/expansion cascade had been unsuccessful so far, a route to access 
the starting materials was achieved. We propose from the results obtained, that increased 
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temperature or longer reaction times will likely be required for the reversible N-acyl transfer 
reaction to occur efficiently and produce the desired product.  
6.3 Future Work 
6.3.1 N-Acyl Transfer Cascade 
With a successful route to the linear precursors established, work to find optimised 
cyclisation/expansion conditions is ongoing. This will include (but not limited to): altering 
temperature, solvent, base, carboxylic acid activation method and the use of additives such as 
DMAP. This work will be completed on the linear precursor 694 (scheme 6.5) initially and then 
extended to the aryl-containing linear precursor 702. Additional aromatic precursors, with a 
DMAP bridge (704) and tertiary amine (705) will also be synthesised. 
 
Scheme 6.5: Future work on the N-acyl transfer cascade towards the synthesis of macrocyclic 
lactones. 
6.3.2 Acylation Conditions for Successive Ring Expansion of Lactams 
When performing a second or third consecutive ring expansion, using either amino acid 
chlorides or hydroxy acid chlorides, the acylation step was often slow or did not work entirely. 
To combat this, some examples required additional equivalents and extended reaction times to 
help improve the conversion obtained. We believe that due to the linear fragments 
incorporated, the conformation(s) which is most energetically favourable orientates the NH into 
the internal cavity of the macrocycle. Therefore, when performing a further acylation, the 
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reaction is sluggish/non-productive as higher energy conformations must be accessed to 
produce the desired imide. Thus, developing improved acylation conditions for these failed 
examples is a high priority moving forward. The macrocycles which failed to acylate are shown 
below (scheme 6.6).  
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Scheme 6.6: Macrocycles that did not acylate for a multiple ring expansion. 
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6.3.3 Nitrogen Induced Cyclisation/Annulation Cascade 
Following on from Chapter five, an alternative cascade reaction is proposed, that if successful, 
will produce a tetracyclic annulated system via de-aromatisation of a pyridine (scheme 6.7). 
Therefore, starting from linear fragment 706, carboxylic activation could form N-acyl pyridinium 
intermediate 707. Conversion to the quinone 708 would allow conjugate addition by the 
pendant alcohol to form tetracyclic N,O-acetal 709.   
 
Scheme 6.7: Pyridine induced cyclisation/de-aromatising annulation cascade reaction. 
The linear precursor is very similar to those previously synthesised, with only the initial 
deprotonation/trapping reaction differing. It is plausible that the deprotonated pyridine (710) 
could attack into bromo ester 424 chemoselectivity to form ester 711. Reduction of ester using 
DIBAL could produce alcohol 712, which would subsequently be subjected to Suzuki–Miyaura 
coupling and hydrolysis to furnish the desired linear precursor 714.    
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Chapter Seven: Experimental 
7.1 General Experimental 
Except where stated, all reagents were purchased from commercial sources and used without 
further purification. Except where stated, all experimental procedures were carried out under 
an atmosphere of argon. Anhydrous CH2Cl2, toluene and acetonitrile were obtained from an 
Innovative Technology Inc. PureSolv® solvent purification system and stored over activated 5Å 
molecular sieves. Triethylamine (Et3N) was purified via distillation and stored over activated 5 Å 
molecular sieves. 1H NMR and 13C NMR spectra were recorded on a JEOL ECX400 or JEOL ECS400 
spectrometer, operating at 400 MHz and 100 MHz, respectively. All spectral data was acquired 
at 295 K unless stated. Chemical shifts (δ) are quoted in parts per million (ppm). The residual 
solvent peak, δH 7.26 and δC 77.0 for CDCl3 was used as a reference. Coupling constants (J) are 
reported in Hertz (Hz) to the nearest 0.1 Hz. The multiplicity abbreviations used are: s singlet, d 
doublet, t triplet, q quartet, td triple doublets, tt triple triplets, dq double quartets,  m multiplet. 
Signal assignment was achieved by analysis of DEPT, COSY, NOESY, HMBC and HSQC experiments 
where required. Infrared (IR) spectra were recorded on a PerkinElmer UATR two spectrometer 
as a thin film. Mass-spectra (low and high-resolution) were obtained by the University of York 
Mass Spectrometry Service, using electrospray ionisation (ESI) on a Bruker Daltonics, Micro-tof 
spectrometer. Melting points were determined using Gallenkamp apparatus and are 
uncorrected. Thin layer chromatography was carried out on Merck silica gel 60F254 pre-coated 
aluminium foil sheets and were visualised using UV light (254 nm) and stained with basic 
aqueous potassium permanganate. Flash column chromatography was carried out using slurry 
packed Fluka silica gel (SiO2), 35–70 µm, 60 Å, under a light positive pressure, eluting with the 
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7.2 Characterisation Data and Procedures 
General procedure for acid chloride formation:  
 
Oxalyl chloride (3 mmol) was added to a suspension of carboxylic acid (1 mmol) in CH2Cl2 (5 mL), 
followed by a catalytic amount of DMF (1 drop/mmol of carboxylic acid). The resulting mixture 
was stirred at room temperature for 1 h [in general the initial suspension became homogeneous 
over this period] and concentrated in vacuo to remove all of the solvent and excess oxalyl 
chloride. 
2-((9H-Fluoren-9-yl)methoxy)-4H-benzo[d][1,3]oxazin-4-one (305) 
A mixture of ethyl 2-oxocyclooctane-1-carboxylate (0.184 g, 0.998 mmol), 
MgCl2 (0.190 g, 2.00 mmol) and pyridine (0.47 mL, 5.99 mmol) in CH2Cl2 (5 
mL) under an argon atmosphere was stirred at room temperature for 30 
min. Next, a solution of acid chloride (3.00 mmol, prepared using the 
general procedure) in CH2Cl2 (5 mL) was added and the reaction mixture was 
stirred for 18 h at room temperature. Upon completion, the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% ethyl acetate in 
hexanes → ethyl acetate) afforded the title compound as a colourless oil (721 mg, 89%); RF 0.78 
(ethyl acetate); δH (400 MHz, CDCl3) 7.83–7.65 (6H, m, 6 × CH), 7.45–7.30 (6H, m, 6 × CH), 4.66 
(2H, d, J = 7.6 Hz, CH2O), 4.41 (1H, t, J = 7.6 Hz, CHCH2O); δC (100 MHz, CDCl3) 159.5 (C=O), 154.6 
(C=N), 148.1 (C), 143.1 (CH), 141.3 (CH), 136.9 (CH), 129.0 (CH), 128.0 (2 × CH), 127.2 (2 × CH), 
126.0 (C), 125.4 (C), 125.3 (2 × CH), 120.1 (2 × CH), 114.5 (C).     
Ethyl 3,15-dioxoazacyclopentadecane-4-carboxylate (309) 
A mixture of ethyl 2-oxocyclododecane-1-carboxylate (100 mg, 0.393 
mmol), MgCl2 (75 mg, 0.786 mmol) and pyridine (190 µL, 2.35 mmol) in 
CH2Cl2 (3 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of acid chloride (1.18 mmol, 
prepared using the general procedure) in CH2Cl2 (2 mL) was added and 
the reaction mixture was stirred for 2 h at r.t. The mixture was then diluted with CH2Cl2 (50 mL) 
and washed with 10% aq. HCl (25 mL). The aqueous layer was extracted with CH2Cl2 (3 × 20 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (4 mL) and piperidine (0.39 mL, 3.93 mmol) was added. 
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The resulting mixture was stirred for 2 h, at room temperature, before the solvent was removed 
in vacuo. Purification by flash column chromatography (SiO2, hexane:ethyl acetate 10:1 → 2:1 
→ ethyl acetate) afforded the title compound (as a 10:1 mixture of keto:enol tautomers) as a 
colourless oil (62 mg, 50%); RF 0.35 (50% ethyl acetate in hexanes); δH (400 MHz, CDCl3) data for 
the keto tautomer only: 6.29 (1H, br s, NH), 4.22 (2H, s, CH2NH), 4.18 (2H, q, J = 6.9 Hz, OCH2CH3), 
3.61 (1H, dd, J = 9.2, 5.4 Hz, CHCO2Et), 2.30–2.23 (2H, m, CH2CONH), 2.00–1.90 (2H, m, CH2), 
1.72–1.64 (2H, m, CH2), 1.33–1.16 (17H, m, 7 × CH2 and CH3). Data is consistent with those 
previously reported.112 
Ethyl-4,11-dioxo-2-phenyl-1-azacycloundecane-5-carboxylate (310)  
A mixture of ethyl 2-oxocycloheptane-1-carboxylate (184 mg, 0.998 
mmol), MgCl2 (0.190 g, 2.00 mmol) and pyridine (0.47 mL, 5.99 mmol) 
in CH2Cl2 (5 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of acid chloride (3.00 mmol, 
prepared using the general procedure) in CH2Cl2 (5 mL) was added and the reaction mixture was 
stirred for 2 h at r.t. The mixture was then diluted with CH2Cl2 (50 mL) and washed with 10% aq. 
HCl (25 mL). The aqueous layer was extracted with CH2Cl2 (3 × 20 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (10 mL) and piperidine (0.99 mL, 9.98 mmol) was added. The resulting mixture was 
stirred for 2 h, at room temperature, before the solvent was removed in vacuo. Purification by 
flash column chromatography (SiO2, hexane:ethyl acetate 10:1 → 2:1 → ethyl acetate) afforded 
the title compound as a white solid (164 mg, 50%) as a 4:1 mixture of diastereoisomers; m.p. 
163–165 °C (chloroform); RF = 0.35 (hexane:ethyl acetate 1:1); νmax/cm–1 (neat) 3303, 2925, 1723, 
1708, 1643, 1540, 1454; δH (400 MHz, CDCl3) 7.37–7.25 (10H, m, Ph, both diastereoisomers), 
6.09 (1H, d, J = 9.9 Hz, NH, major diastereoisomer), 5.90 (1H, d, J = 9.2 Hz, NH, minor 
diastereoisomer), 5.63–5.57 (1H, m, CHN, minor) 5.51 (1H, td, J = 10.7, 3.5, CHN, major), 4.20–
4.12 (4H, m, OCH2, both), 3.88 (1H, dd, J = 11.4, 3.1 Hz, major), 3.58 (1H, dd, J = 12.2, 3.1 Hz, 
minor), 3.39 (1H, dd, J = 13.7, 11.4 Hz, major), 3.30–3.22 (1H, m, minor), 3.01–2.90 (2H, m, both), 
2.34–2.13 (5H, m), 1.97–1.88 (2H, m), 1.85–1.45 and 1.31–1.05 (19H, m, both); δC (100 MHz, 
CDCl3) data for the major diastereoisomer only: 205.2 (CO, ketone), 172.7 (CO, ester/amide), 
169.0 (CO, ester/amide), 140.7 (C), 128.7 (CH), 127.7 (CH), 126.3 (CH), 61.5 (OCH2), 58.9 (CHN), 
51.9 (CHCO2Et), 47.2 (CH2), 38.0 (CH2), 26.7 (CH2), 26.1 (CH2), 24.7 (CH2), 23.5 (CH2), 14.1 (CH3); 
HRMS (ESI): calcd. for C19H25NNaO4, 354.1676. Found: C19H25NaNO4 [MNa]+, 354.1672 (1.0 ppm 
error)]. 
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Ethyl 2-methyl-4,12-dioxoazacyclododecane-5-carboxylate (312) 
A mixture of methyl 2-oxocyclooctane-1-carboxylate (193 mg 0.973 
mmol), MgCl2 (185 mg, 1.95mmol) and pyridine (0.470 mL, 5.84 
mmol) in CH2Cl2 (6.8 mL) under an argon atmosphere was stirred at 
r.t. for 30 min. Next, a solution of acid chloride (2.92 mmol, prepared 
using the general procedure) in CH2Cl2 (2.9 mL) was added and the reaction mixture was stirred 
for 1 h at r.t. The mixture was then diluted with CH2Cl2 (50 mL) and washed with 10% aq. HCl (50 
mL). The aqueous layer was extracted with CH2Cl2 (3 × 50 mL) and the combined organic extracts 
were dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved in 
CH2Cl2 (9.7 mL) and piperidine (0.970 mL, 9.73 mmol) was added. The resulting mixture was 
stirred for 1 h at r.t., before the solvent was removed in vacuo. Purification by column 
chromatography (SiO2, 10:1 → 1:1 hexane:ethyl acetate → ethyl acetate) afforded the title 
compound (180 mg, 65%) as a white solid as a 4:1 mixture of diastereoisomers; m.p. 116–118 °C 
(chloroform); RF = 0.30 (EtOAc); νmax (thin film)/cm-1 3286, 2932, 1742, 1711, 1638, 1540, 1448; 
δH (400 MHz, CDCl3) 5.73 (1H, br s, minor diastereoisomer), 5.65 (1H, br s, major 
diastereoisomer), 4.52–4.42 (1H, m, NCH, major), 4.33–4.26 (1H, m, NCH, minor), 4.18–4.11 (4H, 
m, OCH2 both), 3.67 (1H, dd, J = 10.7, 3.1 Hz, CH, major), 3.41 (1H, dd, J = 10.7, 3.8 Hz, CH, minor), 
3.09 (1H, dd, J = 16.8, 4.6 Hz, CH, major), 2.99 (1H, dd, J = 16.8, 3.8 Hz, CH, minor), 2.77 (1H, dd, 
J = 16.8, 6.1 Hz, CH, minor), 2.65 (1H, dd, J = 16.8, 7.6 Hz, CH, major), 2.25–1.98 (6H, m, both), 
1.79–1.10 (30H, m, both); δC (100 MHz, CDCl3) data for the major diastereoisomer only: 205.8 
(CO, ketone), 173.7 (CO, ester/amide), 169.4 (CO, ester/amide), 61.4 (CH), 56.0 (CH2), 47.7 (CH2), 
42.7 (CH), 37.5 (CH2), 27.8 (CH2), 26.4 (CH2), 26.0 (CH2), 25.1 (CH2), 23.3 (CH2), 20.9 (CH3), 14.0 
(CH3); HRMS (ESI): Found: 306.1676; C15H25NNaO4 [MNa]+. Requires 306.1676 (0.1 ppm error). 
Ethyl 2-oxocyclononane-1-carboxylate (326) 
To a solution of cyclooctenone (7.57 g, 60.0 mmol) in Et2O (120 mL) at 0 
°C, was added a solution of BF3.OEt2 (11.4 mL, 90.0 mmol) in Et2O (30 mL) 
over 5 min. A solution of ethyl diazoacetate (87% wt. in CH2Cl2, 11.0 mL, 
90.0 mmol) in Et2O (31 mL), was then added over a period of 15 min, causing a vigorous evolution 
of gas. The resulting solution was allowed to warm to room temperature under an argon 
atmosphere over 16 h, where the mixture was cooled to 0 °C and neutralised with saturated 
aqueous solution of NaHCO3. The resulting mixture was extracted with chloroform (3 × 100 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo. Purification by 
flash column chromatography (SiO2, 20:1 hexane:ethyl acetate) afforded the title compound (as 
a 1:1 mixture of ketone:enol tautomers) as an orange oil (9.83 g, 77%); Rf 0.75 & 0.65 
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ketone/enol tautomers (CH2Cl2); νmax/cm–1 (neat); 2927, 1745, 1706, 1640, 1609; δH (400 MHz, 
CDCl3) 12.74 (1H, s, OH, enol), [4.19 (2H, q, J = 7.3 Hz, OCH2CH3), 4.12 (2H, q, J = 6.9 Hz, OCH2CH3), 
ketone and enol], 3.66–3.54 (1H, m, CHCO2Et, ketone), [2.67–2.50 (2H, m, CH2COCH), 2.38 (2H, 
t, J = 6.0 Hz, CH2COH), 2.35–2.28 (2H, m, CH2), 2.13–2.03 (2H, m, CH2), 1.94–1.79 (2H, m, CH2), 
1.77–1.67 (2H, m, CH2), 1.67–1.32 (16H, m, 8 × CH2), 1.28 (3H, t, J = 7.3 Hz, CH3), 1.21 (3H, t, J = 
6.9 Hz, CH3), ketone and enol]; δC (100 MHz, CDCl3) 212.0 (COCH2, ketone), 175.9 (CO2Et, ketone), 
173.5 (COH, enol), 170.7 (CO2Et, enol), 100.3 (CCO2Et, enol), 61.3 (OCH2, enol), 60.3 (OCH2, 
ketone), 58.9 (CHCO2Et, ketone), 42.5 (CH2COCH, ketone), [31.5 (CH2), 27.1 (CH2), 27.0 (CH2), 
26.2 (CH2), 25.9 (CH2), 25.2 (CH2), 25.0 (CH2), 24.7 (CH2), 24.64 (CH2), 24.56 (CH2), 24.4 (CH2), 
24.01 (CH2), 23.96 (CH2), ketone and enol], 14.4 (CH3, enol), 14.1 (CH3, ketone); HRMS (ESI): 
calcd. for C12H20NaO3, 235.1305. Found: [MNa]+, 235.1304 (0.7 ppm error)]. Data is consistent 
with those previously reported.144 
Cyclononanone (327) 
 A degassed solution of ethyl 2-oxocyclononane-1-carboxylate (10.6 g, 50.0 mmol) 
in DMSO (50 mL) and H2O (10 mL) was refluxed at 160 °C for 16 h. After cooling to 
room temperature, the mixture was partitioned between water (80 mL) and Et2O 
(3 × 100 mL), the combined organic phases were dried over MgSO4, before the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 20:1 hexane:ethyl acetate 
→ 10:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title compound as a 
yellow oil (6.52 g, 93%); Rf 0.30 (CH2Cl2); δH (400 MHz, CDCl3) 2.47–2.36 (2H, m, CH2), 1.93–1.76 
(2H, m, CH2), 1.61–1.51 (2H, m, CH2), 1.42–1.30 (2H, m, CH2). Data consistent with those 
reported in the literature.145 
Ethyl 2-oxocyclodecane-1-carboxylate (328) 
To a solution of cyclononanone (1.87 g, 13.3 mmol) in Et2O (26 mL) at 0 
°C, was added a solution of BF3.OEt2 (2.51 mL, 20 mmol) in Et2O (10 mL) 
over 5 min. A solution of ethyl diazoacetate (87% wt. in CH2Cl2, 2.45 mL, 
30.0 mmol) in Et2O (7.5 mL), was then added over a period of 15 min, causing a vigorous 
evolution of gas. The resulting solution was allowed to warm to room temperature under an 
argon atmosphere over 16 h, where the mixture was cooled to 0 °C and neutralised with 
saturated aqueous solution of NaHCO3. The resulting mixture was extracted with chloroform (3 
× 40 mL) and the combined organic extracts dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, 20:1 hexane:ethyl acetate) afforded the title 
compound (as a 3:2 mixture of ketone:enol tautomers) as a yellow oil (1.72 g, 57%); Rf 0.72 & 
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0.64 ketone/enol tautomers (CH2Cl2); νmax/cm–1 (neat) 2926, 1744, 1707, 1638, 1602; δH (400 
MHz, CDCl3) 12.95 (1H, s, OH, enol), 4.20 (2H, q, J = 7.3 Hz, OCH2CH3, enol), 4.12 (2H, q, J = 7.3 
Hz, OCH2CH3, keto), 3.81 (1H, dd, J = 3.2, 11.0 Hz, CHCO2Et, keto), 2.76–2.64 (2H, m, CH2CO, 
keto), [2.45–2.34 (2H), 2.24–2.04 (2H), 2.00–1.87 (2H), 1.86–1.70 (4H), 1.69–1.31 (20H), 7 × CH2 
(keto and enol) and CH2CO (enol)], 1.29 (3H, t, J = 7.3 Hz, OCH2CH3, enol), 1.22 (3H, t, J = 7.3 Hz, 
OCH2CH3, keto); δC (100 MHz, CDCl3) data for the ketone tautomer only: 209.0 (COCH), 169.9 
(COOEt), 61.4 (OCH2), 57.9 (CH), 42.2 (CH2CO), 30.2 (CH2), 27.3 (CH2), 25.3 (CH2), 25.2 (CH2), 24.5 
(CH2), 23.7 (CH2), 21.1 (CH2), 14.1 (CH3). Diagnostic 13C NMR resonances for the enol tautomer: 
175.1, 173.7, 99.9 (CCO2Et), 60.3 (OCH2), 38.5 (CH2CO). HRMS (ESI): calcd. for C13H22NaO3, 
249.1461. Found: [MNa]+, 249.1463 (−0.7 ppm error)]. Data is consistent with those previously 
reported.144 
Cyclodecanone (329) 
A degassed solution of ethyl 2-oxocyclodecane-1-carboxylate (1.70 g, 7.52 mmol) 
in DMSO (7.5 mL) and H2O (2 mL) was refluxed at 160 °C for 16 h. After cooling to 
room temperature, the mixture was partitioned between water (30 mL) and Et2O 
(3 × 100 mL), where the combined organic phases were dried over MgSO4, before the solvent 
was removed in vacuo. Purification by flash column chromatography (SiO2, 20:1 hexane:ethyl 
acetate → 10:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title compound 
as a yellow oil (1.04 g, 90%); Rf 0.71 (ethyl acetate); δH (400 MHz, CDCl3) 2.52–2.46 (4H, m, 2 × 
CH2CO), 1.89–1.79 (4H, m, CH2CH2CO), 1.60–1.29 (10H, m, 5 × CH2). Data is consistent with those 
previously reported in the literature.146 
Ethyl 2-oxocyclodecane-1-carboxylate (330) 
To a solution of cyclodecanone (4.86 g, 31.5 mmol) in Et2O (60 mL) at 0 
°C, was added a solution of BF3.OEt2 (5.93 mL, 47.3 mmol) in Et2O (10 mL) 
over 5 min. A solution of ethyl diazoacetate (87% wt. in CH2Cl2, 5.79 mL, 
47.3 mmol) in Et2O (10 mL), was then added over a period of 15 min, 
causing a vigorous evolution of gas. The resulting solution was allowed to warm to room 
temperature under an argon atmosphere over 16 h, where the mixture was cooled to 0 °C and 
neutralised with sat. aq. solution of NaHCO3. The resulting mixture was extracted with CHCl3 (3 
× 100 mL) and the combined organic extracts dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, 20:1 hexane:ethyl acetate) afforded the title 
compound (as a 2:1 mixture of ketone:enol tautomers) as a yellow oil (5.84 g, 77%); RF 
0.81&0.77(CH2Cl2); νmax/cm–1 (thin film) 2929, 2865, 1745, 1710, 1638, 1603; δH (400 MHz, CDCl3) 
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12.96 (1H, s, OH, enol tautomer), 4.26–4.07 (4H, m, CH2O, both tautomers), 3.67 (1H, dd, J = 
10.5, 2.9 Hz, CHCO2Et, keto tautomer), 2.74 (1H, ddd, J = 16.4, 9.2, 3.2 Hz, CHH′, keto), 2.58 (1H, 
ddd, J = 16.4, 9.2, 3.2 Hz, CHH′, keto), 2.53–2.42 (2H, m, CHH′, both), 2.38 (1H, t, J = 6.3 Hz, CHH′, 
keto), 2.35–2.30 (1H, m, CHH′, enol), 2.14–2.02 (1H, m, CHH′, keto), 1.97–1.87 (1H, m, CHH′, 
keto), 1.87–1.14 (34H, m, both); δC (100 MHz, CDCl3) data for the keto tautomer only: 208.6 (CO), 
170.0 (CO), 61.4 (CH2O), 58.2 (CHCO2Et), 41.5 (CH2CO), 26.5 (CH2), 25.6 (CH2), 25.0 (CH2), 24.69 
(CH2), 24.67 (CH2), 24.4 (CH2), 24.3 (CH2), 22.5 (CH2), 14.2 (CH3); HRMS (ESI): calcd. for 
C14H24NaO3, 263.1618. Found: [MNa]+, 263.1615 (1.1 ppm error). Data is consistent with those 
previously reported.144 
Ethyl 4,13-dioxoazacyclotridecane-5-carboxylate (334) 
A mixture of ethyl 2-oxocyclononane-1-carboxylate (84 mg, 0.393 mmol), 
MgCl2 (75 mg, 0.780 mmol) and pyridine (0.190 mL, 2.36 mmol) in CH2Cl2 (3 
mL) under an argon atmosphere was stirred at room temperature for 30 min. 
Next, a solution of acid chloride (1.18 mmol, prepared using the general 
procedure) in CH2Cl2 (1 mL) was added and the reaction mixture was stirred 
for 2 h, at room temperature. The mixture was then diluted with CH2Cl2 (20 mL) and washed 
with 10% aq. HCl (25 mL). The aqueous layer was extracted with CH2Cl2 (3 × 25 mL) and the 
combined organic extracts were dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (4 mL) and piperidine (0.390 mL, 3.93 mmol) was added. 
The resulting mixture was stirred for 2 h, at room temperature, before the solvent was removed 
in vacuo. Purification by column chromatography (SiO2, 5:1 hexane:ethyl acetate→ethyl 
acetate) afforded the title compound as a white solid (83.0 mg, 74%); m.p. 121–123 °C 
(chloroform); RF 0.18 (1:1 hexane:ethyl acetate); νmax/cm–1 (thin film) 3395, 3288, 3072, 2932, 
2862, 1742, 1709, 1640, 1539; δH (400 MHz, CDCl3) 6.38 (1H, br s, NH), 4.07 (2H, q, J = 6.9 Hz, 
OCH2CH3), 3.63–3.50 (1H, m, CHH′NH), 3.43–3.30 (2H, m, CHH′NH and CHCO2Et), 2.95–2.74 (2H, 
m, CH2COCH), 2.18–1.99 (2H, m, CH2CONH), 1.88–1.71 (2H, m, CH2CH), 1.67–0.96 (13H, m, 5 × 
CH2 and CH3); δC (100 MHz, CDCl3) 207.1 (CO), 173.7 (CO), 169.5 (CO), 61.3 (OCH2), 58.3 
(CHCO2Et), 42.2 (CH2COCH), 36.5 (CH2CONH), 34.0 (CH2NH), 27.6 (CH2CH), 26.1 (CH2), 25.6 (CH2), 
25.5 (CH2), 24.4 (CH2), 24.1 (CH2), 14.1 (CH3); HRMS (ESI): calcd. for C15H25NNaO4, 306.1676. 




Chapter Seven: Experimental 
 
136 | P a g e  
 
Ethyl 4,14-dioxoazacyclotetradecane-5-carboxylate (335) 
 A mixture of ethyl 2-oxocyclodecane-1-carboxylate (89 mg, 0.393 
mmol), MgCl2 (75.0 mg, 0.780 mmol) and pyridine (0.190 mL, 2.36 
mmol) in CH2Cl2 (3 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of acid chloride (1.18 mmol, 
prepared using the general procedure) in CH2Cl2 (1 mL) was added and the reaction mixture was 
stirred for 2 h, at room temperature. The mixture was then diluted with CH2Cl2 (20 mL) and 
washed with 10% aq. HCl (25 mL). The aqueous layer was extracted with CH2Cl2 (3 × 25 mL) and 
the combined organic extracts were dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (4 mL) and piperidine (0.390 mL, 3.93 mmol) was added. 
The resulting mixture was stirred for 2 h, at room temperature, before the solvent was removed 
in vacuo. Purification by column chromatography (SiO2, 5:1 hexane:ethyl acetate→ethyl 
acetate) afforded the title compound as a colourless oil (60.0 mg, 52%); RF 0.28 (1:1 hexane:ethyl 
acetate); νmax/cm–1 (thin film) 3300, 3064, 2929, 2859, 1738, 1709, 1643, 1607; δH (400 MHz, 
CDCl3) 6.14 (1H, br s, NH), 4.12 (2H, q, J = 6.9 Hz, OCH2), 3.59–3.48 (2H, m, CH2NH), 3.44 (1H, dd, 
J = 10.7, 3.8 Hz, CHCO2Et), 2.91–2.66 (2H, m, CH2COCH), 2.12 (2H, t, J = 6.1 Hz, CH2CONH), 2.04–
1.90 (1H, m, CHH′CH), 1.85–1.72 (1H, m, CHH′CH), 1.70–1.02 (15H, m, 6 × CH2 and CH2CH3); δC 
(100 MHz, CDCl3) 206.6 (CO), 172.9 (CO), 169.6 (CO), 61.5 (OCH2), 58.3 (CHCO2Et), 41.5 
(CH2COCH), 34.7 (CH2CONH), 33.3 (CH2NH), 28.7 (CH2CH), 26.7 (CH2), 26.2 (CH2), 25.3 (CH2), 25.0 
(CH2), 24.8 (CH2), 24.5 (CH2), 14.2 (CH3); HRMS (ESI): calcd. for C16H27NNaO4, 320.1832. Found: 
[MNa]+, 320.1826 (1.7 ppm error). 
Ethyl 4,15-dioxoazacyclopentadecane-5-carboxylate (336) 
 A mixture of ethyl 2-oxocycloundecane-1-carboxylate (94.0 mg, 
0.393 mmol), MgCl2 (75 mg, 0.780 mmol) and pyridine (0.190 mL, 
2.36 mmol) in CH2Cl2 (3 mL) under an argon atmosphere was stirred 
at room temperature for 30 min. Next, a solution of acid chloride 
(1.18 mmol, prepared using the general procedure) in CH2Cl2 (1 mL) was added and the reaction 
mixture was stirred for 2 h, at room temperature. The mixture was then diluted with CH2Cl2 (20 
mL) and washed with 10% aq. HCl (25 mL). The aqueous layer was extracted with CH2Cl2 (3 × 25 
mL) and the combined organic extracts were dried over MgSO4 and concentrated in vacuo. The 
crude material was then re-dissolved in CH2Cl2 (4 mL) and piperidine (0.390 mL, 3.93 mmol) was 
added. The resulting mixture was stirred for 2 h, at room temperature, before the solvent was 
removed in vacuo. Purification by column chromatography (SiO2, 5:1 hexane:ethyl acetate → 
1:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound (as a 3:1 mixture of 
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rotamers) as a colourless oil (79 mg, 65%); Rf 0.21 (1:1 hexane:ethyl acetate); νmax/cm–1 (thin 
film) 3300, 2928, 2857, 1740, 1710, 1642, 1538; δH (400 MHz, CDCl3) 6.20 (1H, br t, J = 5.5 Hz, 
NH, major rotamer), 6.12 (1H, br t, J = 5.3 Hz, NH, minor rotamer), 4.19–4.08 (4H, m, CH2CH3, 
both rotamers), 3.71–3.62 (1H, m, CHH′NH, major), 3.56–3.50 (1H, m, CHH′NH, minor), 3.45 (1H, 
dd, J = 10.3, 4.0 Hz, CHCO2Et, both), 3.35–3.24 (2H, m, CHH′NH, both), 2.91–2.79 (4H, m, 
CH2COCH, both), 2.37–1.93 (8H, m, 2 × CH2, both), 1.87–1.05 (34H, m, 7 × CH2 and CH3, both); δC 
(100 MHz, CDCl3) data for the major rotamer only: 206.7 (CO), 173.5 (CO), 169.6 (CO), 61.7 
(CH2CH3), 58.0 (CHCO2Et), 43.7 (CH2NH), 36.2 (CH2CO), 34.0 (CH2CO), 28.5 (CH2), 28.0 (CH2), 27.6 
(CH2), 27.2 (CH2), 26.9 (CH2), 26.8 (CH2), 26.6 (CH2), 25.0 (CH3); HRMS (ESI): calcd. for 
C17H29NNaO4, 334.1989. Found: [MNa]+, 334.1983 (1.8 ppm error). 
3-(Benzyloxy)propanoic acid (351) 
This compound has been prepared using the following literature 
procedure.120 β-Propiolactone (15.4 g, 0.214 mol) and benzyl 
alcohol (53.3 mL, 0.514 mol) were stirred at 80 °C for 24 h. Upon 
completion, the reaction was cooled to room temperature and quenched with 1 m NaOH(aq) (400 
mL) and the aqueous phase was washed with CH2Cl2 (3 × 50 mL). The aqueous phase was then 
acidified to pH 1 using 10% HCl(aq) and extracted with ethyl acetate (3 × 150 mL). The combined 
organic extracts were dried over MgSO4, filtered and the solvent was removed in vacuo to afford 
the title compound as a colourless oil (35.1 g, 91%); RF 0.50 (ethyl acetate); δH (400 MHz, CDCl3) 
10.2 (1H, br s, CO2H), 7.39–7.24 (5H, m, 5 × CH), 4.55 (2H, s, OCH2Ph), 3.75 (2H, t, J = 6.1 Hz, 
CH2OBn), 2.66 (2H, t, J = 6.1 Hz, CH2OBn). Data is consistent with those previously reported.120 
Ethyl 4,9-dioxooxonane-5-carboxylate (352) 
 A mixture of ethyl 2-oxocyclopentane-1-carboxylate (61 mg, 0.393 mmol), 
MgCl2 (75 mg, 0.780 mmol) and pyridine (0.190 mL, 2.36 mmol) in CH2Cl2 
(3 mL) under an argon atmosphere was stirred at room temperature for 
30 min. Next, a solution of acid chloride (1.18 mmol, prepared using the general procedure) in 
CH2Cl2 (1 mL) was added and the reaction mixture was stirred for 2 h, at room temperature. The 
solvent was then concentrated in vacuo, loaded onto a short silica plug and eluted with ethyl 
acetate, to remove the majority of excess carboxylic acid and pyridine residues, and 
concentrated in vacuo. This material was re-dissolved in ethyl acetate (3.9 mL) and placed under 
an argon atmosphere. Palladium on carbon (39 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 18 h. The reaction was 
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then purged with argon, filtered through Celite, washed with ethyl acetate and the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (3.9 mL) and 
triethylamine (82 µL, 0.590 mmol) added, and stirred at room temperature for 18 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate) 
afforded the title compound (as a 2:3 mixture of keto:enol tautomeric forms) as a colourless oil 
(53 mg, 59%); RF 0.45 (1:1 hexane:ethyl acetate); νmax/cm–1 (thin film) 2979, 1738, 1641, 1613; 
δH (400 MHz, CDCl3) 12.81 (1H, s, OH, enol tautomer), 4.93–4.84 (1H, m, OCHH′CH2, keto 
tautomer), 4.36–4.28 (1H, m, OCHH′CH2, keto), 4.27–4.08 (6H, m, OCH2CH3, both tautomers and 
OCH2CH2, enol), 3.57 (1H, dd, J = 9.9, 4.0 Hz, CHCO2Et, keto), 3.06–2.98 (1H, m, CHH′CO, keto), 
2.90–2.81 (1H, m, CHH′CO, keto), 2.50–2.27 (6H, m, 3 × CH2, both), 2.21–1.93 (8H, m, 4 × CH2, 
both), 1.34–1.18 (6H, m, CH3, both); δC (100 MHz, CDCl3) 205.4 (CO), 175.2 (CO), 174.5 (CO), 
173.1 (CO), 170.8 (CO), 169.1 (CO), 103.5 (CCO2Et, enol), 61.7 (CH2O), 61.5 (CH2O), 60.8 (CH2O), 
60.6 (CH2O), 57.8 (CHCO2Et, keto), 41.2 (CH2), 38.2 (CH2), 34.8 (CH2), 33.3 (CH2), 27.5 (CH2), 26.8 
(CH2), 23.4 (CH2), 23.3 (CH2), 14.4 (CH3), 14.2 (CH3); HRMS (ESI): calcd. for C11H16NaO5, 251.0890. 
Found: [MNa]+, 251.0886 (1.6 ppm error). 
Ethyl 4,10-dioxooxecane-5-carboxylate (353) 
 A mixture of ethyl 2-oxocyclohexane-1-carboxylate (67 mg, 0.393 
mmol), MgCl2 (75 mg, 0.780 mmol) and pyridine (0.190 mL, 2.36 
mmol) in CH2Cl2 (3 mL) under an argon atmosphere was stirred at 
room temperature for 30 min. Next, a solution of acid chloride (1.18 mmol, prepared using the 
general procedure) in CH2Cl2 (3 mL) was added and the reaction mixture was stirred for 2 h, at 
room temperature. The solvent was then concentrated in vacuo, loaded onto a short silica plug 
and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and 
pyridine residues, and concentrated in vacuo. This material was re-dissolved in ethyl acetate (3.9 
mL) and placed under an argon atmosphere. Palladium on carbon (39 mg, Pd 10% on carbon) 
was then added and the reaction vessel was backfilled with hydrogen (via balloon) several times, 
then stirred at room temperature under a slight positive pressure of hydrogen (balloon) for 16 
h. The reaction was then purged with argon, filtered through Celite, washed with ethyl acetate 
and the solvent was removed in vacuo. The crude material was then re-dissolved in chloroform 
(3.9 mL) and triethylamine (82.0 µL, 0.590 mmol) added, and stirred at room temperature for 
16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 
hexane:ethyl acetate → ethyl acetate) afforded the title compound (as a 3:2 mixture of keto:enol 
tautomeric forms) as a colourless oil (53 mg, 56%); Rf 0.49 (1:1 hexane:ethyl acetate); νmax/cm–1 
(thin film) 2943, 2874, 1732, 1715, 1642; δH (400 MHz, CDCl3) 12.74 (1H, s, OH, enol), 4.72–4.62 
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(1H, m, CHH′O, keto), 4.32–4.07 (7H, m, CHH′O, keto, and CH2O, enol and CH3CH2O, both), 3.68 
(1H, dd, J = 9.9, 4.6 Hz, CHCO), 2.99–2.90 (1H, m, CHH′COCH, keto), 2.85–2.75 (1H, m, CHH′COCH, 
keto), 2.46–2.36 (1H, m, CHH′COO, keto), 2.34–2.10 (5H, m, CHH′COO, keto, and CH2COO, enol 
and CH2COH, enol), 2.02–1.33 (12H, m, 3 × CH2, both), 1.29 (3H, t, J = 6.9 Hz, CH3, enol), 1.24 
(3H, t, J = 6.9 Hz, keto); δC (100 MHz, CDCl3) 206.2 (CO, keto), 174.6 (COH, enol), 173.2 (CO, enol), 
173.0 (CO, keto), 170.7 (CO, enol), 169.4 (CO, keto), 102.5 (C), 61.53 (CH3CH2O, keto/enol), 61.49 
(CH3CH2O, keto/enol), 61.0 (CH2O, enol), 60.5 (CH2O, keto), 58.3 (CH, keto), 39.8 (CH2CO, keto), 
35.9 (CH2COO, enol), 34.6 (CH2COO, keto), 31.1 (CH2COH, enol), 27.9 (CH2, enol), 26.6 (CH2, keto), 
24.5 (CH2, enol), 24.0 (CH2, keto), 23.3 (CH2, enol), 22.1 (CH2, keto), 14.3 (CH3, enol, 14.2 (CH3, 
keto); HRMS (ESI): calcd. for C12H18NaO5, 265.1046. Found: [MNa]+, 265.1035 (1.1 ppm error). 
Ethyl 4,11-dioxooxacycloundecane-5-carboxylate (280) 
 A mixture of ethyl 2-oxocycloheptane-1-carboxylate (72.0 mg, 0.393 
mmol), MgCl2 (75.0 mg, 0.780 mmol) and pyridine (0.190 mL, 2.36 
mmol) in CH2Cl2 (3 mL) under an argon atmosphere was stirred at 
room temperature for 30 min. Next, a solution of acid chloride (1.18 mmol, prepared using the 
general procedure) in CH2Cl2 (1 mL) was added and the reaction mixture was stirred for 2 h, at 
room temperature. The mixture was then loaded onto a short silica plug and eluted with 2:1 
hexane:ethyl acetate to remove excess pyridine and carboxylic acid residues. The crude material 
was then dissolved in ethyl acetate (3.9 mL) and placed under an argon atmosphere. Palladium 
on carbon (39 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled 
with hydrogen (via balloon) several times, then stirred at room temperature under a slight 
positive pressure of hydrogen (balloon) for 3 h. The reaction was then purged with argon, 
filtered through Celite, washed with methanol before the solvent was removed in vacuo. The 
crude material was dissolved in chloroform (3.9 mL) and triethylamine (82.0 µL, 0.590 mmol) 
added and then stirred at room temperature for 18 h, where the solvent was removed in vacuo. 
Purification by flash column chromatography (2:1 hexane:ethyl acetate) afforded the title 
compound as a colourless oil (54.0 mg, 53%); RF 0.55 (solvent); δH (400 MHz, CDCl3) 4.68–4.62 
(1H, m), 4.24–4.11 (3H, m), 3.43 (1H, dd, J = 12.0, 3.0 Hz CH), 3.09 (1H, ddd, J = 14.5, 10.1, 3.7 
Hz), 2.58–2.52 (1H, m), 2.46–2.41 (1H, m), 2.18–2.04 (2H, m), 1.82–1.71 (4H, m), 1.53–1.47 (1H, 
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Ethyl 4,12-dioxooxacyclododecane-5-carboxylate (354) 
 A mixture of ethyl 2-oxocyclooctane-1-carboxylate (78.0 mg, 0.393 
mmol), MgCl2 (75.0 mg, 0.780 mmol) and pyridine (0.190 mL, 2.36 
mmol) in CH2Cl2 (3 mL) under an argon atmosphere was stirred at 
room temperature for 30 min. Next, a solution of acid chloride (1.18 
mmol, prepared using the general procedure) in CH2Cl2 (3 mL) was added and the reaction 
mixture was stirred for 2 h, at room temperature. The solvent was then concentrated in vacuo, 
loaded onto a short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority 
of excess carboxylic acid and pyridine residues, and concentrated in vacuo. This material was re-
dissolved in ethyl acetate (3.9 mL) and placed under an argon atmosphere. Palladium on carbon 
(39 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled with hydrogen 
(via balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 16 h. The reaction was then purged with argon, filtered through Celite, 
washed with ethyl acetate and the solvent was removed in vacuo. The crude material was then 
re-dissolved in chloroform (3.9 mL) and triethylamine (82.0 µL, 0.590 mmol) added, and stirred 
at room temperature for 18 h, then reduced in vacuo. Purification by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound 
(as a 3:1 mixture of keto:enol tautomers) as a yellow oil (64 mg, 60%); RF 0.76 (ethyl acetate); 
νmax/cm–1 (thin film) 2928, 2857, 1745, 1706, 1642; δH (400 MHz, CDCl3) 12.60 (1H, s, OH, enol 
tautomer), 4.28–4.09 (8H, m, 2 × CH2O, both tautomers), 3.55 (1H, dd, J = 11.1, 5.0 Hz, CHCO2Et, 
keto tautomer), 2.68–2.32 (8H, m, 2 × CH2CO, both), 2.17–2.06 (4H, m, CH2, both), 1.97–1.65 
(8H, m, 2 × CH2, both), 1.56–1.19 (14H, m, 2 × CH2 and CH3, both); δC (100 MHz, CDCl3) data for 
the ketone tautomer only: 212.2 (CO), 175.9 (CO), 170.4 (CO), 61.3 (CH2O), 60.3 (CH2O), 57.2 
(CHCO2Et), 41.8 (CH2CO), 30.0 (CH2CO), 29.1 (CH2), 27.1 (CH2), 25.6 (CH2), 25.4 (CH2), 24.7 (CH2), 
14.2 (CH3); HRMS (ESI): calcd. for C14H22NaO5, 293.1359. Found: [MNa]+, 293.1357 (0.7 ppm 
error). 
1,5-Diazacycloheptadecane-2,6-dione (365) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.078 
mmol) and pyridine (0.38 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.5 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting 
mixture was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and 
washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) 
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and the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (8 mL) and piperidine (0.78 mL, 7.86 mmol) was added, 
followed by stirring at room temperature for 18 h, before the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl 
acetate:methanol) afforded the title compound as a white crystalline solid (197 mg, 96%); m.p. 
101-103 °C; RF 0.38 (9:1 ethyl acetate:methanol); νmax/cm–1 (neat) 3265, 3088, 2927, 2857, 1664, 
1636, 1550; δH (400 MHz, CDCl3) 6.33 (1H, br s, NH), 5.67 (1H, br s, NH), 3.60–3.45 (2H, m, CH2), 
3.39–3.23 (2H, m, CH2), 2.42 (2H, t, J = 5.3 Hz, CH2), 2.14 (2H, t, J = 6.9 Hz, CH2), 1.63 - 1.54 (2H, 
m, CH2), 1.50 - 1.40 (2H, m, CH2), 1.36–1.17 (14H, m, (CH2 x 7)); δC (100 MHz, CDCl3) 173.8 (CO), 
171.6 (CO), 39.1 (CH2), 37.0 (CH2), 35.6 (CH2), 35.2 (CH2), 29.2 (CH2), 27.94 (CH2), 27.91 (CH2), 
27.5 (CH2), 27.3 (CH2), 27.0 (CH2), 26.0 (CH2), 25.7 (CH2), 24.8 (CH2); HRMS (ESI): calcd. for 
C15H28N2O2Na, 291.2043. Found [MNa]+, 291.2045 (−1.0 ppm error). 
5-Methyl-1,5-diazacycloheptadecane-2,6-dione (368) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting 
mixture was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and 
washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (8 mL) and piperidine (0.780 mL, 7.86 mmol) was added, 
followed by stirring at room temperature for 18 h, before the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 1:1 ethyl acetate:hexane → 9:1 ethyl 
acetate:methanol) afforded the title compound (as a 5:1 mixture of rotamers) as a yellow oil 
(188 mg, 89%); RF 0.33 (9:1 ethyl acetate:methanol); νmax/cm–1 (neat) 3300, 2928, 2857, 2239, 
1626, 1552; δH (400 MHz, d2-CH2Cl2) 7.36 (1H, br s, NH, major rotamer), 6.45 (1H, br s, NH, minor 
rotamer), 3.71–3.62 (4H, m, CH2, both rotamers), 3.31–3.19 (4H, m, CH2, both), 3.05 (3H, s, NCH3, 
major), 2.92 (3H, s, NCH3, minor), 2.61–2.52 (2H, m, CH2, major), 2.51–2.45 (2H, m, CH2, minor), 
2.43–2.37 (2H, m, CH2, minor), 2.37–2.30 (2H, m, CH2, major), 1.70–1.57 (4H, m, CH2, both), 
1.56–1.46 (4H, m, CH2, both), 1.42–1.22 (28H, m, CH2 x 7, both); δC (100 MHz, CDCl3) data for the 
major rotamer only: 174.4 (CO), 171.0 (CO), 44.1 (CH2), 40.0 (CH2), 36.3 (CH2), 35.4 (CH2), 32.9 
(CH2), 28.2 (CH2), 27.5 (CH2), 27.0 (CH3), 26.9 (CH2), 26.5 (CH2), 26.1 (CH2), 25.3 (CH2), 25.1 (CH2), 
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24.2 (CH2). Diagnostic 13C NMR resonances for the minor rotamer: 173.7 (CO), 170.2 (CO), 46.6 
(CH2); HRMS (ESI): calcd. for C16H30N2NaO2, 305.2199. Found: [MNa]+, 305.2191 (−2.7 ppm error). 
The same product was also prepared using an analagous Cbz-protection strategy via the 
following method: 
A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 mmol) and pyridine 
(0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of (((benzyloxy)carbonyl)(methyl)amino)propanoyl 
chloride (2.36 mmol, 3 equiv., freshly prepared using the general procedure) in CH2Cl2 (4 mL) 
was added and refluxed at 50 °C for 16 h. The mixture was then concentrated in vacuo, loaded 
onto a short silica plug and eluted 2:1 hexane:ethyl actetate, to remove the pyridine and excess 
carboxylic acid residues, and concentrated in vacuo. This material was then re-dissolved in ethyl 
acetate (5.0 mL) and placed under an argon atmosphere. Palladium on carbon (78.4 mg, Pd 10% 
on carbon) was then added and the reaction vessel was backfilled with hydrogen (via balloon) 
several times, then stirred at room temperature under a slight positive pressure of hydrogen 
(balloon) for 16 h. The reaction was then purged with argon, filtered through Celite, washed 
with methanol and the solvent removed in vacuo to afford the title compound (194 mg, 87%). 
Spectral data as above. 
5-Benzyl-1,5-diazacycloheptadecane-2,6-dione (369) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting 
mixture was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and 
washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, 
followed by stirring at room temperature for 18 h, before the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl 
acetate: methanol) afforded the title compound (as a 4:1 mixture of rotamers) as a colourless 
oil (248 mg, 91%); RF 0.55 (9:1 ethyl acetate: methanol); νmax/cm–1 (neat) 3300, 2926, 2856, 1631, 
1551; δH (400 MHz, CDCl3) 7.38–7.09 (10H, m, Ph, both rotamers), 7.07 (1H, br s, NH, major), 
5.63 (1H, br s, NH, minor), 4.62 (2H, s, CH2Ph, major), 4.58 (2H, s, CH2Ph, minor), 3.62 (4H, t, J = 
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5.3 Hz, CH2, both), 3.30–3.22 (2H, m, CH2, major), 3.22–3.15 (2H, m, CH2, minor), 2.58–2.51 (2H, 
m, CH2, major), 2.49–2.41 (2H, m, CH2, minor) 2.37–2.27 (2H, m, CH2, major), 2.20–2.13 (2H, m, 
CH2, minor), 1.74–1.56 (4H, m, CH2, both), 1.55–1.42 (4H, m, CH2, both), 1.42–1.19 (28H, m, CH2 
× 7, both); δC (100 MHz, CDCl3) data for the major rotamer only: 175.1 (CO), 171.3 (CO), 136.7 
(C), 129.0 (CH), 127.7 (CH), 126.3 (CH), 52.1 (CH2Ph), 42.6 (CH2), 39.8 (CH2), 35.7 (CH2), 32.9 (CH2), 
28.5 (CH2), 27.6 (CH2), 27.2 (CH2), 27.1 (CH2), 26.6 (CH2), 26.5 (CH2), 25.6 (CH2), 25.1 (CH2), 24.8 
(CH2). Diagnostic 13C NMR resonances for the minor rotamer: 173.9 (CO), 170.1 (CO), 128.7 (CH), 
128.1 (CH), 44.2 (CH2); HRMS (ESI): calcd. for C22H35N2O2, 359.2693. Found: [MH]+, 359.2681 
(−3.5 ppm error)]. 
3-((((9H-Fluoren-9-yl)methoxy)carbonyl)(benzyl)amino)propanoic acid (381) 
 Methyl 3-(benzylamino)propanoate (11.3 g, 54.4 mmol) was dissolved in 
THF (157 mL) and 1m NaOH(aq) (157 mL) added and stirred at room 
temperature for 2 h. Upon completion, the solution was acidified with 
acetic acid (glacial, 6.84 mL, 0.119 mol) then concentrated in vacuo. The crude salt was then 
dissolved in water (200 mL), dioxane (300 mL) and Na2CO3 (250 mL, 10% solution) added. The 
solution was cooled to 0 °C whilst stirring and a pre-made solution of 9-fluorenylmethyl 
chloroformate (16.9 g, 5.10 mmol) dissolved in dioxane (50 mL) was added slowly. The solution 
was warmed to room temperature and stirred until reaction completion. The mixture was 
diluted with water (600 mL) and washed with EtOAc (2 x 500 mL) and then the aqueous layer 
was acidified to pH 2 using 10% HCl(aq) and extracted with EtOAc (3 x 100 mL). The combined 
organics were washed with brine, dried over MgSO4 and concentrated in vacuo which afforded 
the title compound (as a 1:1 mixture of rotamers) as a yellow viscous oil (21.96 g, 99%); Rf 0.35 
(9:1 ethyl acetate:methanol); νmax/cm–1 (neat) 2964, 1720, 1650; δH (400 MHz, CDCl3) 10.95 (1H, 
br s, CO2H, both rotamers), 7.84–7.68 (4H, m, Ar, both rotamers), 7.61 (2H, d, J = 6.9 Hz, Ar), 
7.46 (2H, d, J = 7.6 Hz, Ar), 7.43–7.20 (14H, m, Ar, both), 7.15 (2H, d, J = 6.9 Hz, Ar), 7.10–7.00 
(2H, m, Ar), 4.66 (2H, d, J = 5.3 Hz, OCH2), 4.55 (2H, d, J = 6.1 Hz, OCH2), 4.46 (2H, s, CH2Ph), 4.41 
(2H, s, CH2Ph), 4.26 (1H, t, J = 5.3 Hz, CH2CH), 4.21 (1H, t, J = 6.2 Hz, CH2CH), 3.55 (2H, t, J = 6.1 
Hz, NCH2), 3.24 (2H, t, J = 6.7 Hz, NCH2), 2.62 (2H, t, J = 6.2 Hz, HO2CCH2), 2.18 (2H, t, J = 6.7 Hz, 
HO2CCH2); δC (100 MHz, CDCl3) 177.5 and 177.3 (CO2H), 156.5 and 156.3 (NCO), 143.9 (fluorenyl, 
both rotamers), 141.53 and 141.45 (fluorenyl), 137.4 (Ph, both), 128.81 and 128.76 (Ph), 127.9 
and 127.8 (Ph), 127.6 (Ph, both), 127.3 and 127.24 (fluorenyl), 127.24 and 127.18 (fluorenyl), 
120.1 (fluorenyl, both), 67.6 and 67.2 (OCH2), 51.3 and 51.2 (NCH2Ph), 47.5 and 47.4 (CH2CH), 
43.4 and 42.1 (NCH2CH2), 32.9 (CH2CO2H, both); HRMS (ESI): calcd. for C25H23NNaO4, 424.1519. 
Found: [MNa]+, 424.1506 (3.6 ppm error).  
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3-(Benzyl-benzyloxycarbonyl-amino)-propionic acid (383) 
Ethyl 3-(benzylamino)propanoate (11.25 g, 54.3 mmol) was added to a 
suspension of K2CO3(aq) (1.05 m, 62.0 mL, 65.1 mmol) in THF (62 mL), and 
cooled to 0 °C. Benzyl chloroformate (9.35 g, 59.7 mmol) was added 
portionwise over 30 min. The mixture was stirred at 0 °C for 30 min and then warmed to room 
temperature, and stirred for 12 h. Upon completion, the solution was diluted with ethyl acetate 
(150 mL) and extracted with ethyl acetate (3 × 50 mL) and concentrated in vacuo. The crude 
product was then reacted with NaOH(aq) (1 m, 157 mL, 0.163 mol) and THF (157 mL) and stirred 
at room temperature for 6 h. The mixture was then diluted with water (100 mL) and washed 
with CH2Cl2 (100 mL). The remaining aqueous phase is acidified with HCl (10% aqueous solution) 
before being extracted with CH2Cl2 (3 × 100 mL) and ethyl acetate (2 × 125 mL). The combined 
organic layers were then dried over MgSO4, filtered and removed in vacuo. Purification by 
column chromatography (SiO2, 20% ethyl acetate in hexanes) afforded the title compound (as a 
1:1 mixture of rotamers) as a yellow oil (15.74 g, 93%); Rf 0.30 (ethyl acetate); δH (400 MHz, 
CDCl3); 7.38–7.17 (20H, m, 10 × CH, both rotamers), 5.21 (2H, s, CH2O, rotamer A), 5.18 (2H, s, 
CH2O, rotamer B), 4.55 (4H, s, NCH2Ph, both), 3.55 (2H, t, J = 8.8 Hz, CH2NBn, rotamer A), 3.45 
(2H, t, J = 6.6 Hz, CH2NBn, rotamer B), 2.65 (2H, t, J = 6.6 Hz, CH2CO2H, rotamer A), 2.54 (2H, t, J 
= 8.8 Hz, CH2CO2H, rotamer B); HRMS (ESI): calcd. for C18H19NNaO4, 336.1206. Found: [MNa]+, 
336.1206 (1.5 ppm error). Data is consistent with those previously reported in the literature.147 
5,9-Dibenzyl-1,5,9-triazacyclohenicosane-2,6,10-trione (389) 
 A mixture of 5-benzyl-1,5-diazacycloheptadecane-2,6-dione (282 mg, 
0.786 mmol), DMAP (10 mg, 0.0786 mmol) and pyridine (0.380 mL, 4.72 
mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at 
room temperature for 30 min. Next, a solution of acid chloride (1.18 
mmol, 1.50 equiv., freshly prepared using the general procedure) in 
CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 
°C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and 
washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, 
followed by stirring at room temperature for 18 h, before the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl 
acetate: methanol) afforded the title compound (as a 1:1:1.5 mixture of rotamers) as a colourless 
oil (223 mg, 65%); RF 0.54 (9:1 ethyl acetate: methanol); νmax/cm–1 (neat) 3315, 2926, 2855, 1628, 
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1551; δH (400 MHz, CDCl3) 7.55–7.01 (30H, m, 2 × Ph, all rotamers), 7.00–6.96 (1H, m, NH, single 
rotamer), 6.96–6.87 (1H, br s, NH, single), 6.56 (1H, br s, NH, single), [4.62 (2H, br s), 4.60–4.52 
(2H, m), 4.42 (1H, s), 4.40 (2H, s), CH2Ph, all)], 3.73–3.49 (12H, m, 2 × CH2NBn, all), 3.35–3.12 
(6H, m, CH2NH, all), 2.76–2.28 (18H, m, 3 × CH2CO, all), 1.76–1.20 (54H, m, 9 × CH2, all); δC (100 
MHz, CDCl3) data for the major rotamer only: 174.4 (CO), 171.1 (CO), 170.1 (CO), 137.6 (C), 136.7 
(C), 129.3 (CH), 129.1 (CH), 128.7 (CH), 128.2 (CH), 127.5 (CH), 126.4 (CH), 60.5 (CH2Ph), 52.6 
(CH2Ph), 49.4 (BnNCH2), 45.3 (BnNCH2), 42.5 (NHCH2), 39.5 (CH2CO), 36.9 (CH2CO), 33.3 (CH2CO), 
31.2 (CH2), 28.8 (CH2), 27.6 (CH2), 27.2 (CH2), 26.8 (CH2), 26.3 (CH2), 25.4 (CH2), 24.6 (CH2), 21.2 
(CH2). Diagnostic 13C NMR resonances for other rotamers: 175.1 (CO), 174.3 (CO), 172.1 (CO), 
171.6 (CO), 171.2 (CO), 170.6 (CO), 137.8 (C), 136.9 (C), 136.8 (C), 136.2 (C); HRMS (ESI): calcd. 
for C32H45N3NaO3, 542.3353. Found: [MNa]+, 542.3352 (−0.7 ppm error). 
5,9,13-Tribenzyl-1,5,9,13-tetraazacyclopentacosane-2,6,10,14-tetraone (390) 
 A mixture of 5,9-dibenzyl-1,5,9-triazacyclohenicosane-2,6,10-
trione (320 mg, 0.615 mmol), DMAP (8 mg, 0.0615 mmol) and 
pyridine (0.300 mL, 3.69 mmol) in CH2Cl2 (5.0 mL) under an 
argon atmosphere was stirred at room temperature for 30 
min. Next, a solution of acid chloride (0.923 mmol, 1.50 equiv., 
freshly prepared using the general procedure) in CH2Cl2 (3 mL) 
was added and the resulting mixture was refluxed at 50 °C for 
16 h. A further two portions of acid chloride (0.923 mmol, 1.5 equiv) in CH2Cl2 (3 mL) were added 
at 40 h and 64 h until full acylation was achieved, analysed by TLC. The mixture was then diluted 
with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted 
with CH2Cl2 (3 × 30 mL) and the combined organic extracts dried over MgSO4 and concentrated 
in vacuo, loaded onto a short silica plug and eluted with 1:1 ethyl acetate:hexane to remove 
excess carboxylic acid and pyridine residues. The crude material was then re-dissolved in CH2Cl2 
(8 mL) and DBU (0.940 mL, 6.15 mmol) was added, followed by stirring at room temperature for 
18 h, before the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 1:2 ethyl acetate:hexane → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound (as a mixture of 7 rotamers) as a yellow oil (280 mg, 77%). Quantity of rotamers was 
determined by number of carbonyl resonances in 13C NMR; Rf 0.69 (9:1 ethyl acetate: methanol); 
νmax/cm–1 (thin film) 3299, 2926, 2856, 1648, 1626, 1543; δH (400 MHz, CDCl3); δH (400 MHz, 
CDCl3) 7.56–6.39 (112H, m, Ph and NH, all rotamers), 4.80–4.34 (40H, m, CH2Ph, all rotamers), 
4.20 (2H, s, CH2Ph, single rotamer), 3.83–3.43 (42H, m, CH2NBn, all rotamers), 3.34–3.10 (14H, 
m, CH2NH), 2.82–2.24 (56H, m, CH2CO, all rotamers), 1.80–1.00 (126H, m, 9 × CH2); δC (100 MHz, 
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CDCl3) 174.5 (CO), 174.2 (CO), 174.0 (CO), 173.94 (CO), 173.85 (CO), 173.72 (CO), 173.67 (CO), 
172.2 (CO), 172.1 (CO), 171.9 (CO), 171.49 (CO), 171.47 (CO), 171.4 (CO), 171.3 (CO), 171.19 
(CO), 171.16 (CO), 171.14–171.06 (m, 3 × CO), 171.0 (CO), 170.94 (CO), 170.88 (CO), 170.72 (CO), 
170.4 (CO), 170.3 (CO), 170.1 (CO), 170.0 (CO), 169.9 (CO), 138.2 (CCH), 137.8 (CCH), 137.7 (CCH), 
137.6 (CCH), 137.50 (CCH), 137.47(CCH), 137.4 (CCH), 137.2 (CCH), 137.0 (CCH), 136.90 (CCH), 
136.87 (CCH), 136.7 (CCH), 136.59 (CCH), 136.56 (CCH), 136.5 (CCH), 126.3 (CH), 129.20 (CH), 
129.16 (CH), 129.1 (CH), 129.02 (CH), 129.98 (CH), 128.95 (CH), 128.9 (CH), 128.84 (CH), 128.81–
128.62 (m, CH), 128.60 (CH), 128.55 (CH), 128.5 (CH), 128.42 (CH), 128.33 (CH), 128.29 (CH), 
128.27 (CH), 128.24 (CH), 128.19 (CH), 128.16 (CH), 128.1 (CH), 128.02 (CH), 127.99 (CH), 127.94 
(CH), 127.81 (CH), 127.78 (CH), 127.7 (CH), 127.6 (CH), 127.54 (CH), 127.50 (CH), 127.4 (CH), 
127.3 (CH), 127.1 (CH), 126.7 (CH), 126.59 (CH), 126.55 (CH), 126.5 (CH), 126.39 (CH), 126.37 
(CH), 126.3 (CH), 126.19 (CH), 126.17 (CH), 126.02(CH), 126.95 (CH), 53.0 (CH2Ph), 52.7 (CH2Ph), 
52.6 (CH2Ph), 52.5 (CH2Ph), 52.4 (CH2Ph), 52.22 (CH2Ph), 52.1 (CH2Ph), 52.0 (CH2Ph), 51.9 
(CH2Ph), 51.8 (CH2Ph), 49.2 (CH2Ph), 49.14 (CH2Ph), 49.09 (CH2Ph), 48.9 (CH2Ph), 48.8 (CH2Ph), 
48.73 (CH2Ph), 48.68 (CH2Ph), 48.6 (CH2Ph), 48.3 (CH2Ph), 45.0 (CH2NBn), 44.73 (CH2NBn), 44.69 
(CH2NBn), 44.67 (CH2NBn), 44.4 (CH2NBn), 44.3 (CH2NBn), 44.1 (CH2NBn), 44.05 (CH2NBn), 44.00 
(CH2NBn), 43.9 (CH2NBn), 43.82 (CH2NBn), 43.75 (CH2NBn), 43.72 (CH2NBn), 43.66 (CH2NBn), 
43.6 (CH2NBn), 43.5 (CH2NBn), 43.4 (CH2NBn), 42.9 (CH2NBn), 39.8 (CH2NH), 39.7 (CH2NH), 39.6 
(CH2NH), 39.49 (CH2NH), 39.45 (CH2NH), 36.9 (CH2CO), 36.3 (CH2CO), 36.1 (CH2CO), 35.4 (CH2CO), 
35.3 (CH2CO), 35.1 (CH2CO), 34.0 (CH2CO), 33.3 (CH2CO), 33.2 (CH2CO), 32.90 (CH2CO), 32.85 
(CH2CO), 32.8 (CH2CO), 32.50 (CH2CO), 32.47 (CH2CO), 32.4 (CH2CO), 32.32 (CH2CO), 32.29 
(CH2CO), 32.14 (CH2CO), 32.09 (CH2CO), 31.9 (CH2CO), 31.7 (CH2CO), 31.5 (CH2CO), 31.4 (CH2CO), 
31.25 (CH2CO), 31.22 (CH2CO), 31.16 (CH2CO), 31.1 (CH2CO), 29.3 (CH2), 29.19–29.06 (m, CH2), 
29.0 (CH2), 28.93 (CH2), 28.86 (CH2), 28.83 (CH2), 28.7 (CH2), 28.59 (CH2), 28.55 (CH2), 28.5 (CH2), 
28.4 (CH2), 28.34 (CH2), 28.28 (CH2), 28.1 (CH2), 28.0 (CH2), 27.9 (CH2), 27.83 (CH2), 27.75 (CH2), 
27.7 (CH2), 27.6 (CH2), 27.5 (CH2), 27.42 (CH2), 27.38 (CH2), 27.24 (CH2), 27.16 (CH2), 26.9 (CH2), 
26.6 (CH2), 26.48–26.27 (m, CH2), 26.2 (CH2), 26.1 (CH2), 25.96–25.84 (m, CH2), 25.5 (CH2), 25.4 
(CH2), 25.24 (CH2), 25.21 (CH2), 25.1 (CH2), 25.0 (CH2), 24.83 (CH2), 24.78 (CH2), 24.4 (CH2); HRMS 
(ESI): calcd. for C42H56N4NaO4, 703.419377. Found: [MNa]+, 703.420607 (−2.7 ppm error). 
Azonan-2-one (394) 
 Cyclooctanone (633 mg, 5.0 mmol) in formic acid (5 mL) was added a solution 
of hydroxylamine-o-sulphonic acid (850 mg, 7.5 mmol) in formic acid (2.5 mL) 
and heated to 110 °C for 16 h. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
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compound as an orange solid (560 mg, 79%). Data consistent with those reported in the 
literature.148 
Azecan-2-one (395) 
 To a magnetically stirred solution of the cyclononanone (462 mg, 3.3 mmol) 
and formic acid (≥95%, 3.5 mL), a solution of hydroxylamine-o-sulphonic acid 
(560 mg, 4.95 mmol) in formic acid (1.65 mL) was added dropwise at room 
temperature over a period of 10 min. The reaction mixture was then heated under reflux for 16 
h. After cooling, it was quenched with water, neutralised with NaOH (2M) and then extracted 
with CHCl3 (4 × 30 mL). The organic extracts were combined, dried over MgSO4, and 
concentrated in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl 
acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound as a yellow 
solid (327 mg, 68%); Rf 0.46 (9:1 ethyl acetate:methanol); δH (400 MHz, CDCl3) 5.69 (1H, br s, 
NH), 3.51–3.21 (2H, m, CH2NH), 2.50–2.14 (2H, m, CH2CONH), 1.93–1.17 (12H, m, 6 × CH2); δC 
(100 MHz, CDCl3) 174.5 (CO), 40.8 (CH2NH), 37.6 (CH2CO), 26.3 (CH2), 26.1 (CH2), 24.42 (CH2), 
24.37 (CH2), 23.9 (CH2), 23.2 (CH2). Data is consistent with those previously reported in the 
literature.148 
Azacycloundecan-2-one (396) 
 Cyclodecanone (1.240 g, 8.04 mmol) in formic acid (9 mL) was added to a 
solution of hydroxylamine-o-sulfonic acid (1.37 g, 12.1 mmol) in formic acid (4 
mL) and heated to 110 °C for 16 h. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) 
afforded the title compound as an orange solid (803 mg, 59%). Data consistent with those 
reported in the literature.149 
Azacyclododecan-2-one (397) 
 Cycloundecanone (500 mg, 3.0 mmol) in formic acid (4 mL) was added to a 
solution of hydroxy-o-sulfonic acid (511 mg, 4.51 mmol) in formic acid (2 mL) and 
heated to 110 °C for 16 h. Purification by flash column chromatography (SiO2, 50% 
ethyl acetate in hexanes → ethyl acetate) afforded the title compound as a white 
solid (453 mg, 82%). Data is consistent with those previously reported in the literature.150 
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5-Benzyl-1,5-diazecane-2,6-dione (400) 
 A mixture of δ-valerolactam (78.0 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 °C for 16 h. 
The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 mL). The 
aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic extracts 
dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 
(8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room temperature for 
18 h, before the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl acetate: methanol) afforded the title compound (as 
a 10:1 mixture of rotamers) as a colourless oil (129 mg, 65%); RF 0.26 (9:1 ethyl acetate: 
methanol); νmax/cm–1 (neat) 3326, 2929, 1645, 1607, 1535; δH (400 MHz, CDCl3) 7.35–7.17 (10H, 
m, Ph, both rotamers), 6.00 (1H, d, J = 9.2 Hz, NH, minor), 5.85 (1H, br s, NH, major), 5.01 (1H, 
d, J = 14.5 Hz, NCH2Ph, major), 4.84 (1H, d, J = 16.8 Hz, NCH2Ph, minor), 4.28 (1H, d, J = 16.8 Hz, 
NCH2Ph, minor), 4.20 (1H, d, J = 14.5 Hz, NCH2Ph, major), 3.97–3.82 (2H, m, BnNCH2, both), 3.80–
3.65 (2H, m, BnNCH2, both), 3.30–3.20 (1H, m, CH2NH, major), 3.19–3.14 (1H, m, CH2NH, minor), 
2.97–2.90 (1H, m, CH2NH, minor), 2.89–2.78 (1H, m, CH2NH, major), 2.75–2.59 (2H, m, COCH2, 
both), 2.50 (1H, m, COCH2, major), 2.43–2.34 (1H, m, COCH2, minor), 2.20–2.04 (8H, m, 2 × CH2, 
both), 1.69–1.55 (4H, m, CH2, both); δC (100 MHz, CDCl3) data for the major rotamer only: 174.1 
(CO), 171.2 (CO), 138.0 (CCH), 129.0 (CCH), 128.1 (CH), 127.8 (CH), 49.1 (CH2Ph), 45.2 (CH2), 39.3 
(CH2), 37.4 (CH2), 28.3 (CH2), 25.8 (CH2), 24.0 (CH2). Diagnostic 13C NMR resonances for the minor 
rotamer: 179.2 (CO), 176.4 (CO), 136.7 (Ph), 60.5 (CH2). HRMS (ESI): calcd. for C15H20N2NaO2, 
283.1417. Found: [MNa]+, 283.1417 (−0.1 ppm error)]. 
5-Benzyl-1,5-diazacycloundecane-2,6-dione (401) 
 A mixture of ε-caprolactam (89 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv, freshly prepared using the 
general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 °C 
for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
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in CH2Cl2 (8 mL) and DBU (1.20 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 hexane:ethyl acetate → 1:1 hexane:ethyl acetate → 9:1 ethyl 
acetate:methanol) afforded the title compound (as a 6:1 mixture of rotamers determined by 1H 
NMR in CDCl3 at room temperature) as a colourless oil (170 mg, 79%). Note, to aid 
characterisation the 1H NMR data was recorded at 80 °C, which resolved the rotamer 
resonances. RF 0.37 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3289, 2931, 1620, 1554; 
δH (400 MHz, d6-DMSO, 80 °C) 7.85 (1H, br s, NH), 7.39–7.15 (5H, m, Ph), 4.53 (2H, br s, PhCH2), 
3.50 (2H, br s, BnNCH2), 2.96 (2H, br s, NHCH2), 2.22 (4H, br s, 2 × CH2), 1.68–1.41 (4H, m, 2 × 
CH2), 1.27 (2H, br s, CH2). Diagnostic 1H NMR resonances recorded in CDCl3 at room temperature, 
which confirm the presence of the two rotamer forms can be found at: 6.10 (1H, br s, NH, major), 
5.97 (1H, br s, NH, minor); δC (100 MHz, CDCl3) 173.5 (CO), 171.4 (CO), 138.5 (C), 129.0 (CH), 
128.3 (CH), 127.9 (CH), 49.2 (CH2Ph), 45.2 (BnNCH2), 41.8 (NHCH2), 37.07 (CH2CONH), 28.6 
(CH2CO), 25.3 (CH2), 24.4 (CH2), 22.8 (CH2); HRMS (ESI): calcd. for C16H22N2NaO2, 297.1573. 
Found: [MNa]+, 297.1567 (2.2 ppm error). 
5-Benzyl-1,5-diazacyclododecane-2,6-dione (402) 
 A mixture of azocan-2-one (100 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 
°C for 16 h. The mixture was then diluted with CH2CH2 (30 mL) and washed with 10% aq. HCl (30 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl acetate: methanol) afforded the 
title compound (as a 5:1 mixture of rotamers determined by 1H NMR in CDCl3 at room 
temperature) as a colourless oil (190 mg, 84%). Note, to aid characterisation the 1H NMR data 
was recorded at high temperature, which resolved the rotamer resonances. RF 0.42 (9:1 ethyl 
acetate: methanol); νmax/cm–1 (neat) 3299, 2928, 1623, 1552, 1448; δH (400 MHz, d6-DMSO, 120 
°C) 7.60–7.15 (6H, m, Ph, NH), 4.57 (2H, br s, PhCH2), 3.15 (2H, s, BnNCH2), 2.57–2.18 (4H, m, 
NHCH2, CH2CONH), 1.84–1.02 (10H, m, 5 × CH2). Diagnostic 1H NMR resonances recorded in 
CDCl3 at room temperature, which confirm the presence of the two rotamer forms can be found 
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at: 6.57 (1H, br s, NH, major), 5.71 (1H, br s, NH, minor); δC (100 MHz, CDCl3) data for the major 
rotamer only: 175.9 (CO), 170.4 (CO), 136.6 (C), 129.0 (CH), 127.8 (CH), 126.5 (CH), 51.9 (CH2Ph), 
41.1 (BnNCH2), 39.2 (CH2NH), 35.1 (CH2), 32.5 (CH2), 27.3 (CH2), 25.9 (CH2), 24.0 (CH2), 22.3 (CH2). 
13C NMR resonances for the minor rotamer: 174.9 (CO), 171.0 (CO), 138.5 (C), 128.8 (CH), 128.6 
(CH), 127.7 (CH), 60.5 (CH2), 48.7 (CH2), 44.9 (CH2), 36.7 (CH2), 30.9 (CH2), 26.7 (CH2), 23.6 (CH2), 
22.5 (CH2), 14.3 (CH2). HRMS (ESI): calcd. for C17H24N2NaO2, 311.1730. Found: [MNa]+, 311.1718 
(3.4 ppm error). 
5-Benzyl-1,5-diazacyclotridecane-2,6-dione (403) 
 A mixture of azonan-2-one (111 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.38 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.5 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 
°C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate:hexane → 9:1 ethyl acetate:methanol) afforded the 
title compound (as a mixture of two rotamers in a 9:1 ratio) as an orange oil (158 mg, 90%); RF 
0.40 (9:1 ethyl acetate:methanol); δH (400 MHz, CDCl3) 7.37–7.19 (6H, m, 3 × aromatic CH, both 
rotamers), 7.14–7.06 (4H, m, 2 × aromatic CH, both), 6.91 (1H, br s, NH, major rotamer), 5.69 
(1H, br s, NH, minor rotamer), 4.66 (4H, br s, CH2Ph, both), 3.72–3.60 (4H, m, CH2N, both), 3.33–
3.21 (4H, m, CH2N, both), 2.80–2.54 (4H, m, CH2CO, both), 2.42–2.17 (4H, m, CH2CO, both), 
[1.85–1.66, 1.62–1.49, 1.45–1.24 (20H, m, 5 × CH2, both)]; νmax/cm-1 (thin film) 3300, 2928, 2859, 
1625, 1552; δC (100MHz, CDCl3) 176.0 (CO), 170.7 (CO), 136.7 (C), 129.0 (CH), 127.7 (CH), 126.4 
(CH), 52.7 (CH2Ph), 42.5 (CH2NBn), 39.7 (CH2NH), 34.9 (CH2CONH), 32.9 (CH2CONBn), 27.9 (CH2), 
27.2 (CH2), 27.0 (CH2), 25.7 (CH2), 24.1 (CH2); HRMS (ESI): calcd. for C18H26N2NaO2, 325.1886. 
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5-Benzyl-1,5-diazacyclotetradecane-2,6-dione (404) 
 A mixture of azecan-2-one (122 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.38 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution of 
acid chloride (1.18 mmol, 1.5 equiv., freshly prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed 
at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. 
HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined 
organic extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-
dissolved in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate:hexane → 9:1 ethyl acetate:methanol) afforded the 
title compound (as a mixture of two rotamers in a 9:1 ratio) as an orange oil (158 mg, 64%); RF 
0.40 (9:1 ethyl acetate:methanol); νmax/cm–1 (neat) 3343, 2927, 2854, 1664, 1616, 1534; δH (400 
MHz, CDCl3) 7.40–7.28 (6H, m, Ph, both rotamers), 7.16 (4H, d, J = 6.9 Hz, Ph, both), 6.20 (1H, br 
s, NH, major rotamer), 4.74 (2H, s, CH2Ph, major), 4.64 (2H, s, CH2Ph, minor rotamer), 3.70–3.57 
(4H, m, CH2, both), 3.38–3.25 (4H, m, CH2, both), 2.77–2.66 (4H, m, CH2, both), 2.44–2.35 (4H, 
m, CH2, both), 1.76–1.23 (24H, m, 6 x CH2, both); δC (100 MHz, CDCl3) resonances for the major 
rotamer only observed: 175.0 (CO), 171.0 (CO), 137.3 (Ph), 128.9 (Ph), 127.6 (Ph), 126.4 (Ph), 
53.8 (CH2Ph), 43.72 (CH2), 38.9 (CH2), 34.9 (CH2), 32.9 (CH2), 27.5 (CH2), 25.5 (CH2), 25.3 (CH2), 
25.2 (CH2), 24.9 (CH2), 23.1 (CH2); HRMS (ESI): calcd. for C19H28N2NaO2, 339.2043. Found: [MNa]+, 
339.2028 (4.0 ppm error). 
5-Benzyl-1,5-diazacyclopentadecane-2,6-dione (405) 
 A mixture of azacycloundecan-2-one (100 mg, 0.591 mmol), DMAP (7 mg, 
0.0591 mmol) and pyridine (0.285 mL, 3.55 mmol) in CH2Cl2 (4 mL) under 
an argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (0.887 mmol, 1.50 equiv. prepared using the 
general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 °C 
for 16 h. The mixture was then diluted with CH2Cl2 (20 mL) and washed with 10% aq. HCl (15 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 20 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (7.5 mL) and DBU (0.905 mL, 5.91 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 ethyl acetate:hexane → 1:1 ethyl acetate:hexane → 9:1 ethyl 
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acetate:methanol) afforded the title compound (as a 9:1 mixture of rotamers) as a yellow oil 
(171 mg, 88%); RF 0.58 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film); 3314, 2930, 2858, 
2240, 1623, 1552; δH (400 MHz, CDCl3) 7.33–7.05 (10H, m, Ph, both rotamers), 7.03 (1H, br s, 
NH, major rotamer), 6.46 (1H, br s, NH, minor rotamer), 4.72 (2H, s, CH2Ph, major), 4.53 (2H, s, 
CH2Ph, minor), 3.63–3.43 (4H, m, CH2NBn, both), 3.37–3.07 (4H, m, CH2NH, both), 2.70–2.36 
(4H, m, CH2CONH, both), 2.35–2.03 (4H, m, CH2CONBn, both), 1.70–1.10 (28H, m, 7 × CH2, both); 
δC (100 MHz, CDCl3) data for the major rotamer only: 175.0 (CO), 171.4 (CO), 137.5 (C), 128.9 
(CH), 127.4 (CH), 126.3 (CH), 53.8 (CH2Ph), 43.8 (CH2NBn), 38.0 (CH2NH), 34.6 (CH2CONH), 32.3 
(CH2CONBn), 27.8 (CH2), 26.8 (CH2), 26.6 (CH2), 26.41 (CH2), 26.36 (CH2), 25.6 (CH2), 23.6 (CH2). 
Diagnostic 13C NMR resonances for the minor rotamer: 174.5 (CO), 170.9 (CO), 138.3 (C), 128.6 
(CH), 128.1 (CH), 60.4 (CH2Ph), 48.5 (CH2NBn), 39.7 (CH2NH), 36.0 (CH2CONBn), 31.8 (CH2CONH); 
HRMS (ESI): calcd. for C20H30N2NaO2, 353.2199. Found: [MNa]+, 353.2201 (−0.1 ppm error). 
5-Benzyl-1,5-diazacyclohexadecane-2,6-dione (406) 
 A mixture of azacyclododecan-2-one (144 mg, 0.786 mmol), DMAP (10 
mg, 0.0786 mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) 
under an argon atmosphere was stirred at room temperature for 30 min. 
Next, a solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared 
using the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed 
at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl 
(30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.20 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate:hexane → 9:1 ethyl acetate:methanol) afforded the 
title compound (as a 2:1 mixture of rotamers) as a yellow oil (239 mg, 88%); RF 0.60 (9:1 ethyl 
acetate:methanol); νmax/cm–1 (neat) 3300, 2927, 2857, 1632, 1550; δH (400 MHz, CDCl3) 7.37–
7.10 (10H, m, Ph, both rotamers), 6.29 (1H, br s, NH, major rotamer), 5.67 (1H, br s, NH, minor 
rotamer), 4.65 (2H, s, CH2Ph, major), 4.58 (2H, s, CH2Ph, minor), 3.69–3.58 (4H, m, CH2, both 
rotamers), 3.36–3.26 (4H, m, CH2, both), 2.58 (2H, t, J = 5.3 Hz, CH2, major), 2.46 (2H, t, J = 7.6 
Hz, CH2, minor), 2.29 (2H, t, J = 6.9 Hz, CH2, major), 2.24–2.17 (2H, m, CH2, minor), 1.77–1.20 
(32H, m, 8 x CH2, both); δC (100 MHz, CDCl3) 174.4 (CO), 171.2 (CO), 137.2 (CCH), 129.0 (CH), 
127.6 (CH), 126.3 (CH), 53.1 (CH2), 43.4 (CH2), 39.2 (CH2), 35.2 (CH2), 31.9 (CH2), 28.9 (CH2), 26.6 
(CH2), 26.0 (CH2), 25.5 (CH2), 25.2 (CH2), 24.7 (CH2), 24.3 (CH2), 24.0 (CH2). Diagnostic 13C NMR 
resonances for the minor rotamer: 173.6 (CO), 128.7 (CH), 128.0 (CH), 127.4 (CH), 48.9 (CH2), 
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39.4 (CH2), 36.7 (CH2); HRMS (ESI): calcd. for C21H32N2NaO2, 367.2356. Found: [MNa]+, 367.2348 
(2.4 ppm error). 
1-Methyl-1,5-diazocane-2,6-dione (410) 
 A mixture of 2-azetidinone (56 mg, 0.786 mmol), DMAP (10 mg, 0.0786 mmol) and 
pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was 
stirred at room temperature for 30 min. Next, a solution of acid chloride (1.18 mmol, 
1.50 equiv., freshly prepared using the general procedure) in CH2Cl2 (3 mL) was 
added and the resulting mixture was stirred at room temperature for 2 h. The mixture was then 
concentrated in vacuo, loaded onto a short silica plug and eluted ethyl actetate, to remove the 
pyridine and excess carboxylic acid residues, and concentrated in vacuo. This material was then 
re-dissolved in ethyl acetate (5.0 mL) and placed under an argon atmosphere. Palladium on 
carbon (55.0 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled with 
hydrogen (via balloon) several times, then stirred at room temperature under a slight positive 
pressure of hydrogen (balloon) for 16 h. The reaction was then purged with argon, filtered 
through Celite, washed with methanol and the solvent removed in vacuo to afford the title 
compound as yellow solid (74 mg, 61%); RF 0.05 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin 
film)  3204, 3079, 2951, 1632, 1480; δH (400 MHz, CDCl3) 6.80 (1H, br t, J = 6.9 Hz, NH), 3.62 (2H, 
t, J = 6.9 Hz, MeNCH2), 3.49 (2H, dt, J = 6.9, 7.6 Hz, HNCH2), 2.93 (3H, s, CH3N), 2.87–2.79 (4H, m, 
2 × CH2CO); δC (100 MHz, CDCl3) 172.9 (CO), 170.8 (CO), 45.1 (CH2NMe), 38.0 (CH2NH), 37.8 
(CH2CONMe), 35.5 (CH2CONH), 34.4 (CH3N). HRMS (ESI): calcd. for C7H12N2NaO2, 179.0791. 
Found: [MNa]+, 179.0793 (−1.3 ppm error). 
1-Methylhexahydropyrrolo[1,2-a]pyrimidin-4(1H)-one (413) 
 A mixture of 2-pyrrolidinone (67 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 eqv prepared using the general procedure) in CH2Cl2 (3 mL) was 
added and the resulting mixture was refluxed at 50 °C for 16 h. The mixture was then diluted 
with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted 
with CH2Cl2 (3 × 30 mL) and the combined organic extracts dried over MgSO4 and concentrated 
in vacuo, loaded onto a short silica plug and eluted 1:1 hexane:ethyl actetate, to remove the 
pyridine and excess carboxylic acid residues, and concentrated in vacuo. This material was then 
re-dissolved in ethyl acetate (7.9 mL) and placed under an argon atmosphere. Palladium on 
carbon (78.6 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled with 
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hydrogen (via balloon) several times, then stirred at room temperature under a slight positive 
pressure of hydrogen (balloon) for 16 h. The reaction was then purged with argon, filtered 
through Celite, washed with methanol and the solvent was removed in vacuo to afford the title 
compound as a colourless oil (118 mg, 97%); Rf 0.05 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin 
film) 3436, 2953, 2799, 1623; δH (400 MHz, CDCl3) 3.59–3.45 (2H, m, CH and CHH′NCO), 3.44–
3.35 (1H, m, CHH′NCO), 2.93–2.82 (1H, m, CHH′NMe), 2.59–2.28 (3H, m, CHH′NMe and CH2CH), 
2.24 (3H, s, CH3N), 2.07 (1H, dt, J = 5.3, 11.4 Hz, CHH′CO), 1.95–1.84 (1H, m, CH2CHH′CH2), 1.79–
1.61 (1H, m, CH2CHH′CH2), 1.60–1.46 (1H, m, CHH′CO); δC (100 MHz, CDCl3) 167.3 (CO), 79.8 
(CHNMe), 52.6 (CH2NMe), 44.7 (CH2NCO), 41.0 (CH3N), 32.4 (CH2CO), 31.3 (CHCH2), 20.6 
(CH2CH2CH2); HRMS (ESI): calcd. for C8H14N2NaO, 177.1004. Found: [MNa]+, 177.0997 (−4.0 ppm 
error). 
2-Benzyl-3,4,7,8-tetrahydro-2,6-benzodiazecine-1,5-(2H,6H)-dione (420) 
 A mixture of 3,4-dihydroisoquinolin-1(2H)-one (100 mg, 0.680 mmol), 
DMAP (8.31 mg, 0.0680 mmol) and pyridine (0.330 mL, 4.08 mmol) in 
CH2Cl2 (4.8 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. A solution of acid chloride (1.02 mmol, 1.50 
equiv., freshly prepared using the general procedure) in CH2Cl2 (3.1 mL) was added and the 
resulting mixture was refluxed at 50 °C for 18 h. An additional solution of acid chloride (1.02 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3.1 mL) was added and the 
reaction heated, at reflux at 50 °C  for another 12 h to achieve reaction completion. The mixture 
was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 mL). The aqueous layer 
was then extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 (6.9 mL) and DBU 
(1.04 mL, 6.97 mmol) was added, followed by stirring at room temperature for 18 h, before the 
solvent was removed in vacuo. Purification by flash column chromatography (SiO2, ethyl 
acetate/hexane 4:1 → 98:2 ethyl acetate:methanol) afforded the title compound as a yellow oil 
(84 mg, 40%); Rf 0.46 (9:1 ethyl acetate: methanol); νmax/cm-1 (neat) 3287, 3064, 2936, 2239, 
1730, 1655, 1614, 1597, 1551, 1494, 1418 ; δH (400 MHz, CDCl3) 7.39–7.24 (7H, m, ArH), 7.20 
(1H, t, J = 8.0 Hz, ArH), 7.10–7.08 (1H, m, ArH), 5.75 (1H, s, NH), 5.44 (1H, d, J = 14.9 Hz, CHHPh), 
4.13 (1H, d, J = 14.9 Hz, CHHPh), 3.90–3.83 (1H, m, CHHNBn), 3.48–3.13 (4H, m, CH2NH and 
CHHNBn and CHHCH2NH), 2.62–2.58 (1H, m, CHHCH2NH), 2.28–2.23 (1H, m, CHHCO), 1.97−1.93 
(1H, m, CHHCO);  δc (100 MHz, CDCl3) 172.4 (CO), 171.6 (CO), 137.8 (ArC), 137.6 (ArC), 131.6 
(ArC), 129.9 (ArC), 129.2 (ArC), 128.4 (ArC), 128.0 (ArC), 126.4 (ArC), 126.3 (ArC), 47.0 (CH2Ph), 
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46.9 (CH2NBn), 40.7 (CH2NH), 36.2 (CH2CO), 33.1 (CH2CH2NH). HRMS (ESI): calcd. for C19H20N2O2, 
331.1417. Found; [MNa]+, 331.1416 (1.0 ppm error). 
2-Benzyl-3,4,6,7,8,9-hexahydro-1H-benzo[g][1,5]diazacycloundecine-1,5(2H)-dione (421) 
 A mixture of 2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (127 mg, 
0.786 mmol), DMAP (10.0 mg, 0.0786 mmol) and pyridine (0.380 mL, 
4.72 mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at 
room temperature for 30 min. A solution of acid chloride (1.18 mmol, 
1.50 equiv., freshly prepared using the general procedure) in CH2Cl2 (3.0 mL) was added and the 
resulting mixture was refluxed at 50 °C for 18 h. The mixture was then diluted with CH2Cl2 (30 
mL) and washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 
× 20 mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude material was then re-dissolved in CH2Cl2 (8.0 mL) and DBU (1.20 mL, 7.86 mmol) was 
added, followed by stirring at room temperature for 18 h, before the solvent was removed in 
vacuo. Purification by flash column chromatography (SiO2, 5:1 → 2:1 → 1:1 hexane:ethyl 
acetate) afforded the title compound (as a 3:1 mixture of rotamers) as a yellow oil (189 mg, 
77%); Rf 0.54 (98:2 ethyl acetate: methanol); νmax/cm-1 (thin film) 3299, 1646, 1615, 1549, 1495, 
1443, 1421, 1351; Data for the major rotamers only: δH (400 MHz, CDCl3, 50 °C) 7.40−7.05 (9H, 
m, ArH), 6.81 (1H, br m, NH), 4.50 (1H, d, J = 16.0 Hz, CHH-Ph), 4.38−4.28 (2H, m, CHH-Ph and 
CHH-NBn), 3.99−3.90 (1H, m, CHH-NH), 3.13−3.03 (2H, m, CHH-NBn and CHH-CO), 2.80−2.72 
(2H, m, CHH-NH and CH2-CHH-CH2), 2.67−2.64 (1H, m, CH2-CHH-CH2), 2.58−2.52 (1H, m, CHH-
CO), 1.86−1.60 (2H, m, CH2-CH2-CH2); Data for major rotamer only: δc (100 MHz, CDCl3) 172.9 
(CO-NBn), 169.9 (CO-NH), 139.2 (ArC), 136.3 (ArC), 136.0 (ArC), 130.0 (ArC), 129.3 (ArC), 128.9 
(ArC), 28.4 (ArC), 127.8 (ArC), 127.1 (ArC), 53.8 (CH2-Ph), 41.0 (CH2-NBn), 39.1 (CH2-NH), 34.9 
(CH2-CO), 32.2 (CH2-CH2-CH2), 29.1 (CH2-CH2-CH2); Diagnostic 1H NMR resonances for the minor 
rotamer: 5.59 (d, J = 14.7 Hz, CHH-Ph), 5.77 (1H, br m, NH), 4.19 (1H, d, J = 14.7 Hz, CHH-Ph), 
3.85−3.81 (1H, m, CHH-NH), 3.22−3.15 (1H, m, CHH-NH); Diagnostic 13C NMR resonances for the 
minor rotamer: 174.9 (CO), 171.6 (CO-NBn), 45.8 (CH2-Ph), 39.0 (CH2-NH); HRMS (ESI): calcd. for 
C20H22N2NaO2, 345.1573. Found; [MNa]+ 345.1574 (-0.2 ppm error). 
4-Methyl-1,4-diazacyclohexadecane-2,5-dione (433) 
 A mixture of laurolactam (349 mg, 1.77 mmol), DMAP (21.6 mg, 0.177 
mmol) and pyridine (0.860 mL, 10.6 mmol) in CH2Cl2 (12.4 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (2.65 mmol, 1.50 equiv., freshly prepared using the 
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general procedure) in CH2Cl2 (6.2 mL) was added and the resulting mixture was refluxed at 50 °C 
for 16 h. The mixture was then diluted with CH2Cl2 (100 mL) and washed with 10% aq. HCl (100 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 50 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (17.7 mL) and DBU (2.64 mL, 17.7 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 hexane:ethyl acetate → 1:1 hexane:ethyl acetate →ethyl acetate) 
afforded the title compound (as a 4:1 (A:B) mixture of rotamers) as a white solid (444 mg, 94%); 
RF 0.48 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3315, 2923, 1659, 1636, 1395, 1114, 
726; δH (400 MHz, CDCl3) 6.52 (1H, br s, NH, rotamer A), 5.83 (1H, br s, NH, rotamer B), 3.99 (2H, 
s, NCH2CO, B), 3.95 (2H, s, NCH2CO, B), 3.41–3.35 (2H, m, CH2NH, B), 3.27–3.22 (2H, m, CH2NH, 
A), 3.13 (3H, s, CH3, A), 2.99 (3H, s, CH3, B), 2.39 (2H, t, J = 6.5, COCH2, A), 2.25 (2H, t, J = 8.0, 
COCH2, B), 1.71–1.18 (36H, m, both rotamers); δC (100 MHz, CDCl3) data for the major rotamer 
only: 174.4 (CO), 169.5 (CO), 53.7 (NCH2CO), 39.0 (CH2NH), 37.3 (CH3), 32.1 (CH2CONCH), 28.5 
(CH2), 27.1 (CH2), 26.9 (CH2), 26.3 (CH2), 26.1 (CH2), 25.9 (CH2), 25.1 (CH2), 24.8 (CH2), 24.3 (CH2). 
Diagnostic 13C NMR resonance for the minor rotamers: 54.9 (NCH2CO); HRMS (ESI): calcd. for 
C15H28N2NaO2, 291.2043. Found: [MNa]+, 291.2045 (–0.5 ppm error). 
4-Isopropyl-1,4-diazacyclohexadecane-2,5-dione (434) 
 A mixture of laurolactam (130 mg, 0.658 mmol), DMAP (8 mg, 0.065 mmol) 
and pyridine (0.320 mL, 4.72 mmol) in CH2Cl2 (5 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution 
of acid chloride (0.988 mmol, 1.50 equiv., freshly prepared using the 
general procedure) in CH2Cl2 (4 mL) was added and the resulting mixture was refluxed at 50 °C 
for 16 h. The mixture was then diluted with CH2Cl2 (20 mL) and washed with 10% aq. HCl (20 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.00 mL, 6.58 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate:hexane → ethyl acetate → 9:1 ethyl acetate: methanol) 
afforded the title compound (as a 10:1:4 (A:B:C) mixture of rotamers) as a white solid (160 mg, 
82%); RF 0.57 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3301, 2926, 2856, 1622, 1547; 
δH (400 MHz, CDCl3) 6.91 (1H, br s, NH, rotamer A), 6.02 (1H, br s, NH, rotamer B, 5.69 (1H, br s, 
NH, rotamer C), 4.90–4.77 (1H, m, NCH(CH3)2, rotamer B), 4.24–4.07 (2H, m, NCH(CH3)2, 
rotamers A and C), 3.86 (4H, br s, NCH2CO, rotamers A and B), 3.82 (2H, br s, NCH2CO, rotamer 
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C), 3.37–3.29 (2H, m, CH2NH, rotamer C), 3.29–3.17 (4H, m, CH2NH, rotamers A and B), 2.46–
2.37 (2H, m, CH2CONCH, rotamer A), 2.20–2.12 (2H, m,  CH2CONCH, rotamer C), 2.04–1.99 (2H, 
m, CH2CONCH, rotamer B), 1.76–1.23 (48H, m, 9 × CH2, all rotamers), 1.20 (12H, d, J = 6.4 Hz, 
CH(CH3)2, rotamers A and B), 1.05 (6H, d, J = 6.4 Hz, CH(CH3)2, rotamer B); δC (100 MHz, CDCl3) 
data for the major rotamer only: 174.5 (CO), 171.1 (CO), 49.4 (NCH), 46.1 (NCH2CO), 39.0 
(CH2NH), 32.7 (CH2CONCH), 28.7 (CH2), 27.1 (CH2), 26.9 (CH2), 26.4 (CH2), 26.00 (CH2), 25.97 
(CH2), 25.1 (CH2), 24.9 (CH2), 24.8 (CH2), 20.9 (CH3). Diagnostic 13C NMR resonances for the minor 
rotamers: 173.6 (CO), 169.5 (CO), 37.0 (CH2CONCH), 28.4 (CH2); HRMS (ESI): calcd. for 
C17H32N2NaO2, 319.2356. Found: [MNa]+, 319.2353 (0.6 ppm error). 
4-Benzyl-1,4-diazacyclohexadecane-2,5-dione (435) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using the 
general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 °C 
for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl acetate: methanol) afforded the 
title compound (as a 3:1 mixture of rotamers) as a yellow solid (244 mg, 89%); m.p. 119.5–121.0 
°C; RF 0.66 (9:1 ethyl acetate: methanol); νmax/cm–1 (thin film) 3301, 2926, 2856, 1632, 1548; δH 
(400 MHz, CDCl3) 7.52–7.07 (10H, m, Ph, both rotamers), 6.66 (1H, br s, NH, major), 5.60 (1H, br 
s, NH, minor), 4.67 (2H, s, CH2Ph, major), 4.63 (2H, s, CH2Ph, minor), 3.94 (4H, s, NCH2CO, both), 
3.34–3.21 (2H, m, NHCH2, major), 3.20–3.10 (2H, m, NHCH2, minor), 2.43 (2H, t, J = 6.8 Hz, 
CH2CONBn, major), 2.27 (2H, t, J = 7.6 Hz, CH2CONBn, minor), 1.82–1.09 (36H, m, 9 × CH2, both); 
δC (100 MHz, CDCl3) data for the major rotamer only: 175.1 (CO), 169.6 (CO), 136.0 (C), 129.1 
(CH), 128.0 (CH), 126.7 (CH), 53.1 (CH2Ph). 51.9 (NCH2CO), 39.2 (NHCH2), 32.2 (CH2CONBn), 28.8 
(CH2), 27.2 (CH2), 27.1 (CH2), 26.5 (CH2), 26.2 (CH2), 26.0 (CH2), 25.3 (CH2), 24.9 (CH2), 24.7 (CH2). 
HRMS (ESI): calcd. for C21H32N2NaO2, 367.2356. Found: [MNa]+, 367.2331 (4.5 ppm error). 
 
 
Chapter Seven: Experimental 
 
158 | P a g e  
 
4-Isobutyl-1,4-diazacyclohexadecane-2,5-dione (436) 
 A mixture of laurolactam (70 mg, 0.353 mmol), DMAP (5 mg, 0.035 mmol) 
and pyridine (0.170 mL, 2.12 mmol) in CH2Cl2 (3 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution 
of acid chloride (0.530 mmol, 1.50 equiv., freshly prepared using the 
general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture 
was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (20 mL) and washed 
with 10% aq. HCl (20 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 15 mL) and the 
combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude material was 
then re-dissolved in CH2Cl2 (5 mL) and DBU (0.540 mL, 3.53 mmol) was added, followed by 
stirring at room temperature for 18 h, before the solvent was removed in vacuo. Purification by 
flash column chromatography (SiO2, 1:1 ethyl acetate: hexane → ethyl acetate → 9:1 ethyl 
acetate: methanol) afforded the title compound (as an 8:1 mixture of rotamers) as a yellow oil 
(105 mg, 94%); RF 0.69 (9:1 ethyl acetate: methanol); νmax/cm–1 (neat) 3300, 2928, 2855, 1648, 
1549; δH (400 MHz, CDCl3) 6.89 (1H, br s, NH, major rotamer), 5.83 (1H, br s, NH, minor rotamer), 
3.98 (2H, s, NCH2CO, minor), 3.94 (2H, s, NCH2CO, major), 3.50–3.12 (8H, m, NCH2CH and CH2NH, 
both), 2.45–2.33 (2H, m, CH2CON, major), 2.29–2.19 (2H, m, CH2CON, minor), 2.10–1.92 (2H, m, 
CH(CH3)2, both), 1.76–1.11 (36H, m, 9 × CH2, both), 0.89 (6H, d, J = 6.9 Hz, CH(CH3)2, major), 0.86 
(6H, d, J = 6.9 Hz, CH(CH3)2, minor); δC (100 MHz, CDCl3) data for the major rotamer only: 174.8 
(CO), 170.1 (CO), 57.4 (NCH2CO), 52.5 (NCH2CH), 39.3 (CH2NH), 32.1 (CH2CON), 28.6 (CH2), 27.7 
(CH(CH3)2), 27.2 (CH2), 27.0 (CH2), 26.4 (CH2), 26.1 (CH2), 25.9 (CH2), 25.3 (CH2), 24.8 (CH2), 24.4 
(CH2), 19.9 (2 × CH3); Diagnostic 13C NMR resonances for the minor rotamer: 54.3 (NCH2CO), 52.2 
(NCH2CH), 44.3 (CH2NH), 32.8 (CH2CON); HRMS (ESI): calcd. for C18H34N2NaO2, 333.2512. Found: 
[MNa]+, 333.2496 (4.5 ppm error). 
N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N-benzylglycine (442) 
 Glycine (300 mg, 4.00 mmol) was dissolved in 2M aq. NaOH (2 mL), and the 
following procedure was repeated three times: benzaldehyde (0.410 mL, 4.00 
mmol), was added and the reaction emulsion stirred for 15 min at room temperature, during 
which time the solution becomes homogenous. The solution was then cooled to 0 ⁰C and sodium 
borohydride (51 mg, 1.33 mmol), added over 10 min. The solution was then removed from the 
ice bath and stirred for 30 min at room temperature, and acidified to pH 11 via dropwise addition 
of 2M HClaq. Upon completing the third cycle, the solution was diluted with de-ionised water (50 
mL) and washed with ethyl acetate (3 × 50 mL). The aqueous was concentrated in vacuo to yield 
the benzylated amino acid salt. This crude material was re-dissolved in de-ionised water (15 mL) 
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and 1,4-dioxane (25 mL) and a solution of Na2CO3 (10% aq. solution, 20 mL) added. A pre-made 
solution of 9-fluorenylmethyl chloroformate (1.24 g, 4.8 mmol) in 1,4-dioxane (5 mL) was added 
at 0 ⁰C and the mixture stirred for 16 h. The mixture was diluted with de-ionised water (50 mL), 
acidified to pH 1, and extracted with ethyl acetate (3 × 100 mL). The combined organics were 
washed with brine, dried over MgSO4, and solvent removed in vacuo. Purification by flash 
column chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound (as a 5:4 
mixture of rotamers) as a viscous oil (1.09 g, 70%); RF 0.50 (9:1 ethyl acetate:methanol); δH (400 
MHz, CDCl3) 7.84–6.99 (26H, m, 13 × aromatic CH, both rotamers), 4.63–4.46 (8H, m, CH2Ph and 
CH2CHO, both rotamers), 4.30–4.19 (2H, m, CH2CH, both rotamers), 3.99 (2H, s, CH2CO2H, major 
rotamer), 3.75 (2H, s, CH2CO2H, minor). Spectral data are consistent with those previously 
reported.151 
The same product was also prepared using an alternative substitution strategy via the following 
procedure:  
A solution of benzylamine (2.80 mL, 22 mmol) in anhydrous THF (5 mL) was added dropwise to 
a stirring solution of ethyl bromoacetate (1.12 mL, 10 mmol) in anhydrous THF (5 mL) at 0 °C. 
The reaction mixture was stirred for 2 h at room temperature, where the reaction mixture was 
concentrated in vacuo to afford a yellow oil. Diethyl ether (20 mL) was added to the oil  and the 
resulting suspension was filtered and washed with ice cold diethyl ether (3 x 10 mL). The 
collected solute was then concentrated in vacuo to afford the desired amino ester intermediate 
as yellow oil (1.84 g, 88%). Sodium hydroxide (4N aq., 2.5 mL, 10 mmol) was added to a solution 
of the amino ester intermediate in 1,4-dioxane (35 mL) and methanol (12.5 mL) and stirred at 
room temperature for 1 h. The reaction mixture was concentrated in vacuo to afford the 
carboxylic acid sodium salt as a white solid. The sodium salt intermediate was then dissolved in 
a mixture of water (30 mL), 1,4-dioxane (50 mL) and 10% aq. Na2CO3 (50 mL) and cooled to 0 °C. 
A pre-made solution of 9-fluorenylmethyl chloroformate (3.10 g, 12.0 mmol) dissolved in 1,4-
dioxane (10 mL) was added dropwise to the sodium salt solution at 0 °C. The solution was then 
left to warm to room temperature and left stirring for 48 h. The reaction mixture was then 
diluted with water (50 mL), acidified to approx. pH 2 using 10% aq. HCl and extracted with ethyl 
acetate (3 × 50 mL). The combined organic layers were washed with sat. aq. brine (2 × 50 mL), 
dried (MgSO4), filtered and concentrated in vacuo to afford a yellow oil (5.60 g). Purification by 
flash column chromatography (4:1→1:1 ethyl acetate:hexane) afforded the title compound as a 
white solid (2.13 g, 52% over three steps). Data is consistent with those above. 
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N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N-benzyl-L-alanine (443) 
 Alanine (356 mg, 4.00 mmol) was dissolved in aq. NaOH (2M, 2 mL), and the 
following procedure was repeated three times: benzaldehyde (0.410 mL, 4.00 
mmol), was added and the reaction emulsion stirred for 15 min at room 
temperature, during which time the solution became homogenous. The solution was then 
cooled to 0 °C and sodium borohydride (51 mg, 1.33 mmol), added over 10 min. The solution 
was then removed from the ice bath and stirred for 30 min at room temperature, and acidified 
to pH 11 via dropwise addition of 2M HClaq (then repeat × 2). Upon completing the third cycle, 
the solution was diluted with de-ionised water (50 mL) and washed with ethyl acetate (3 × 50 
mL). The aqueous was concentrated in vacuo to yield the benzylated amino acid salt. This crude 
material was re-dissolved in de-ionised water (15 mL) and 1,4-dioxane (25 mL) and a solution of 
Na2CO3 (10% aq. solution, 20 mL) added. A pre-made solution of 9-fluorenylmethyl 
chloroformate (1.24 g, 4.8 mmol) in 1,4-dioxane (5 mL) was added at 0 ⁰C and the mixture stirred 
for 16 h. The mixture was diluted with de-ionised water (50 mL), acidified to pH 1, and extracted 
with ethyl acetate (3 × 100 mL). The combined organics were washed with brine, dried over 
MgSO4, and solvent removed in vacuo. Purification by flash column chromatography (SiO2, 2:1 
hexane:ethyl acetate) afforded the title compound (as a 2:1 mixture of rotamers) as a viscous oil 
(1.24 g, 78%); Rf 0.58 (9:1 ethyl acetate:methanol); δH (400 MHz, CDCl3) 8.17–7.06 (26H, m, 13 × 
aromatic CH, both rotamers), 4.79–4.15 (12H, m, CH2Ph, CH2CH, CH2CH, CHCO2H, both), 1.38 
(3H, d, J = 7.6 Hz, CHCH3, major rotamer), 1.10 (3H, d, J = 6.9 Hz, CHCH3, minor rotamer). Data 
consistent with those previously reported.152 
2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(benzyl)amino)-3-phenylpropanoic acid (444) 
2-(Benzylamino)-3-phenylpropanoic acid (1.00 g, 4.44 mmol) was dissolved in 
de-ionised water (18 mL) and 1,4-dioxane (23 mL) and Na2CO3 (20 mL, 10% 
solution) were added. The solution was cooled to 0 °C whilst stirring and a 
pre-made solution of 9-fluorenylmethyl chloroformate (1.38 g, 5.33 mmol) dissolved in 1,4-
dioxane (20 mL) added slowly. The solution was allowed to warm to room temperature and 
stirred until reaction completion. The mixture was diluted with water (60 mL) and acidified to 
pH 2 using 10% aq. HCl and extracted with ethyl acetate (3 × 50 mL). The combined organics 
were washed with brine, dried over MgSO4 and concentrated in vacuo which afforded the title 
compound (as a 4:1 mixture of rotamers) as a white solid (1.602 g, 75%), m.p. 95–97 °C; [α]D25 
−63.1 (c = 1.0, CHCl3); RF 0.40 (9:1 ethyl acetate:methanol); max/cm-1 (neat) 3029, 1699, 1451; 
δH (400 MHz, CDCl3) 8.42 (2H, br s, CO2H, both rotamers), 7.80–7.50 (4H, m, Ar, both rotamers), 
7.45–6.50 (32H, m, Ar, both rotamers), 5.00–3.70 (12H, m, NCH2Ph, OCH2CH, OCH2CH and 
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NCHCO2H, both rotamers), 3.50–3.10 (2H, m, PhCH2CHN, rotamer A), 3.08–2.30 (2H, m, 
PhCH2CHN, rotamer B); δC (100 MHz, CDCl3) 176.6 (CO2H, rotamer A), 175.6 (CO2H, rotamer B), 
156.8 (CO, both rotamers), 143.7 (C, both rotamers), 141.1 (C, both rotamers), 138.4 (CH, 
rotamer A), 136.9 (CH, rotamer A), 129.1 (CH, rotamer A), 129.0 (CH, rotamer B), 128.3 (CH, 
rotamer B), 128.2 (CH, rotamer A), 127.6 (CH, rotamer B), 127.5 (CH, rotamer A), 126.9 (CH, 
rotamer A), 126.2 (CH, rotamer B), 125.0 (CH, rotamer B), 124.9 (CH, rotamer B), 119.7 (CH, both 
rotamers), 67.6 (CH2, rotamer A), 66.9 (CH2, rotamer B), 63.9 (CH, rotamer A), 61.6 (CH, rotamer 
B), 52.8 (CH2, rotamer A), 51.9 (CH2, rotamer B), 47.3 (CH, rotamer B), 47.0 (CH, rotamer A), 35.8 
(CH, rotamer B), 35.5 (CH, rotamer A); HRMS (ESI): calcd. for C31H27NNaO4, 500.1832. Found: 
[MNa]+, 500.1814 (3.8 ppm error). 
2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(benzyl)amino)-4-methylpentanoic acid (445) 
2-(Benzylamino)-4-methylpentanoic acid (1.00 g, 4.48 mmol) was dissolved 
in de-ionised water (18 mL) and 1,4-dioxane (23 mL) and Na2CO3 (20 mL, 10% 
solution) were added. The solution was cooled to 0 °C whilst stirring and a 
pre-made solution of 9-fluorenylmethyl chloroformate (1.372 g, 5.4 mmol) 
dissolved in 1,4-dioxane (20 mL) added slowly. The solution was allowed to warm to room 
temperature and stirred until reaction completion. The mixture was diluted with water (60 mL) 
and acidified to pH 2 using 10% HCl(aq) and extracted with ethyl acetate (3 × 50 mL). The 
combined organics were washed with saturated aqueous brine, dried over MgSO4 and 
concentrated in vacuo which afforded the title compound (as a 1:1 mixture of rotamers) as a 
viscous oil (1.312 g, 65%); [α]D25 −22.6 (c = 1.0, CHCl3); RF 0.30 (9:1 ethyl acetate:methanol); 
max/cm-1 (neat) 2956, 1697, 1450; δH (400 MHz, CDCl3) 8.27 (2H, br s, CO2H, both rotamers), 
7.90–7.55 (6H, m, Ar, both), 7.53–7.00 (20H, m, Ar, both), 5.00–4.00 (12H, m, OCH2CH and 
CHNCH2Ph, both), 2.00–1.20 (6H, m, CH2CH, both), 1.10–0.75 and 0.74–0.41  (12H, m, CH3CHCH3, 
both); δC (100 MHz, CDCl3) 177.5 and 177.2 (CO2H), 157.5 and 156.8 (NCO), 143.7 (C, both), 141.4  
and 141.2 (C), 138.1 and 137.9 (C), 128.3 and 128.2 (CH), 127.9  and 127.5 (CH), 127.4 and 127.0 
(CH), 126.9 (CH), 124.9 and 124.8 (CH), 119.9 (CH, both), 67.7 and 67.3 (NCHCO2H), 59.1 and 
57.9 (OCH2), 50.4 (NCH2Ph, both), 47.2 and 47.0 (OCH2CH), 38.6 and 38.2 (NCHCH2), 24.8 and 
24.6 (CH3CHCH3), 22.4 and 22.2 (CH3CHCH3), 21.7 and 21.4 (CH3CHCH3); HRMS (ESI): calcd. for 
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2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(benzyl)amino)-4-(methylthio)butanoic acid (446) 
2-(Benzylamino)-4-(methylthio)butanoic acid (1.00 g, 4.16 mmol) was 
dissolved in de-ionised water (18 mL) and 1,4-dioxane (23 mL) and Na2CO3 
(20 mL, 10% solution) were added. The solution was cooled to 0 °C whilst 
stirring and a pre-made solution of 9-fluorenylmethyl chloroformate (1.29 g, 
4.08 mmol) dissolved in 1,4-dioxane (20 mL) added slowly. The solution was allowed to warm to 
room temperature and stirred until reaction completion. The mixture was diluted with water 
(60 mL) and acidified to pH 2 using 10% HCl(aq) and extracted with ethyl acetate (3 × 50 mL). 
The combined organics were washed with brine, dried over MgSO4 and concentrated in vacuo 
which afforded the title compound (as a 3:1 mixture of rotamers) as a viscous oil (200 mg, 10%); 
[α]D25 −51.6 (c = 1.0, CHCl3); RF 0.30 (1:1 ethyl acetate:hexane); max/cm-1 (neat) 2916, 1698, 1450; 
δH (400 MHz, CDCl3) 8.46 (2H, CO2H, both rotamers), 7.74 (4H, d, J=6.9 Hz, Ar, both), 7.65–7.45 
(4H, m, Ar, both), 7.42–7.05 (18H, m, Ar, both), 4.90–4.51 (4H, m, OCH2, both), 4.50–4.19 (6H, 
m, OCH2CH and PhCH2, both), 4.18–3.40 (2H, m, CHCO2H, both), 2.74–2.17 (4H, m, SCH2, both), 
2.16–1.70 (8H, m, CHaHbCH2SCH3, both), 1.60–1.18 (2H, m, CHaHbCH2S, both); δC (100 MHz, 
CDCl3) data for the major rotamer only: 176.2 (CO2H), 156.4 (NCO), 143.7 (C), 141.3 (C), 137.0 
(C), 128.5 (CH), 128.3 (CH), 127.9 (CH), 127.7 (CH), 127.0 (CH), 124.8 (CH), 124.5 (CH), 119.9 (CH), 
67.5 (NCHCO2H), 59.0 (OCH2), 51.9 (CH), 47.2 (NCH2Ph), 30.8 (CH2), 28.4 (CH2), 14.9 (CH3). 
Diagnostic 13C NMR resonances for minor rotamers: 176.3 (CO2H), 156.7 (NCO), 143.6 (C), 137.3 
(C), 129.0 (CH), 128.4 (CH), 127.1 (CH), 124.9 (CH), 119.9 (CH), 67.1 (OCH2), 60.4 (NCHCO2H), 57.8 
(OCH2), 47.3 (NCH2Ph), 30.8 (CH2), 28.9 (CH2), 14.8 (CH3); HRMS (ESI): calcd. for C27H27NNaO4S, 
484.1553. Found: [MNa]+, 484.1553 (−1.1 ppm error). 
2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(benzyl)amino)-3-phenylpropanoic acid (447) 
2-(Benzylamino)-3-(1H-indol-3-yl)propanoic acid (1.00 g, 3.39 mmol) 
was dissolved in de-ionised water (18 mL) and 1,4-dioxane (23 mL) and 
Na2CO3 (20 mL, 10% solution) were added. The solution was cooled to 0 
°C whilst stirring and a pre-made solution of 9-fluorenylmethyl 
chloroformate (1.05 g, 4.08 mmol) dissolved in 1,4-dioxane (20 mL) 
added slowly. The solution was allowed to warm to room temperature and stirred until reaction 
completion. The mixture was diluted with water (60 mL) and acidified to pH 2 using 10% HCl(aq) 
and extracted with ethyl acetate (3 × 50 mL). The combined organics were washed with brine, 
dried over MgSO4 and concentrated in vacuo which afforded the title compound (as a 2:1 
mixture of rotamers) as a white solid (410 mg, 23%), m.p. 75–77 °C; [α]D25 −57.5 (c = 1, CHCl3); 
RF 0.30 (9:1 ethyl acetate:methanol);max/cm-1 (neat) 3421, 1683, 1452; δH (400 MHz, CDCl3) 8.80 
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(2H, CO2H, both rotamers), 8.20–7.67 (6H, m, Ar, both), 7.65–7.07 (24H, m, Ar, both), 7.06–6.28 
(6H, m, Ar, both), 5.20–4.28 (6H, m, OCH2 and CHCO2H, both), 4.25–4.02 (2H, m, OCH2CH, both), 
4.01–2.28 (8H, m, PhCH2 and CH2CHCO2H, both); δC (100 MHz, CDCl3) data for the major rotamer: 
175.6 (CO2H), 156.6 (NCO), 143.7 (C), 141.3 (C), 136.7 (C), 136.0 (C), 128.3 (CH), 128.1 (CH), 127.7 
(CH), 127.6 (CH), 127.2 (CH), 127.1 (CH), 126.8 (C), 124.9 (CH), 124.5 (CH), 123.3 (CH), 121.9 (CH), 
119.9 (CH), 119.4 (CH), 118.3 (CH), 111.2 (CH), 67.6 (OCH2), 59.5 (NCHCO2H), 52.2 (NCH2Ph), 47.1 
(NCH2CH), 25.0 (CH2). Diagnostic 13C NMR resonances for minor rotamer: 175.5 (C), 156.4 (NCO), 
143.8 (C), 141.2 (C), 128.4 (CH), 127.6 (CH), 127.2 (CH), 127.0 (CH), 124.9 (CH), 124.5 (CH), 120.1 
(CH), 118.1 (CH), 111.3 (CH), 66.8 (OCH2), 61.5 (NCHCO2H), 52.3 (NCH2Ph), 47.3 (NCH2CH), 25.5 
(CH2); HRMS (ESI): calcd. for C33H28N2NaO4, 539.1941. Found: [M+Na]+, 539.1918 (2.3 ppm error). 
(S)-4-Benzyl-3-methyl-1,4-diazacyclohexadecane-2,5-dione (450) 
 A mixture of laurolactam (24 mg, 0.120 mmol), DMAP (2 mg, 0.0124 mmol) 
and pyridine (0.060 mL, 0.72 mmol) in CH2Cl2 (2.0 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution 
of acid chloride (0.36 mmol, 3.0 eqv prepared using the general procedure) 
in CH2Cl2 (1 mL) was added and the resulting mixture was refluxed at 50 °C for 16 h. The mixture 
was then diluted with CH2Cl2 (15 mL) and washed with 10% aq. HCl (10 mL). The aqueous layer 
was then extracted with CH2Cl2 (3 × 15 mL) and the combined organic extracts dried over MgSO4 
and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 (2 mL) and DBU 
(0.180 mL, 1.2 mmol) was added, followed by stirring at room temperature for 18 h, before the 
solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 5:1 
hexane:ethyl acetate → 1:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound 
as a yellow oil (28 mg, 64%); [α]D25 −24.1 (c = 1.0, CHCl3); RF 0.71 (9:1 ethyl acetate:methanol); 
νmax/cm–1 (thin film) 3319, 2927, 2856, 1717, 1626, 1530; δH (400 MHz, CDCl3) 7.42–7.07 (5H, m, 
Ph), 6.59 (1H, br s, NH), 5.11 (1H, q, J = 7.3 Hz, CHCH3). 4.63 (2H, s, CH2Ph), 3.63–3.48 (1H, m, 
CHH′NH), 3.05–2.88 (1H, m, CHH′NH), 2.44–2.29 (1H, m, CHH′CONBn), 2.26–2.11 (1H, m, 
CHH′CONBn), 1.89–1.12 (21H, m, 9 × CH2 and CH3); δC (100 MHz, CDCl3) 175.9 (CO), 171.8 (CO), 
138.0 (C), 128.8 (CH), 127.3 (CH), 125.9 (CH), 53.1 (CH), 48.2 (CH2Ph), 39.3 (CH2NH), 33.2 
(CH2CO), 28.9 (CH2), 27.1 (CH2), 26.4 (CH2), 26.2 (CH2), 26.0 (CH2), 25.4 (CH2), 24.9 (CH2), 24.7 
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(S)-3-Benzyl-4-benzyl-1,4-diazacyclohexadecane-2,5-dione (451) 
 A mixture of laurolactam (78.9 mg, 0.405 mmol), DMAP (4.9 mg, 0.0405 
mmol) and pyridine (0.196 mL, 2.43 mmol) in CH2Cl2 (2.8 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (0.607 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (1.4 mL) was added and the resulting mixture was refluxed at 
50 °C for 16 h. The mixture was then diluted with CH2Cl2 (50 mL) and washed with 10% aq. HCl 
(50 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (4.1 mL) and DBU (0.607 mL, 4.05 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 10:1 hexane:ethyl acetate → 5:1 hexane:ethyl acetate) afforded the title 
compound as a colourless oil (176 mg, 72%); RF 0.50 (2:1 hexane:ethyl acetate); [α]D20 −17.0 (c = 
1.0, CHCl3); νmax/cm–1 (thin film) 2927, 1629, 1453, 908, 727, 696; δH (400 MHz, CDCl3) 7.32–7.08 
(10H, m, Ph), 6.62 (1H, br s, NH), 5.10–4.80 (1H, br m, CHBn), 4.58 (1H, d, J = 17.6, NCHH′Ph), 
4.47 (1H, d, J = 17.6, NCHH′Ph), 3.49–3.38 (1H, m), 3.22 (1H, dd, J = 13.7, 8.4), 3.07–2.87 (2H, m), 
2.39–2.30 (1H, m, CHH′CO), 2.27–2.17 (1H, m, CHH′CO), 1.77–1.16 (18H, m, 9 × CH2); δC (100 
MHz, CDCl3) 175.7 (CO), 170.4 (CO), 137.5 (C), 137.3 (C), 129.1 (CH), 128.7 (CH), 128.4 (CH), 127.3 
(CH), 126.5 (CH), 126.2 (CH), 60.9 (broadened, CH), 50.0 (broadened, CH2), 39.2 (CH2), 34.6 (CH2), 
33.1 (CH2), 28.7 (CH2), 27.1 (CH2), 26.9 (CH2), 26.2 (CH2), 26.0 (CH2), 25.9 (CH2), 25.4 (CH2), 24.8 
(CH2), 24.3 (CH2); HRMS (ESI): calcd. for C28H38N2NaO2, 457.2825. Found: [MNa]+, 457.2824 (0.9 
ppm error). 
(S)-3-Benzyl-4-methyl-1,4-diazacyclohexadecane-2,5-dione (452) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using the 
general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture 
was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed 
with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the 
combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude material was 
then re-dissolved in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring 
at room temperature for 18 h, before the solvent was removed in vacuo. Purification by flash 
column chromatography (SiO2, 1:5 ethyl acetate:hexane → 1:1 ethyl acetate:hexane → ethyl 
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acetate) afforded the title compound as a yellow oil (229 mg, 84%); RF 0.78 (9:1 ethyl acetate: 
methanol); [α]D20 −18.40 (c = 1.0, CHCl3); νmax/cm–1 (thin film) 3315, 2927, 2856, 1626, 1524; δH 
(400 MHz, CDCl3) 7.28–7.20 (3H, m, Ph), 7.19–7.13 (2H, m, Ph), 6.33 (1H, br s, NH), 5.37–5.24 
(1H, m, CHBn), 3.63–3.50 (1H, m, CHH′NH), 3.26 (1H, dd, J = 14.5, 7.6 Hz, CHH′Ph), 2.98 (1H, dd, 
J = 14.5, 7.6 Hz, CHH′Ph), 2.91 (3H, s, CH3), 2.89–2.78 (1H, m, CHH′NH), 2.50–2.35 (1H, m, 
CHH′CO), 2.16–1.99 (1H, m, CHH′CO), 1.83–1.08 (18H, m, 9 × CH2); δC (100 MHz, CDCl3) 174.7 
(CO), 170.2 (CO), 137.4 (C), 129.0 (CH), 128.5 (CH), 126.6 (CH), 57.5 (NCHBn), 39.2 (CH2NH), 33.8 
(CH2Ph), 32.5 (CH2CO), 31.6 (CH3), 28.8 (CH2), 27.2 (CH2), 27.1 (CH2), 26.5 (CH2), 26.3 (CH2), 26.1 
(CH2), 25.3 (CH2), 25.1 (CH2), 24.4 (CH2); HRMS (ESI): calcd. for C22H34N2NaO2, 381.2512. Found: 
[MNa]+, 381.2498 (3.7 ppm error). 
(S)-3-Butyl-4-methyl-1,4-diazacyclohexadecane-2,5-dione (453) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 
°C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 hexane:ethyl acetate → 1:1 hexane:ethyl acetate → ethyl acetate) 
afforded the title compound (as an 8:1 mixture of rotamers) as a yellow oil (182 mg, 71%); RF 
0.71 (9:1 ethyl acetate: methanol); νmax/cm–1 (thin film) 3318, 2927, 2857, 1624, 1529; δH (400 
MHz, CDCl3) 6.29 (1H, br s, NH, major rotamer), 5.91 (1H, br s, NH, minor), 5.00–4.89 (2H, m, 
CHNMe, both), 3.64–3.52 (2H, m, CHH′NH, both), 2.92 (3H, s, NCH3, major), 2.89–2.80 (2H, m, 
CHH′NH, both), 2.77 (3H, s, NCH3, minor), 2.57–2.45 (2H, m, CHH′CONMe, both), 2.26–2.14 (2H, 
m, CHH′CONMe, both), [1.93–1.74 (4H), 1.68–1.54 (4H), 1.51–1.05 (40H), 10 × CH2, both], 0.86 
(6H, t, J = 6.9 Hz, CH2CH3, both); δC (100 MHz, CDCl3) data for the major rotamer only: 174.7 (CO), 
170.9 (CO), 56.3 (CHNMe), 39.1 (CH2NH), 32.6 (CH2CO), 30.9 (NCH3), 28.8 (CH2), 28.2 (CH2), 27.20 
(CH2), 27.18 (CH2), 27.0 (CH2), 26.6 (CH2), 26.3 (CH2), 26.1 (CH2), 25.3 (CH2), 25.1 (CH2), 24.6 (CH2), 
22.6 (CH2), 14.1 (CH3). Diagnostic 13C NMR resonances for minor rotamer: 175.0 (CO), 170.3 (CO), 
67.2 (CHNMe), 62.0 (CH2), 60.5 (CH2); HRMS (ESI): calcd. for C19H36N2NaO2, 347.2669. Found: 
[MNa]+, 347.2660 (2.8 ppm error). 
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(S)-4-Benzyl-3-isobutyl-1,4-diazacyclohexadecane-2,5-dione (454) 
 A mixture of laurolactam (77.1 mg, 0.391 mmol), DMAP (4.8 mg, 0.0391 
mmol) and pyridine (0.189 mL, 2.34 mmol) in CH2Cl2 (2.7 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (0.586 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (1.3 mL) was added and the resulting 
mixture was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (50 mL) and 
washed with 10% aq. HCl (50 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (3.9 mL) and DBU (0.583 mL, 3.91 mmol) was added, 
followed by stirring at room temperature for 18 h, before the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 10:1 hexane:ethyl acetate → 3:1 
hexane:ethyl acetate) afforded the title compound (as a roughly 10:1 mixture of rotamers) as a 
colourless oil (63 mg, 40%); RF 0.40 (2:1 hexane:ethyl acetate); [α]D20 −21.2 (c = 1.0, CHCl3); 
νmax/cm–1 (thin film) 3318, 2927, 1627, 1543, 1451, 730; δH (400 MHz, CDCl3) NMR data for the 
major rotamer only 7.34–7.20 (3H, m, Ph), 7.15 (2H, d, J = 7.0, Ph), 6.62 (1H, br s, NH), 5.01 (1H, 
t, J = 7.0, CHN), 4.66 (1H, d, J = 17.6, NCHH′Ph), 4.59 (1H, d, J = 17.6, NCHH′Ph), 3.59–3.49 (1H, 
m), 2.99–2.90 (1H, m), 2.40–2.32 (1H, m), 2.24–2.16 (1H, m), 1.89–1.70 (2H, m), 1.54–1.10 (19H, 
m, 9 × CH2 and CH), 0.82 (3H, d, J = 6.9, CH3), 0.78 (3H, d, J = 6.9, CH3); δC (100 MHz, CDCl3) 175.8 
(CO), 171.2 (CO), 137.9 (C), 128.6 (CH), 127.2 (CH), 126.1 (CH), 56.4 (broadened, CH), 48.6 (CH2), 
39.2 (CH2), 37.0 (CH2), 33.0 (CH2), 28.7 (CH2), 27.1 (CH2), 27.0 (CH2), 26.3 (CH2), 26.0 (CH2), 25.8 
(CH2), 25.4 (CH2), 25.1 (CH), 24.8 (CH2), 24.4 (CH2), 22.9 (CH3), 22.3 (CH3); HRMS (ESI): calcd. for 
C25H40N2NaO2, 423.2982. Found: [MNa]+, 423.2984 (–0.5 ppm error). 
(S)-3-Indolyl-4-benzyl-1,4-diazacyclohexadecane-2,5-dione (455) 
 A mixture of laurolactam (141 mg, 0.713 mmol), DMAP (8.7 mg, 
0.0713 mmol) and pyridine (0.350 mL, 4.28 mmol) in CH2Cl2 (5.0 mL) 
under an argon atmosphere was stirred at room temperature for 30 
min. Next, a solution of acid chloride (1.07 mmol, 1.50 equiv., freshly 
prepared using the general procedure) in CH2Cl2 (2.5 mL) was added 
and the resulting mixture was refluxed at 50 °C for 16 h. The mixture 
was then diluted with CH2Cl2 (50 mL) and washed with 10% aq. HCl (50 mL). The aqueous layer 
was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic extracts dried over MgSO4 
and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 (7.1 mL) and DBU 
(1.06 mL, 7.13 mmol) was added, followed by stirring at room temperature for 18 h, before the 
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solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 5:1 
hexane:ethyl acetate → 1:1 hexane:ethyl acetate) afforded the title compound (as a roughly 5:1 
mixture of rotamers) as a yellow oil (180 mg, 53%); RF 0.50 (2:1 hexane:ethyl acetate); [α]D20 
−18.5 (c = 1.0, CHCl3); νmax/cm–1 (thin film) 3302, 2928, 1657, 1450, 909, 733; δH (400 MHz, CDCl3) 
For the major rotamer only: 8.38 (1H, s, indole NH), 7.52 (1H, d, J = 7.6, CH), 7.33–7.04 (8H, m, 
Ar), 6.93 (1H, br s, NH), 5.24–5.14 (1H, br m, CHN), 4.60 (2H, s, CH2Ph) 3.50–3.34 (2H, m), 3.18–
3.08 (1H, m), 2.90–2.81 (1H, m), 2.43–2.32 (1H, m), 2.28–2.20 (1H, m), 1.77–1.15 (18H, m, 9 × 
CH2); δC (100 MHz, CDCl3) 175.7 (CO), 170.9 (CO), 137.6 (C), 136.1 (C), 128.7 (CH), 127.3 (CH), 
127.2 (C), 126.2 (CH), 122.9 (CH), 121.8 (CH), 119.3 (CH), 118.6 (CH), 111.2 (C), 111.1 (CH), 59.5 
(broadened, CH), 49.6 (broadened, CH2), 39.2 (CH2), 33.1 (CH2), 28.7 (CH2), 27.1 (CH2), 26.9 (CH2), 
26.3 (CH2), 26.0 (CH2), 25.9 (CH2), 25.3 (CH2), 24.8 (CH2), 24.4 (CH2) 24.3 (CH2); HRMS (ESI): calcd. 
for C30H39N3NaO2, 496.2934. Found: [MNa]+, 496.2939 (1.1 ppm error) 
(S)-Decahydropyrrolo[1,2-a][1,4]diazecine-1,8-dione (456) 
 A mixture of ε-caprolactam (200 mg, 1.77 mmol), DMAP (21.6 mg, 0.177 
mmol) and pyridine (0.860 mL, 10.6 mmol) in CH2Cl2 (12.4 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution of 
acid chloride (2.65 mmol, 1.50 equiv., freshly prepared using the general 
procedure) in CH2Cl2 (6.2 mL) was added and the resulting mixture was refluxed at 50 °C for 16 
h. The mixture was then diluted with CH2Cl2 (100 mL) and washed with 10% aq. HCl (100 mL). 
The aqueous layer was then extracted with CH2Cl2 (3 × 50 mL) and the combined organic extracts 
dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 
(17.7 mL) and DBU (2.64 mL, 17.7 mmol) was added, followed by stirring at room temperature 
for 18 h, before the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 10:1 hexane:ethyl acetate → 1:1 hexane:ethyl acetate → ethyl acetate) afforded the title 
compound (as a roughly 5:1:1 mixture of rotamers) as a white solid (340 mg, 91%); m.p. 142–
145 °C; [α]D20 −25.2 (c = 1.0, CHCl3); RF 0.18 (19:1 ethyl acetate: methanol); νmax/cm–1 (thin film) 
3292, 2922, 1635, 1557, 1441, 1155, 735, 519; δH (400 MHz, CDCl3) a very broad spectrum was 
obtained: 6.96 (1H, br s, NH, minor rotamer), 6.78 (1H, br s, NH, major rotamer) [4.22–4.15 (m), 
4.12–3.95 (m), 3.75–3.30 (m), 3.15–3.07 (m), 4H, all rotamers], 2.75–0.80 (13H, m, all rotamers); 
δC (100 MHz, CDCl3) data for the major rotamer only: 174.7 (CO), 173.3 (CO), 62.7 (NCHCO), 46.7 
(NCH2), 39.9 (NHCH2), 31.0 (CH2CONCH), 30.7 (CH2), 26.2 (CH2), 25.0 (CH2), 23.4 (CH2), 22.0 (CH2). 
Diagnostic 13C NMR resonances for the minor rotamers 178.9, 60.3, 60.2, 45.0, 42.5, 36.4, 30.3, 
29.5, 27.4, 23.0, 20.6, 14.0. HRMS (ESI): calcd. for C11H18N2NaO2, 233.1260. Found: [MNa]+, 
233.1259 (0.9 ppm error). 
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(S)-Decahydro-1H-pyrrolo[1,2-a][1,4]diazacycloundecine-1,9(2H)-dione (457) 
 A mixture of azocan-2-one (225 mg, 1.77 mmol), DMAP (21.6 mg, 0.177 
mmol) and pyridine (0.860 mL, 10.6 mmol) in CH2Cl2 (12.4 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution of 
acid chloride (2.65 mmol, 1.50 equiv., freshly prepared using the general 
procedure) in CH2Cl2 (6.2 mL) was added and the resulting mixture was refluxed at 50 °C for 16 
h. The mixture was then diluted with CH2Cl2 (100 mL) and washed with 10% aq. HCl (100 mL). 
The aqueous layer was then extracted with CH2Cl2 (3 × 50 mL) and the combined organic extracts 
dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 
(17.7 mL) and DBU (2.64 mL, 17.7 mmol) was added, followed by stirring at room temperature 
for 18 h, before the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 10:1 hexane:ethyl acetate → 1:1 hexane:ethyl acetate → ethyl acetate) afforded the title 
compound as a white solid (370 mg, 95%); m.p. 137–141 °C; [α]D20 −50.6 (c = 1.0, CHCl3); RF 0.18 
(19:1 ethyl acetate: methanol); νmax/cm–1 (thin film) 3277, 2927, 1674, 1603, 1420, 1238, 729, 
688; δH (400 MHz, CDCl3) 6.06–5.95 (1H, m, NH), 4.35 (1H, dd, J = 8.7, 3.2, NCH), [3.95 (1H, m), 
3.70–3.52 (2H, m) and 3.00–2.90 (1H, m) 2 × NCH2), 2.47–1.22 (10H, m), 1.06–0.84 (2H, m); δC 
(100 MHz, CDCl3) 174.0 (CO), 173.1 (CO), 62.3 (NCHCO), 47.0 (NCH2), 39.3 (NHCH2), 31.8 
(CH2CONCH), 31.6 (CH2), 28.9 (CH2), 25.9 (CH2), 24.1 (CH2), 23.1 (CH2), 22.3 (CH2). HRMS (ESI): 
calcd. for C12H20N2NaO2, 247.1417. Found: [MNa]+, 247.1422 (0.9 ppm error). 
(S)-Hexadecahydropyrrolo[1,2-a][1,4]diazacyclohexadecine-1,14-dione (458) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 
°C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 
mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (8 mL) and DBU (1.2 mL, 7.86 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 1:1 ethyl acetate:hexane → ethyl acetate) afforded the title compound 
(as a 10:1 mixture of rotamers) as a colourless oil (183 mg, 82%); RF 0.45 (9:1 ethyl acetate: 
methanol); [α]D20 −93.3 (c = 1.0, CHCl3); νmax/cm–1 (thin film) 3299, 2926, 2856, 1648, 1626, 1543; 
δH (400 MHz, CDCl3) 7.35 (1H, br s, NH, major rotamer), 5.96 (1H, br s, NH, minor), 4.60 (1H, d, J 
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= 7.6 Hz, NCHCO, major), 4.34 (1H, dd, J = 8.4, 2.3 Hz, NCHCO, minor), 3.75–3.63 (2H, m, 
CHH′NCH and CHH′NH, minor), 3.62–3.45 (2H, m, CHH′NCH and CHH′NH, major), 3.42–3.31 (1H, 
m, CHH′NCH, major), 3.30–3.24 (1H, m, CHH′NCH, minor), 3.04–2.87 (2H, m, CHH′NH, both), 
2.53–2.43 (2H, m, CHH′CONCH, both), 2.42–2.24 (2H, m, CHH′CONCH and CHH′CH2NH, major), 
[2.23–1.61 (12H), 1.52–1.15 (32H), m, CHH′CONCH (minor), CHH′CH2NH (minor), CHH′CH2NH 
(both), 10 × CH2 (both)]. δC (100 MHz, CDCl3) data for the major rotamer only: 174.0 (CO), 171.3 
(CO), 59.7 (NCHCO), 47.7 (NCH2), 39.5 (NHCH2), 34.0 (CH2CONCH), 28.7 (CH2), 27.2 (CH2), 27.0 
(CH2), 26.6 (CH2), 26.2 (CH2), 26.0 (CH2), 25.9 (CH2), 25.4 (CH2), 25.2 (CH2), 24.7 (CH2), 26.3 (CH2). 
Diagnostic 13C NMR resonances for the minor rotamer: 173.6 (CO), 172.1 (CO), 61.8 (CH), 46.9 
(CH2), 34.4 (CH2). HRMS (ESI): calcd. for C17H30N2NaO2, 317.2199. Found: [MNa]+, 317.2188 (3.3 
ppm error). 
(S)-4-Benzyl-3-(2-(methylthio)ethyl)-1,4-diazacyclohexadecane-2,5-dione (459) 
 A mixture of laurolactam (49.5 mg, 0.251 mmol), DMAP (3.1 mg, 0.0251 
mmol) and pyridine (0.122 mL, 1.51 mmol) in CH2Cl2 (1.8 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (0.376 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (0.9 mL) was added and the resulting mixture was refluxed at 
50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl 
(30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 20 mL) and the combined organic 
extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-dissolved 
in CH2Cl2 (2.5 mL) and DBU (0.370 mL, 2.51 mmol) was added, followed by stirring at room 
temperature for 18 h, before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 10:1 hexane:ethyl acetate → 3:1 hexane:ethyl acetate) afforded the title 
compound (as a roughly 10:1 mixture of rotamers) as a colourless oil (45 mg, 43%); RF 0.45 (2:1 
hexane:ethyl acetate); [α]D20 −48.8 (c = 0.9, CHCl3); νmax/cm–1 (thin film) 2925, 1628, 1535, 1452, 
728; δH (400 MHz, CDCl3) NMR data for the major rotamer only 7.37–7.14 (5H, m, Ph), 6.65 (1H, 
br s, NH), 5.07–5.01 (1H, m, CHN), 4.64 (2H, s, CH2Ph), 3.58–3.48 (1H, m), 3.00–2.92 (1H, m), 
2.47–2.20 (1H, m), 1.97 (3H, s, SCH3), 1.81–1.70 (2H, m), 1.53–1.20 (18H, m); δC (100 MHz, CDCl3) 
175.8 (CO), 170.5 (CO), 137.6 (C), 128.8 (CH), 127.4 (CH), 126.1 (CH), 57.3 (broadened, CH), 49.1 
(CH2), 39.3 (CH2), 33.0 (CH2), 30.9 (CH2), 28.7 (CH2), 27.8 (CH2), 27.04 (CH2), 27.02 (CH2), 26.3 
(CH2), 26.0 (CH2), 25.8 (CH2), 25.4 (CH2), 24.8 (CH2), 24.4 (CH2), 15.2 (CH3); HRMS (ESI): calcd. for 
C24H38N2NaO2S, 441.2546. Found: [MNa]+, 441.2531 (3.4 ppm error). Diagnostic NMR 
resonances for minor rotamer be found at: δH (400 MHz, CDCl3) 4.69 (2H, s, CH2Ph), 2.02 (3H, s, 
SCH3).  
Chapter Seven: Experimental 
 
170 | P a g e  
 
8-Benzyl-4-methyl-1,4,8-triazacyclotetradecane-2,5,9-trione (465) 
 A mixture of 5-benzyl-1,5-diazacycloundecane-2,6-dione (54 mg, 0.197 
mmol), DMAP (3 mg, 0.0197 mmol) and pyridine (95.0 μL, 1.18 mmol) in 
CH2Cl2 (1.5 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of acid chloride (0.380 mmol, 
1.50 equiv., freshly prepared using the general procedure) in CH2Cl2 (1 
mL) was added and the resulting mixture was heated at 50 °C for 16 h. The mixture was then 
diluted with CH2Cl2 (10 mL) and washed with 10% aq. HCl (10 mL). The aqueous layer was then 
extracted with CH2Cl2 (3 × 15 mL) and the combined organic extracts dried over MgSO4 and 
concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 (3 mL) and DBU (300 
μL, 1.97 mmol) was added, followed by stirring at room temperature for 18 h, before the solvent 
was removed in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl 
acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound (as a 10:1:1 
A:B:C mixture of rotamers) as a yellow oil (61 mg, 89%); RF 0.39 (9:1 ethyl acetate:methanol); 
νmax/cm–1 (neat) 3311, 2933, 2239, 1623, 1538; δH (400 MHz, CDCl3) 7.39–7.09 (18H, m, Ph and 
NH, all rotamers), 4.68 (4H, br s, CH2Ph, rotamers A and B), 4.62 (2H, s, CH2Ph. rotamer C), 4.01–
3.84 (6H, m, COCH2NMe, all rotamers), 3.83–3.60 (6H, m, CH2NBn, all rotamers), 3.43–3.25 (6H, 
m, CH2NH, all rotamers), 3.13 (3H, s, NCH3, rotamer A), 3.02 (3H, s, NCH3, rotamer B), 2.93 (3H, 
s, NCH3, rotamer C), 2.74–2.55 (6H, m, CH2CONMe, all rotamers), 2.43–2.23 (6H, m, CH2CONBn, 
all rotamers), 1.76–1.55 (6H, m, CH2, all rotamers), 1.54–1.40 (6H, m, CH2, all rotamers), 1.27–
1.12 (6H, m, CH2, all rotamers); δC (100 MHz, CDCl3) data for the major rotamer only: 175.3 (CO), 
171.8 (CO), 168.6 (CO), 136.6 (CCH), 129.1 (CH), 127.8 (CH), 126.6 (CH), 53.3 (CH2NMe), 52.1 
(CH2Ph), 43.1 (CH2NBn), 37.1 (NCH3), 36.2 (CH2NH), 32.8 (CH2CONMe), 32.3 (CH2CONBn), 26.7 
(CH2), 23.5 (CH2), 20.6 (CH2). Diagnostic 13C NMR resonances for minor rotamers: 174.2 (CO), 
173.5 (CO), 172.7 (CO), 171.6 (CO), 171.2 (CO), 168.2 (CO), 137.5 (CCH), 128.9 (CH), 128.3 (CH), 
127.5 (CH), 60.5 (CH2NMe), 14.3 (CH2); HRMS (ESI): calcd. for C19H27N3NaO3, 368.1945. Found: 
[MNa]+, 368.1939 (1.7 ppm error). 
8-Benzyl-4-methyl-1,4,8-triazacyclopentadecane-2,5,9-trione (466) 
 A mixture of 5-benzyl-1,5-diazacyclododecane-2,6-dione (140 mg, 
0.485 mmol), DMAP (6 mg, 0.0485 mmol) and pyridine (235 μL, 2.91 
mmol) in CH2Cl2 (4 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of acid chloride (0.728 mmol, 
1.50 equiv. freshly prepared using the general procedure) in CH2Cl2 (1 mL) was added and the 
resulting mixture was heated at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (10 mL) 
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and washed with 10% aq. HCl (10 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 15 
mL) and the combined organic extracts dried over MgSO4, concentrated in vacuo. The crude 
material was then re-dissolved in CH2Cl2 (6 mL) and DBU (740 μL, 4.85 mmol) was added, 
followed by stirring at room temperature for 18 h, before the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 5:1 hexane:ethyl acetate → ethyl acetate → 
9:1 ethyl acetate:methanol) afforded the title compound (as a 4:2:1:1 mixture of rotamers 
A:B:C:D) as a yellow oil (158 mg, 85%); Rf 0.44 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 
3300, 2931, 1630, 1541; δH (400 MHz, CDCl3) 7.38–7.05 (20H, m, Ph, all rotamers), 6.99 (1H, br 
s, NH, rotamer A), 6.90 (1H, br s, NH, rotamer B), 6.60 (1H, br s, NH, rotamer C), 6.28 (1H, br s, 
NH, rotamer D), 4.73 (2H, s, CH2NMe, rotamer B), 4.65 (2H, s, CH2NMe, rotamer A), [4.56 (2H, s, 
CH2NMe), 4.52 (2H, s, CH2NMe) rotamers C and D], 4.00–3.71 (8H, m, CH2Ph, all rotamers), 3.71–
3.47 (8H, m, CH2NBn, all rotamers), 3.46–3.15 (8H, m, CH2NH), 3.05 (3H, s, CH3, rotamer A), 2.98 
(3H, s, CH3, rotamer B), [2.94 (3H, s, CH3), 2.66 (3H, s, CH3), rotamers C and D], 2.64–2.50 (8H, 
m, CH2CONMe, all rotamers), 2.43–2.20 (8H, m, CH2CONBn, all rotamers), 1.81–1.22 (32H, m, 4 
× CH2, all rotamers); δC (100 MHz, CDCl3) data for the major rotamer only: 175.3 (CO), 172.0 (CO), 
169.0 (CO), 136.5 (C), 129.1 (CH), 127.8 (CH), 126.3 (CH), 60.5 (CH2NMe), 52.5 (CH2Ph), 51.4 
(CH2NBn), 42.4 (CH2CONBn), 40.4 (CH2NH), 36.6 (CH3N), 32.3 (CH2CONMe), 27.8 (CH2), 25.3 
(CH2), 22.7 (CH2), 14.3 (CH2). Diagnostic 13C NMR resonances for minor rotamers: 175.9 (CO), 
174.4 (CO), 173.6 (CO), 172.8 (CO), 172.2 (CO), 171.3 (CO), 170.4 (CO), 168.5 (CO), 168.1 (CO), 
138.4 (C), 138.0 (C), 137.6 (C), 65.2 (CH2NMe); HRMS (ESI): calcd. for C20H29N3NaO3, 382.2101. 
Found: [MNa]+, 382.2086 (4.3 ppm error). 
(S)-12-Benzyltetradecahydro-1H-pyrrolo[2,1-c][1,4,8]triazacycloheptadecine-
1,11,15(2H,12H)-trione (467) 
 A mixture of 5-benzyl-1,5-diazacyclotetradecane-2,6-dione (90 mg, 
0.284 mmol), DMAP (3 mg, 0.0284 mmol) and pyridine (140 μL, 1.70 
mmol) in CH2Cl2 (2.5 mL) under an argon atmosphere was stirred at 
room temperature for 30 min. Next, a solution of acid chloride (0.426 
mmol, 1.50 equiv. freshly prepared using the general procedure) in 
CH2Cl2 (1.0 mL) was added and the resulting mixture was heated at 50 °C for 16 h. The mixture 
was then diluted with CH2Cl2 (10 mL) and washed with 10% aq. HCl (10 mL). The aqueous layer 
was then extracted with CH2Cl2 (3 × 15 mL) and the combined organic extracts dried over MgSO4 
and concentrated in vacuo. The crude material was then re-dissolved in CH2Cl2 (3 mL) and DBU 
(435 μL, 2.84 mmol) was added, followed by stirring at room temperature for 18 h, before the 
solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 2:1 
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hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound (as a mixture of predominantly 3 rotamers) as a pale yellow oil (90 mg, 77%). The 
number of rotamers was determined by the number of resonances in the carbonyl region of the 
13C NMR spectrum; [α]D25 −22.4 (c = 1.0, CHCl3); RF 0.47 (9:1 ethyl acetate:methanol); νmax/cm–1 
(thin film); 3301, 2928, 2857, 1624, 1542; δH (400 MHz, CDCl3) 7.34–7.07 (5H, m, Ph, all 
rotamers), 6.61 (1H, br s, NH, one of the minor rotamers), [4.89 (1H, d, J = 17.5), 4.78 (1H, d, J = 
17.5), 4.70–4.44 (m), 4.13–3.95 (m), 3.81–3.72 (m), 3.59–3.36 (m), 3.35–3.21 (m) and 3.16–2.88 
(m) 9H, 4 × CH2N and CHN, all rotamers], 2.71–1.16 (16H, m, 2 × CH2O and  6 × CH2O, all 
rotamers); δC (100 MHz, CDCl3) data for the major rotamer only: 174.8 (CO), 172.6 (CO), 171.3 
(CO), 137.6 (C), 128.9 (CH), 127.8 (CH), 126.4 (CH), 60.3 (CHCONH), 53.7 (CH2NCH), 47.7 (CH2Ph), 
43.8 (CH2NBn), 39.0 (CH2NH), 33.9 (CH2CONCH), 32.2 (CH2CONBn), 28.5 (CH2), 27.8 (CH2), 27.6 
(CH2), 26.4 (CH2), 26.1 (CH2), 25.4 (CH2), 24.9 (CH2), 24.8 (CH2). Diagnostic 13C NMR resonances 
for the minor rotamers: 174.5 (CO), 174.1 (CO), 172.0 (CO), 170.6 (CO), 170.4 (CO), 170.1 (CO), 
138.0 (C), 136.7 (C), 60.8 (CHCONH), 59.7 (CHCONH), 52.5 (CH2NCH), 48.7 (CH2Ph), 47.3 (CH2Ph); 
HRMS (ESI): calcd. for C24H35N3NaO3, 436.2571. Found: MNa+, 436.2561 (2.6 ppm error). 
9-Methyl-1,5,9-triazacyclohenicosane-2,6,10-trione (468) 
 A mixture of 5-methyl-1,5-diazacycloheptadecane-2,6-dione (165 mg, 
0.584 mmol), DMAP (8 mg, 0.058 mmol) and pyridine (0.28 mL, 3.5 mmol) 
in CH2Cl2 (5 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. Next, a solution of acid chloride (0.876 mmol, 1.5 
equiv., freshly prepared using the general procedure) in CH2Cl2 (2.5 mL) 
was added and the resulting mixture was refluxed at 50 ⁰C for 16 h. The 
mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. 
HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined 
organic extracts dried over MgSO4 and concentrated in vacuo. The crude material was then re-
dissolved in CH2Cl2 (8 mL) and piperidine (0.59 mL, 5.84 mmol) was added, followed by stirring 
at room temperature for 18 h, before the solvent was removed in vacuo. Purification by flash 
column chromatography (SiO2, 1:1 ethyl acetate: hexane → 9:1 ethyl acetate:methanol) 
afforded the title compound (as a 3:1.5:1 mixture of 3 rotamers A:B:C) as an orange oil (80 mg, 
42%); RF 0.26 (4:1 ethyl acetate:methanol); δH (400 MHz, CDCl3) 6.88 (1H, br s, NH, rotamer A), 
6.66 (1H, br s, NH, rotamer B), 6.48 (1H, br s, NH, rotamer C), 6.38 (1H, br s, NH, rotamer A), 6.08 
(1H, br s, NH, rotamer C), 5.95 (1H, br s, NH, rotamer B), 3.68–3.57 (6H, m, CH2N, all rotamers), 
3.55–3.43 (6H, m, CH2N, all rotamers), 3.30–3.22 (6H, m, CH2N, all rotamers), 3.01 (3H, s, NCH3, 
rotamer A), 2.96 and 2.94 (3H, s, NCH3, rotamer C), 2.90 (3H, s, NCH3, rotamer B), 2.45–2.36 (6H, 
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m, CH2CO, all rotamers), 2.35–2.28 (6H, m, CH2CO, all rotamers), 1.70–1.15 (60H, m, 10 × CH2, 
all rotamers); δC (100 MHz, CDCl3) data for the major rotamer only: 173.9 (CO), 171.7 (CO), 171.1 
(CO), 44.8 (NCH3), 39.2 (CH2N), 36.3 (CH2N), 36.1 (CH2N), 36.0 (CH2CO), 34.9 (CH2CO), 33.0 
(CH2CO), 28.9 (CH2), 28.3 (CH2), 28.1 (CH2), 28.0 (CH2), 27.82 (CH2), 27.79 (CH2), 27.3 (CH2), 25.7 
(CH2), 24.5 (CH2). 
8-Benzyl-4-methyl-1,4,8-triazacyclotridecane-2,5,9-trione (469) 
 A mixture of 5-benzyl-1,5-diazecane-2,6-dione (67 mg, 0.269 mmol), 
DMAP (4 mg, 0.0269 mmol) and pyridine (130 μL, 1.61 mmol) in CH2Cl2 (2 
mL) under an argon atmosphere was stirred at room temperature for 30 
min. Next, a solution of acid chloride (0.403 mmol, 1.50 equiv., freshly 
prepared using the general procedure) in CH2Cl2 (1 mL) was added and 
the resulting mixture was heated at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (10 
mL) and washed with 10% aq. HCl (10 mL). The aqueous layer was then extracted with CH2Cl2 (3 
× 15 mL) and the combined organic extracts dried over MgSO4, concentrated in vacuo and loaded 
onto a short silica plug eluted with 2:1 (hexane:ethyl acetate) to remove excess carboxylic acid 
and pyridine residues. The crude material was then re-dissolved in CH2Cl2 (4 mL) and DBU (410 
μL, 2.69 mmol) was added, followed by stirring at room temperature for 18 h, before the solvent 
was removed in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl 
acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound (as a 6:1 
mixture of rotamers) as a yellow oil (61 mg, 70%); RF 0.32 (9:1 ethyl acetate:methanol); νmax/cm–
1 (thin film) 3300, 2933, 1625, 1534; δH (400 MHz, CDCl3) 7.50–7.09 (10H, m, Ph, both rotamers), 
7.04 (1H, br s, NH, major), 6.66 (1H, br s, NH, minor), 4.92–4.37 (6H, m, CH2Ph and CHH′NMe, 
both), 3.77–3.26 (4H, m, CH2NBn, both), 3.25–2.90 (12H, m, CH3, CHH′NMe and CH2NBn, both), 
2.89–2.18 (8H, m, CH2CONMe and CH2CONBn, both), 1.97–1.12 (8H, m, 2 × CH2, both); δC (100 
MHz, CDCl3) data for the major rotamer only: 176.1 (CO), 171.0 (CO), 168.1 (CO), 136.1 (CCH), 
129.1 (CH), 127.9 (CH), 126.5 (CH), 53.2 (CH2NMe), 50.1 (CH2Ph), 39.3 (CH2NBn), 39.2 (CH2NH), 
37.5 (CH3), 33.6 (CH2CONMe), 32.4 (CH2CONBn), 29.5 (CH2), 22.1 (CH2). Diagnostic 13C NMR 
resonances for the minor rotamers: 174.6 (CO), 172.2 (CO), 167.9 (CO), 137.3 (CCH), 128.8 (CH), 
128.3 (CH), 126.4 (CH); HRMS (ESI): calcd. for C18H25N3NaO3, 354.1788. Found: [MNa]+, 354.1804 
(−4.5 ppm error). 
2-(Benzyloxy)acetic acid (477) 
This compound has been prepared using the following literature procedure.153 
Sodium metal (6.83 g, 0.297 mol) and benzyl alcohol (48.2 mL, 0.464 mol) was 
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added to a RBF and heated to 100 °C, until the sodium had dissolved completed. The solution 
was then cooled to room temperature where a solution of chloroacetic acid (11.4 g, 0.121 mol) 
in benzyl alcohol (12 mL) was added very slowly. The resulting suspension was stirred, at 120 °C, 
for 2 h and then cooled to room temperature. The reaction was quenched with water (50 mL) 
and the aqueous phase was washed with CH2Cl2 (3 × 50 mL). The aqueous phase was then 
acidified to pH 1 with 10% HCl(aq) and extracted with ethyl acetate (3 × 100 mL). The combined 
organic extracts were dried over MgSO4, filtered and the solvent was removed in vacuo to afford 
the title compound as a colourless oil (16.8 g, 84%); RF 0.40 (ethyl acetate); δH (400 MHz, CDCl3) 
9.83 (1H, br s, CO2H), 7.39–7.28 (5H, m, 5 × CH), 4.65 (2H, s, CH2Ph), 4.15 (2H, s, CH2CO2H). Data 
is consistent with those previously reported in the literature.153 
1-Oxa-5-azacycloheptadecane-4,17-dione (481) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 30 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting 
mixture was refluxed at 50 °C for 16 h. The mixture was then diluted with CH2Cl2 (30 mL) and 
washed with 10% aq. HCl (30 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) 
and the combined organic extracts dried over MgSO4 and concentrated in vacuo, loaded onto a 
short silica plug and eluted 2:1 hexane:ethyl actetate, to remove the pyridine and excess 
carboxylic acid residues, and concentrated in vacuo. This material was then re-dissolved in ethyl 
acetate (7.9 mL) and placed under an argon atmosphere. Palladium on carbon (78.6 mg, Pd 10% 
on carbon) was then added and the reaction vessel was backfilled with hydrogen (via balloon) 
several times, then stirred at room temperature under a slight positive pressure of hydrogen 
(balloon) for 16 h. The reaction was then purged with argon, filtered through Celite, washed 
with methanol and concentrated in vacuo. This material was re-dissolved in CHCl3 and stirred at 
room temperature for a further 16 h, before the solvent was removed in vacuo. Purification by 
flash column chromatography (SiO2, 1:1 ethyl acetate:hexane → ethyl acetate → 9:1 ethyl 
acetate:methanol) afforded the title compound (as a 5:1 mixture of rotamers) as a colourless oil 
(100 mg, 47%); RF 0.53 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film); 3290, 3094, 2926, 
2857, 1734, 1643, 1551; δH (400 MHz, CDCl3) 6.08–5.84 (2H, m, NH, both rotamers), 4.34 (2H, t, 
J = 5.3 Hz, OCH2, major), 3.82 (2H, t, J = 5.3 Hz, OCH2, minor), 3.33–3.21 (4H, m, NHCH2, both), 
2.55 (2H, t, J = 5.3 Hz, CH2CONH, minor), 2.46 (2H, t, J = 5.3 Hz, CH2CONH, major), 2.25 (2H, t, J 
= 7.6 Hz, CH2CO2, major), 2.20–2.14 (2H, m, CH2CO2, minor), 1.69–1.15 (36H, m, 9 × CH2, both); 
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δC (100 MHz, CDCl3) 175.3 (CO, minor), 174.0 (CO, minor), 178.8 (CO, major), 170.5 (CO, major), 
60.6 (CO2CH2, major), 58.3 (CO2CH2, minor), 39.5 (NHCH2, major), 39.2 (NHCH2, minor), 39.9 
(CH2CONH, minor), 36.5 (CH2CO2, minor), 36.2 (CH2CONH, major), 34.5 (CH2CO2, major), 29.2 
(CH2, major), 28.3 (CH2, minor), 27.4 (CH2, major), 27.2 (CH2, major), 27.01 (CH2, major), 26.95 
(CH2, major), 26.8 (CH2, minor), 26.4 (CH2, minor), 26.3 (CH2, major), 26.2 (CH2, minor), 26.1 (CH2, 
major), 25.7 (CH2, minor), 25.4 (CH2, major), 25.3 (CH2, minor), 25.0 (CH2, minor), 24.6 (CH2, 
minor), 24.2 (CH2, major), 23.9 (CH2, minor); HRMS (ESI): calcd. for C15H27N2NaO2, 292.1883. 
Found: [MNa]+, 292.1882 (−0.4 ppm error). 
1-Oxa-4-azacyclohexadecane-3,16-dione (484) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (0.380 mL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 30 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 equiv., freshly prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was refluxed at 50 °C for 16 h. 
The mixture was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (30 mL). The 
aqueous layer was then extracted with CH2Cl2 (3 × 30 mL) and the combined organic extracts 
dried over MgSO4 and concentrated in vacuo, loaded onto a short silica plug and eluted 2:1 
hexane:ethyl actetate, to remove the pyridine and excess carboxylic acid residues, and 
concentrated in vacuo. This material was then re-dissolved in ethyl acetate (7.9 mL) and placed 
under an argon atmosphere. Palladium on carbon (78.6 mg, Pd 10% on carbon) was then added 
and the reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at 
room temperature under a slight positive pressure of hydrogen (balloon) for 16 h. The reaction 
was then purged with argon, filtered through Celite, washed with methanol and concentrated 
in vacuo. This material was re-dissolved in CHCl3 and stirred at room temperature for a further 
16 h, where the solvent was removed in vacuo to afford the title compound as a white solid (175 
mg, 88%); RF 0.55 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3314, 2927, 2857, 1741, 
1659 1538; δH (400 MHz, CDCl3) 6.21 (1H, br s, NH), 4.54 (2H, s, OCH2CO), 3.48–3.27 (2H, m, 
CH2NH), 2.39 (2H, t, J = 6.9 Hz, CH2CO), 1.74–1.19 (18H, m, 9 × CH2); δC (100 MHz, CDCl3) 172.0 
(CO), 167.2 (CO), 63.2 (OCH2CO), 38.5 (NHCH2), 34.6 (CH2CO), 28.2 (CH2), 27.3 (CH2), 27.2 (CH2), 
26.5 (CH2), 26.3 (CH2), 25.9 (CH2), 25.1 (CH2), 24.7 (CH2), 24.6 (CH2); HRMS (ESI): calcd. for 
C14H25NNaO3, 278.1727. Found: [MNa]+, 278.1732 (−2.1 ppm error). 
1-(3-(Benzyloxy)propanoyl)azetidin-2-one (487) 
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 A mixture of 2-azetidinone (56 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 
(3 mL) was added and the resulting mixture was stirred at room temperature for 16 h. The 
mixture was then diluted with CH2Cl2 (50 mL), washed with 10% HCl(aq) (15 mL) and NaHCO3(aq) 
(2 × 20 mL), dried over MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound as a yellow oil 
(167 mg, 91%); RF 0.64 (ethyl acetate); νmax/cm–1 (thin film) 1784, 1698; δH (400 MHz, CDCl3) 
7.42–7.19 (5H, m, Ph), 4.53 (2H, s, CH2Ph), 3.80 (2H, t, J = 6.1 Hz, CH2NH), 3.57 (2H, t, J = 5.3 Hz, 
CH2OBn), 3.06–2.94 (4H, m, CH2CH2OBn and CH2CON); δC (100 MHz, CDCl3) 168.9 (CO), 165.1 
(CO), 138.2 (C), 128.5 (CH), 127.8 (CH), 127.7 (CH), 73.1 (CH2Ph), 64.7 (CH2OBn), 37.1 (CH2), 36.7 
(CH2), 36.0 (CH2); HRMS (ESI): calcd. for C13H15NNaO3, 256.0944. Found: [MNa]+, 256.0945 (−1.1 
ppm error). 
1-(3-(Benzyloxy)propanoyl)pyrrolidin-2-one (488) 
 A mixture of pyrrolidinone (60 μL, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution 
of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) 
was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture was 
allowed to cool before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title 
compound as a colourless oil (149 mg, 77%). RF 0.65 (ethyl acetate); νmax/cm–1 (thin film); 2870, 
1734, 1687; δH (400 MHz, CDCl3) 7.38–7.17 (5H, m, Ph), 4.51 (2H, s, CH2Ph), 3.87–3.68 (4H, m, 
CH2N and CH2OBn), 3.19 (2H, t, J = 6.1 Hz, (CH2)2CH2CO), 2.52 (2H, t, J = 8.0 Hz, CH2CH2OBn), 
2.05–1.88 (2H, m, CH2CH2N); δC (100 MHz, CDCl3) 175.6 (CO), 172.0 (CO), 138.4 (C), 128.4 (CH), 
127.8 (CH), 127.7 (CH), 73.1 (CH2Ph), 65.1 (CH2OBn), 45.5 (CH2N), 37.4 (CH2CO), 33.7 (CH2CO), 
17.2 (CH2CH2N); HRMS (ESI): calcd. for C14H18NO3, 248.1281. Found: [MH]+, 248.1285 (−1.0 ppm 
error). 
1-(3-(Benzyloxy)propanoyl)piperidin-2-one (489) 
 A mixture of 2-piperidinone (78 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a 
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solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 
(3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture 
was allowed to cool before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title 
compound as a colourless oil (170 mg, 83%). Rf 0.63 (ethyl acetate); νmax/cm–1 (thin film) 2872, 
1692; δH (400 MHz, CDCl3) 7.40–7.21 (5H, m, Ph), 4.53 (2H, s, CH2Ph), 3.79 (2H, t, J = 6.1 Hz, 
CH2OBn), 3.74–3.67 (2H, m, CH2N), 3.22 (2H, t, J = 6.1 Hz, CH2CH2OBn), 2.57 (2H, m, CH2), 1.87–
1.73 (4H, m, 2 × CH2); δC (100 MHz, CDCl3) 174.8 (CO), 173.5 (CO), 138.4 (C), 128.5 (CH), 127.8 
(CH), 127.7 (CH), 73.2 (CH2Ph), 65.8 (CH2OBn), 44.1 (CH2N), 40.2 (CH2), 34.9 (CH2), 22.5 (CH2), 
20.4 (CH2); HRMS (ESI): calcd. for C15H20NO3, 262.1438. Found: [MH]+, 262.1441 (−2.0 ppm error). 
1-(3-(Benzyloxy)propanoyl)azepan-2-one (490) 
 A mixture of ε-caprolactam (90 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 
(3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture 
was allowed to cool before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 5:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title 
compound as a colourless oil (194 mg, 90%); Rf 0.70 (ethyl acetate); νmax/cm–1 (thin film) 2930, 
2860, 1694; δH (400 MHz, CDCl3) 7.41–7.20 (5H, m, Ph), 4.52 (2H, s, CH2Ph), 3.94–3.84 (2H, m, 
CH2N), 3.79 (2H, t, J = 6.1 Hz, CH2OBn), 3.19 (2H, t, J = 6.1 Hz, CH2CH2OBn), 2.71–2.65 (2H, m, 
CH2), 1.80–1.60 (6H, m, 3 × CH2); δC (100 MHz, CDCl3) 177.9 (CO), 174.1 (CO), 138.4 (C), 128.4 
(CH), 127.8 (CH), 127.7 (CH), 73.2 (CH2Ph), 66.0 (CH2OBn), 43.4 (CH2N), 39.83 (CH2CO), 39.75 
(CH2CO), 29.3 (CH2), 28.6 (CH2), 23.7 (CH2); HRMS (ESI): calcd. for C16H22NO3, 276.1594. Found: 
[MH]+, 276.1598 (−1.4 ppm error). 
1-(3-(Benzyloxy)propanoyl)azocan-2-one (491) 
 A mixture of azocan-2-one (100 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) 
under an argon atmosphere was stirred at room temperature for 5 
min. Next, a solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The mixture was allowed to cool before the solvent was removed in vacuo. Purification 
by flash column chromatography (SiO2, 5:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) 
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afforded the title compound as a colourless oil (206 mg, 91%); Rf 0.72 (ethyl acetate); νmax/cm–1 
(thin film) 2927, 2859, 1688; δH (400 MHz, CDCl3) 7.38–7.20 (5H, m, Ph), 4.52 (2H, s, CH2Ph), 
3.93–3.84 (2H, m, CH2N), 3.79 (2H, t, J = 6.1 Hz, CH2OBn), 3.17 (2H, t, J = 6.1 Hz, CH2CH2OBn), 
2.66–2.58 (2H, m, CH2CO), 1.90–1.81 (2H, m, CH2), 1.74–1.64 (2H, m, CH2), 1.60–1.53 (2H, m, 
CH2), 1.47–1.39 (2H, m, CH2); δC (100 MHz, CDCl3) 178.5 (CO), 174.7 (CO), 138.4 (C), 128.4 (CH), 
127.8 (CH), 127.7 (CH), 73.2 (CH2Ph), 66.0 (CH2OBn), 43.5 (CH2N), 39.9 (CH2CH2OBn), 37.1 
(CH2CO), 29.7 (CH2), 29.2 (CH2), 26.3 (CH2), 24.0 (CH2); HRMS (ESI): calcd. for C17H24NO3, 
290.1751. Found: [MH]+, 290.1756 (−1.8 ppm error). 
1-(3-(Benzyloxy)propanoyl)azonan-2-one (492) 
 A mixture of azonan-2-one (111 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) 
under an argon atmosphere was stirred at room temperature for 5 
min. Next, a solution of acid chloride (1.18 mmol, 1.50 equiv. 
prepared using the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was 
heated, at reflux, at 50 °C for 16 h. The mixture was allowed to cool before the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 5:1 hexane:ethyl acetate 
→ 2:1 hexane:ethyl acetate) afforded the title compound as a colourless oil (222 mg, 93%); Rf 
0.77 (ethyl acetate); νmax/cm–1 (thin film)  2927, 2867, 1688; δH (400 MHz, CDCl3) 7.38–7.20 (5H, 
m, Ph), 4.51 (2H, s, CH2Ph), 3.89–3.82 (2H, m, CH2N), 3.79 (2H, t, J = 6.1 Hz, CH2OBn), 3.09 (2H, 
t, J = 6.1 Hz, CH2CH2OBn), 2.67–2.58 (2H, m, CH2CO), 1.92–1.81 (2H, m, CH2), 1.79–1.70 (2H, m, 
CH2), 1.69–1.59 (2H, m, CH2), 1.52–1.43 (2H, m, CH2), 1.42–1.33 (2H, m, CH2); δC (100 MHz, CDCl3) 
180.1 (CO), 174.1 (CO), 138.4 (C), 128.4 (CH), 127.8 (CH), 127.7 (CH), 73.3 (CH2Ph), 66.1 (CH-
2OBn), 44.8 (CH2N), 39.02 (CH2CO), 38.98 (CH2CO), 28.8 (CH2), 28.0 (CH2), 26.0 (CH2), 25.5 (CH2), 
21.2 (CH2); HRMS (ESI): calcd. for C18H26NO3, 304.1907. Found: [MH]+, 304.1908 (−0.2 ppm error). 
1-(3-(Benzyloxy)propanoyl)azecan-2-one (493) 
 A mixture of azecan-2-one (122 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) 
under an argon atmosphere was stirred at room temperature for 5 
min. Next, a solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The mixture was allowed to cool then diluted with CH2Cl2 (50 mL), washed with 10% 
HCl(aq) (15 mL) and NaHCO3(aq) (2 × 20 mL), dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, 5:1 hexane:ethyl acetate → 2:1 hexane:ethyl 
Chapter Seven: Experimental 
 
179 | P a g e  
 
acetate) afforded the title compound as a yellow oil (212 mg, 87%); Rf 0.74 (ethyl acetate); 
νmax/cm–1 (thin film) 2927, 2870, 1686; δH (400 MHz, CDCl3) 7.40–7.20 (5H, m, Ph), 4.52 (2H, s, 
CH2Ph), 3.91–3.85 (2H, m, CH2N), 3.82 (2H, t, J = 6.1 Hz, CH2OBn), 2.99 (2H, t, J = 6.1 Hz, 
CH2CH2OBn), 2.84–2.76 (2H, m, (CH2)7CH2CO), 1.86–1.77 (2H, m, CH2), 1.75–1.67 (2H, m, CH2), 
1.52–1.33 (8H, m, 4 × CH2); δC (100 MHz, CDCl3) 179.6 (CO), 174.5 (CO), 138.3 (C), 128.5 (CH), 
127.8 (CH), 127.7 (CH), 73.4 (CH2Ph), 66.2 (CH2OBn), 44.5 (CH2N), 38.4 (CH2CH2OBn), 37.0 
(CH2CO), 25.6 (CH2), 25.4 (CH2), 25.0 (CH2), 24.3 (CH2), 23.7 (CH2), 22.2 (CH2); HRMS (ESI): calcd. 
for C19H27NNaO3, 340.1883. Found: [MNa]+, 340.1885 (−0.4 ppm error). 
1-(3-(Benzyloxy)propanoyl)azacycloundecan-2-one (494) 
 A mixture of azacycloundecan-2-one (133 mg, 0.786 mmol), DMAP 
(10 mg, 0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 
(5.5 mL) under an argon atmosphere was stirred at room 
temperature for 5 min. Next, a solution of acid chloride (1.18 mmol, 
1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) was added and the resulting 
mixture was heated, at reflux, at 50 °C for 16 h. The mixture was allowed to cool then diluted 
with CH2Cl2 (50 mL), washed with 10% HCl(aq) (15 mL) and NaHCO3(aq) (2 × 20 mL), dried over 
MgSO4 and concentrated in vacuo. Purification by flash column chromatography (SiO2, 5:1 
hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title compound as a yellow oil 
(193 mg, 77%); Rf 0.74 (ethyl acetate); νmax/cm–1 (thin film) 3031, 2929, 2866, 1738, 1689; δH 
(400 MHz, CDCl3) 7.42–7.18 (5H, m, Ph), 4.53 (2H, s, CH2Ph), 3.91–3.79 (4H, m, CH2NH and 
CH2OBn), 2.94 (2H, t, J = 6.4 Hz, CH2CH2OBn), 2.84–2.74 (2H, m, CH2CO), 1.85–1.75 (2H, m, CH2), 
1.73–1.65 (2H, m, CH2), 1.48–1.17 (10H, m, 5 × CH2); δC (100 MHz, CDCl3) 179.1 (CO), 174.5 (CO), 
138.2 (C), 128.5 (CH), 127.8 (CH), 127.7 (CH), 73.4 (CH2Ph), 66.2 (CH2OBn), 44.1 (CH2NH), 38.1 
(CH2CO), 36.8 (CH2CO), 26.3 (CH2), 25.5 (CH2), 25.2 (CH2), 25.1 (CH2), 23.8 (CH2), 23.0 (CH2), 22.7 
(CH2); HRMS (ESI): calcd. for C20H29NNaO3, 354.2040. Found: [MNa]+, 354.2040 (−0.1 ppm error). 
1-(3-(Benzyloxy)propanoyl)azacyclododecan-2-one (495) 
 A mixture of azacycloundecan-2-one (133 mg, 0.786 mmol), DMAP 
(10 mg, 0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 
mL) under an argon atmosphere was stirred at room temperature for 
5 min. Next, a solution of acid chloride (1.18 mmol, 1.50 equiv. 
prepared using the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was 
heated, at reflux, at 50 °C for 16 h. The mixture was allowed to cool then diluted with CH2Cl2 (50 
mL), washed with 10% HCl(aq) (15 mL) and NaHCO3(aq) (2 × 20 mL), dried over MgSO4 and 
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concentrated in vacuo. Purification by flash column chromatography (SiO2, 5:1 hexane:ethyl 
acetate → 2:1 hexane:ethyl acetate) afforded the title compound (as a mixture of two rotamers 
determined by 13C NMR resonances) as a colourless oil (209 mg, 77%); Rf 0.78 (ethyl acetate); 
νmax/cm–1 (thin film) 2928, 2863, 1688; δH (400 MHz, CDCl3) 7.39–7.18 (10H, m, Ph, both 
rotamers), 4.52 (4H, s, CH2Ph, both), 3.88–3.72 (8H, m, CH2OBn and CH2NH, both), 2.96–2.88 
(4H, m, CH2CH2OBn, both), 2.83 (4H, m, CH2CO, both), 1.83–1.15 (32H, m, 8 × CH2, both); δC (100 
MHz, CDCl3) data for the major rotamer only: 178.2 (CO), 174.3 (CO), 138.2 (C), 128.5 (CH), 127.8 
(CH), 127.7 (CH), 73.4 (CH2Ph), 66.2 (CH2OBn), 43.6 (CH2NH), 38.1 (CH2CO), 37.3 (CH2CO), 25.7 
(CH2), 25.6 (CH2), 24.8 (CH2), 24.5 (CH2), 24.0 (CH2), 23.8 (CH2), 23.4 (CH2), 23.2 (CH2). Diagnostic 
13C NMR resonances for the minor rotamer: 179.1 (CO), 174.5 (CO), 44.1 (CH2NH), 36.8 (CH2CO), 
26.3 (CH2), 25.5 (CH2), 25.2 (CH2), 25.1 (CH2), 23.7 (CH2), 23.0 (CH2), 22.7 (CH2); HRMS (ESI): calcd. 
for C21H31NNaO3, 368.2196. Found: [MNa]+, 368.2195 (0.1 ppm error). 
1-(3-Hydroxypropanoyl)azetidin-2-one (499) 
1-(3-(Benzyloxy)propanoyl)azetidin-2-one (153 mg, 0.657 mmol) was 
dissolved in ethyl acetate (6.6 mL) and placed under an argon 
atmosphere. Palladium on carbon (66 mg, Pd 10% on carbon) was then 
added and the reaction vessel was backfilled with hydrogen (via balloon) several times, then 
stirred at room temperature under a slight positive pressure of hydrogen (balloon) for 2 h. The 
reaction was then purged with argon, filtered through Celite, washed with methanol where the 
solvent was removed in vacuo. The crude material was then re-dissolved in chloroform (6.6 mL) 
and triethylamine (137 µL, 0.986 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate) afforded the title compound as a colourless oil (86 mg, 92%); Rf 0.28 (ethyl 
acetate); νmax/cm–1 (thin film) 3407, 2913, 1777, 1682; δH (400 MHz, CDCl3) 3.90 (2H, t, J = 5.3 
Hz, CH2OH), 3.59 (2H, t, J = 5.3 Hz, CH2N), 3.05 (2H, t, J = 5.3 Hz, CH2CH2N), 2.92 (2H, t, J = 5.3 Hz, 
CH2CH2OH), 2.61 (1H, br s, OH); δC (100 MHz, CDCl3) 170.4 (CO), 165.3 (CO), 57.8 (CH2OH), 39.1 
(CH2N), 36.7 (CH2CO), 36.2 (CH2CO); HRMS (ESI): calcd. for C6H9NNaO3, 166.0475. Found: [MNa]+, 
166.0476 (−0.6 ppm error). 
1-(3-Hydroxypropanoyl)pyrrolidin-2-one (500) 
1-(3-(Benzyloxy)propanoyl)pyrrolidin-2-one (95 mg, 0.383 mmol) was 
dissolved in ethyl acetate (3.8 mL) and placed under an argon atmosphere. 
Palladium on carbon (38 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
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temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (3.8 mL) and 
triethylamine (80 µL, 0.575 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate) afforded the title compound as a colourless oil (58 mg, 96%); Rf 0.30 (ethyl 
acetate); νmax/cm–1 (thin film) 3406, 2896, 1732, 1682; δH (400 MHz, CDCl3) 3.87 (2H, t, J = 5.3 
Hz, CH2OH), 3.78 (2H, t, J = 7.3 Hz, CH2N), 3.10 (2H, t, J = 5.3 Hz, CH2CH2OH), 2.74 (1H, br s, OH), 
2.56 (2H, t, J = 7.3 Hz, CH2CON), 2.07–1.96 (2H, m, CH2CH2N); δC (100 MHz, CDCl3) 175.8 (CO), 
173.8 (CO), 58.0 (CH2OH), 45.3 (CH2N), 39.6 (CH2CH2OH), 33.6 (CH2CON), 17.3 (CH2); HRMS (ESI): 
calcd. for C7H11NNaO3, 180.0631. Found: [MNa]+, 180.0632 (−1.5 ppm error). 
1,5-Oxazecane-4,10-dione (501) 
1-(3-(Benzyloxy)propanoyl)piperidin-2-one (80 mg, 0.318 mmol) was 
dissolved in ethyl acetate (3.2 mL) and placed under an argon atmosphere. 
Palladium on carbon (32 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then 
stirred at room temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The 
reaction was then purged with argon, filtered through Celite, washed with methanol where the 
solvent was removed in vacuo. The crude material was then re-dissolved in chloroform (3.2 mL) 
and triethylamine (66 uL, 0.468 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound (as a 1:3 mixture of 
rotamers) as a colourless oil (46 mg, 85%); Rf 0.11 (ethyl acetate); νmax/cm–1 (thin film) 3288, 
3088, 2932, 1727, 1647, 1552; δH (400 MHz, CDCl3) 5.95 (1H, s, NH, minor rotamer), 5.57 (1H, s, 
NH, major rotamer), 4.54–4.40 (4H, m, CH2O, both rotamers), 3.41–3.18 (4H, m, CH2NH, both), 
2.60–2.45 (4H, m, CH2CONH, both), 2.38–2.25 (4H, m, CH2CO2, both), 1.88–1.77 (4H, m, CH2, 
both), 1.74–1.61 (4H, m, CH2, both); δC (100 MHz, CDCl3) data for the major rotamer only: 174.9 
(CO), 170.1 (CO), 61.0 (CH2O), 40.1 (CH2NH), 37.1 (CH2CO), 36.5 (CH2CO), 28.1 (CH2), 24.5 (CH2). 
Diagnostic 13C NMR resonances for the minor rotamer: 174.3 (CO), 173.4 (CO), 41.0 (CH2NH), 
35.0 (CH2CO), 31.2 (CH2CO), 30.0 (CH2), 20.4 (CH2); HRMS (ESI): calcd. for C8H14NO3, 172.0968. 
Found: [MH]+, 172.0970 (0.6 ppm error). 
1-Oxa-5-azacycloundecane-4,11-dione (502) 
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1-(3-(Benzyloxy)propanoyl)azepan-2-one (115 mg, 0.422 mmol) was 
dissolved in ethyl acetate (4.2 mL) and placed under an argon atmosphere. 
Palladium on carbon (42 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo to afford the title compound as a white solid (74 mg, 94%); m.p: 103–105 °C; 
Rf 0.31 (ethyl acetate); νmax/cm–1 (thin film) 3288, 2932, 1724, 1637, 1559; δH (400 MHz, CDCl3) 
6.16 (1H, s, NH), 4.51–4.35 (2H, m, CH2O), 3.40–3.23 (2H, m, CH2), 2.54–2.38 (2H, m, CH2CONH), 
2.34–2.20 (2H, m, CH2CO2), 1.69–1.55 (2H, m, CH2), 1.52–1.39 (2H, m, CH2), 1.36–1.24 (2H, m, 
CH2); δC (100 MHz, CDCl3) 173.1 (CO), 171.1 (CO), 60.9 (CH2O), 39.1 (CH2N), 37.1 (CH2CONH), 34.5 
(CH2CO2), 27.2 (CH2), 25.8 (CH2), 23.9 (CH2); HRMS (ESI): calcd. for C9H16NO3, 186.1125. Found: 
[MH]+, 186.1126 (3.7 ppm error). 
1-Oxa-5-azacyclododecane-4,12-dione (503) 
1-(3-(Benzyloxy)propanoyl)azocan-2-one (105 mg, 0.363 mmol) was 
dissolved in ethyl acetate (3.6 mL) and placed under an argon atmosphere. 
Palladium on carbon (36 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (3.6 mL) and 
triethylamine (76 uL, 0.545 mmol) was added, and then stirred at room temperature for 16 h, 
then reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl 
acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound as a white 
solid (68 mg, 94%); m.p. 128–129 °C; Rf 0.25 (ethyl acetate); νmax/cm–1 (thin film) 3301, 2922, 
2858, 1723, 1639, 1561; δH (400 MHz, CDCl3) 6.13 (1H, s, NH), 4.54–4.30 (2H, m, CH2O), 3.45–
3.21 (2H, m, CH2NH), 2.59–2.43 (2H, m, CH2CO), 2.42–2.21 (2H, m, CH2CO), 1.78–1.11 (8H, m, 4 
× CH2); δC (100 MHz, CDCl3) 171.7 (CO), 168.9 (CO), 59.4 (CH2O), 36.7 (CH2NH), 35.4 (CH2CO), 
32.0 (CH2CO), 23.9 (CH2), 23.8 (CH2), 23.0 (CH2), 22.4 (CH2); HRMS (ESI): calcd. for C10H17NNaO3, 
222.1101. Found: [MNa]+, 222.1103 (−1.5 ppm error). 
1-Oxa-5-azacyclotridecane-4,13-dione (504) 
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1-(3-(Benzyloxy)propanoyl)azonan-2-one (220 mg, 0.725 mmol) was dissolved 
in ethyl acetate (7.2 mL) and placed under an argon atmosphere. Palladium on 
carbon (72 mg, Pd 10% on carbon) was then added and the reaction vessel was 
backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The 
reaction was then purged with argon, filtered through Celite, washed with methanol where the 
solvent was removed in vacuo. The crude material was dissolved in chloroform (7.2 mL) and 
trimethylamine (152 µL, 1.09 mmol) was added and stirred at room temperature for 16 h, after 
which the solvent was then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol)  to afford the title 
compound as a white solid (142 mg, 92%); m.p. 129–130 °C; Rf 0.31 (ethyl acetate); νmax/cm–1 
(thin film) 3299, 2928, 2847, 1724, 1641, 1554; δH (400 MHz, CDCl3) 5.85 (1H, s, NH), 4.36 (2H, t, 
J = 5.3 Hz, CH2O), 3.37–3.21 (2H, m, CH2NH), 2.50 (2H, t, J = 5.3 Hz, CH2CH2O), 2.42–2.30 (2H, m, 
CH2COO), 1.73–1.60 (2H, m, CH2), 1.59–1.50 (2H, m, CH2), 1.47–1.25 (6H, m, 3 × CH2); δC (100 
MHz, CDCl3) 173.5 (CO), 170.3 (CO), 61.7 (CH2O), 40.3 (CH2NH), 36.6 (CH2CO), 34.1 (CH2CO), 27.2 
(CH2), 26.8 (CH2), 26.4 (CH2), 25.5 (CH2), 24.2 (CH2); HRMS (ESI): calcd. for C11H19NNaO3, 
236.1257. Found: [MNa]+, 236.1257 (−0.6 ppm error). 
1-Oxa-5-azacyclotetradecane-4,14-dione (505) 
1-(3-(Benzyloxy)propanoyl)azecan-2-one (212 mg, 0.630 mmol) was dissolved 
in ethyl acetate (6.8 mL) and placed under an argon atmosphere. Palladium on 
carbon (68 mg, Pd 10% on carbon) was then added and the reaction vessel was 
backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The 
reaction was then purged with argon, filtered through Celite, washed with methanol where the 
solvent was removed in vacuo. The crude material was then re-dissolved in chloroform (6.3 mL) 
and triethylamine (131 uL, 0.945 mmol) was added, and then stirred at room temperature for 
16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 
hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound as a white solid (137 mg, 96%); m.p. 121–122 °C; Rf 0.40 (ethyl acetate); νmax/cm–1 
(thin film) 3284, 3096, 2929, 2861, 1722, 1646, 1556; δH (400 MHz, CDCl3) 5.87 (1H, br s, NH), 
4.38 (2H, t, J = 5.2 Hz, CH2O), 3.35–3.21 (2H, m, CH2NH), 2.54–2.43 (2H, m, CH2CONH), 2.39–2.28 
(2H, m, CH2COO), 1.64–1.20 (12H, m, 6 × CH2); δC (100 MHz, CDCl3) 173.6 (CO), 170.2 (CO), 61.4 
(CH2O), 38.9 (CH2NH), 36.4 (CH2CO), 34.7 (CH2CO), 28.1 (CH2), 25.9 (CH2), 25.7 (CH2), 25.6 (CH2), 
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23.9 (CH2), 23.0 (CH2); HRMS (ESI): calcd. for C12H21NNaO3, 250.1414. Found: [MNa]+, 250.1415 






1-(3-(Benzyloxy)propanoyl)azacycloundecan-2-one (193 mg, 0.582 mmol) 
was dissolved in ethyl acetate (5.8 mL) and placed under an argon 
atmosphere. Palladium on carbon (58 mg, Pd 10% on carbon) was then 
added and the reaction vessel was backfilled with hydrogen (via balloon) 
several times, then stirred at room temperature under a slight positive pressure of hydrogen 
(balloon) for 1 h. The reaction was then purged with argon, filtered through Celite, washed with 
methanol where the solvent was removed in vacuo. The crude material was then re-dissolved in 
chloroform (5.5 mL) and triethylamine (115 uL, 0.825 mmol) was added, and then stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound (as a 10:1 mixture of rotamers) as a white solid (130 mg, 92%); m.p. 126–128 °C; Rf 
0.42 (ethyl acetate); νmax/cm–1 (thin film) 3311, 2924, 2855, 1725, 1646, 1549; δH (400 MHz, 
CDCl3) 5.90 (1H, s, NH, minor rotamer), 5.72 (1H, s, NH, major rotamer), 4.46–4.27 (4H, m, CH2O, 
both rotamers), 3.42–3.20 (4H, m, CH2NH, both), 2.57–2.40 (4H, m, CH2CONH, both), 2.39–2.22 
(4H, m, CH2COO, both), 1.69–1.15 (28H, m, 7 × CH2, both); δC (100 MHz, CDCl3) data for the major 
rotamer only: 174.2 (CO), 170.1 (CO), 61.1 (CH2O), 38.5 (CH2NH), 36.1 (CH2CO), 33.7 (CH2CO), 
28.3 (CH2), 26.9 (CH2), 26.7 (CH2), 25.8 (CH2), 25.7 (CH2), 25.1 (CH2), 23.8 (CH2). Diagnostic 13C 
NMR resonances for minor rotamer: 173.7 (CO), 170.3 (CO), 61.4 (CH2O), 38.9 (CH2NH), 36.4 
(CH2CO), 34.7 (CH2CO); HRMS (ESI): calcd. for C13H23NNaO3, 264.1570. Found: [MNa]+, 264.1578 
(−2.7 ppm error). 
1-Oxa-5-azacyclohexadecane-4,16-dione (507) 
1-(3-(Benzyloxy)propanoyl)azacyclododecan-2-one (180 mg, 0.521 mmol) 
was dissolved in ethyl acetate (5.2 mL) and placed under an argon 
atmosphere. Palladium on carbon (52 mg, Pd 10% on carbon) was then 
added and the reaction vessel was backfilled with hydrogen (via balloon) several times, then 
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stirred at room temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The 
reaction was then purged with argon, filtered through Celite, washed with methanol where the 
solvent was removed in vacuo. The crude material was then re-dissolved in chloroform (5.2 mL) 
and triethylamine (110 µL, 0.782 mmol) was added, and then stirred at room temperature for 
16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 
hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound (as a 7:2 mixture of rotamers) as a white solid (119 mg, 91%); m.p. 127–129 °C; Rf 
0.45 (ethyl acetate); νmax/cm–1 (thin film) 3272, 2930, 2860, 1722, 1643, 1559; δH (400 MHz, 
CDCl3) 5.89 (1H, s, NH, major rotamer), 5.80 (1H, s, NH, minor rotamer), 4.41–4.29 (4H, m, CH2O, 
both rotamers), 3.36–3.24 (4H, m, CH2NH, both), 2.48 (2H, t, J = 5.3 Hz, CH2CONH, minor), 2.43 
(2H, t, J = 5.3 Hz, CH2CONH, major), 2.34–2.28 (2H, m, CH2COO, minor), 2.24 (2H, t, J = 7.7 Hz, 
CH2COO, major), 1.67–1.56 (4H, m, CH2, both), 1.53–1.42 (4H, m, CH2, both), 1.39–1.15 (24H, m, 
6 × CH2, both); δC (100 MHz, CDCl3) data for the major rotamer only: 173.7 (CO), 170.1 (CO), 60.6 
(CH2O), 39.2 (CH2NH), 36.2 (CH2CO), 33.6 (CH2CO), 29.1 (CH2), 26.8 (CH2), 26.52 (CH2), 26.46 
(CH2), 25.5 (CH2), 25.1 (CH2), 24.8 (CH2), 23.7 (CH2). Diagnostic 13C NMR resonances for minor 
rotamer: 174.1 (CO), 61.0 (CH2O), 38.5 (CH2NH), 36.0 (CH2CO), 33.7 (CH2CO); HRMS (ESI): calcd. 
for C14H25NNaO3, 278.1727. Found: [MNa]+, 278.1732 (−0.9 ppm error). 
1-(2-(Benzyloxy)acetyl)azetidin-2-one (510) 
 A mixture of 2-azetidinone (56 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 eqv prepared using the general procedure) in CH2Cl2 (3 mL) was 
added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture was allowed 
to cool before the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 5:1 hexane:ethyl acetate → 2:1 hexane:ethyl acetate) afforded the title compound as a 
colourless oil (145 mg, 87%); Rf 0.66 (ethyl acetate); νmax/cm–1 (thin film) 2981, 2870, 1781, 1706; 
δH (400 MHz, CDCl3) 7.42–7.22 (5H, m, Ph), 4.63 (2H, s, CH2Ph), 4.42 (2H, s, CH2OBn), 3.55 (2H, t, 
J = 5.3 Hz, CH2N), 2.99 (2H, t, J = 5.3 Hz, CH2CO); δC (100 MHz, CDCl3) 168.1 (CO), 164.7 (CO), 
137.1 (C), 128.6 (CH), 128.2 (CH), 128.1 (CH), 73.6 (CH2Ph), 69.7 (CH2OBn), 36.2 (CH2), 36.0 (CH2); 
HRMS (ESI): calcd. for C12H13NNaO3, 242.0788. Found: [MNa]+, 242.0787 (0.7 ppm error). 
1-(2-(Benzyloxy)acetyl)pyrrolidin-2-one (511) 
 A mixture of pyrrolidin-2-one (60 µL, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
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atmosphere was stirred at room temperature for 5 min. Next, a solution of acid chloride (1.18 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) was added and the 
resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture was allowed to cool before 
the solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 2:1 
hexane:ethyl acetate) afforded the title compound as a colourless oil (137 mg, 75%); Data 




 A mixture of δ-valerolactam (78 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) 
was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture was 
allowed to cool before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound as a yellow oil 
(193 mg, 99%); Rf 0.65 (ethyl acetate); νmax/cm–1 (thin film) 2950, 1690; δH (400 MHz, CDCl3) 
7.47–7.20 (5H, m, Ph), 4.63 (2H, s, CH2O), 4.62 (2H, s, CH2O), 3.80–3.66 (2H, m, CH2NH), 2.59–
2.45 (2H, m, CH2CO), 1.90–1.71 (4H, m, 2 × CH2); δC (100 MHz, CDCl3) 174.3 (CO), 173.3 (CO), 
137.8 (C), 128.5 (CH), 128.1 (CH), 127.9 (CH), 73.3 (CH2O), 73.0 (CH2O), 44.1 (CH2NH), 34.5 
(CH2CO), 22.3 (CH2), 20.2 (CH2); HRMS (ESI): calcd. for C14H17NNaO3, 270.1101. Found: [MNa]+, 
270.1105 (−1.8 ppm error). 
1-(2-(Benzyloxy)acetyl)azepan-2-one (513) 
 A mixture of ε-caprolactam (90 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) 
was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture was 
allowed to cool before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound as a yellow oil 
(203 mg, 98%); Rf 0.73 (ethyl acetate); νmax/cm–1 (thin film) 2931, 2859, 1694; δH (400 MHz, CDCl3) 
7.48–7.19 (5H, m, Ph), 4.63 (2H, s, CH2Ph), 4.60 (2H, s, CH2OBn), 3.98–3.85 (2H, m, CH2NH), 2.74–
2.62 (2H, m, CH2CO), 1.82–1.62 (6H, m, 3 × CH2); δC (100 MHz, CDCl3) 177.8 (CO), 173.5 (CO), 
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137.8 (C), 128.5 (CH), 128.1 (CH), 127.9 (CH), 73.3 (CH2Ph), 72.9 (CH2OBn), 43.1 (CH2NH), 39.5 
(CH2CO), 29.2 (CH2), 28.5 (CH2), 23.6 (CH2); HRMS (ESI): calcd. for C15H19NNaO3, 284.1257. Found: 
[MNa]+, 284.1254 (1.5 ppm error). 
1-(2-(Benzyloxy)acetyl)azocan-2-one (514) 
 A mixture of azocan-2-one (100 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 
(3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture 
was allowed to cool before the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound as a yellow oil 
(216 mg, 98%); Rf 0.74 (ethyl acetate); νmax/cm–1 (thin film) 2925, 2859, 1687; δH (400 MHz, CDCl3) 
7.47–7.19 (5H, m, Ph), 4.63 (2H, s, CH2Ph), 4.61 (2H, s, CH2OBn), 4.00–3.86 (2H, m, CH2NH), 2.68–
2.57 (2H, m, CH2CO), 1.91–1.79 (2H, m, CH2), 1.77–1.67 (2H, m, CH2), 1.61–1.52 (2H, m, CH2), 
1.48–1.39 (2H, m, CH2); δC (100 MHz, CDCl3) 178.2 (CO), 173.9 (CO), 137.8 (C), 128.5 (CH), 128.1 
(CH), 127.9 (CH), 73.3 (CH2Ph), 73.0 (CH2OBn), 43.4 (CH2NH), 37.0 (CH2CO), 29.3 (CH2), 29.0 (CH2), 
26.3 (CH2), 24.1 (CH2); HRMS (ESI): calcd. for C16H21NNaO3, 298.1414. Found: [MNa]+, 298.1417 
(−0.9 ppm error). 
1-(2-(Benzyloxy)acetyl)azonan-2-one (515) 
 A mixture of azonan-2-one (111 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under 
an argon atmosphere was stirred at room temperature for 5 min. Next, 
a solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in 
CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The 
mixture was allowed to cool before the solvent was removed in vacuo. Purification by flash 
column chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound as a 
yellow oil (213 mg, 93%); Rf 0.77 (ethyl acetate); νmax/cm–1 (thin film) 3030, 2926, 2864, 1687; δH 
(400 MHz, CDCl3) 7.46–7.17 (5H, m, Ph), 4.62 (2H, s, CH2O), 4.58 (2H, s, CH2O), 3.94–3.82 (2H, m, 
CH2N), 2.68–2.57 (2H, m, CH2CO), 1.91–1.81 (2H, m, CH2), 1.80–1.72 (2H, m, CH2), 1.65–1.55 (2H, 
m, CH2), 1.54–1.46 (2H, m, CH2), 1.45–1.37 (2H, m, CH2); δC (100 MHz, CDCl3) 179.2 (CO), 173.6 
(CO), 137.7 (C), 128.5 (CH), 128.1 (CH), 127.9 (CH), 73.4 (CH2O), 72.5 (CH2O), 45.0 (CH2N), 38.4 
(CH2CO), 28.8 (CH2), 27.6 (CH2), 25.7 (CH2), 25.4 (CH2), 21.7 (CH2); HRMS (ESI): calcd. for 
C17H23NNaO3, 312.1570. Found: [MNa]+, 312.1576 (−2.8 ppm error). 
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1-(2-(Benzyloxy)acetyl)azecan-2-one (516) 
 A mixture of azecan-2-one (122 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) 
under an argon atmosphere was stirred at room temperature for 5 
min. Next, a solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The mixture was allowed to cool before the solvent was removed in vacuo. Purification 
by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate) afforded the title compound 
as a yellow oil (229 mg, 96%); Rf 0.78 (ethyl acetate); νmax/cm–1 (thin film) 2929, 2869, 1687; δH 
(400 MHz, CDCl3) 7.44–7.21 (5H, m, Ph), 4.61 (2H, s, CH2O), 4.55 (2H, s, CH2O), 3.96–3.85 (2H, m, 
CH2N), 2.80–2.70 (2H, m, CH2CO), 1.91–1.79 (2H, m, CH2), 1.76–1.67 (2H, m, CH2), 1.52–1.38 (6H, 
m, 3 × CH2), 1.37–1.23 (2H, m, CH2); δC (100 MHz, CDCl3) 178.2 (CO), 174.1 (CO), 137.6 (C), 128.5 
(CH), 128.1 (CH), 127.9 (CH), 73.4 (CH2O), 72.5 (CH2O), 43.9 (CH2N), 34.4 (CH2CO), 26.6 (CH2), 
26.2 (CH2), 25.3 (CH2), 25.2 (CH2), 22.3 (CH2), 20.2 (CH2); HRMS (ESI): calcd. for C18H25NNaO3, 
326.1727. Found: [MNa]+, 326.1728 (−0.6 ppm error). 
Tetrahydro-5H-oxazolo[3,2-a]pyridin-3(2H)-one (520) 
1-(2-(Benzyloxy)acetyl)piperidin-2-one (54 mg, 0.217 mmol) was dissolved in 
ethyl acetate (3.2 mL) and placed under an argon atmosphere. Palladium on 
carbon (22 mg, Pd 10% on carbon) was then added and the reaction vessel was 
backfilled with hydrogen (via balloon) several times, then stirred at room temperature under a 
slight positive pressure of hydrogen (balloon) for 16 h. The reaction was then purged with argon, 
filtered through Celite, washed with methanol. The solvent was then removed in vacuo to afford 
the title compound as a colourless oil (25 mg, 82%); Rf 0.30 (ethyl acetate); νmax/cm–1 (thin film) 
3477, 2947, 2862, 1694; δH (400 MHz, CDCl3) 4.98 (1H, d, J = 9.2 Hz, CH), 4.23 (2H, s, CH2CO), 
4.13 (1H, dd, J = 13.1, 4.1 Hz, CHH′N), 2.74 (1H, td, J = 13.1, 3.1 Hz, CHH′N), 2.16–2.04 (1H, m, 
CHH′CH), 1.98–1.88 (1H, m, CHH′CH), 1.73–1.62 (2H, m, CH2), 1.49–1.30 (2H, m, CH2); δC (100 
MHz, CDCl3) 168.2 (CO), 89.5 (CH), 67.7 (CH2CO), 39.6 (CH2N), 32.9 (CH2CH), 24.0 (CH2), 21.4 
(CH2); HRMS (ESI): calcd. for C7H12NO2, 142.0863. Found: [MH]+, 142.0863 (2.3 ppm error). 
Hexahydrooxazolo[3,2-a]azepin-3(2H)-one (521) 
1-(2-(Benzyloxy)acetyl)azepan-2-one (120 mg, 0.459 mmol) was dissolved in 
ethyl acetate (4.6 mL) and placed under an argon atmosphere. Palladium on 
carbon (46 mg, Pd 10% on carbon) was then added and the reaction vessel was 
backfilled with hydrogen (via balloon) several times, then stirred at room temperature under a 
Chapter Seven: Experimental 
 
189 | P a g e  
 
slight positive pressure of hydrogen (balloon) for 16 h. The reaction was then purged with argon, 
filtered through Celite, washed with methanol. The solvent was then removed in vacuo to afford 
the title compound as a colourless oil (62 mg, 87%); Rf 0.37 (ethyl acetate); νmax/cm–1 (thin film) 
2928, 2855, 1698; δH (400 MHz, CDCl3) 5.34–5.20 (1H, m, CH), 4.21 (1H, d, J = 13.7 Hz, CHH′O), 
4.12 (1H, d, J = 13.7 Hz, CHH′O), 3.82–3.66 (1H, m, CHH′N), 2.99–2.82 (1H, m, CHH′N), 2.02–1.31 
(8H, m, 4 × CH2); δC (100 MHz, CDCl3) 170.4 (CO), 91.7 (CH), 68.0 (CH2O), 40.8 (CH2N), 35.5 (CH2), 
29.6 (CH2), 28.1 (CH2), 22.0 (CH2); HRMS (ESI): calcd. for C8H13NNaO2, 178.0838. Found: [MNa]+, 
178.0840 (−1.0 ppm error). 
Hexahydro-5H-oxazolo[3,2-a]azocin-3(2H)-one (522) 
1-(2-(Benzyloxy)acetyl)azocan-2-one (120 mg, 0.436 mmol) was dissolved in ethyl 
acetate (4.4 mL) and placed under an argon atmosphere. Palladium on carbon 
(44 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled 
with hydrogen (via balloon) several times, then stirred at room temperature 
under a slight positive pressure of hydrogen (balloon) for 16 h. The reaction was then purged 
with argon, filtered through Celite, washed with methanol. The solvent was then removed in 
vacuo to afford the title compound as a colourless oil (66 mg, 90%); Rf 0.42 (ethyl acetate); 
νmax/cm–1 (thin film) 2925, 2856, 1699; δH (400 MHz, CDCl3) 5.17–5.10 (1H, m, CH), 4.26 (1H, dd, 
J = 13.0, 1.5 Hz, CHH′O), 4.13 (1H, dd, J = 13.0, 1.5 Hz, CHH′O), 3.90–3.77 (1H, m, CHH′N), 2.81–
2.69 (1H, m, CHH′N), 1.92–1.75 (3H, m, CHH′CH and CH2), 1.65–1.35 (7H, m, CHH′CH and 3 × 
CH2); δC (100 MHz, CDCl3) 170.7 (CO), 91.7 (CH), 68.0 (CH2O), 39.9 (CH2N), 31.0 (CH2), 27.2 (CH2), 
27.0 (CH2), 24.1 (CH2), 20.2 (CH2); HRMS (ESI): calcd. for C9H15NNaO2, 195.0995. Found: [MNa]+, 
195.0999 (−2.6 ppm error). 
Octahydrooxazolo[3,2-a]azonin-3(2H)-one (523) 
1-(2-(Benzyloxy)acetyl)azonan-2-one (64 mg, 0.219 mmol) was dissolved in ethyl 
acetate (3.2 mL) and placed under an argon atmosphere. Palladium on carbon 
(22 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled 
with hydrogen (via balloon) several times, then stirred at room temperature 
under a slight positive pressure of hydrogen (balloon) for 16 h. The reaction was then purged 
with argon, filtered through Celite, washed with methanol and the solvent was removed in 
vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl 
acetate) afforded the title compound as a colourless oil (32 mg, 82%); Rf 0.49 (ethyl acetate); 
νmax/cm–1 (thin film) 3424, 2924, 2857, 1694; δH (400 MHz, CDCl3) 5.18 (1H, br s, CH), 4.34 (1H, 
d, J = 13.7 Hz, CHH′CO), 4.18 (1H, d, J = 13.7 Hz, CHH′CO), 3.86–3.73 (1H, m, CHH′N), 2.87–2.74 
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(1H, m, CHH′N), 2.01–1.31 (12H, m, 6 × CH2); δC (100 MHz, CDCl3) 171.7 (CO), 92.7 (CH), 68.2 
(CH2CO), 41.3 (CH2N), 30.7 (CH2), 25.9 (CH2), 25.5 (CH2), 25.3 (CH2), 24.3 (CH2), 19.8 (CH2); HRMS 
(ESI): calcd. for C10H18NO2, 184.1332. Found: [MH]+, 184.1331 (0.7 ppm error). 
10a-Methoxyhexahydro-5H-oxazolo[3,2-a]azocin-3(2H)-one (529) 
1-(2-(Benzyloxy)acetyl)azocan-2-one (120 mg, 0.436 mmol) was dissolved in 
methanol (4.4 mL) and placed under an argon atmosphere. Palladium on 
carbon (44 mg, Pd 10% on carbon) was then added and the reaction vessel 
was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo to afford the title compound as a colourless oil (82 mg, 95%); Rf 0.52 (ethyl 
acetate); νmax/cm–1 (thin film) 2928, 2859, 1712; δH (400 MHz, CDCl3) 4.29 (2H, s, CH2O), 3.74 (1H, 
dt, J = 13.7, 5.0 Hz, CHH′N), 3.03 (3H, s, OCH3), 2.81 (1H, ddd, J = 13.7, 9.2, 4.5 Hz, CHH′N), 2.05–
1.85 (2H, m, CH2C), 1.63–1.30 (8H, m, 4 × CH2); δC (100 MHz, CDCl3) 170.5 (CO), 115.1 (COMe), 
68.5 (CH2O), 48.2 (CH3O), 39.0 (CH2N), 34.5 (CH2C), 27.0 (CH2), 26.2 (CH2), 23.8 (CH2), 21.5 (CH2); 
HRMS (ESI): calcd. for C10H17NNaO3, 222.1101. Found: [MNa]+, 222.1105 (−1.3 ppm error). 
1-(2-Hydroxyacetyl)azetidin-2-one (534) 
1-(3-(Benzyloxy)propanoyl)azetidin-2-one (147 mg, 0.671 mmol) was 
dissolved in ethyl acetate (6.7 mL) and placed under an argon atmosphere. 
Palladium on carbon (67 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 2 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (6.7 mL) and 
triethylamine (140 µL, 1.01 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound as a colourless oil 
(86 mg, 99%); Rf 0.26 (ethyl acetate); νmax/cm–1 (thin film) 3425, 2913, 1778, 1694; δH (400 MHz, 
CDCl3) 4.44 (2H, s, CH2OH), 3.62 (2H, t, J = 5.3 Hz, CH2N), 3.22 (1H, s, OH), 3.08 (2H, t, J = 5.3 Hz, 
CH2CON); δC (100 MHz, CDCl3) 170.9 (CO), 164.9 (CO), 63.4 (CH2OH), 36.5 (CH2N), 36.3 (CH2CON); 
HRMS (ESI): calcd. for C5H8NO3, 130.0499. Found: [MH]+, 130.0498 (0.2 ppm error). 
1-(2-Hydroxyacetyl)pyrrolidin-2-one (535) 
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1-(2-(Benzyloxy)acetyl)pyrrolidin-2-one (135 mg, 0.579 mmol) was dissolved 
in ethyl acetate (5.8 mL) and placed under an argon atmosphere. Palladium 
on carbon (58 mg, Pd 10% on carbon) was then added and the reaction vessel 
was backfilled with hydrogen (via balloon) several times, then stirred at room temperature 
under a slight positive pressure of hydrogen (balloon) for 2 h. The reaction was then purged with 
argon, filtered through Celite, washed with methanol where the solvent was removed in vacuo. 
The crude material was then re-dissolved in chloroform (5.8 mL) and triethylamine (121 µL, 
0.869 mmol) added, and stirred at room temperature for 16 h, then reduced in vacuo. 
Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) 
afforded the title compound as a white oil (83 mg, 100%); Rf 0.31 (ethyl acetate); νmax/cm–1 (thin 
film) 3456, 2905, 1732, 1686; δH (400 MHz, CDCl3) 4.56 (2H, s, CH2OH), 3.77 (2H, t, J = 7.3 Hz, 
CH2N), 3.30 (1H, br s, OH), 2.53 (2H, t, J = 8.0 Hz, CH2CON), 2.12–2.01 (2H, m, CH2CH2N); δC (100 
MHz, CDCl3) 176.0 (CO), 174.4 (CO), 64.2 (CH2OH), 45.0 (CH2N), 32.9 (CH2CO), 18.0 (CH2); HRMS 
(ESI): calcd. for C6H9NNaO3, 166.0475. Found: [MNa]+, 166.0477 (−0.9 ppm error). 
8a-Hydroxytetrahydro-5H-oxazolo[3,2-a]pyridin-3(2H)-one (536) 
1-(2-(Benzyloxy)acetyl)piperidin-2-one (188 mg, 0.768 mmol) was dissolved in 
THF (7.7 mL) and placed under an argon atmosphere. Palladium on carbon (77 
mg, Pd 10% on carbon) and water (1.38 mL, 76.8 mmol) was then added and 
the reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 2 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (7.7 mL) and 
triethylamine (161 µL, 1.15 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate) afforded an inseparable mixture of the title compounds (as a 10:7 mixture of 
536:524) as a colourless oil (109 mg, 90%); Rf 0.39 (ethyl acetate); νmax/cm–1 (thin film) 3375, 
2947, 2874, 1688. Data for 8a-hydroxytetrahydro-5H-oxazolo[3,2-a]pyridin-3(2H)-one: δH (400 
MHz, CDCl3) 4.91 (1H, br s, OH), 4.37 (1H, d, J = 13.9 Hz, CHH′O), 4.17 (1H, d, J = 13.9 Hz, CHH′O), 
3.97 (1H, dd, J = 13.3, 5.0 Hz, CHH′N), 3.02–2.90 (1H, m, CHH′N), 2.19–2.11 (1H, m, CHH′COH), 
1.91–1.26 (5H, m, CHH′COH and 2 × CHH′); δC (100 MHz, CDCl3) 168.1 (CO), 109.2 (COH), 66.8 
(CH2O), 38.4 (CH2N), 36.2 (CH2COH), 24.3 (CH2), 21.3 (CH2). Data for 1-(2-hydroxyacetyl)piperidin-
2-one: 4.61 (1H, s, CH2OH), 3.82–3.72 (2H, m, CH2N), 3.44 (1H, br s, OH), 2.60–2.52 (2H, m, 
CH2CO), 1.94–1.26 (4H, m, 2 × CH2); δC (100 MHz, CDCl3) 177.5 (CO), 173.1 (CO), 66.1 (CH2OH), 
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44.6 (CH2N), 34.5 (CH2CO), 22.2 (CH2), 20.0 (CH2); HRMS (ESI): calcd. for C7H11NNaO3, 180.0631. 
Found: [MNa]+, 180.0634 (−1.6 ppm error). 
9a-Hydroxyhexahydrooxazolo[3,2-a]azepin-3(2H)-one (537) 
1-(2-(Benzyloxy)acetyl)azepan-2-one (203 mg, 0.776 mmol) was dissolved in 
THF (7.7 mL) and placed under an argon atmosphere. Palladium on carbon (77 
mg, Pd 10% on carbon) and water (1.40 mL, 77.6 mmol) was then added and 
the reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 2 h. The reaction was 
purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo. The crude material was re-dissolved in chloroform (7.7 mL) and triethylamine 
(162 µL, 1.16 mmol) added, and stirred at room temperature for 16 h, then reduced in vacuo. 
Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) 
afforded an inseparable mixture of the title compounds (as a 69:13:1 mixture of 525:524:526 
isomers) as a colourless oil (128 mg, 96%); Rf 0.42 (ethyl acetate); νmax/cm–1 (thin film) 3331, 
2932, 2857, 1688; δH (400 MHz, CDCl3) data for the 9a-hydroxyhexahydrooxazolo[3,2-a]azepin-
3(2H)-one: 5.91 (1H, s, OH), 4.29 (1H, d, J = 13.7 Hz, CHH′O), 4.11 (1H, d, J = 13.7 Hz, CHH′O), 
3.78–3.69 (1H, m, CHH′COH), 2.94–2.83 (1H, m, CHH′COH), 2.28–2.18 (1H, m, CHH′N), 1.90–1.80 
(1H, m, CHH′N), [1.80–1.55 (3H, m) 1.54–1.39 (1H, m), 1.37–1.23 (1H, m), 1.22–1.09 (1H, m), 3 
× CHH′]. Diagnostic 1H NMR resonances for 1-(2-hydroxyacetyl)azepan-2-one: 4.52 (2H, d, J = 4.6 
Hz, CH2OH), 3.93–3.86 (2H, m, CH2N), 2.79 (1H, br s, OH), 2.69–2.59 (2H, m, CH2CO). Diagnostic 
1H NMR resonances for 1,4-oxazecane-3,10-dione: 6.16 (1H, br s, NH), 3.41–3.32 (2H, m, 
CH2NH); δC (100 MHz, CDCl3) data for the 9a-hydroxyhexahydrooxazolo[3,2-a]azepin-3(2H)-one 
only: 170.5 (CO), 113.9 (COH), 66.5 (CH2O), [40.2, 39.9 (CH2COH and CH2N)], 29.6 (CH2), 27.9 
(CH2), 22.7 (CH2). 13C NMR resonances for 1-(2-hydroxyacetyl)azepan-2-one: 177.7 (CO), 176.7 
(CO), 65.8 (CH2OH), 43.8 (CH2N), 39.3 (CH2CO), 29.1 (CH2), 28.3 (CH2), 23.6 (CH2). Diagnostic 13C 
NMR resonances for 1,4-oxazecane-3,10-dione: 178.0 (CO), 172.5 (CO), 68.0 (CH2O), 43.4 
(CH2NH), 35.0 (CH2CO), 27.2 (CH2), 22.5 (CH2); HRMS (ESI): calcd. for C8H13NNaO3, 194.0788. 
Found: [MNa]+, 194.0788 (−0.9 ppm error). 
1-Oxa-4-azacycloundecane-3,11-dione (532) 
1-(2-(Benzyloxy)acetyl)azocan-2-one (207 mg, 0.751 mmol) was dissolved in 
ethyl acetate (7.5 mL) and placed under an argon atmosphere. Palladium on 
carbon (75 mg, Pd 10% on carbon) was then added and the reaction vessel 
was backfilled with hydrogen (via balloon) several times, then stirred at 
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room temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The reaction 
was then purged with argon, filtered through Celite, washed with methanol where the solvent 
was removed in vacuo. The crude material was then re-dissolved in chloroform (7.5 mL) and 
triethylamine (157 µL, 1.13 mmol) was added, and then stirred at room temperature for 16 h, 
and reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl 
acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound (as a 9:1 
mixture of rotamers) as a white solid (123 mg, 89%); m.p. 98–99 °C; Rf 0.35 (ethyl acetate); 
νmax/cm–1 (thin film) 3287, 2928, 2889, 2868, 2842, 1731, 1659; δH (400 MHz, CDCl3) 6.06 (1H, s, 
NH, minor rotamer), 5.94 (1H, s, NH, major rotamer), 4.58 (2H, s, CH2O, minor), 4.53 (2H, s, CH2O, 
major), 3.26–3.12 (4H, m, CH2NH, both rotamers), 2.43–2.29 (4H, m, CH2COO, both), 1.77–1.64 
(4H, m, CH2, both), 1.60–1.50 (4H, m, CH2, both), 1.46–1.37 (4H, m, CH2, both), 1.36–1.25 (4H, 
m, CH2, both); δC (100 MHz, CDCl3) data for the major rotamer only: 173.5 (CO), 168.3 (CO), 64.2 
(CH2O), 39.4 (CH2NH), 34.7 (CH2COO), 25.8 (CH2), 25.2 (CH2), 25.1 (CH2), 23.1 (CH2). Diagnostic 
13C NMR resonances for the minor rotamer: 172.7 (CO), 169.4 (CO), 63.9 (CH2O), 40.4 (CH2NH), 
28.9 (CH2); HRMS (ESI): calcd. for C9H16NO3, 186.1125. Found: [MH]+, 186.1129 (−0.4 ppm error). 
1-Oxa-4-azacyclododecane-3,12-dione (538) 
1-(2-(Benzyloxy)acetyl)azonan-2-one (209 mg, 0.729 mmol) was dissolved in 
THF (7.2 mL) and placed under an argon atmosphere. Palladium on carbon 
(72 mg, Pd 10% on carbon) and water (1.3 mL, 72.9 mmol) was then added 
and the reaction vessel was backfilled with hydrogen (via balloon) several 
times, then stirred at room temperature under a slight positive pressure of hydrogen (balloon) 
for 2 h. The reaction was then purged with argon, filtered through Celite, washed with methanol 
where the solvent was removed in vacuo. The crude material was then re-dissolved in 
chloroform (7.2 mL) and triethylamine (151 µL, 1.09 mmol) added, and stirred at room 
temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 
2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound as a white solid (139 mg, 97%); m.p. 78–79 °C; Rf 0.43 (ethyl acetate); νmax/cm–1 (thin 
film) 3274, 2935, 1733, 1660, 1551; δH (400 MHz, CDCl3) 6.26 (1H, s, NH), 4.60 (2H, s, CH2O), 
3.34–3.23 (2H, m, CH2NH), 2.49–2.38 (2H, m, CH2COO), 1.82–1.70 (2H, m, CH2), 1.55–1.29 (8H, 
m, 4 × CH2); δC (100 MHz, CDCl3) 172.7 (CO), 167.2 (CO), 62.8 (CH2O), 39.6 (CH2NH), 33.9 (CH2CO), 
27.2 (CH2), 25.9 (CH2), 25.3 (CH2), 24.7 (CH2), 24.3 (CH2); HRMS (ESI): calcd. for C10H17NNaO3, 
222.1101. Found: [MNa]+, 222.1102 (−1.2 ppm error). 
1-Oxa-4-azacyclotridecane-3,13-dione (539) 
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1-(2-(Benzyloxy)acetyl)azecan-2-one (207 mg, 0.681 mmol) was dissolved in 
THF (6.8 mL) and placed under an argon atmosphere. Palladium on carbon (68 
mg, Pd 10% on carbon) and water (1.2 mL, 68.1 mmol) was then added and 
the reaction vessel was backfilled with hydrogen (via balloon) several times, 
then stirred at room temperature under a slight positive pressure of hydrogen 
(balloon) for 2 h. The reaction was then purged with argon, filtered through Celite, washed with 
methanol where the solvent was removed in vacuo. The crude material was then re-dissolved in 
chloroform (6.8 mL) and triethylamine (142 µL, 1.02 mmol) added, and stirred at room 
temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 
2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound (as a 5:1 mixture of rotamers) as a white solid (135 mg, 93%); m.p. 82.0–83.0 °C; Rf 
0.48 (ethyl acetate); νmax/cm–1 (thin film) 3384, 3282, 2919, 2859, 1720, 1662, 1541; δH (400 
MHz, CDCl3) 6.01 (1H, br s, NH, major rotamer), 4.63 (2H, s, CH2O, major), 4.14 (2H, s, CH2O, 
minor rotamer), 3.73 (1H, br s, NH, minor), 3.53–3.46 (2H, m, CH2NH, minor), 3.33–3.24 (2H, m, 
CH2NH, major), 3.22–3.16 (2H, m, CH2CO, minor), 2.50–2.39 (2H, m, CH2CO, major), 1.85–1.68 
(4H, m, CH2, both rotamers), 1.62–1.28 (20H, m, 5 × CH2, both); δC (100 MHz, CDCl3) 172.4 (CO), 
167.6 (CO), 62.8 (CH2O), 38.9 (CH2NH), 34.0 (CH2CO), 26.3 (CH2), 26.0 (CH2), 25.7 (CH2), 25.5 
(CH2), 24.0 (CH2), 23.3 (CH2). Diagnostic 13C NMR resonances for minor rotamer: 173.0 (CO), 60.5 
(CH2O), 48.3 (CH2NH), 25.4 (CH2), 25.2 (CH2), 24.2 (CH2), 23.6 (CH2), 23.0 (CH2); HRMS (ESI): calcd. 
for C11H19NNaO3, 236.1257. Found: [MNa]+, 236.1259 (−0.6 ppm error). 
1-Oxa-4-azacyclotetradecane-3,14-dione (540) 
 A mixture of azacycloundecan-2-one (133 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The solvent was concentrated in vacuo, loaded onto a short silica plug and eluted with 
2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and pyridine residues, 
and concentrated in vacuo. This material was re-dissolved in THF (7.8 mL) and placed under an 
argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) and water (1.42 mL, 78.6 
mmol) was then added and the reaction vessel was backfilled with hydrogen (via balloon) several 
times, then stirred at room temperature under a slight positive pressure of hydrogen (balloon) 
for 1 h. The reaction was then purged with argon, filtered through Celite, washed with methanol 
where the solvent was removed in vacuo. The crude material was then re-dissolved in 
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chloroform (7.8 mL) and triethylamine (165 µL, 1.18 mmol) added, and stirred at room 
temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 
2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a white solid (154 mg, 
86%); m.p. 97.0–98.0 °C; Rf 0.52 (ethyl acetate); νmax/cm–1 (thin film) 3397, 2921, 2861, 1722, 
1678, 1663, 1534; δH (400 MHz, CDCl3) 6.13 (1H, br s, NH), 4.58 (2H, s, CH2O), 3.40–3.29 (2H, m, 
CH2NH), 2.50–2.38 (2H, m, CH2COO), 1.77–1.64 (2H, m, CH2), 1.58–1.48 (2H, m, CH2), 1.44–1.21 
(10H, m, 5 × CH2); δC (100 MHz, CDCl3) 172.4 (CO), 167.2 (CO), 63.1 (CH2O), 38.2 (CH2NH), 33.4 
(CH2CO), 26.6 (CH2), 26.2 (CH2), 25.8 (CH2), 25.7 (CH2), 25.2 (CH2), 24.2 (CH2), 23.9 (CH2); HRMS 
(ESI): calcd. for C12H21NNaO3, 250.1414. Found: [MNa]+, 250.1416 (−1.3 ppm error). 
 
1-Oxa-4-azacyclopentadecane-3,15-dione (541) 
 A mixture of azacyclododecan-2-one (144 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The solvent was concentrated in vacuo, loaded onto a short silica plug and eluted with 
2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and pyridine residues, 
and concentrated in vacuo. This material was re-dissolved in THF (7.8 mL) and placed under an 
argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) and water (1.42 mL, 78.6 
mmol) was then added and the reaction vessel was backfilled with hydrogen (via balloon) several 
times, then stirred at room temperature under a slight positive pressure of hydrogen (balloon) 
for 1 h. The reaction was then purged with argon, filtered through Celite, washed with methanol 
where the solvent was removed in vacuo. The crude material was then re-dissolved in 
chloroform (7.8 mL) and triethylamine (165 µL, 1.18 mmol) added, and stirred at room 
temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 
2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound (as a 3:1 mixture of 
rotamers) as a white solid (155 mg, 83%); m.p. 82.0–83.0 °C; Rf 0.54 (ethyl acetate); νmax/cm–1 
(thin film) 3398, 2927, 2857, 1725, 1677, 1530; δH (400 MHz, CDCl3) 6.16 (2H, br s, NH, both 
rotamers), 4.58 (2H, s, CH2O, minor rotamer), 4.55 (2H, s, CH2O, major rotamer), 3.40–3.27 (4H, 
m, CH2NH, both), 2.48–2.37 (4H, m, CH2COO, both), 1.79–1.65 (4H, m, CH2, both), 1.59–1.48 (4H, 
m, CH2, both), 1.42–1.19 (24H, m, 6 × CH2, both); δC (100 MHz, CDCl3) data for the major rotamer 
only: 172.2 (CO), 167.3 (CO), 63.0 (CH2O), 38.5 (CH2NH), 33.3 (CH2CO), 29.9 (CH2), 27.3 (CH2), 
26.7 (CH2), 26.5 (CH2), 26.4 (CH2), 26.3 (CH2), 24.8 (CH2), 24.3 (CH2). Diagnostic 13C NMR 
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resonances for the minor rotamer: 172.4 (CO), 167.2 (CO), 63.1 (CH2O), 38.2 (CH2NH), 33.4 
(CH2CO), 26.6 (CH2), 26.2 (CH2), 25.8 (CH2), 25.7 (CH2), 25.2 (CH2), 24.2 (CH2), 23.9 (CH2); HRMS 
(ESI): calcd. for C13H23NNaO3, 264.1570. Found: [MNa]+, 264.1574 (−1.1 ppm error). 
3,4,6,7,8,9-Hexahydrobenzo[i][1]oxa[5]azacycloundecine-1,5-dione (549) 
 A mixture of 2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (127 mg, 
0.786 mmol), DMAP (10 mg, 0.0786 mmol) and pyridine (380 μL, 4.72 
mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at room 
temperature for 5 min. Next, a solution of acid chloride (1.18 mmol, 1.50 
equiv. prepared using the general procedure) in CH2Cl2 (3 mL) was added and the resulting 
mixture was heated, at reflux, at 50 °C for 16 h. The solvent was concentrated in vacuo, loaded 
onto a short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of 
excess carboxylic acid and pyridine residues, and concentrated in vacuo. This material was re-
dissolved in ethyl acetate (7.8 mL) and placed under an argon atmosphere. Palladium on carbon 
(78 mg, Pd 10% on carbon) was then added, and the reaction vessel was backfilled with hydrogen 
(via balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 16 h. The reaction was purged with argon, filtered through Celite, washed 
with methanol where the solvent was removed in vacuo. The crude material was then re-
dissolved in chloroform (7.8 mL) and triethylamine (165 µL, 1.18 mmol) added, and stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a colourless oil 
(98 mg, 53%). 2-(3-Hydroxypropanoyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (48 mg, 
26%) was also isolated, and re-subjected to the reaction conditions where it was re-dissolved in 
chloroform (2.1 mL) and triethylamine (45 µL, 0.309 mmol) was added and stirred at room 
temperature for 16 h. Purification of this second reaction mixture by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound, 
which was combined with the initial purified compound, as a colourless oil (130 mg, 71%); Rf 
0.32 (ethyl acetate); νmax/cm–1 (thin film) 3302, 3071, 2949, 1703, 1651, 1547; δH (400 MHz, 
CDCl3) 7.76 (1H, d, J = 6.9 Hz, CH), 7.40–7.31 (1H, m, CH), 7.23–7.17 (1H, m, CH), 7.13 (1H, d, J = 
7.6 Hz, CH), 6.16 (1H, br s, NH), 4.57 (2H, t, J = 6.1 Hz, CH2O), 3.41–3.19 (2H, m, CH2NH), 2.86 
(2H, t, J = 7.6 Hz, CH2C), 2.58 (2H, t, J = 6.1 Hz, CH2CON), 1.80–1.63 (2H, m, CH2CH2NH); δC (100 
MHz, CDCl3) 172.6 (CO), 168.8 (CO), 142.9 (C), 132.1 (CH), 131.3 (CH), 131.1 (CH), 130.0 (C), 126.3 
(CH), 63.2 (CH2O), 40.1 (CH2NH), 37.0 (CH2C), 32.1 (CH2CON), 30.4 (CH2CH2NH); HRMS (ESI): 
calcd. for C13H15NNaO3, 256.0944. Found: [MNa]+, 256.0945 (−0.2 ppm error). 
2-(2-Hydroxybenzoyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (552) 
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A mixture of 2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (127 mg, 
0.786 mmol), DMAP (10 mg, 0.0786 mmol) and pyridine (380 μL, 4.72 
mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at 
room temperature for 5 min. Next, a solution of acid chloride (1.18 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 
mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The solvent 
was concentrated in vacuo, loaded onto a short silica plug and eluted with 2:1 hexane:ethyl 
acetate, to remove the majority of excess carboxylic acid and pyridine residues, and 
concentrated in vacuo. This material was re-dissolved in ethyl acetate (7.8 mL) and placed under 
an argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) was then added, and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 16 h. The reaction was 
purged with argon, filtered through Celite, washed with methanol where the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (7.8 mL) and 
triethylamine (165 µL, 1.18 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate) afforded the title compound (as a 4:1 mixture of rotamers) as a colourless oil 
(142 mg, 73%); Rf 0.71 (ethyl acetate); νmax/cm–1 (neat) 3280, 2958, 1649, 1601, 1452; δH (400 
MHz, CDCl3) 10.01 (1H, br s, OH, major rotamer), 9.51 (1H, s, OH, minor rotamer), 7.79 (1H, d, J 
= 7.6 Hz, CH, major), 7.73 (1H, d, J = 7.6 Hz, minor), 7.57–7.23 (11H, m, 5 × CH, both rotamers 
and 1 × CH, minor rotamer), 7.22–7.18 (1H, d, J = 7.6 Hz, minor), 6.91 (1H, d, J = 8.4 Hz, CH, 
major), 6.83–6.75 (1H, m, CH, major), 3.87 (2H, t, J = 6.4 Hz, CH2N, major), 3.63 (2H, t, J = 6.5 Hz, 
CH2N, minor), 3.03 (2H, t, J = 6.9 Hz, CH2C, major), 2.84–2.76 (2H, m, CH2C, minor), 2.09–1.94 
(4H, m, CH2CH2N, both rotamers); δC (100 MHz, CDCl3) data for major rotamer only: 175.4 (CO), 
173.0 (CO), 159.8 (COH), 139.2 (C), 134.9 (CH), 133.7 (C), 133.5 (CH), 133.3 (C), 130.9 (CH), 130.8 
(CH), 129.7 (CH), 127.6 (CH), 119.1 (CH), 118.1 (CH), 42.1 (CH2), 30.6 (CH2), 28.0 (CH2). Diagnostic 
13C NMR resonances for minor rotamer: 173.4 (CO), 162.3 (COH), 138.2 (CH), 129.3 (CH), 117.9 
(CH), 38.7 (CH2), 30.1 (CH2), 26.9 (CH2); HRMS (ESI): calcd. for C17H15NNaO3, 304.0944. Found: 
[MNa]+, 304.0947 (−1.3 ppm error). 
4,5,6,7,8,9-Hexahydro-2H-benzo[b][1]oxa[5]azacyclododecine-2,10(3H)-dione (555) 
 A mixture of azacyclooctan-2-one (100 mg, 0.786 mmol), DMAP (10 mg, 
0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an 
argon atmosphere was stirred at room temperature for 5 min. Next, a solution 
of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) 
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in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. An 
additional solution of acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and heated, to reflux, at 50 °C for a further 16 h in order 
to achieve reaction completion.  The solvent was then concentrated in vacuo, loaded onto a 
short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess 
carboxylic acid and pyridine residues, and concentrated in vacuo. This material was re-dissolved 
in ethyl acetate (7.8 mL) and placed under an argon atmosphere. Palladium on carbon (78 mg, 
Pd 10% on carbon) was then added and the reaction vessel was backfilled with hydrogen (via 
balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 1 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol where the solvent was removed in vacuo. The crude material was then 
re-dissolved in chloroform (7.8 mL) and triethylamine (165 µL, 1.18 mmol) added, and stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a white solid 
(174 mg, 90%); m.p. 138.0–140.0 °C; Rf 0.62 (ethyl acetate); νmax/cm–1 (thin film) 3296, 2939, 
2900, 2849, 1742, 1632, 1542; δH (400 MHz, CDCl3) 7.74 (1H, d, J = 7.7 Hz, CH), 7.44–7.35 (1H, 
m, CH), 7.30–7.20 (1H, m, CH), 7.01 (1H, d, J = 8.1 Hz, CH), 6.46 (1H, br s, NH), 3.50–3.34 (2H, m, 
CH2NH), 2.67–2.53 (2H, m, CH2COO), 1.90–1.75 (2H, m, CH2), 1.71–1.61 (2H, m, CH2), 1.59–1.43 
(4H, m, 2 × CH2); δC (100 MHz, CDCl3) 171.9 (CO), 165.4 (CO), 147.2 (C), 131.5 (CH), 130.5 (CH), 
129.1 (C), 126.5 (CH), 123.3 (CH), 40.1 (CH2NH), 34.6 (CH2CO), 26.3 (CH2), 25.8 (CH2), 24.7 (CH2), 
22.5 (CH2); HRMS (ESI): calcd. for C14H17NNaO3, 270.1101. Found: [MNa]+, 270.1107 (−2.1 ppm 
error). 
3-(Ethylamino)-3-oxopropyl propionate (558) 
 A mixture of N-ethylpropionamide (80 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of acid 
chloride (1.18 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (3 
mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The 
solvent was concentrated in vacuo, loaded onto a short silica plug and eluted with 
2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and pyridine residues, 
and concentrated in vacuo. This material was re-dissolved in ethyl acetate (7.8 mL) and placed 
under an argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) was then added 
and the reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at 
room temperature under a slight positive pressure of hydrogen (balloon) for 1 h. The reaction 
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was then purged with argon, filtered through Celite, washed with methanol where the solvent 
was removed in vacuo. The crude material was then re-dissolved in chloroform (7.8 mL) and 
triethylamine (165 µL, 1.18 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate) afforded the title compound as a colourless oil (102 mg, 75%); Rf 0.36 (ethyl 
acetate); νmax/cm–1 (thin film) 3299, 3094, 2978, 2941, 1736, 1644, 1551; δH (400 MHz, CDCl3) 
6.12 (1H, br s, NH), 4.36–4.25 (2H, m, CH2O), 3.29–3.16 (2H, m, CH2NH), 2.43 (2H, t, J = 6.3 Hz, 
CH2CONH), 2.25 (2H, q, J = 7.6 Hz, CH2COO), 1.15–0.97 (6H, m, 2 × CH3); δC (100 MHz, CDCl3) 
174.5 (CO), 169.9 (CO), 60.6 (CH2O), 35.9 (CH2NH), 34.5 (CH2CON), 27.5 (CH2COO), 14.8 (CH3), 
9.1 (CH3); HRMS (ESI): calcd. for C8H15NNaO3, 1986.0944. Found: [MNa]+, 196.0948 (−1.5 ppm 
error). 
2-Methyl-1-oxa-4-azacyclohexadecane-3,16-dione (561) 
 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The solvent was concentrated in vacuo, loaded onto a short silica plug and eluted with 
2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and pyridine residues, 
and concentrated in vacuo. This material was re-dissolved in THF (7.8 mL) and placed under an 
argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) and water (1.42 mL, 78.6 
mmol) was then added and the reaction vessel was backfilled with hydrogen (via balloon) several 
times, then stirred at room temperature under a slight positive pressure of hydrogen (balloon) 
for 2 h. The reaction was then purged with argon, filtered through Celite, washed with methanol 
where the solvent was removed in vacuo. The crude material was then re-dissolved in 
chloroform (7.8 mL) and triethylamine (165 µL, 1.18 mmol) added, and stirred at room 
temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 
2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a colourless oil (124 
mg, 59%). 1-(2-Hydroxypropanoyl)azacyclotridecan-2-one (82 mg, 38%) was also isolated, and 
re-subjected to the reaction conditions where it was re-dissolved in chloroform (3.0 mL) and 
triethylamine (65 µL, 0.452 mmol) was added and stirred at room temperature for 16 h. 
Purification of this second reaction mixture by flash column chromatography (SiO2, 2:1 
hexane:ethyl acetate → ethyl acetate) afforded the title compound, which was combined with 
the initial purified compound, as a colourless oil (180 mg, 85%); Rf 0.67 (ethyl acetate); νmax/cm–
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1 (thin film)  3314, 2928, 2857, 1738, 1659, 1536; δH (400 MHz, CDCl3) 6.24 (1H, br s, NH), 5.17 
(1H, q, J = 6.9 Hz, CHCH3), 3.47–3.37 (1H, m, CHH′NH), 3.20 (1H, m, CHH′NH), 2.39 (2H, m, 
CH2COO), 1.73–1.14 (21H, m, 9 × CH2 and CH3); δC (100 MHz, CDCl3) 172.2 (CO), 170.4 (CO), 70.8 
(CHO), 38.6 (CH2NH), 34.8 (CH2COO), 28.5 (CH2), 27.1 (CH2), 27.0 (CH2), 26.40 (CH2), 26.36 (CH2), 
25.7 (CH2), 24.9 (CH2), 24.7 (CH2), 24.6 (CH2), 18.1 (CH3); HRMS (ESI): calcd. for C15H28NO3, 




 A mixture of laurolactam (155 mg, 0.786 mmol), DMAP (10 mg, 0.0786 
mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of 
acid chloride (1.18 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C 
for 16 h. The solvent was concentrated in vacuo, loaded onto a short silica plug and eluted with 
2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and pyridine residues, 
and concentrated in vacuo. This material was re-dissolved in THF (7.8 mL) and placed under an 
argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) and water (1.42 mL, 78.6 
mmol) was then added and the reaction vessel was backfilled with hydrogen (via balloon) several 
times, then stirred at room temperature under a slight positive pressure of hydrogen (balloon) 
for 2 h. The reaction was then purged with argon, filtered through Celite, washed with methanol 
where the solvent was removed in vacuo. The crude material was then re-dissolved in 
chloroform (7.8 mL) and triethylamine (165 µL, 1.18 mmol) added, and stirred at room 
temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography (SiO2, 
2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a white solid (176 mg, 
68%); m.p. 126–128 °C; Rf 0.73 (ethyl acetate); νmax/cm–1 (thin film) 3300, 2927, 2856, 1736, 
1654, 1537; δH (400 MHz, CDCl3) 7.53–7.16 (5H, m, Ph), 6.41 (1H, br s, NH), 6.13 (1H, s, CHPh), 
3.61–3.50 (1H, m, CHH′NH), 3.21–3.10 (1H, m, CHH′NH), 2.49–2.34 (2H, m, CHH′COO), 1.83–1.21 
(18H, m, 9 × CH2); δC (100 MHz, CDCl3) 171.7 (CO), 168.4 (CO), 136.0 (C), 128.9 (CH), 128.7 (CH), 
127.3 (CH), 75.6 (CHPh), 38.7 (CH2NH), 34.8 (CH2CO), 28.8 (CH2), 27.2 (CH2), 27.1 (CH2), 26.6 
(CH2), 26.5 (CH2), 25.7 (CH2), 25.0 (CH2), 24.8 (CH2), 24.6 (CH2); HRMS (ESI): calcd. for 
C20H29NNaO3, 354.2040. Found: [MNa]+, 354.2041 (−0.5 ppm error). 
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14-Benzyl-1-oxa-4,14-diazacycloheptadecane-3,13,17-trione (568) 
A mixture of 5-benzyl-1,5-diazacyclotetradecane-2,6-dione (65 mg, 
0.205 mmol), DMAP (3 mg, 0.0205 mmol) and pyridine (100 μL, 1.23 
mmol) in CH2Cl2 (1.5 mL) under an argon atmosphere was stirred at 
room temperature for 5 min. Next, a solution of acid chloride (0.308 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 
(1 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. An additional 
solution of acid chloride (0.308 mmol, 1.50 equiv. prepared using the general procedure) in 
CH2Cl2 (1 mL) was added and heated, to reflux, at 50 °C for a further 16 h in order to achieve 
reaction completion.  The solvent was then concentrated in vacuo, loaded onto a short silica 
plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid 
and pyridine residues, and concentrated in vacuo. This material was re-dissolved in THF (2.1 mL) 
and placed under an argon atmosphere. Palladium on carbon (21 mg, Pd 10% on carbon) and 
water (370 µL, 20.5 mmol) was then added and the reaction vessel was backfilled with hydrogen 
(via balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 3 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol and the solvent was removed in vacuo. The crude material was then re-
dissolved in chloroform (2.1 mL) and triethylamine (45 µL, 0.308 mmol) added, and stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound as a colourless oil (75 mg, 98%); Rf 0.43 (ethyl acetate); νmax/cm–1 (thin film) 3331, 
2930, 2857, 1744, 1634, 1546; δH (400 MHz, CDCl3) 7.56 (1H, br s, NH), 7.40–7.07 (5H, m, Ph), 
4.61 (2H, s, CH2O), 4.59 (2H, s, CH2Ph), 3.72–3.54 (2H, m, CH2NBn), 3.41–3.27 (2H, m, CH2NH), 
2.65–2.51 (2H, m, CH2COO), 2.45–2.28 (2H, m, CH2CONBn), 1.66–1.17 (12H, m, 6 × CH2); δC (100 
MHz, CDCl3) 174.3 (CO), 171.3 (CO), 167.7 (CO), 136.4 (C), 129.1 (CH), 127.9 (CH), 126.4 (CH), 
63.3 (CH2O), 52.4 (CH2Ph), 43.3 (CH2NBn), 38.1 (CH2NH), 34.5 (CH2COO), 32.2 (CH2CONBn), 27.9 
(CH2), 26.7 (CH2), 26.0 (CH2), 25.5 (CH2), 23.2 (2 × CH2); HRMS (ESI): calcd. for C21H30N2NaO4, 
397.2098. Found: [MNa]+, 397.2108 (−2.6 ppm error). 
(S)-Hexadecahydro-16H-pyrrolo[1,2-e][1]oxa[5,8]diazacycloicosine-1,14,18(17H)-trione (569) 
 A mixture of 1-oxa-5-azacycloheptadecane-4,17-dione (110 mg, 
0.408 mmol), DMAP (5 mg, 0.0408 mmol) and pyridine (0.200 mL, 
2.45 mmol) in CH2Cl2 (3 mL) under an argon atmosphere was stirred 
at room temperature for 30 min. Next, a solution of acid chloride 
(0.613 mmol, 1.50 eqv prepared using the general procedure) in 
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CH2Cl2 (2 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. An 
additional solution of acid chloride (0.613 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (2 mL) was added and heated, to reflux, at 50 °C for a further 24 h in order 
to achieve reaction completion. The solvent was then concentrated in vacuo, loaded onto a 
short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess 
carboxylic acid and pyridine residues, and concentrated in vacuo. The crude material was then 
re-dissolved in CH2Cl2 (4.1 mL) and DBU (0.620 mL, 4.083 mmol) was added, followed by stirring 
at room temperature for 16 h, before the solvent was removed in vacuo. Purification by flash 
column chromatography (2:1 hexane:ethyl acetate→ethyl acetate→9:1 ethyl acetate:methanol) 
afforded the title compound (as a 4.4:1 mixture of rotamers) as a colourless oil (119 mg, 81%); 
[α]D25 −43.6 (c = 1.0, CHCl3); Rf 0.20 (ethyl acetate); νmax/cm–1 (neat) 3309, 2917, 1739, 1621, 
1551; δH (400 MHz, CDCl3) 7.18 (1H, br s, NH, major rotamer), 6.16 (1H, br s, NH, minor rotamer), 
4.59 (1H, d, J = 8.4 Hz, CH, major), 4.42 (1H, d, J = 5.3 Hz, CH, minor), 4.40–4.27 (4H, m, CH2NCO, 
both rotamers), 3.63–3.48 (2H, m, CHH′N, both), 3.44–3.25 (4H, m, CHH′NCO and CHH′NH, 
both), 3.11–2.96 (2H, m, CHH′NH), 2.71–2.53 (4H, m, CH2CON, both), 2.52–2.41 (2H, m, 
CHH′CHN, both), 2.33–2.16 (4H, m, CH2COO), 2.15–2.02 (2H, m, CHH′CHN, both), 2.03–1.92 (2H, 
m, CHH′CH2N, both), 1.87–1.72 (2H, m, CHH′CH2N, both), 1.70–1.54 (4H, m, CH2, both), 1.53–
1.40 (4H, m, CH2, both), 1.37–1.16 (28H, m, 7 × CH2, both); δC (100 MHz, CDCl3) data for the 
major rotamer only: 174.1 (CO), 170.8 (CO), 170.4 (CO), [59.8, 59.7 (CHN and CH2O)], 47.6 
(CH2NCO), 39.5 (CH2NH), 33.9 (CH2CO), 33.8 (CH2CO), 28.7 (CH2), 28.1 (CH2), 27.38 (CH2), 27.36 
(CH2), 27.3 (CH2), 27.1 (CH2), 26.9 (CH2), 26.7 (CH2), 26.0 (CH2), 25.1 (CH2), 24.2 (CH2). Diagnostic 
13C NMR resonances for the minor rotamer: 173.9 (CO), 171.4 (CO), 169.9 (CO), [61.8, 60.2 (CHN 
and CH2O)], 46.9 (CH2NCO), 39.6 (CH2NH), 33.5 (CH2CO), 32.0 (CH2CO), 29.3 (CH2), 28.2 (CH2), 
26.5 (CH2), 26.1 (CH2), 22.7 (CH2); HRMS (ESI): calcd. for C20H34N2NaO4, 389.2411. Found: [MNa]+, 
389.2413 (−0.5 ppm error). 
5-Benzyl-1-oxa-5,9-diazacyclohenicosane-4,8,21-trione (570) 
 A mixture of 1-oxa-5-azacycloheptadecane-4,17-dione (45 mg, 
0.167 mmol), DMAP (2 mg, 0.0167 mmol) and pyridine (81 μL, 
1.00 mmol) in CH2Cl2 (1.5 mL) under an argon atmosphere was 
stirred at room temperature for 5 min. Next, a solution of acid chloride (0.251 mmol, 1.50 equiv. 
prepared using the general procedure) in CH2Cl2 (1 mL) was added and the resulting mixture was 
heated, at reflux, at 50 °C for 16 h. The solvent was then concentrated in vacuo, loaded onto a 
short silica plug and eluted with ethyl acetate, to remove the majority of excess carboxylic acid 
and pyridine residues. The crude material was then re-dissolved in CH2Cl2 (1.67 mL) and DBU 
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(0.250 mL, 1.67 mmol) was added, followed by stirring at room temperature for 16 h, before the 
solvent was removed in vacuo. Purification by flash column chromatography (2:1 hexane:ethyl 
acetate→ethyl acetate→9:1 ethyl acetate:methanol) afforded the title compound (as a mixture 
of rotamers) as a colourless oil (58 mg, 84%); Rf 0.13 (ethyl acetate); νmax/cm–1 (thin film) 3300, 
2927, 2856, 1642, 1554; δH (400 MHz, CDCl3) 7.40–7.04 (5H, m, Ph), 6.97 (1H, br s, NH), 4.62 (2H, 
s, CH2Ph), 3.76–3.15 (6H, m, 2 × CH2N and CH2O), 2.62–2.14 (6H, m, 3 × CH2CO), 1.94–1.17 (18H, 
m, 9 × CH2); δC (100 MHz, CDCl3) 175.2 (CO), 172.9 (CO), 171.3 (CO), 136.6 (C), 129.1 (CH), 127.2 
(CH), 126.3 (CH), 66.4 (CH2O), 54.9 (CH2Ph), 52.2 (CH2NBn), 42.7 (CH2NH), 39.9 (CH2CO), 35.6 
(CH2CO), 32.9 (CH2CO), 31.4 (CH2), 28.5 (CH2), 27.6 (CH2), 27.2 (CH2), 26.6 (CH2), 25.6 (CH2), 25.1 
(CH2), 24.8 (CH2), 24.5 (CH2); HRMS (ESI): calcd. for C25H39N2O4, 431.2904. Found: [MH]+, 
431.2912 (0.1 ppm error). 
(S)-Dodecahydropyrrolo[1,2-d][1]oxa[4,7]diazacyclopentadecine-1,10,13(12H)-trione (571) 
 A mixture of 1-oxa-4-azacyclododecane-3,12-dione (80 mg, 0.402 mmol), 
DMAP (5 mg, 0.0402 mmol) and pyridine (195 μL, 2.41 mmol) in CH2Cl2 (3 
mL) under an argon atmosphere was stirred at room temperature for 5 
min. Next, a solution of acid chloride (0.602 mmol, 1.50 equiv. prepared 
using the general procedure) in CH2Cl2 (1.5 mL) was added and the resulting mixture was heated, 
at reflux, at 50 °C for 16 h. The solvent was then concentrated in vacuo, loaded onto a short 
silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic 
acid and pyridine residues, and concentrated in vacuo. This material was re-dissolved in CH2Cl2 
(4.0 mL) and placed under an argon atmosphere. DBU (615 µL, 4.02 mmol) was then added and 
stirred at room temperature for 16 h, then reduced in vacuo. Purification by flash column 
chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) 
afforded the title compound as a colourless oil (217 mg, 74%); [α]D25 −95.1 (c = 1.0, chloroform); 
Rf 0.64 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3316, 2856, 1725, 1660, 1544; δH (400 
MHz, CDCl3) 6.96 (1H, br s, NH), 4.88 (1H, d, J = 13.3 Hz, CHH′O), 4.55 (1H, d, J = 6.9 Hz, NCH), 
4.24 (1H, d, J = 13.3 Hz, CHH′O), 3.85–3.73 (1H, m, CHH′N), 3.46–3.34 (1H, m, CHH′N), 3.32–3.20 
(1H, m, CHH′NH), 3.19–3.04 (1H, m, CHH′NH), 2.54–1.10 (16H, m, 8 × CH2); δC (100 MHz, CDCl3) 
174.8 (CO), 170.2 (CO), 167.4 (CO), 61.9 (CH2O), 60.4 (CHN), 46.8 (CH2N), 39.1 (CH2NH), 33.7 
(CH2COO), 28.4 (CH2), 28.1 (CH2), 27.3 (CH2), 26.8 (CH2), 25.6 (CH2), 24.8 (CH2), 23.3 (CH2); HRMS 
(ESI): calcd. for C15H24N2NaO4, 319.1628. Found: [MNa]+, 319.1633 (−1.5 ppm error). 
5-Benzyl-1-oxa-5,13-diazacyclohexadecane-2,6,14-trione (572) 
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 A mixture of 5-benzyl-1,5-diazacyclododecane-2,6-dione (340 mg, 
1.179 mmol), DMAP (14 mg, 0.118 mmol) and pyridine (570 μL, 7.07 
mmol) in CH2Cl2 (8 mL) under an argon atmosphere was stirred at 
room temperature for 5 min. Next, a solution of acid chloride (1.77 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (4.5 mL) was added and the 
resulting mixture was heated, at reflux, at 50 °C for 16 h. The solvent was then concentrated in 
vacuo, loaded onto a short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the 
majority of excess carboxylic acid and pyridine residues, and concentrated in vacuo. This 
material was re-dissolved in ethyl acetate (11.8 mL) and placed under an argon atmosphere. 
Palladium on carbon (118 mg, Pd 10% on carbon) was then added and the reaction vessel was 
backfilled with hydrogen (via balloon) several times, then stirred at room temperature under a 
slight positive pressure of hydrogen (balloon) for 3 h. The reaction was then purged with argon, 
filtered through Celite, washed with methanol and the solvent was removed in vacuo. The crude 
material was then re-dissolved in chloroform (11.8 mL) and triethylamine (245 µL, 1.77 mmol) 
added, and stirred at room temperature for 16 h, then reduced in vacuo. Purification by flash 
column chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl 
acetate:methanol) afforded the title compound (as a mixture of 3 rotamers, comprising one 
major rotamer and two minor rotamers which could not be accurately measured due to overlap 
of resonances in 1H NMR) as a colourless oil (260 mg, 61%); Rf 0.23 (9:1 ethyl acetate:methanol); 
νmax/cm–1 (thin film) 3311, 2932, 2859, 1732, 1631, 1552; δH (400 MHz, CDCl3) 7.35–7.01 (15H, 
m, Ph, all rotamers), 6.42–6.28 (2H, m, NH, two rotamers), 6.15 (1H, br s, NH, single rotamer), 
4.58 (2H, s, CH2Ph, single rotamer), 4.51 (2H, s, CH2Ph, single rotamer), 4.41–4.24 (8H, m, CH2Ph, 
single rotamer and CH2O, all rotamers), 3.60–3.51 (2H, m, CH2NBn, single rotamer), 3.48–3.40 
(2H, m, CH2NBn, single rotamer), 3.35–3.18 (8H, m, CH2NBn, single rotamer and CH2NH, all 
rotamers), 2.65–2.19 (18H, m, CH2CONBn and CH2COO and CH2CONH, all rotamers), 1.80–1.13 
(24H, m, 4 × CH2, all rotamers); δC (100 MHz, CDCl3) data for the major rotamer only: 173.7 (CO), 
170.1 (CO), 169.9 (CO), 137.4 (C), 128.8 (CH), 127.9 (CH), 126.4 (CH), 61.3 (CH2O), 48.8 (CH2NPh), 
43.8 (CH2NBn), 38.9 (CH2NH), 35.1 (CH2CO), 33.6 (CH2CO), 31.6 (CH2CO), 29.4 (CH2), 27.82 (CH2), 
25.2 (CH2), 25.1 (CH2). Diagnostic 13C NMR resonances for minor rotamers: 174.2 (CO), 173.4 
(CO), 173.0 (CO), 170.5 (CO), 170.3 (CO), 137.2 (C), 129.0 (CH), 127.6 (CH), 61.5 (CH2O), 61.0 
(CH2O), 44.0 (CH2NBn), 38.3 (CH2NH), 37.1 (CH2NH), 36.4 (CH2CO), 35.8 (CH2CO), 33.7 (CH2CO), 
32.0 (CH2CO), 29.0 (CH2), 27.78 (CH2), 25.6 (CH2), 25.5 (CH2), 25.4 (CH2), 24.6 (CH2), 24.1 (CH2), 
24.0 (CH2); HRMS (ESI): calcd. for C20H28N2NaO4, 383.1941. Found: [MNa]+, 383.1949 (−1.9 ppm 
error). 
1,17-Dioxa-4-azacycloicosane-3,16,20-trione (573) 
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 A mixture of 1-oxa-5-azacycloheptadecane-4,17-dione (240 mg, 
0.891 mmol), DMAP (11 mg, 0.0891 mmol) and pyridine (430 μL, 5.35 
mmol) in CH2Cl2 (6 mL) under an argon atmosphere was stirred at 
room temperature for 5 min. Next, a solution of acid chloride (1.34 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 
(3.5 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. An 
additional solution of acid chloride (1.34 mmol, 1.50 equiv. prepared using the general 
procedure) in CH2Cl2 (3.5 mL) was added and heated, to reflux, at 50 °C for a further 24 h in order 
to achieve reaction completion.  The solvent was then concentrated in vacuo, loaded onto a 
short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess 
carboxylic acid and pyridine residues, and concentrated in vacuo. This material was re-dissolved 
in THF (8.9 mL) and placed under an argon atmosphere. Palladium on carbon (89 mg, Pd 10% on 
carbon) and water (1.60 mL, 89.1 mmol) was then added and the reaction vessel was backfilled 
with hydrogen (via balloon) several times, then stirred at room temperature under a slight 
positive pressure of hydrogen (balloon) for 4 h. The reaction was then purged with argon, 
filtered through Celite, washed with methanol where the solvent was removed in vacuo. The 
crude material was then re-dissolved in chloroform (8.9 mL) and triethylamine (185 µL, 1.34 
mmol) added, and stirred at room temperature for 16 h, then reduced in vacuo. Purification by 
flash column chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title 
compound as a colourless oil (217 mg, 74%); Rf 0.64 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin 
film) 3314, 2927, 2856, 1735, 1662, 1545; δH (400 MHz, CDCl3) 6.41 (1H, br s, NH), 4.51 (2H, s, 
OCH2CO), 4.35 (2H, t, J = 6.0 Hz, OCH2CH2), 3.34–3.19 (2H, m, CH2NH), 2.66 (2H, t, J = 6.0 Hz, 
CH2CH2COO), 2.24 (2H, t, J = 6.9 Hz, CH2COOCH2CH2), 1.65–1.06 (18H, m, 9 × CH2); δC (100 MHz, 
CDCl3) 173.8 (CO), 169.3 (CO), 166.7 (CO), 63.3 (OCH2CO), 59.3 (OCH2CH2), 38.9 (CH2NH), 34.3 
(CH2CO), 33.8 (CH2CO), 28.5 (CH2), 27.8 (CH2), 27.6 (CH2), 27.5 (2 × CH2), 27.4 (CH2), 26.9 (CH2), 
25.5 (CH2), 24.4 (CH2); HRMS (ESI): calcd. for C17H29NNaO5, 250.1938. Found: [MNa]+, 350.1943 
(−1.6 ppm error). 
1,4-Dioxa-8-azacyclopentadecane-3,7,15-trione (574) 
 A mixture of 1-oxa-4-azacycloundecane-3,11-dione (50 mg, 0.270 
mmol), DMAP (6 mg, 0.0270 mmol) and pyridine (130 μL, 1.62 mmol) in 
CH2Cl2 (2 mL) under an argon atmosphere was stirred at room 
temperature for 5 min. Next, a solution of acid chloride (0.405 mmol, 
1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 mL) was added and the resulting 
mixture was heated, at reflux, at 50 °C for 16 h. The solvent was concentrated in vacuo, loaded 
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onto a short silica plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of 
excess carboxylic acid and pyridine residues, and concentrated in vacuo. This material was re-
dissolved in ethyl acetate (2.7 mL) and placed under an argon atmosphere. Palladium on carbon 
(27 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled with hydrogen 
(via balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 4 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol where the solvent was removed in vacuo. The crude material was then 
re-dissolved in chloroform (2.7 mL) and triethylamine (56 µL, 0.405 mmol) added, and stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a white solid (61 
mg, 88%); m.p. 114–116 °C; Rf 0.26 (ethyl acetate); νmax/cm–1 (thin film) 3290, 3087, 2926, 2858, 
1732, 1639, 1566; δH (400 MHz, CDCl3) 5.77 (1H, br s, NH), 4.60 (2H, s, OCH2CO), 4.46 (2H, t, J = 
5.2 Hz, OCH2CH2CO), 3.37–3.26 (2H, m, CH2NH), 2.44 (2H, t, J = 5.2 Hz, OCH2CH2CO), 2.40 (2H, t, 
J = 6.1 Hz, CH2CO), 1.73–1.63 (2H, m, CH2), 1.60–1.51 (2H, m, CH2), 1.44–1.27 (4H, m, 2 × CH2); 
δC (100 MHz, CDCl3) 173.2 (CO), 169.8 (CO), 168.1 (CO), 62.2 (CH2O), 61.1 (CH2O), 39.3 (CH2NH), 
36.1 (CH2CO), 32.6 (CO), 28.0 (CH2), 27.9 (CH2), 25.2 (CH2), 23.4 (CH2); HRMS (ESI): calcd. for 
C12H19NNaO5, 280.1155. Found: [MNa]+, 280.1154 (0.4 ppm error). 
1,5-Dioxa-9-azacyclohexadecane-4,8,16-trione (575) 
 A mixture of 1-oxa-5-azacyclododecane-4,12-dione (60 mg, 0.301 
mmol), DMAP (4 mg, 0.0301 mmol) and pyridine (145 μL, 1.81 mmol) 
in CH2Cl2 (2.5 mL) under an argon atmosphere was stirred at room 
temperature for 5 min. Next, a solution of acid chloride (0.452 mmol, 
1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 mL) was added and the resulting 
mixture was heated, at reflux, at 50 °C for 16 h. An additional solution of acid chloride (0.452 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 mL) was added and heated, 
to reflux, at 50 °C for a further 16 h in order to achieve reaction completion.  The solvent was 
then concentrated in vacuo, loaded onto a short silica plug and eluted with 2:1 hexane:ethyl 
acetate, to remove the majority of excess carboxylic acid and pyridine residues, and 
concentrated in vacuo. This material was re-dissolved in ethyl acetate (3.0 mL) and placed under 
an argon atmosphere. Palladium on carbon (30 mg, Pd 10% on carbon) was then added and the 
reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 16 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol and the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (3.0 mL) and 
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triethylamine (63 µL, 0.452 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate) afforded the title compound as a yellow oil (69 mg, 84%); Rf 0.31 (9:1 ethyl 
acetate:methanol); νmax/cm–1 (thin film) 3311, 2932, 1735, 1649, 1552; δH (400 MHz, CDCl3) 5.80 
(1H, s, NH), 4.47–4.32 (4H, m, 2 × CH2O), 3.38–3.23 (2H, m, CH2NH), 2.65–2.49 (4H, m, 
OCH2CH2CO), 2.38–2.26 (2H, m, CH2CO), 1.73–1.63 (2H, m, CH2), 1.55–1.43 (2H, m, CH2), 1.39–
1.18 (4H, m, 2 × CH2); δC (100 MHz, CDCl3) 173.7 (CO), 171.3 (CO), 170.0 (CO), 61.7 (OCH2), 59.6 
(OCH2), 39.0 (CH2NH), 36.5 (CH2CO), 34.6 (CH2CO), 32.8 (CH2CO), 29.3 (CH2), 27.6 (CH2), 25.1 
(CH2), 24.2 (CH2); HRMS (ESI): calcd. for C13H21NNaO5, 294.1312. Found: [MNa]+, 294.1309 (1.1 
ppm error). 
1,15-Dioxa-4-azacyclooctadecane-3,14,18-trione (576) 
 A mixture of 1-oxa-5-azacyclopentadecane-4,15-dione (50 mg, 0.207 
mmol), DMAP (3 mg, 0.0207 mmol) and pyridine (100 μL, 1.24 mmol) in 
CH2Cl2 (1.5 mL) under an argon atmosphere was stirred at room 
temperature for 5 min. Next, a solution of acid chloride (0.311 mmol, 
1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 mL) was 
added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. An additional solution 
of acid chloride (0.311 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 mL) 
was added and heated, to reflux, at 50 °C for a further 16 h in order to achieve reaction 
completion.  The solvent was then concentrated in vacuo, loaded onto a short silica plug and 
eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid and 
pyridine residues, and concentrated in vacuo. This material was re-dissolved in THF (2.1 mL) and 
placed under an argon atmosphere. Palladium on carbon (21 mg, Pd 10% on carbon) and water 
(380 µL, 20.7 mmol) was then added and the reaction vessel was backfilled with hydrogen (via 
balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 16 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol and the solvent was removed in vacuo. The crude material was then re-
dissolved in chloroform (2.1 mL) and triethylamine (45 µL, 0.311 mmol) added, and stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate) afforded the title compound as a colourless oil 
(53 mg, 86%); Rf 0.56 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3313, 2929, 2857, 1733, 
1662, 1545; δH (400 MHz, CDCl3) 6.28 (1H, br s, NH), 4.60 (2H, s, OCH2CO), 4.41 (2H, t, J = 5.3 Hz, 
OCH2CH2CO), 3.40–3.29 (2H, m, CH2NH), 2.70 (2H, t, J = 5.3 Hz, OCH2CH2CO), 2.30 (2H, t, J = 6.9 
Hz, CH2CO), 1.71–1.13 (14H, m, 7 × CH2); δC (100 MHz, CDCl3) 173.9 (CO), 169.7 (CO), 166.9 (CO), 
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63.5 (OCH2CO), 59.6 (OCH2CH2), 39.0 (CH2NH), 34.6 (CH2CO), 33.4 (CH2CO), 28.2 (CH2), 27.1 (2 × 
CH2), 26.8 (CH2), 26.4 (CH2), 25.4 (CH2), 23.9 (CH2); HRMS (ESI): calcd. for C15H25NNaO5, 322.1625. 






A mixture of 3,4,6,7,8,9-hexahydrobenzo[i][1]oxa[5]azacycloundecine-
1,5-dione (60 mg, 0.269 mmol), DMAP (4 mg, 0.0269 mmol) and 
pyridine (130 μL, 1.61 mmol) in CH2Cl2 (2.0 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (0.403 mmol, 1.50 equiv. prepared using the general procedure) in 
CH2Cl2 (1 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The 
solvent was then concentrated in vacuo, loaded onto a short silica plug and eluted with 2:1 
hexane:ethyl acetate, to remove the majority of excess carboxylic acid and pyridine residues, 
and concentrated in vacuo. This material was re-dissolved in ethyl acetate (2.7 mL) and placed 
under an argon atmosphere. Palladium on carbon (27 mg, Pd 10% on carbon) was then added 
and the reaction vessel was backfilled with hydrogen (via balloon) several times, then stirred at 
room temperature under a slight positive pressure of hydrogen (balloon) for 16 h. The reaction 
was then purged with argon, filtered through Celite, washed with methanol and the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (2.7 mL) and 
triethylamine (56 µL, 0.403 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, 2:1 hexane:ethyl acetate 
→ ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound as a colourless oil 
(74 mg, 90%); Rf 0.50 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3316, 1707, 1640, 1557; 
δH (400 MHz, CDCl3) 7.81 (1H, d, J = 7.6 Hz, CH), 7.50–7.38 (1H, m, CH), 7.29–7.17 (2H, m, 2 × 
CH), 6.09 (1H, br s, NH), 4.62 (2H, t, J = 4.6 Hz, CH2O), 4.45 (2H, t, J = 4.6 Hz, CH2O), 3.39–3.29 
(2H, m, CH2NH), 2.96 (2H, t, J = 7.6 Hz, CH2C), 2.74 (2H, t, J = 4.6 Hz, CH2CH2O), 2.58 (2H, t, J = 4.6 
Hz, CH2CH2O). 1.88–1.72 (2H, m, CH2); δC (100 MHz, CDCl3) 171.6 (CO), 170.2 (CO), 168.9 (CO), 
142.7 (C), 132.5 (CH), 131.0 (CH), 130.8 (CH), 129.6 (C), 126.3 (CH), 61.7 (CH2O), 61.4 (CH2O), 
39.0 (CH2NH), 36.7 (CH2CO), 35.2 (CH2CO), 31.5 (CH2), 31.3 (CH2); HRMS (ESI): calcd. for 
C16H19NNaO5, 328.1155. Found: [MNa]+, 328.1158 (−0.7 ppm error). 
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12-Benzyl-1,16-dioxa-4,12-diazacyclononadecane-3,11,15,19-tetraone (584) 
 A mixture of 5-benzyl-1-oxa-5,13-diazacyclohexadecane-2,6,14-
trione (90 mg, 0.250 mmol), DMAP (3 mg, 0.0250 mmol) and 
pyridine (121 μL, 1.50 mmol) in CH2Cl2 (2.0 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (0.375 mmol, 1.50 equiv. prepared using 
the general procedure) in CH2Cl2 (1 mL) was added and the resulting mixture was heated, at 
reflux, at 50 °C for 16 h. The solvent was then concentrated in vacuo, loaded onto a short silica 
plug and eluted with 2:1 hexane:ethyl acetate, to remove the majority of excess carboxylic acid 
and pyridine residues, and concentrated in vacuo. This material was re-dissolved in THF (2.5 mL) 
and placed under an argon atmosphere. Palladium on carbon (25 mg, Pd 10% on carbon) and 
water (450 µL, 25 mmol) was then added and the reaction vessel was backfilled with hydrogen 
(via balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 3 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol and the solvent was removed in vacuo. The crude material was then re-
dissolved in chloroform (2.5 mL) and triethylamine (53 µL, 0.375 mmol) added, and stirred at 
room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate → ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title 
compound (as a 1:1:1.4:2.1 {A:B:C:D} mixture of rotamers) as a yellow oil (71 mg, 68%); Rf 0.18 
(ethyl acetate); νmax/cm–1 (thin film) 3312, 2931, 2858, 1735, 1636, 1548; δH (400 MHz, CDCl3) 
7.50–7.08 (20H, m, Ph, all rotamers), 7.05 (1H, br s, NH, rotamer A), 6.37 (1H, br s, NH, rotamer 
B), 6.09 (1H, br s, NH, rotamer C), 5.73 (1H, br s, NH, rotamer D), 4.67–4.54 (8H, m, NCH2Ph, all 
rotamers), 4.49–4.33 (8H, m, CH2CH2O, all rotamers), 3.73–3.23 (24H, m, CH2NBn and CH2NH 
and CH2O, all rotamers), 2.80–2.27 (24H, m, 3 × CH2CO, all rotamers), 1.82–1.20 (32H, m, 4 × 
CH2, all rotamers); δC (100 MHz, CDCl3) 174.22 (CO), 174.16 (CO), 173.6 (CO), 173.4 (CO), 173.0 
(CO), 172.0 (CO), 171.0 (CO), 170.6 (CO), 170.2 (CO), 169.7 (CO), 169.4 (CO), 167.3 (CO), 166.9 
(CO), 137.5 (C), 137.4 (C), 137.2 (C), 136.7 (C), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.0 (CH), 
127.9 (CH), 127.7–127.6 (3 × CH), 126.5 (CH), 126.4 (CH), 63.5 (CH2), 63.2 (CH2), 61.6 (CH2), 61.3 
(CH2), 60.2 (CH2), 59.9 (CH2), 53.7 (CH2O), 51.6 (CH2O), 48.9 (CH2), 48.3 (CH2O), 44.1 (CH2NBn), 
43.8 (CH2NBn), 42.9 (CH2NBn), 42.2 (CH2NBn), 39.1 (CH2NH), 39.0 (CH2NH), 38.9 (CH2NH), 37.5 
(CH2CO), 36.6 (CH2CO), 36.0 (CH2CO), 35.2 (CH2CO), 34.5 (CH2CO), 34.0 (CH2CO), 33.8 (CH2CO), 
33.3 (CH2CO), 32.5 (CH2CO), 32.14 (CH2CO), 32.09 (CH2CO), 31.7 (CH2CO), 29.5 (CH2), 29.0 (CH2), 
28.7 (CH2), 27.92 (CH2), 27.89 (CH2), 27.85 (CH2), 27.81 (CH2), 26.4 (CH2), 25.7 (CH2), 25.5 (CH2), 
25.2 (CH2), 25.0 (CH2), 24.62 (CH2), 24.56 (CH2), 24.4 (CH2), 24.0 (CH2); HRMS (ESI): calcd. for 
C22H30N2NaO6, 441.1996. Found: [MNa]+, 441.1994 (1.0 ppm error). 
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17,21-Dibenzyl-1-oxa-4,17,21-triazacyclotetracosane-3,16,20,24-tetraone (585) 
A mixture of 5,9-dibenzyl-1,5,9-triazacyclohenicosane-2,6,10-
trione (50 mg, 0.0962 mmol), DMAP (1 mg, 9.62×10-3 mmol) and 
pyridine (46 μL, 0.577 mmol) in CH2Cl2 (1 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (0.144 mmol, 1.50 equiv. prepared 
using the general procedure) in CH2Cl2 (1 mL) was added and the resulting mixture was heated, 
at reflux, at 50 °C for 16 h. An additional solution of acid chloride (0.144 mmol, 1.50 equiv. 
prepared using the general procedure) in CH2Cl2 (1 mL) was added and heated, to reflux, at 50 
°C for a further 16 h in order to achieve reaction completion.  The solvent was then concentrated 
in vacuo, loaded onto a short silica plug and eluted with ethyl acetate, to remove the majority 
of excess carboxylic acid and pyridine residues, and concentrated in vacuo. This material was re-
dissolved in THF (1.0 mL) and placed under an argon atmosphere. Palladium on carbon (18 mg, 
Pd 10% on carbon) and water (173 µL) was then added and the reaction vessel was backfilled 
with hydrogen (via balloon) several times, then stirred at room temperature under a slight 
positive pressure of hydrogen (balloon) for 5 h. The reaction was then purged with argon, 
filtered through Celite, washed with ethyl acetate and the solvent was removed in vacuo. The 
crude material was then re-dissolved in chloroform (1.0 mL) and triethylamine (20 µL, 0.144 
mmol) added, and stirred at room temperature for 16 h, then reduced in vacuo. Purification by 
flash column chromatography (SiO2, 2:1 hexane:ethyl acetate→ethyl acetate→9:1 ethyl 
acetate:methanol) afforded the title compound (as a mixture of 2 rotamers) as a yellow oil (38 
mg, 68%). The number of rotamers was determined by number of carbonyl resonances in the 
13C NMR spectrum; Rf 0.18 (ethyl acetate); νmax/cm–1 (thin film) 3313, 2927, 2855, 1731, 1637, 
1452; δH (400 MHz, CDCl3) 7.47–6.93 (22H, m, 2 × Ph and NH, both rotamers), 4.76–4.05 (12H, 
m, CH2O and 2 × NCH2Ph, both), 3.73–3.48 (8H, m, 2 × CH2NBn, both), 3.36–3.10 (4H, m, CH2NH, 
both), 2.79–2.13 (12H, m, 3 × CH2CO, both), 1.87–0.72 (36H, m, 9 × CH2, both); δC (100 MHz, 
CDCl3) 174.7 (CO), 174.5 (CO), 172.4 (CO), 172.1 (CO), 171.9 (CO), 171.4 (CO), 171.2 (CO), 170.4 
(CO), 137.7 (C), 137.6 (C), 136.8 (C), 136.69 (C), 136.65 (C), 136.6 (C), 136.1 (C), 129.3 (CH), 129.1 
(CH), 129.0 (CH), 128.7 (CH), 128.3 (CH), 128.23 (CH), 128.19 (CH), 128.0 (CH), 127.9 (CH), 127.7 
(CH), 127.5 (CH), 126.6 (CH), 126.43 (CH), 126.37 (CH), 126.0 (CH), 73.5 (CH2O), 66.9 (CH2O), 52.6 
(CH2Ph), 52.5 (CH2Ph), 52.0 (CH2Ph), 51.3 (CH2Ph), 49.4 (NCH2CH2), 48.6 (NCH2CH2), 45.5 
(NCH2CH2), 45.3 (NCH2CH2), 44.0 (CH2NH), 42.6 (CH2NH), 39.7 (CH2CO), 39.6 (CH2CO), 39.4 
(CH2CO), 36.7 (CH2CO), 35.5 (CH2CO), 35.3 (CH2CO), 33.3 (CH2), 32.9 (CH2), 32.3 (CH2), 31.7 (CH2), 
31.2 (CH2), 28.9 (CH2), 28.7 (CH2), 28.6 (CH2), 28.3 (CH2), 28.1 (CH2), 27.8 (CH2), 27.7 (CH2), 27.64 
(CH2), 27.57 (CH2), 27.4 (CH2), 27.3 (CH2), 27.1 (CH2), 26.9 (CH2), 26.4 (CH2), 26.1 (CH2), 26.0 (CH2), 
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25.4 (CH2), 24.9 (CH2), 24.6 (CH2), 24.5 (CH2); HRMS (ESI): calcd. for C34H47N3NaO5, 600.3408. 
Found: [MNa]+, 600.3419 (0.9 ppm error). 
1,5,9-Trioxa-13-azacycloicosane-4,8,12,20-tetraone (586) 
 A mixture of 1,5-dioxa-9-azacyclohexadecane-4,8,16-trione (50 mg, 0.184 
mmol), DMAP (2 mg, 0.0184 mmol) and pyridine (90 μL, 1.10 mmol) in CH2Cl2 
(2 mL) under an argon atmosphere was stirred at room temperature for 5 
min. Next, a solution of acid chloride (0.276 mmol, 1.50 equiv. prepared using 
the general procedure) in CH2Cl2 (1 mL) was added and the resulting mixture 
was heated, at reflux, at 50 °C for 16 h. An additional solution of acid chloride 
(0.276 mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 mL) was added and 
heated, to reflux, at 50 °C for a further 16 h in order to achieve reaction completion.  The solvent 
was then concentrated in vacuo, loaded onto a short silica plug and eluted with ethyl acetate, 
to remove the majority of excess carboxylic acid and pyridine residues, and concentrated in 
vacuo. This material was re-dissolved in ethyl acetate (1.8 mL) and placed under an argon 
atmosphere. Palladium on carbon (18 mg, Pd 10% on carbon) was then added and the reaction 
vessel was backfilled with hydrogen (via balloon) several times, then stirred at room 
temperature under a slight positive pressure of hydrogen (balloon) for 3 h. The reaction was 
then purged with argon, filtered through Celite, washed with methanol and the solvent was 
removed in vacuo. The crude material was then re-dissolved in chloroform (1.8 mL) and 
triethylamine (40 µL, 0.276 mmol) added, and stirred at room temperature for 16 h, then 
reduced in vacuo. Purification by flash column chromatography (SiO2, ethyl acetate→9:1 ethyl 
acetate:methanol) afforded the title compound as a white solid (49 mg, 79%); m.p. 121–123 °C; 
Rf 0.50 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3301, 2932, 2858, 1732, 1646, 1551; 
δH (400 MHz, CDCl3) 5.86 (1H, br s, NH), 4.49–4.27 (6H, m, 3 × CH2O), 3.36–3.23 (2H, m, CH2NH), 
2.68–2.58 (4H, m, 2 × CH2COO), 2.44 (2H, t, J = 5.3 Hz, CH2CONH), 2.28 (2H, t, J = 6.9 Hz, CH2COO), 
1.61–1.53 (2H, m, CH2), 1.52–1.43 (2H, m, CH2), 1.37–1.26 (4H, m, 2 × CH2); δC (100 MHz, CDCl3) 
173.3 (CO), 170.8 (CO), 169.93 (CO), 169.91 (CO), 61.4 (CH2O), 60.0 (CH2O), 59.9 (CH2O), 39.3 
(CH2NH), 36.4 (CH2CO), 34.7 (CH2CO), 34.2 (CH2CO), 33.9 (CH2CO), 29.2 (CH2), 28.7 (CH2), 26.4 
(CH2), 25.2 (CH2); HRMS (ESI): calcd. for C16H25NNaO7, 366.1523. Found: [MNa]+, 366.1521 (1.0 
ppm error). 
Procedure for one single the synthesis of 586 from 553 with one chromatographic purification 
A mixture of azocan-2-one 4f (100 mg, 0.786 mmol), DMAP (10 mg, 0.0786 mmol) and pyridine 
(380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at room 
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temperature for 5 min. Next, a solution of acid chloride (2.36 mmol, 3.0 equiv. prepared using 
the general procedure) in CH2Cl2 (3 mL) was added and the resulting mixture was heated, at 
reflux, at 50 °C for 16 h. The mixture was then diluted with diethyl ether (30 mL) and washed 
with 10% aq. HCl (15 mL). The aqueous layer was then extracted with diethyl ether (3 × 20 mL) 
and washed with sat. aq. NaHCO3 (10 mL). The combined organic extracts dried over MgSO4 and 
concentrated in vacuo. The crude material was then re-dissolved in ethyl acetate (7.8 mL) and 
placed under an argon atmosphere. Palladium on carbon (78 mg, Pd 10% on carbon) was then 
added and the reaction vessel was backfilled with hydrogen (via balloon) several times, then 
stirred at room temperature under a slight positive pressure of hydrogen (balloon) for 4 h. The 
reaction was then purged with argon, filtered through Celite, washed with ethyl acetate and the 
solvent was removed in vacuo. The crude material was then re-dissolved in chloroform (7.8 mL) 
and triethylamine (164 µL, 1.18 mmol) added, stirred at room temperature for 16 h, and the 
solvent was removed in vacuo. The residue was dissolved in CH2Cl2 (30 mL), washed with sat. aq. 
NaHCO3 (10 mL) and brine (10 mL), dried over MgSO4 and the solvent removed in vacuo. The 
crude material was added to DMAP (10 mg, 0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in 
CH2Cl2 (5.5 mL) under an argon atmosphere was stirred at room temperature for 5 min. Next, a 
solution of acid chloride (2.36 mmol, 3.0 equiv. prepared using the general procedure) in CH2Cl2 
(3 mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. The mixture 
was then diluted with diethyl ether (30 mL) and washed with 10% aq. HCl (15 mL). The aqueous 
layer was then extracted with diethyl ether (3 × 20 mL) and washed with sat. aq. NaHCO3 (10 
mL). The combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
material was then re-dissolved in ethyl acetate (7.8 mL) and placed under an argon atmosphere. 
Palladium on carbon (78 mg, Pd 10% on carbon) was then added and the reaction vessel was 
backfilled with hydrogen (via balloon) several times, then stirred at room temperature under a 
slight positive pressure of hydrogen (balloon) for 16 h. The reaction was then purged with argon, 
filtered through Celite, washed with ethyl acetate and the solvent was removed in vacuo. The 
crude material was then re-dissolved in chloroform (7.8 mL) and triethylamine (164 µL, 1.18 
mmol) added, stirred at room temperature for 16 h, and the solvent was removed in vacuo. The 
residue was dissolved in CH2Cl2 (30 mL), washed with sat. aq. NaHCO3 (10 mL) and brine (10 mL), 
dried over MgSO4 and the solvent removed in vacuo. The crude material was added to DMAP 
(10 mg, 0.0786 mmol) and pyridine (380 μL, 4.72 mmol) in CH2Cl2 (5.5 mL) under an argon 
atmosphere was stirred at room temperature for 5 min. Next, a solution of acid chloride (2.36 
mmol, 3.0 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) was added and the 
resulting mixture was heated, at reflux, at 50 °C for 16 h. An additional solution of acid chloride 
(2.36 mmol, 3.0 equiv. prepared using the general procedure) in CH2Cl2 (3 mL) was added and 
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heated, to reflux, at 50 °C for a further 16 h in order to achieve reaction completion. The mixture 
was then diluted with CH2Cl2 (30 mL) and washed with 10% aq. HCl (15 mL). The aqueous layer 
was then extracted with CH2Cl2 (3 × 30 mL) and washed with sat. aq. NaHCO3 (10 mL). The 
combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude material was 
then re-dissolved in ethyl acetate (7.8 mL) and placed under an argon atmosphere. Palladium 
on carbon (78 mg, Pd 10% on carbon) was then added and the reaction vessel was backfilled 
with hydrogen (via balloon) several times, then stirred at room temperature under a slight 
positive pressure of hydrogen (balloon) for 16 h. The reaction was then purged with argon, 
filtered through Celite, washed with ethyl acetate and the solvent was removed in vacuo. The 
crude material was then re-dissolved in chloroform (7.8 mL) and triethylamine (164 µL, 1.18 
mmol) added, stirred at room temperature for 16 h, and concentrated in vacuo. Purification by 
flash column chromatography (SiO2, 2:1 hexane:ethyl acetate → ethyl acetate→9:1 ethyl 
acetate:methanol) afforded the title compound as a white solid (130 mg, 48%); RF 0.50 (9:1 ethyl 
acetate:methanol); δH (400 MHz, CDCl3) 5.87 (1H, br s, NH), 4.49–4.27 (6H, m, 3 × CH2O), 3.36–
3.23 (2H, m, CH2NH), 2.68–2.58 (4H, m, 2 × CH2COO), 2.44 (2H, t, J = 5.3 Hz, CH2CONH), 2.28 (2H, 
t, J = 6.9 Hz, CH2COO), 1.76–1.18 (8H, m, 4 × CH2). Data consistent with those reported above. 
1,12,16-Trioxa-4-azacyclononadecane-3,11,15,19-tetraone (587) 
 A mixture of 1,5-dioxa-9-azacyclohexadecane-4,8,16-trione (50 mg, 
0.184 mmol), DMAP (2 mg, 0.0184 mmol) and pyridine (90 μL, 1.10 
mmol) in CH2Cl2 (2 mL) under an argon atmosphere was stirred at 
room temperature for 5 min. Next, a solution of acid chloride (0.276 
mmol, 1.50 equiv. prepared using the general procedure) in CH2Cl2 (1 
mL) was added and the resulting mixture was heated, at reflux, at 50 °C for 16 h. An additional 
solution of acid chloride (0.276 mmol, 1.50 equiv. prepared using the general procedure) in 
CH2Cl2 (1 mL) was added and heated, to reflux, at 50 °C for a further 16 h in order to achieve 
reaction completion.  The solvent was then concentrated in vacuo, loaded onto a short silica 
plug and eluted with ethyl acetate, to remove the majority of excess carboxylic acid and pyridine 
residues, and concentrated in vacuo. This material was re-dissolved in THF (1.8 mL) and placed 
under an argon atmosphere. Palladium on carbon (18 mg, Pd 10% on carbon) and water (330 
µL, 18.4 mmol) was then added and the reaction vessel was backfilled with hydrogen (via 
balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 4 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol and the solvent was removed in vacuo. The crude material was then re-
dissolved in chloroform (1.8 mL) and triethylamine (40 µL, 0.276 mmol) added, and stirred at 
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room temperature for 16 h, then reduced in vacuo. Purification by flash column chromatography 
(SiO2, 2:1 hexane:ethyl acetate→ethyl acetate) afforded the title compound as a colourless oil 
(51 mg, 84%); Rf 0.60 (9:1 ethyl acetate:methanol); νmax/cm–1 (thin film) 3385, 2935, 2860, 1732, 
1667, 1543; δH (400 MHz, CDCl3) 6.61 (1H, br s, NH), 4.59 (2H, s,OCH2CO), 4.48 (2H, t, J = 5.3 Hz, 
CH2O), 4.32 (2H, t, J = 5.3 Hz, CH2O), 3.36–3.27 (2H, m, CH2NH), 2.72 (2H, t, J = 5.3 Hz, CH2CH2O), 
2.61 (2H, t, J = 5.3 Hz, CH2CH2O), 2.29 (2H, t, J = 6.1 Hz, CH2COO), 1.66–1.57 (2H, m, CH2), 1.56–
1.48 (2H, m, CH2), 1.36–1.25 (4H, m, 2 × CH2); δC (100 MHz, CDCl3) 173.5 (CO), 171.3 (CO), 169.4 
(CO), 167.0 (CO), 63.5 (CH2O), 60.3 (CH2O), 59.6 (CH2O), 38.2 (CH2NH), 34.9 (CH2CO), 34.2 
(CH2CO), 33.8 (CH2CO), 28.3 (CH2), 27.3 (CH2), 25.2 (CH2), 24.5 (CH2); HRMS (ESI): calcd. for 
C15H23NNaO7, 352.1367. Found: [MNa]+, 352.1363 (0.7 ppm error). 
1,7,11,15-Tetraoxa-4-azacyclooctadecane-3,10,14,18-tetraone (588) 
 A mixture of 1,8,12-trioxa-4-azacyclopentadecane-5,9,13-trione (35 mg, 
0.133 mmol), DMAP (2 mg, 0.0133 mmol) and pyridine (0.064 mL, 0.79 
mmol) in CH2Cl2 (1.0 mL) under an argon atmosphere was stirred at room 
temperature for 30 min. A solution of acid chloride (0.199 mmol, 1.5 equiv. 
prepared using the general procedure) in CH2Cl2 (1.0 mL) was then added 
and the resulting mixture was heated, at reflux, at 50 °C for 16 h. A further 
three portions of acid chloride (0.131 mmol, 1.5 equiv. prepared using the general procedure) 
in CH2Cl2 (0.5 mL) were added at 48 h, 72 h and 96 h. The solvent was concentrated in vacuo, 
loaded onto a short silica plug and eluted with 3:2 hexane:ethyl acetate →1:4 hexane:ethyl 
acetate to remove the excess carboxylic acid and pyridine. 12 mg of starting material was 
recovered. The acylated product was concentrated in vacuo, re-dissolved in THF (1.5 mL) and 
placed under an argon atmosphere. Palladium on carbon (13 mg, Pd 10% on carbon) and water 
(0.24 mL, 13.3 mmol) was added and the reaction vessel was backfilled with hydrogen (via 
balloon) several times. The reaction was stirred at room temperature under a slight positive 
pressure of hydrogen (balloon) for 18 h. The reaction was then purged with argon, filtered 
through Celite, washed with methanol and the solvent was removed in vacuo. The crude 
material was re-dissolved in chloroform (1.5 mL) and triethylamine (29 µL, 0.21 mmol) and 
stirred at room temperature for 18 h, then concentrate in vacuo.  Purification by flash column 
chromatography (SiO2, ethyl acetate → 9:1 ethyl acetate:methanol) afforded the title compound 
as a colourless oil (15 mg, 36% or 54% brsm); Rf  0.55 (4:1 ethyl acetate:methanol); νmax (thin 
film)/cm−1 3382, 2926, 1736, 1677, 1542; δH (400 MHz, CDCl3) 6.93 (1H, br s, NH), 4.66 (2H, s, 
CH2-CO-NH), 4.49 (2H, t, J = 5.3 Hz, COO-CH2-CH2-COO), 4.41 (2H, t, J = 5.5 Hz, OCH2-CH2-COO-
CH2), 3.72 (2H, t, J = 5.3 Hz, OCH2-CH2-COO), 3.56−3.54 (2H, m, OCH2-CH2-NH), 3.50−3.46 (2H, m, 
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CH2-NH), 2.73 (2H, t, J = 5.3 Hz, CH2-COO-CH2-CO-NH), 2.60 (2H, t, J = 5.3 Hz, CH2-COO-CH2-CH2-
COO), 2.53 (2H, t, J = 5.3 Hz, OCH2-CH2-COO); δC (100 MHz, CDCl3) 172.0 (OCH2-CH2-COO), 171.0 
(COO-CH2-CH2-COO), 169.6 (COO-CH2-CO-NH), 167.2 (CO-NH), 69.2 (OCH2-CH2-NH), 66.4 (OCH2-
CH2-COO), 63.5 (CH2-CO-NH), 60.2 (OCH2-CH2-COO-CH2), 60.0 (COO-CH2-CH2), 39.3 (CH2-NH), 
35.1 (OCH2-CH2-COO), 35.0 (CH2-COO-CH2-CH2-COO), 34.6 (CH2-COO-CH2-CO-NH); HRMS (ESI+): 
calcd. for C13H19NNaO8, 340.1003. Found: [MNa+], 340.1007 (−1.2 ppm error). 
Methyl 2-(2-bromophenyl)acetate (603) 
To a stirring solution of 2-(2-bromophenyl)acetic acid (13.2 g, 61.6 mmol) 
in methanol (130 mL) was added concentrated sulfuric acid (2.50 mL) and 
the resulting solution was stirred at 70 °C for 18 h. After cooling to room temperature, the 
reaction was quenched with water (50 mL) and extracted with diethyl ether (3 × 100 mL). The 
combined organic extracts were washed with brine (30 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to afford the title compound as a clear oil (13.4 g, 95%); δH 
(400 MHz, CDCl3) 7.56 (1H, d, J = 8.4 Hz, ArH), 7.28−7.26 (2H, m, ArH), 7.16–7.12 (1H, m, ArH), 
3.79 (2H, s, CH2), 3.71 (3H, s, CH3). Data is consistent with those reported in the literature.155  
Methyl 2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (631) 
To a stirring solution of methyl 2-(2-bromophenyl)acetate (12.5 g, 55.0 
mmol) in 1,4-dioxane (200 mL), was added bis(pinacalato)diboron (15.3 g, 
60.6 mmol), potassium acetate (19.9 g, 203.7 mmol) and PdCl2(dppf).CH2Cl2 
(2.25 g, 3.53 mmol). The reaction mixture was purged with argon and 
heated at 80 °C for 4 h. The reaction mixture was then diluted with ethyl acetate, passed through 
Celite and concentrated in vacuo. Purification via flash column chromatography (SiO2, CH2Cl2 → 
1:9 ethyl acetate:CH2Cl2) afforded the title compound as a white solid (8.20 g, 54%); δH (400 MHz, 
CDCl3) 7.83 (dd, J = 7.6, 1.5 Hz, 1H, ArH), 7.40−7.36 (m, 1H, ArH), 7.28−7.24 (m, 1H, ArH), 7.18 
(d, J = 7.6 Hz, 1H, ArH), 3.97 (s, 2H, CH2), 3.66 (s, 3H, OCH3), 1.31 (s, 12H, 4 × CH3). Data is 
consistent with those reported in the literature.156 
4-Methyl-4,5-dihydro-6,10-(azeno)benzo[d][1]oxacyclododecin-2(1H)-one (606) 
 To a stirring solution of 2-(2-(6-(2-hydroxypropyl)pyridin-2-
yl)phenyl)acetic acid (44.0 mg, 0.163 mmol) in chloroform (3 mL), was 
added diisopropylethylamine (50.0 μL, 0.302 mmol), followed by the 
addition of T3P (78.0 mg, 0.284 mmol, 156 mg of a 50% solution in ethyl 
acetate). Upon the addition of T3P, the solution rapidly changed from a colourless to an orange 
solution. After stirring for 30 min at room temperature, the solution was concentrated in vacuo. 
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Purification via flash column chromatography (SiO2, 1:1 ethyl acetate:hexane) afforded the title 
compound as a pale yellow solid (37 mg, 90%); RF  0.45 (3:7 ethyl acetate:hexane); m.p. 110−114 
°C;  νmax/cm-1 (thin film) 3063, 2973, 2928, 1720, 1586, 1575, 1450, 1422; δH (400 MHz, CDCl3) 
7.80–7.78 (1H, m, ArH), 7.69 (1H, t, J = 7.6 Hz, ArH), 7.54 (1H, d, J = 7.6 Hz, ArH), 7.43–7.40 (3H, 
m, ArH), 7.04 (1H, dd, J = 7.6, 0.5 Hz, ArH), 5.64–5.55 (1H, m, OCH), 3.65 (1H, d, J = 14.5 Hz, 
CHHCO), 3.54 (1H, d, J = 14.5 Hz, CHHCO), 3.12–3.00 (2H, m, NCCH2), 1.50 (3H, d, J = 6.4 Hz, CH3); 
δC (100 MHz, CDCl3) 174.3 (CO), 155.6 (ArC), 154.9 (ArC), 137.2 (ArC), 135.1 (ArC), 133.9 (ArC), 
129.2 (ArC), 127.9 (ArC), 127.7 (ArC), 121.0 (ArC), 118.4 (ArC), 70.4 (OCH), 44.4 (CO-CH2), 40.4 
(NCCH2), 21.4 (CH3); HRMS (ESI): calcd. for C16H16NO2 254.1176. Found: [MH]+, 254.1173 (1.0 
ppm error). 
1-(6-Bromopyridin-2-yl)-2-phenylpropan-2-ol (610) 
 Phenyl magnesium bromide (3.0 m in diethyl ether, 2.34 mL, 7.07 mmol) 
was added dropwise to a solution of 1-(6-bromopyridin-2-yl)propan-2-
one (504 mg, 2.36 mmol) in THF (5.0 mL) at 0 °C. The reaction mixture 
was slowly warmed to room temperature and stirred for 3 h. Another portion of phenyl 
magnesium bromide (3.0 m in diethyl ether, 2.34 mL, 7.07 mmol) was added and the reaction 
was stirred for further 3 h. The reaction was quenched with saturated aq. NH4Cl (10 mL) and the 
aqueous layer was extracted with ethyl acetate (3 × 30 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated to afford the title compound as a pale-yellow oil 
(148 mg, 21%), together with (193 mg, 38%) of the starting material recovered. Rf 0.70 (1:1 ethyl 
acetate:hexane); νmax/cm-1 (thin film) 3348, 3060, 2974, 1585, 1554, 1493, 1473, 1436, 1406, 
1371, 1276, 1224, 1163, 1119, 1092, 1066, 1028; δH (400 MHz, CDCl3) 7.43−7.40 (2H, m, ArH), 
7.34 (1H, t, J = 7.6 Hz, ArH), 7.27−7.24 (3H, m, ArH), 7.16−7.13 (1H, m, ArH), 6.89 (1H, d, J = 6.9 
Hz, ArH), 5.39 (1H, s, OH), 3.25 (1H, d, J = 14.5 Hz, NCCHH), 3.20 (1H, d, J = 14.5 Hz, NCCHH), 1.56 
(3H, s, CH3); δC (100 MHz, CDCl3) 160.4 (ArC), 147.5 (ArC), 140.6 (ArC), 138.8 (ArC), 127.8 (ArC), 
126.4 (ArC), 125.9 (ArC), 124.8 (ArC), 123.2 (ArC), 74.5 (COH), 49.2 (NCCH2), 30.5 (CH3); HRMS 
(ESI): calcd. for C14H1479BrNNaO 314.0151. Found: [MNa]+, 314.0146 (1.7 ppm error). 
Methyl 2-(2-(6-(2-hydroxy-2-phenylpropyl)pyridin-2-yl)phenyl)acetate (611) 
 To a microwave vial, methyl 2-(2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetate (218 mg, 0.790 mmol), potassium 
triphosphate (251 mg, 1.10 mmol) and Pd(PPh3)4 (45.5 mg, 0.0394 
mmol) was added and the vial was purged with argon. 
Dimethylformamide (3 mL) and 1-(6-bromopyridin-2yl)-2-phenylpropan-2-ol (121 mg, 0.394 
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mmol) were added, and the solution was heated and stirred for 90 min at 150 °C in a microwave 
reactor. The solution was then cooled, diluted with ethyl acetate and passed through Celite®. 
The solvent was then evaporated in vacuo. Water (10 mL), followed by ethyl acetate (30 mL) 
were added and both layers were separated. The aqueous layers were extracted with ethyl 
acetate (3 × 30 mL). The combined organic layers were dried with anhydrous MgSO4, filtered, 
and concentrated in vacuo. Purification via flash column chromatography (SiO2, 1:4 → 1:3 ethyl 
acetate:hexane) afforded the title compound as a yellow oil (56.5 mg, 44%); RF 0.58 (3:2 
hexane:ethyl acetate); νmax/cm-1 (thin film) 3417, 3029, 2951, 1733, 1582, 1571, 1454, 1435, 
1340, 1305, 1264, 1210, 1155; δH (400 MHz, CDCl3) 7.57 (1H, t, J = 7.8 Hz, ArH), 7.45−7.43 (2H, 
m, ArH), 7.38−7.34 (5H, m, ArH), 7.27−7.23 (3H, m, ArH), 7.16−7.12 (1H, m, ArH), 6.91 (1H, d, J = 
7.8 Hz, ArH), 6.20 (1H, br s, OH), 3.73 (1H, d, J = 16.5 Hz, CHH-COO), 3.65 (1H, d, J = 16.5 Hz, CHH-
COO), 3.60 (3H, s, OCH3), 3.33 (1H, d, J = 14.2 Hz, NCCHH), 3.27 (1H, d, J = 14.2 Hz, NCCHH), 1.56 
(3H s, CH3); δC (100 MHz, CDCl3) 172.4 (CO), 158.7 (ArC), 158.2 (ArC), 148.3 (ArC), 140.3 (ArC), 
137.3 (ArC), 132.3 (ArC), 131.3 (ArC), 130.0 (ArC), 128.8 (ArC), 128.0 (ArC), 127.5 (ArC), 126.3 
(ArC), 125.0 (ArC), 122.8 (ArC), 122.1 (ArC), 74.6 (COH), 52.1 (CH2COO), 49.4 (NCCH2), 39.1 
(OCH3), 30.9 (CH3); HRMS (ESI): calcd. for C23H24NO3 362.1751. Found: [MH]+, 362.1750 (0.2 ppm 
error). 
2-(2-(6-(2-Hydroxy-2-phenylpropyl)pyridin-2-yl)phenyl)acetic acid (612) 
 To methyl 2-(2-(6-(2-hydroxy-2-phenylpropyl)pyridin-2-
yl)phenyl)acetate (56.5 mg, 0.156 mmol), was added 0.5 m aqueous 
LiOH (0.4 mL) and THF (0.4 mL) and the resulting solution was stirred 
for 16 h. The resulting solution was then removed in vacuo to afford 
the crude compound. Purification via flash column chromatography (SiO2, 100% ethyl acetate 
→ 4:1 ethyl acetate:methanol) afforded the title compound as a colourless oil (54.2 mg, 100%); 
Rf 0.45 (95:5 ethyl acetate:methanol); νmax/cm-1 (thin film) 3385, 3059, 2976, 2931, 1713, 1598, 
1578, 1493, 1447, 1372, 1298, 1263, 1222, 1144, 1120, 1102, 1027, 1016; δH (400 MHz, CDCl3) 
7.77 (1H, t, J = 7.9 Hz, ArH), 7.48−7.33 (7H, m, ArH), 7.28−7.17 (4H, m, ArH), 3.49 (1H, d, J = 12.2 
Hz, CHH-COO), 3.39 (1H, d, J = 13.7 Hz, NC-CHH), 3.31 (1H, d, J = 13.7 Hz, NC-CHH), 3.27 (1H, d, 
J = 12.2 Hz, CHH-COO), 1.67 (3H, s, CH3); δC (100 MHz, CDCl3) 173.2 (CO), 156.3 (ArC), 155.9 (ArC), 
146.2 (ArC), 138.6 (ArC), 137.2 (ArC), 133.1 (ArC), 132.1 (ArC), 131.5 (ArC), 130.6 (ArC), 129.8 
(ArC), 128.5 (ArC), 128.2 (ArC), 127.7 (ArC), 126.9 (ArC), 124.9 (ArC), 124.8 (ArC), 122.8 (ArC), 
74.7 (C-OH), 50.2 (NC-CH2), 41.8 (CH2-COO), 30.2 (CH3); HRMS (ESI): calcd. for C22H22NO3 
348.1594. Found: [MH]+, 348.1589. 
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1-(6-Bromopyridin-2-yl)propan-2-one (600) 
 To a stirring solution of N,N-diisopropylamine (11.0 mL, 78.6 mmol) in dry 
THF (200 mL), was added n-butyllithium (32.7 mL, 78.6 mmol, 2.4 m 
solution in hexanes) dropwise at −10 °C. The resulting solution was stirred at 0 °C for 30 min, 
after which the solution was cooled to −78 °C. 6-Bromo-2-methylpyridine (4.44 mL, 39.3 mmol) 
was then added dropwise and the solution was stirred for 1 h. N-Methoxy-N-methylacetamide 
(8.73 mL, 78.6 mmol) was then added and the solution was stirred for a further 2 h. After 
allowing to warm to room temperature, the solution was quenched with water (150 mL), 
extracted with diethyl ether (3 × 150 mL) and the organic layer was washed with brine (300 mL). 
The organic layer was dried (MgSO4), filtered and solvent removed in vacuo to yield the crude 
product. Purification via flash column chromatography (SiO2, 7:3 → 3:2 hexane:ethyl acetate) 
afforded the title compound as a yellow oil (7.00 g, 83%); Rf  0.50 (3:7 ethyl acetate:hexane); 
νmax/cm-1 (thin film) 2976, 1716, 1579, 1554, 1406; δH (400 MHz, CDCl3) 7.51 (1H, t, J = 7.8 Hz, 
ArH) 7.38 (1H, d, J = 7.8 Hz, ArH), 7.17 (1H, d, J = 7.8 Hz, ArH), 3.90 (2H, s, CH2), 2.24 (3H, s, CH3); 
δC (100  MHz, CDCl3) 204.0 (CO), 155.6 (ArC), 141.7 (ArC), 139.0 (ArC), 126.5 (ArC), 123.3 (ArC), 
52.5 (CH2), 30.3 (CH3); HRMS (ESI): calcd. for C8H979BrNO 213.9858. Found: [MH]+, 213.9862 (1.7 
ppm error). 
1-(6-Bromopyridin-2-yl)-2,3,3-trimethylbutan-2-ol (616) 
N,N-Diisopropylamine (734 µL, 5.25 mmol) was dissolved in THF (12 mL) 
and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 3.28 mL, 5.25 
mmol) was added dropwise and stirred for 30 min. The LDA solution was 
then cooled to −78 °C, where 2-bromo-6-methylpyridine (296 µL, 2.63 mmol) was added 
dropwise and stirred for 30 min. Pinacolone (665 µL, 5.25 mmol) was added and stirred for a 
further 30 min at −78 °C before slowly warming to RT. The solution was then quenched with sat. 
NH4Cl(aq) (15 mL) and extracted with ethyl acetate (3 × 50 mL) and washed with brine (10 mL). 
The combined organic extracts were dried over MgSO4, filtered and removed in vacuo. 
Purification by flash column chromatography (SiO2, 50% ethyl acetate in hexane) afforded the 
title compound as a yellow oil (724 mg, 100%); RF 0.55 (50% ethyl acetate in hexane); νmax/cm–1 
(thin film) 3432, 2958, 2874, 1584, 1552; δH (400 MHz, CDCl3) 7.47 (1H, t, J = 7.8 Hz, CH), 7.34 
(1H, d, J = 7.8 Hz, CH), 7.13 (1H, d, J = 7.8 Hz, CH), 4.43 (1H, br s, OH), 3.05 (1H, d, J = 13.7 Hz, 
CHH′COH), 2.76 (1H, d, J = 13.7 Hz, CHH′COH), 1.01 (9H, s, 3 × CH3), 0.97 (3H, s, CH3); δC (100 
MHz, CDCl3) 162.3 (CN), 140.9 (CN), 138.9 (CH), 125.8 (CH), 123.8 (CH), 76.4 (COH), 42.5 
(CH2COH), 38.1 (C(CH3)3), 25.5 (3 × CH3), 22.0 (CH3); HRMS (ESI): calcd. for C12H1979BrNO, 
272.0645. Found: [MH]+, 272.0642 (0.9 ppm error). 
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Key to intermediates used to make lactone 618 
*Synthesis of S1 and S2 was completed by Dr. Aggie Lawer 
2-(2-(6-(2-Hydroxy-2-methylpent-4-en-1-yl)pyridin-2-yl)phenyl)acetic acid (617) 
 Zinc (34.1 mg, 0.521 mmol) and allyl bromide (63.0 mg, 0.521 
mmol) were added to methyl 2-(2-(6-(2-oxopropyl)pyridin-2-
yl)phenyl)acetate (49.2 mg, 0.174 mmol) in THF (1.0 mL). The 
mixture was stirred at room temperature for 30 min. Excess 
saturated aq. solution of ammonium chloride was added slowly at 0 °C. It was warmed to room 
temperature and stirred for 1 h. The mixture was extracted with ethyl acetate (3 × 10 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated. Purification via flash 
column chromatography (SiO2, 1:4 → 1:1 ethyl acetate:hexane) afforded the title compound as 
a yellow oil (22.0 mg, 39%). To methyl 2-(2-(6-(2-hydroxy-2-methylpent-4-en-1-yl)pyridin-2-
yl)phenyl)acetate (38.9 mg, 0.119 mmol), was added 0.5 M aqueous LiOH (0.28 mL) and THF 
(0.28 mL) and the resulting solution was stirred for 18 h. The resulting solution was then 
removed in vacuo to afford the crude title compound as a colourless oil (37.1 mg, 100%); RF 0.72 
(4:1 ethyl acetate:methanol); νmax/cm-1 (thin film) 3292, 3072, 2974, 2926, 1590, 1444, 1396, 
1307, 1162, 1121, 1000; δH (400 MHz, CDCl3) 7.63 (1H, t, J = 7.6 Hz, ArH), 7.30–7.13 (5H, m, ArH), 
7.02 (1H, d, J = 8.4 Hz, ArH), 5.80 (1H, m, CH=CH2), 4.97 (2H, m, CH=CH2), 3.21 (2H, s, CH2COO), 
2.80 (1H, d, J = 14.5 Hz, NCCHH), 2.82 (1H, d, J = 14.5 Hz, NCCHH), 2.15 (2H, br m, CH2CH), 1.03 
(3H, br s, CH3COH); δC (100 MHz, CDCl3) 178.7 (COO), 159.8 (ArC), 158.6 (ArC), 139.8 (ArC), 137.6 
(ArC), 136.2 (ArC), 134.6 (CH=CH2), 130.5 (ArC), 129.8 (ArC), 128.4 (ArC), 125.9 (ArC), 123.5 (ArC), 
Chapter Seven: Experimental 
 
220 | P a g e  
 
122.9 (ArC), 117.8 (CH=CH2), 72.1 (COH), 47.1 (NCCH2 or CH2CH), 46.9 (NCCH2 or CH2CH), 42.3 
(CH2COO), 26.9 (CH3COH); HRMS (ESI): calcd. for C19H21NNaO3 334.1414 found: [MNa]+, 
334.1419.  
4-Allyl-4-methyl-4,5-dihydro-6,10-(azeno)benzo[d][1]oxacyclododecin-2(1H)-one (618) 
 To a stirring solution of 2-(2-(6-(2-hydroxy-2-methylpent-4-en-1-
yl)pyridin-2-yl)phenyl)acetic acid (37.1 mg, 0.119 mmol) in 
chloroform (2.1 mL), was added diisopropylethylamine (38.0 μL, 
0.220 mmol), followed by the addition of T3P (50% solution in ethyl 
acetate, 0.106 mL, 0.179 mmol). After stirring for 30 min at room temperature, the solution was 
taken directly to purification with no work-up. Purification via flash column chromatography 
(SiO2, 3:7 ethyl acetate:hexane) afforded an inseparable mixture of diastereoisomers of the title 
compound as an orange oil (34.9 mg, 100%, d.r. 1.1:1); RF  0.43 (7:3 hexane:ethyl acetate); 
νmax/cm-1 (thin film) 3070, 2976, 2929, 1722, 1586, 1578, 1451; δH (400 MHz, CDCl3) 7.75−7.70 
(2H, m, ArH), 7.62−7.58 (2H, m, ArH), 7.49−7.46 (2H, m, ArH), 7.40−7.33 (6H, m, ArH), 7.11 (1H, 
d, J = 7.6 Hz, ArH), 7.07 (1H, d, J = 7.6 Hz, ArH), 6.00−5.89 (1H, m, CH=CH2), 5.86−5.76 (1H, m, 
CH=CH2), 5.21–5.11 (4H, m, 2 × CH=CH2), 3.59 (1H, d, J = 12.9 Hz, NCCHH), 3.50−3.44 (3H, m, 
CH2CO and NCCHH), 3.40 (1H, dd, J = 13.7, 6.5 Hz, CHH-CH=CH2), 3.34 (1H, d, J = 14.5 Hz, CHHCO), 
3.28 (1H, d, J = 14.5 Hz, CHHCO), 2.90 (1H, d, J = 13.7 Hz, NCCHH), 2.79 (1H, d, J = 12.9 Hz, 
NCCHH), 2.75 (1H, dd, J = 13.7, 8.2 Hz, CHH-CH=CH2), 2.29 (1H, dd, J = 13.7, 6.5 Hz, CHH-CH=CH2), 
2.13 (1H, dd, J = 13.7, 8.2 Hz, CHH-CH=CH2), 1.83 (3H, s, CH3), 1.15 (3H, s, CH3); δC (100 MHz, 
CDCl3) 171.4 (CO), 171.2 (CO), 155.8 (ArC), 155.6 (ArC), 154.9 (ArC), 154.8 (ArC), 139.8 (ArC), 
139.4 (ArC), 137.7 (ArC), 137.6 (ArC), 135.3 (ArC), 133.8 (CH=CH2), 133.7 (CH=CH2), 133.5 (ArC), 
133.4 (ArC), 129.0 (ArC), 127.8 (ArC), 127.4 (ArC), 121.5 (ArC), 121.3 (ArC), 118.8 (CH=CH2),  
118.4 (CH=CH2), 118.2 (ArC),  118.1 (ArC),  83.4 (CCH3), 83.3 (CCH3), 46.3 (CH2-CH=CH2), 45.4 
(CH2-CH=CH2), 45.1 (CH2CO), 44.9 (CH2CO), 42.5 (NCCH2), 41.2 (NCCH2), 25.9 (CH3), 25.8 (CH3); 
HRMS (ESI): calcd. for C19H20NO2 294.1491 found: [MH]+, 294.1489. 
4-Methyl-4-phenyl-4,5-dihydro-6,10-(azeno)benzo[d][1]oxacyclododecin-2(1H)-one (619) 
 To a stirring solution of 2-(2-(6-(2-hydroxy-2-phenylpropyl)pyridin-2-
yl)phenyl)acetic acid (58.5 mg, 0.168 mmol) in chloroform (3 mL), was 
added diisopropylethylamine (54.1 μL, 0.312 mmol), followed by the 
addition of T3P (50% solution in ethyl acetate, 0.150 mL, 0.253 mmol). 
After stirring for 30 min at room temperature, the solution was taken directly to purification 
with no work-up. Purification via flash column chromatography (SiO2, 1:4 → 3:7 ethyl 
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acetate:hexane) afforded an inseparable mixture of the title compound as a colourless oil (40.7 
mg, 74%, d.r. 3:2); Rf 0.70 (3:7 ethyl acetate:hexane); νmax/cm-1 (thin film) 3061, 2976, 2244, 
1728. 1579, 1451, 1494, 1422, 1372, 1296, 1205, 1086, 1074, 1063, 1029, 1003; δH (400 MHz, 
CDCl3) 7.80 (1H, t, J = 7.6 Hz, ArH), 7.64−7.20 (22H, m, ArH), 6.60 (1H, d, J = 7.6 Hz, ArH), 4.11 
(1H, d, J = 12.2 Hz, NC-CHH), 3.94 (1H, d, J = 12.9 Hz, NC-CHH), 3.62 (1H, d, J = 14.5 Hz, CHH-
COO), 3.54 (1H, d, J = 14.5 Hz, CHH-COO), 3.53 (1H, d, J = 14.5 Hz, CHH-COO), 3.43 (1H, d, J = 
14.5 Hz, CHH-COO), 3.35 (1H, d, J = 12.2 Hz, NC-CHH), 3.15 (1H, d, J = 12.9 Hz, NC-CHH), 2.24 
(3H, s, CH3), 1.41 (3H, s, CH3); δC (100 MHz, CDCl3) 170.9 (CO), 169.5  (CO), 155.7 (ArC), 155.5 
(ArC), 154.9 (ArC), 154.4 (ArC), 146.9 (ArC), 146.1 (ArC), 139.9 (ArC), 139.6 (ArC), 137.9 (ArC), 
137.5 (ArC), 135.3 (ArC), 135.2 (ArC), 134.1 (ArC), 133.9 (ArC), 129.2 (ArC), 129.1 (ArC), 128.3 
(ArC), 128.2 (ArC), 127.9 (ArC), 127.6 (ArC), 127.5 (ArC), 127.1 (ArC), 126.9 (ArC), 124.6 (ArC), 
124.2 (ArC), 121.7 (ArC), 121.5 (ArC), 118.4 (ArC), 84.9 (C-Ph), 82.3 (C-Ph), 45.3 (CH2-COO), 44.7 
(NC-CH2), 44.6 (CH2-COO), 40.3 (NC-CH2), 32.1 (CH3), 28.5 (CH3); HRMS (ESI): calcd. for C22H20NO2 
330.1489 found: [MH]+, 330.1484. 
Key to intermediates used to make lactone 621 
*Synthesis of S3 was completed by Dr. Aggie Lawer 
2-(2-(6-(2-Hydroxy-2,3,3-trimethylbutyl)pyridin-2-yl)phenyl)acetic acid (620) 
 To methyl 2-(2-(6-(2-hydroxy-2,3,3-trimethylbutyl)pyridin-2-
yl)phenyl)acetate (87.9 mg, 0.257 mmol), 0.5 M aqueous LiOH (0.6 
mL) and THF (0.6 mL) were added and the resulting solution was 
stirred for 16 h. The resulting solution was then removed in vacuo. 
Purification by column chromatography (SiO2, 4:1 ethyl acetate:methanol) afforded the title 
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compound as a white solid (66.0 mg, 78%); Rf 0.67 (3:7 ethyl acetate:methanol); m.p. 138−141 
°C; νmax/cm-1 (thin film) 3422, 2969, 1718, 1598, 1577, 1374, 1301, 1262, 1014;  δH (400 MHz, 
CDCl3) 7.88−7.84 (1H, m, ArH), 7.50−7.34 (6H, m, ArH), 3.70−3.60 (2H, m, CH2CO), 3.16 (1H, d, J 
= 12.9 Hz, NCCHH), 2.99 (1H, d, J = 12.9 Hz, NCCHH), 1.03 (9H, s, (CH3)3), 0.99 (3H, s, CH3); δC (100 
MHz, CDCl3) 173.0 (CO), 157.9 (ArC), 156.6 (ArC), 138.6 (ArC), 137.5 (ArC), 133.1 (ArC), 131.5 
(ArC), 130.6 (ArC), 129.7 (ArC), 127.7 (ArC), 125.3 (ArC), 122.6 (ArC), 76.9 (COH), 42.3 (NCCH2), 
41.9 (CH2CO), 38.3 (C(CH3)3), 25.3 ((CH3)3), 21.1 (CH3); HRMS (ESI): calcd. for C20H26NO3 328.1907. 
Found: [MH]+, 328.1909 (−0.4 ppm error). 
4-(tert-Butyl)-4-methyl-4,5-dihydro-6,10-(azeno)benzo[d][1]oxacyclododecin-2(1H)-one (621) 
 To 2-(2-(6-(2-hydroxy-2,3,3-trimethylbutyl)pyridin-2-yl)phenyl)acetic 
acid (66.0 mg, 0.202 mmol) in chloroform (3.4 mL), was added 
diisopropylethylamine (0.0652 mL, 0.374 mmol), followed by the 
addition of T3P (50% solution in ethyl acetate, 0.180 mL, 0.303 mmol). 
After stirring for 30 min at room temperature, the solution was taken directly to purification 
with no work-up. Purification via flash column chromatography (SiO2, 3:7 ethyl acetate:hexane) 
afforded the title compound as a colourless oil (52.5 mg, 84%), Rf 0.58 (7:3 hexane:ethyl acetate); 
νmax/cm-1 (thin film) 2960, 1721, 1578, 1451, 1396, 1371, 1325, 1294, 1224, 1208, 1134, 1088, 
1011; δH (400 MHz, CDCl3) 7.76−7.73 (1H, m, ArH), 7.70 (1H, t, J = 7.6 Hz, ArH), 7.55 (1H, d, J = 
8.4 Hz, ArH), 7.41−7.38 (3H, m, ArH), 7.09 (1H, m, ArH), 3.69 (1H, d, J =  14.5 Hz, CHHCO), 3.56 
(1H, d, J = 14.5 Hz, CHHCO), 3.30 (1H, d, J = 14.5 Hz, NCCHH), 3.09 (1H, d, J = 14.5 Hz, NCCHH), 
1.77 (3H, s, CH3), 1.02 (9H, s, (CH3)3); δC (100 MHz, CDCl3) 171.7 (CO), 156.2 (ArC), 154.6 (ArC), 
137.6 (ArC), 137.4 (ArC), 135.4 (ArC), 133.9 (ArC), 129.0 (ArC), 127.7 (ArC), 127.3 (ArC), 122.1 
(ArC), 117.8 (ArC), 89.1 (CO), 45.7 (CH2CO), 39.5 (C(CH3)3), 38.9 (NCCH2), 25.7 ((CH3)3), 21.8 (CH3); 
HRMS (ESI): calcd. for C20H24NO2 310.1802. Found: [MH]+, 310.1797 (1.6 ppm error). 
Ethyl 2-(6-bromopyridin-2-yl)acetate (624) 
N,N-Diisopropylamine (1.13 mL, 8.00 mmol) was dissolved in THF (20 
mL) and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 5.0 mL, 
8.00 mmol) was added dropwise and stirred for 30 min. The LDA solution was then cooled to 
−78 °C, where a solution of 2-bromo-6-methylpyridine (456 µL, 4.00 mmol) in THF (5.0 mL), was 
added dropwise and stirred for 30 min. Ethyl chloroformate (191 µL, 2.00 mmol) was added and 
stirred for a further 30 min at −78 °C before slowly warming to room temperature. The solution 
was then quenched with sat. NH4Cl(aq) (20 mL) and extracted with ethyl acetate (3 × 50 mL) and 
washed with brine (10 mL). The combined organic extracts were dried over MgSO4, filtered and 
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removed in vacuo. Purification by flash column chromatography (SiO2, 33% → 50% diethyl ether 
in hexanes) afforded the title compound (as a 10:1 mixture of ester:enol tautomers) as a yellow 
oil (419 mg, 86%); RF 0.71 (ethyl acetate); δH (400 MHz, CDCl3) data for the ester tautomer only: 
7.51 (1H, t, J = 7.6 Hz, CH), 7.38 (1H, d, J = 7.6 Hz, CH), 7.26 (1H, d, J = 7.6 Hz, CH), 4.16 (2H, q, J 
= 6.9 Hz, OCH2CH3), 3.80 (2H, s, CH2CO2Et), 1.24 (3H, t, J = 6.9 Hz, CH2CH3). Data is consistent 
with those previously reported in the literature.157 
2-(6-bromopyridin-2-yl)ethan-1-ol (622) 
 Ethyl 2-(6-bromopyridin-2-yl)acetate (187 mg, 0.766 mmol) was 
dissolved in anhydrous THF (7.6 mL) and cooled to 0 °C. A solution of 
DIBAL-H (1.0 m, 1.69 mL, 1.69 mmol) was added and stirred at 0 °C for 2 h, where the solution 
was slowly warmed to room temperature. Upon completion, the reaction was quenched with 
Rochelle’s salt (10 ml) at 0 °C for 10 min, followed by water (10 mL) and extracted with ethyl 
acetate (3 × 50 mL). The combined organic extracts were dried over MgSO4, filtered and the 
solvent removed in vacuo. Purification by flash column chromatography (SiO2, 50% diethyl ether 
in hexanes → diethyl ether) afforded the title compound as a colourless oil (127 mg, 82%); RF 
0.50 (ethyl acetate); δH (400 MHz, CDCl3) 7.45 (1H, t, J = 7.6 Hz, CH), 7.31 (1H, d, J = 7.6 Hz, CH), 
7.12 (1H, d, J = 7.6 Hz, CH), 4.02–3.93 (2H, m, CH2OH), 3.25 (1H, br s, OH), 2.97 (2H, t, J = 6.1 Hz, 
CH2CH2OH). Data is consistent with those previously reported in the literature.158    
Methyl 2-(2-bromophenyl)propanoate (625) 
 Methyl 2-(2-bromophenyl)acetate (1.00 g, 4.37 mmol) was dissolved in 
anhydrous THF (14.6 mL) and cooled to 0 °C, where NaHMDS solution (1.0 
m in THF, 4.80 mL, 4.80 mmol) was added slowly. The resulting solution was 
stirred at 0 °C for 30 min where methyl iodide (272 µL, 4.37 mmol) was added and the solution 
allowed to warm to room temperature over 2 h. Upon completion, the reaction was quenched 
with 10% HCl(aq) (15 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic 
extracts were dried over MgSO4, filtered and the solvent was removed in vacuo. Purification by 
flash column chromatography (SiO2, 50% diethyl ether in hexanes) afforded the title compound 
as a yellow oil (0.976 g, 92%); RF 0.60 (50% ethyl acetate in hexanes); δH (400 MHz, CDCl3) 7.55 
(1H, d, J = 8.4 Hz, CH), 7.31–7.27 (2H, m, 2 × CH), 7.14–7.08 (1H, m, CH), 4.22 (1H, q, J = 6.9 Hz, 
CHCH3), 3.68 (3H, s, CO2CH3), 1.48 (3H, d, J = 6.9 Hz, CHCH3). Data is consistent with those 
previously reported in the literature.159    
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Methyl 2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (626) 
Methyl 2-(2-bromophenyl)propanoate (760 mg, 3.13 mmol), 
bis(pinacolato)diboron (873 mg, 3.44 mmol), potassium acetate (921 mg, 
9.38 mmol) and PdCl2(dppf).CH2Cl2 (128 mg, 0.156 mmol) were dissolved in 
anhydrous 1,4-dioxane (11.0 mL) under an argon atmosphere and heated to 80 °C for 18 h. Upon 
completion, the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 50% diethyl ether in hexanes→diethyl ether) afforded the title compound as an orange oil 
(887 mg, 98%); RF 0.59 (50% ethyl acetate in hexanes); νmax/cm–1 (thin film) 2978, 1736; δH (400 
MHz, CDCl3) 7.79 (1H, dd, J = 7.6, 1.5 Hz, CH), 7.38 (1H, td, J = 7.6, 1.5 Hz, CH), 7.31–7.18 (2H, m, 
2 × CH), 4.65 (1H, q, J = 6.9 Hz, CHCH3), 3.61 (3H, s, CO2CH3), 1.45 (3H, d, J = 6.9 Hz, CHCH3), 1.24 
(12H, s, 4 × CH3); δC (100 MHz, CDCl3) 175.8 (CO2Me), 147.2 (C), 136.1 (CH), 131.2 (CH), 126.2 
(CH), 126.1 (CH), 83.6 (OCCH3), 51.8 (CO2CH3), 43.2 (CHCO2Me), 25.0 (CCH3), 19.1 (CHCH3); HRMS 
(ESI): calcd. for C16H23BNaO4, 313.1582. Found: [MNa]+, 313.1582 (0.7 ppm error). 
Methyl 2-(2-(6-(2-hydroxyethyl)pyridin-2-yl)phenyl)propanoate (627) 
2-(6-Bromopyridin-2-yl)ethan-1-ol (109 mg, 0.539 mmol), methyl 2-
(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-
oate (235 mg, 0.809 mmol), potassium phosphate (229 mg, 1.08 
mmol) and PdCl2(dppf).CH2Cl2 (22.0 mg, 26.9 µmol) was dissolved in 
THF (5.4 mL) under a nitrogen atmosphere. H2O (49.0 µL, 2.70 mmol) was added and the solution 
heated, at reflux, to 80 °C for 18 h. Upon completion, the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 50% diethyl ether in hexanes→66% diethyl 
ether in hexanes) afforded the title compound as a colourless oil (100 mg, 65%); RF 0.50 (ethyl 
acetate); νmax/cm–1 (thin film) 3405, 2950, 1732, 1588, 1571, 1446; δH (400 MHz, CDCl3) 7.71 (1H, 
t, J = 7.6 Hz, CH), 7.48–7.28 (5H, m, 5 × CH), 7.16 (1H, d, J = 7.6 Hz, CH), 4.20–3.97 (4H, m, OH 
and CHCH3 and CH2OH), 3.59 (3H, s, CO2CH3), 3.13–3.02 (2H, m, CH2CH2OH), 1.45 (3H, d, J = 7.6 
Hz, CHCH3); δC (100 MHz, CDCl3) 175.4 (CO2CH3), 160.0 (CN), 158.7 (CN), 139.9 (C), 138.6 (C), 
137.1 (CH), 130.0 (CH), 128.8 (CH), 127.4 (CH), 126.9 (CH), 122.1 (CH), 121.7 (CH), 61.6 (CH2OH), 
52.0 (CO2CH3), 41.2 (CH2CH2OH), 39.1 (CHCO2Me), 24.8 (CHCH3); HRMS (ESI): calcd. for 
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2-(2-(6-(2-Hydroxyethyl)pyridin-2-yl)phenyl)propanoic acid (628) 
 Methyl 2-(2-(6-(2-hydroxyethyl)pyridin-2-yl)phenyl)propanoate (90 
mg, 0.315 mmol) was dissolved in THF (0.95 mL) and LiOH(aq) (0.5 m, 
0.95 mL, 0.473 mmol) was added and stirred at room temperature 
for 18 h. Upon completion, the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, diethyl ether→20% methanol in diethyl 
ether) afforded the title compound as a colourless oil (66 mg, 77%); RF 0.52 (20% methanol in 
ethyl acetate); νmax/cm–1 (thin film) 3411, 2952, 1732, 1589, 1569, 1444; δH (400 MHz, CDCl3) 
7.88 (1H, t, J = 8.4 Hz, CH), 7.56–7.48 (2H, m, 2 × CH), 7.45–7.29 (4H, m, 4 × CH), 4.01–3.87 (3H, 
m, CH2OH and CHCH3), 3.14–3.06 (2H, m, CH2CH2OH), 1.44 (3H, d, J = 7.6 Hz, CHCH3); δC (100 
MHz, CDCl3) 175.6 (CO2H), 157.5 (CN), 157.3 (CN), 139.5 (CH), 138.8 (C), 137.3 (C), 130.6 (CH), 
129.8 (CH), 127.5 (CH), 127.3 (CH), 123.3 (CH), 122.9 (CH), 61.9 (CH2OH), 41.0 (CH2CH2OH), 39.7 
(CHCH3), 16.5 (CH3); HRMS (ESI): calcd. for C16H17NNaO3, 294.1101. Found: [MNa]+, 294.1104 
(−1.2 ppm error). 
2-(6-Bromopyridin-2-yl)propan-1-ol (630) 
 Ethyl 2-(6-bromopyridin-2-yl)acetate (233 mg, 0.955 mmol) was 
dissolved in THF (3.2 mL) and cooled to 0 °C, before NaHMDS (1.0 m, 
1.05 mL, 1.05 mmol) was added dropwise and the solution stirred for 30 
min. Then, methyl iodide (60 µL, 0.955 mmol) was added and the solution allowed to slowly 
warm to room temperature over 2 h. The reaction was quenched with sat. NH4Cl(aq) (10 mL) and 
extracted with ethyl acetate (3 × 50 mL) and washed with brine (10 mL). The combined organic 
extracts were dried over MgSO4, filtered and removed in vacuo. This crude material was then 
re-dissolved in THF (7.4 mL) cooled to 0 °C and DIBAL-H (1.0 m in THF, 1.63 mL, 1.63 mmol) 
added slowly. The solution was then stirred, at room temperature for 18 h, where upon 
completion the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 50% diethyl ether in hexanes) afforded the title compound as a colourless oil (76 mg, 37% 
over two steps); RF 0.54 (ethyl acetate); νmax/cm–1 (thin film) 3351, 2966, 2931, 2875, 1582, 1552, 
1435, 1407; δH (400 MHz, CDCl3) 7.40 (1H, t, J = 7.6 Hz, CH), 7.32 (1H, d, J = 7.6 Hz, CH), 7.14 (1H, 
d, J = 7.6 Hz, CH), 3.89–3.78 (2H, m, CH2OH), 3.11–2.99 (2H, m, OH and CHCH3), 1.28 (3H, d, J = 
7.6 Hz, CH3); δC (100 MHz, CDCl3) 166.1 (CN), 141.3 (CBr), 138.9 (CH), 125.8 (CH), 121.1 (CH), 66.7 
(CH2OH), 42.5 (CHCH3), 16.9 (CH3); HRMS (ESI): calcd. for C8H1079BrNNaO, 237.9838. Found: 
[MNa]+, 237.9836 (0.8 ppm error). 
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Methyl 2-(2-(6-(1-hydroxypropan-2-yl)pyridin-2-yl)phenyl)acetate (632) 
2-(6-Bromopyridin-2-yl)propan-1-ol (70.0 mg, 0.324 mmol), methyl 
2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 
(134 mg, 0.486 mmol), potassium phosphate (138 mg, 0.648 mmol) 
and PdCl2(dppf).CH2Cl2 (13.0 mg, 16.2 µmol) was dissolved in THF 
(3.2 mL) under a nitrogen atmosphere. H2O (29 µL, 1.62 mmol) was added and the solution 
heated, at reflux, to 80 °C for 18 h. Upon completion, the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 25% diethyl ether in hexane→50% diethyl 
ether in hexane) afforded the title compound as a yellow oil (73 mg, 79%); RF 0.60 (ethyl acetate); 
νmax/cm–1 (thin film) 3416, 2952, 2875, 1732, 1589, 1569, 1444; δH (400 MHz, CDCl3) 7.71 (1H, t, 
J = 7.6 Hz, CH), 7.44–7.31 (4H, m, 4 × CH), 7.28 (1H, d, J = 7.6 Hz, CH), 7.15 (1H, d, J = 7.6 Hz, CH), 
3.94–3.78 (5H, m, CH2OH and CH2CO2Me and OH), 3.53 (3H, s, CO2CH3), 3.17–3.06 (1H, m, 
CHCH3), 1.31 (3H, d, J = 6.9 Hz, CHCH3); δC (100 MHz, CDCl3) 172.4 (CO2Me), 164.0 (CN), 158.5 
(CN), 140.4 (C), 137.3 (CH), 132.3 (C), 131.4 (CH), 129.9 (CH), 128.5 (CH), 127.4 (CH), 121.8 (CH), 
120.4 (CH), 67.1 (CH2OH), 51.9 (CO2CH3), 42.6 (CHCH2OH), 39.3 (CH2CO2Me), 17.1 (CHCH3); HRMS 
(ESI): calcd. for C17H20NO3, 286.1438. Found: [MH]+, 286.1441 (−1.1 ppm error). 
2-(2-(6-(1-Hydroxypropan-2-yl)pyridin-2-yl)phenyl)acetic acid (633) 
 Methyl 2-(2-(6-(1-hydroxypropan-2-yl)pyridin-2-yl)phenyl)acetate 
(70.0 mg, 0.245 mmol) was dissolved in THF (0.74 mL) and LiOH(aq) 
(0.5 m, 0.74 mL, 0.368 mmol) was added and stirred at room 
temperature for 18 h. Upon completion, the solvent was removed 
in vacuo. Purification by flash column chromatography (SiO2, diethyl ether→25% methanol in 
diethyl ether) afforded the title compound as a colourless oil (61 mg, 92%); RF 0.51 (20% 
methanol in ethyl acetate); νmax/cm–1 (thin film) 3384, 2934, 1714, 1598, 1578, 1445; δH (400 
MHz, CDCl3) 7.89 (1H, t, J = 7.6 Hz, CH), 7.49–7.28 (6H, m, 6 × CH), 3.85–3.74 (2H, m, CH2OH), 
3.65 (1H, d, J = 13.0 Hz, CHH′CO2H), 3.59 (1H, d, J = 13.0 Hz, CHH′CO2H), 3.34–3.22 (1H, m, 
CHCH3), 1.30 (3H, d, J = 6.9 Hz, CHCH3); δC (100 MHz, CDCl3) 173.6 (CO2H), 162.7 (CN), 156.9 (CN), 
139.9 (CH), 137.5 (C), 133.2 (C), 131.5 (CH), 130.8 (CH), 129.9 (CH), 127.9 (CH), 123.2 (CH), 121.3 
(CH), 67.0 (CH2OH), 43.0 (CHCH3), 42.0 (CH2CO2H), 16.6 (CH3); HRMS (ESI): calcd. for C16H18NO3, 
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1-Methyl-4,5-dihydro-6,10-(azeno)benzo[d][1]oxacyclododecin-2(1H)-one (634) 
2-(2-(6-(2-Hydroxyethyl)pyridin-2-yl)phenyl)propanoic acid (61.0 mg, 0.225 
mmol) was dissolved in CHCl3 (2.2 mL) where DIPEA (71.0 µL, 0.405 mmol) 
and T3P (50% solution in ethyl acetate, 201 µL, 0.337 mmol) were added 
sequentially and stirred at room temperature for 30 min. Upon completion 
the solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 50% 
diethyl ether in hexanes) afforded the title compound (as a 1:1 mixture of diastereomers) as a 
yellow oil (54 mg, 95%); RF 0.72 (ethyl acetate); νmax/cm–1 (thin film) 2959, 1720, 1587, 1450; δH 
(400 MHz, CDCl3) 7.80–7.75 (1H, m, CH, single diastereomer), 7.72–7.59 (4H, m, 4 × CH), 7.54–
7.44 (3H, m, 3 × CH), 7.43–7.34 (4H, m, 4 × CH), 7.07 (1H, d, J = 7.6 Hz, CH, single), 7.04 (1H, d, J 
= 7.6 Hz, CH, single), 5.46 (1H, td, J = 12.2, 3.1 Hz, CHH′O, single), 5.40 (1H, td, J = 12.2, 3.8 Hz, 
CHH′O, single), 4.32–4.19 (2H, m, CH2O, single), 3.80 (1H, q, J = 7.6 Hz, CHCH3, single), 3.63 (1H, 
q, J = 6.9 Hz, CHCH3, single), 3.37–3.23 (2H, m, CH2CH2O, single), 3.05 (1H, dd, J = 17.6, 3.1 Hz, 
CHH′CH2O, single), 3.00–2.91 (1H, m, CHH′CH2O, single), 1.61 (3H, d, J = 7.6 Hz, CHCH3, single), 
1.04 (3H, d, J = 6.9 Hz, CHCH3, single); δC (100 MHz, CDCl3) 178.5 (CO2CH2) 175.5 (CO2CH2), 156.4 
(CN), 155.5 (CN), 155.2 (CN), 154.8 (CN), 141.9 (C), 139.1 (C), 137.5 (C), 137.3 (CH), 137.1 (CH), 
135.3 (C), 133.9 (CH), 129.4 (CH), 129.2 (CH), 128.6 (CH), 128.1 (CH), 127.9 (CH), 127.5 (CH), 
127.1 (CH), 121.3 (CH), 121.1 (CH), 118.8 (CH), 118.3 (CH), 62.9 (CH2O), 62.7 (CH2O), 49.0 
(CHCH3), 45.1 (CHCH3), 32.7 (CH2CH2O), 32.6 (CH2CH2O), 17.0 (CH3), 15.2 (CH3); HRMS (ESI): calcd. 
for C16H16NO2, 254.1176. Found: [MH]+, 254.1179 (−1.3 ppm error). 
5-Methyl-4,5-dihydro-6,10-(azeno)benzo[d][1]oxacyclododecin-2(1H)-one (635) 
2-(2-(6-(1-Hydroxypropan-2-yl)pyridin-2-yl)phenyl)acetic acid (57.0 mg, 
0.210 mmol) was dissolved in CHCl3 (2.1 mL) where DIPEA (66.0 µL, 0.378 
mmol) and T3P (50% solution in ethyl acetate, 188 µL, 0.315 mmol) were 
added sequentially and stirred at room temperature for 30 min. Upon 
completion, the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, 50% diethyl ether in hexanes) afforded the title compound (as a 3:2 mixture of 
diastereomers) as a yellow oil (53 mg, 99%); RF 0.76 (ethyl acetate); νmax/cm–1 (thin film) 2963, 
1726, 1587, 1576, 1445; δH (400 MHz, CDCl3) 7.85–7.79 (1H, m, CH, minor diastereomer), 7.77–
7.66 (3H, m, CH, major diastereomer and CH, both diastereomers), 7.58 (1H, d, J = 7.6 Hz, CH, 
minor), 7.48 (1H, d, J = 7.6 Hz, CH, major), 7.44–7.36 (6H, m, 3 × CH, both), 7.18 (1H, d, J = 7.6 
Hz, CH, major), 7.07 (1H, d, J = 7.6 Hz, CH, minor), 5.40 (1H, dd, J = 11.4, 3.1 Hz, CHH′O, minor), 
5.11 (1H, t, J = 11.4 Hz, CHH′O, major), 4.13 (1H, dd, J = 12.2, 5.3 Hz, CHH′O, major), 3.98 (1H, 
dd, J = 12.2, 2.3 Hz, CHH′O, minor), 3.85 (1H, d, J = 14.5 Hz, CHH′CO2, minor), 3.57 (1H, d, J = 14.5 
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Hz, CHH′CO2, minor), 3.52 (2H, s, CH2CO2, major), 3.46–3.34 (1H, m, CHCH3, major), 3.16–3.07 
(1H, m, CHCH3, minor), 1.52 (3H, d, J = 7.6 Hz, CHCH3, minor), 1.32 (3H, d, J = 7.6 Hz, CHCH3, 
major); δC (100 MHz, CDCl3) 175.2 (CO2CH2, major), 174.7 (CO2CH2, minor), 160.8 (CN, minor), 
160.7 (CN, minor), 155.1 (CN, major), 154.3 (CN, minor), 137.6 (C, major), 137.5 (CH, minor), 
137.3 (CH, major), 136.5 (C, minor), 135.1 (C, major), 134.8 (C, minor), 134.0 (CH, minor), 133.6 
(CH, major), 129.2 (CH, minor), 129.1 (CH, major), 128.1 (CH, major), 127.9 (CH, minor), 127.7 
(CH, both), 120.2 (CH, minor), 120.0 (CH, major), 118.8 (CH, major), 118.3 (CH, major) 69.3 
(CH2O, both), 44.7 (CH2CO2, minor), 43.9 (CH2CO2, major), 37.7 (CHCH3, major), 37.6 (CHCH3, 
minor), 19.6 (CH3CH, minor), 16.3 (CHCH3, major); HRMS (ESI): calcd. for C16H16NO2, 254.1176. 
Found: [MH]+, 254.1172 (1.5 ppm error). 
1-(6-Bromopyrazin-2-yl)propan-2-one (643) 
 N,N-Diisopropylamine (282 µL, 2.00 mmol) was dissolved in THF (5 mL) 
and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 1.25 mL, 2.00 
mmol) was added dropwise and stirred for 30 min. The LDA solution was 
then cooled to −78 °C, where a solution of 2-bromo-6-methylpyrazine (173 µL, 1.00 mmol) in 
THF (1.0 mL), was added dropwise and stirred for 30 min. N-Methoxy-N-methylacetamide (213 
µL, 2.00 mmol) was added and stirred for a further 30 min at −78 °C before slowly warming to 
room temperature. The solution was then quenched with sat. NH4Cl(aq) (20 mL) and extracted 
with ethyl acetate (3 × 50 mL) and washed with brine (10 mL). The combined organic extracts 
were dried over MgSO4, filtered and removed in vacuo. Purification by flash column 
chromatography (SiO2, 50% ethyl acetate in hexanes→ethyl acetate) afforded the title 
compound (as a 10:1 mixture of keto:enol tautomers) as a colourless oil (174 mg, 81%); RF 0.59 
(ethyl acetate); νmax/cm–1 (thin film) 1722, 1639, 1563, 1511; δH (400 MHz, CDCl3) 12.1 (1H, s, 
OH, enol), 8.58 (1H, s, CH, keto), 8.42 (1H, s, CH, keto), 8.28 (1H, s, CH, enol), 8.15 (1H, s, CH, 
enol), 5.35 (1H, s, CHCOH, enol), 3.95 (2H, s, CH2CO, keto), 2.29 (3H, s, CH3, keto), 2.05 (3H, s, 
CH3, enol); δC (100 MHz, CDCl3) data for ketone tautomer only: 203.0 (CO), 151.0 (CN), 145.6 
(CHN), 143.4 (CHN), 140.1 (CBr), 49.3 (CH2), 30.3 (CH3); HRMS (ESI): calcd. for C7H779BrN2O, 
236.9634. Found: [MNa]+, 236.9630 (1.6 ppm error). 
1-(6-Bromopyrazin-2-yl)propan-2-ol (644) 
2-(6-Bromopyrazin-2-yl)-1-phenylethan-1-ol (160 mg, 0.744 mmol) was 
dissolved in methanol (7.4 mL) and cooled to 0 °C. Sodium borohydride (85 
mg, 2.23 mmol) was added portionwise and stirred at 0 °C for 1 h then 
allowed to warm to room temperature. Upon completion, the solvent was removed in vacuo. 
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Purification by flash column chromatography (SiO2, diethyl ether) afforded the title compound 
as a yellow oil (152 mg, 94%); RF 0.50 (ethyl acetate); νmax/cm–1 (thin film) 3378, 2968, 2928, 
1561, 1508; δH (400 MHz, CDCl3) 8.54 (1H, s, CH), 8.40 (1H, s, CH), 4.33–4.20 (1H, m, CHOH), 2.93 
(1H, dd, J = 14.5, 3.8 Hz, CHH′CHOH), 2.86 (1H, dd, J = 14.5, 8.4 Hz, CHH′CHOH), 2.75 (1H, d, J = 
3.8 Hz, OH), 1.30 (3H, d, J = 6.5 Hz, CH3); δC (100 MHz, CDCl3) 156.1 (CCH2), 145.2 (CH), 143.1 
(CH), 140.0 (CBr), 66.9 (CHOH), 43.2 (CH2), 23.3 (CH3); HRMS (ESI): calcd. for C7H979BrN2NaO, 
238.9790. Found: [MNa]+, 239.9788 (1.0 ppm error). 
Methyl 2-(2-(6-(2-hydroxypropyl)pyrazin-2-yl)phenyl)acetate (645) 
1-(6-Bromopyrazin-2-yl)propan-2-ol (135 mg, 0.622 mmmol), methyl 
2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (258 
mg, 0.933 mmol), potassium phosphate (264 mg, 1.24 mmol) and 
PdCl2(dppf).CH2Cl2 (26.0 mg, 12.5 µmmol) were dissolved in THF (6.2 
mL) under a nitrogen atmosphere. H2O (56.0 µL, 3.11 mmol) was added 
and the solution heated, at reflux, to 80 °C for 18 h. Upon completion, the solvent was removed 
in vacuo. Purification by flash column chromatography (SiO2, 33% diethyl ether in 
hexanes→diethyl ether) afforded the title compound as a colourless oil (97 mg, 55%); RF 0.10 
(50% ethyl acetate in hexanes); νmax/cm–1 (thin film) 3406, 2967, 1735, 1529; δH (400 MHz, CDCl3) 
8.59 (1H, s, CHN), 8.41 (1H, s, CHN), 7.48–7.33 (4H, m, 4 × CH), 4.33–4.23 (1H, m, CHOH), 3.83 
(1H, d, J = 16.0 Hz, CHH′CO2Me), 3.75 (1H, d, J = 16.0 Hz, CHH′CO2Me), 3.55 (3H, s, OCH3), 3.46 
(1H, br s, OH), 2.99 (1H, dd, J = 14.5, 3.1 Hz, CHH′CH), 2.88 (1H, dd, J = 14.5, 9.2 Hz, CHH′CH), 
1.30 (3H, d, J = 6.1 Hz, CHCH3); δC (100 MHz, CDCl3) 172.2 (CO2Me), 153.8 (CN), 153.6 (CN), 143.0 
(CHN), 142.5 (CHN), 136.6 (C), 133.0 (C), 132.0 (CH), 129.9 (CH), 129.5 (CH), 127.8 (CH), 67.0 
(CHOH), 52.1 (OCH3), 43.5 (CH2CHOH), 39.5 (CH2CO2Me), 23.3 (CH3); HRMS (ESI): calcd. for 
C16H18N2NaO3, 309.1210. Found: [MNa]+, 309.1202 (2.4 ppm error). 
2-(2-(6-(2-Hydroxypropyl)pyrazin-2-yl)phenyl)acetic acid (646) 
 Methyl 2-(2-(6-(2-hydroxypropyl)pyrazin-2-yl)phenyl)acetate (90.0 
mg, 0.314 mmol) was dissolved in THF (1.0 mL) and LiOH(aq) (0.5 m, 0.94 
mL, 0.472 mmol) was added and stirred for 18 h. Upon completion, the 
solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, diethyl ether→20% methanol in diethyl ether) afforded the title 
compound as a colourless oil (74 mg, 87%); RF 0.21 (20% methanol in diethyl ether); νmax/cm–1 
(thin film) 3360, 2967, 2926, 1711, 1579, 1530; δH (400 MHz, CDCl3) 8.63 (1H, s, CHN), 8.45 (1H, 
s, CHN), 7.46–7.32 (4H, m, 4 × CH), 4.21–4.11 (1H, m, CHOH), 3.63 (1H, d, J = 15.3 Hz, 
Chapter Seven: Experimental 
 
230 | P a g e  
 
CHH′CO2Me), 3.54 (1H, d, J = 15.3 Hz, CHH′CO2Me), 2.95 (1H, dd, J = 13.7, 3.8 Hz, CHH′CHOH), 
2.86 (1H, dd, J = 13.7, 8.4 Hz, CHH′CHOH), 1.21 (3H, d, J = 6.1 Hz, CH3); δC (100 MHz, CDCl3) 166.3 
(CO2H), 153.1 (CN), 152.5 (CN), 143.5 (CHN), 142.9 (CHN), 135.6 (C), 134.1 (C), 132.2 (CH), 130.0 
(CH), 127.6 (CH), 127.5 (CH), 67.2 (CHOH), 43.1 (CH2CH), 41.2 (CH2CO2H), 23.2 (CH3); HRMS (ESI): 
calcd. for C15H16N2NaO3, 295.1053. Found: [MNa]+, 295.1054 (−0.2 ppm error). 
4-Methyl-4,5-dihydro-6,10-(azeno)benzo[i][1]oxa[6]azacyclododecin-2(1H)-one (647) 
2-(2-(6-(2-Hydroxypropyl)pyrazin-2-yl)phenyl)acetic acid (65 mg, 0.239 
mmol) was dissolved in CHCl3 (2.4 mL), where DIPEA (75 µL, 0.430 mmol) 
and T3P (50% in ethyl acetate, 213 µL, 0.359 mmol) were added 
sequentially and stirred for 30 min. Upon completion, the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% diethyl ether in 
hexanes) afforded the title compound as a colourless oil (55 mg, 90%); RF 0.55 (ethyl acetate); 
νmax/cm–1 (thin film) 2975, 2929, 1723, 1546; δH (400 MHz, CDCl3) 8.81 (1H, s, CHN), 8.34 (1H, s, 
CHN), 7.85–7.78 (1H, m, CH), 7.47–7.38 (3H, m, 3 × CH), 5.60–5.48 (1H, m, CHO), 3.58 (1H, d, J = 
15.3 Hz, CHH′CO2), 3.54 (1H, d, J = 15.3 Hz, CHH′CO2), 3.11 (1H, dd, J = 17.6, 3.8 Hz, CHH′CH), 
3.01 (1H, dd, J = 17.6, 9.9 Hz, CHH′CH), 1.50 (3H, d, J = 6.1 Hz, CH3); δC (100 MHz, CDCl3) 174.1 
(CO2CH), 150.7 (CN), 150.0 (CN), 141.6 (CHN), 139.5 (CHN), 135.6 (C), 134.4 (C), 134.3 (CH), 130.2 
(CH), 127.9 (CH), 127.6 (CH), 70.3 (CHO), 44.1 (CH2CH), 37.9 (CH2CO2), 21.3 (CH3); HRMS (ESI): 
calcd. for C15H14N2NaO2, 277.0947. Found: [MNa]+, 277.0953 (−2.0 ppm error). 
2-(6-Bromopyrazin-2-yl)-1-phenylethan-1-ol (S1) 
 N,N-Diisopropylamine (564 µL, 4.00 mmol) was dissolved in THF (10 mL) 
and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 2.5 mL, 4.00 
mmol) was added dropwise and stirred for 30 min. The LDA solution was 
then cooled to −78 °C, where a solution of 2-bromo-6-methylpyrazine (346 µL, 2.00 mmol) in 
THF (2.0 mL), was added dropwise and stirred for 30 min. Benzaldehyde (408 µL, 4.00 mmol) 
was added and stirred for a further 30 min at −78 °C before slowly warming to room 
temperature. The solution was then quenched with sat. NH4Cl(aq) (20 mL) and extracted with 
ethyl acetate (3 × 50 mL) and washed with brine (10 mL). The combined organic extracts were 
dried over MgSO4, filtered and removed in vacuo. Purification by flash column chromatography 
(SiO2, diethyl ether) afforded the title compound as a yellow oil (524 mg, 94%); RF 0.68 (ethyl 
acetate); νmax/cm–1 (thin film) 3369, 3030, 2927, 1563, 1509; δH (400 MHz, CDCl3) 8.54 (1H, s, 
CHN), 8.33 (1H, s, CHN), 7.43–7.23 (5H, m, 5 × CH), 5.20–5.12 (1H, m, CHOH), 4.68 (1H, br s, OH), 
3.22–3.12 (2H, m, CH2CHOH); δC (100 MHz, CDCl3) 155.5 (CCH2), 145.3 (CH), 143.3 (CH), 143.1 
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(CBr), 140.0 (C), 128.6 (CH), 125.7 (CH), 73.0 (CHOH), 43.8 (CH2CHOH); HRMS (ESI): calcd. for 
C12H1179BrN2NaO, 300.9947. Found: [MNa]+, 300.9945 (0.5 ppm error). 
Methyl 2-(2-(6-(2-hydroxy-2-phenylethyl)pyrazin-2-yl)-4,5-dimethoxyphenyl)acetate (S2) 
2-(6-Bromopyrazin-2-yl)-1-phenylethan-1-ol (240 mg, 0.860 
mmmol), methyl 2-(4,5-dimethoxy-2-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl)acetate (434 mg, 1.29 mmol), 
potassium phosphate (365 mg, 1.72 mmol) and 
PdCl2(dppf).CH2Cl2 (35.0 mg, 43.0 µmol) were dissolved in THF (8.6 mL) under a nitrogen 
atmosphere. H2O (78.0 µL, 4.30 mmol) was added and the solution heated, at reflux, to 80 °C for 
18 h. Upon completion, the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 50% diethyl ether in hexanes→diethyl ether) afforded the title 
compound as a colourless oil (194 mg, 55%); RF 0.46 (ethyl acetate); νmax/cm–1 (thin film) 3418, 
2951, 1732, 1607, 1520; δH (400 MHz, CDCl3) 8.60 (1H, s, CHN), 8.31 (1H, s, CHN), 7.44–7.26 (5H, 
m, 5 × CH), 6.97 (1H, s, CHOCH3), 6.88 (1H, s, CHOCH3), 5.23–5.16 (1H, m, CHOH), 3.98 (1H, br d, 
J = 3.8 Hz, OH), 3.94 (3H, s, OCH3), 3.91 (3H, s, OCH3), 3.78 (1H, d, J = 16.0 Hz, CHH′CO2Me), 3.70 
(1H, d, J = 16.0 Hz, CHH′CO2Me), 3.62 (3H, s, CO2CH3), 3.25–3.15 (2H, m, CH2CHOH); δC (100 MHz, 
CDCl3) 176.5 (CO2Me), 157.3 (CN), 157.2 (CN), 153.7 (COCH3), 152.2 (COCH3), 147.5 (CCN), 146.6 
(CHN), 146.4 (CHN), 132.8 (C), 132.4 (CH), 131.5 (CH), 129.6 (CH), 129.6 (CCH2CO2Me), 118.6 
(CHCOCH3), 116.6 (CHCOCH3), 77.0 (CHOH), 60.04 (OCH3), 59.99 (OCH3), 56.1 (CO2CH3), 48.0 
(CH2CH), 43.1 (CH2CO2Me); HRMS (ESI): calcd. for C23H24N2NaO5, 431.1577. Found: [MNa]+, 
431.1582 (−1.0 ppm error). 
2-(2-(6-(2-Hydroxy-2-phenylethyl)pyrazin-2-yl)-4,5-dimethoxyphenyl)acetic acid (648) 
 Methyl 2-(2-(6-(2-hydroxy-2-phenylethyl)pyrazin-2-yl)-4,5-
dimethoxyphenyl)acetate (180 mg, 0.441 mmol) was dissolved 
in THF (1.30 mL) and LiOH(aq) (0.5 m, 1.30 mL, 0.661 mmol) was 
added and stirred for 3 h, at room temperature. Upon 
completion, the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, ethyl acetate→20% methanol in ethyl acetate) afforded the title compound as a colourless 
oil (166 mg, 95%); RF 0.44 (20% methanol in ethyl acetate); νmax/cm–1 (thin film) 2938, 2253, 
1721, 1519; δH (400 MHz, CDCl3) 8.66 (1H, s, CHN), 8.43 (1H, s, CHN), 7.30–7.19 (5H, m, 5 × CH), 
6.91 (1H, s, CHCOCH3), 6.90 (1H, s, CHCOCH3), 5.10 (1H, t, J = 6.9 Hz, CHOH), 3.88 (6H, s, 2 × 
OCH3), 3.39 (2H, s, CH2CO2H), 3.22 (2H, d, J = 6.9 Hz, CH2CHOH); δC (100 MHz, CDCl3) 177.4 
(CO2H), 155.6 (CN), 155.2 (CN), 154.1 (COCH3), 152.0 (COCH3), 147.6 (CHN), 146.7 (CHN), 146.5 
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(CCN), 132.3 (CH), 131.6 (CH), 130.6 (C), 130.2 (C), 129.3 (CH), 117.9 (CHCOCH3), 116.3 
(CHCOCH3), 77.0 (CHOH), 59.82 (OCH3), 58.75 (OCH3), 47.5 (CH2CHOH), 44.6 (CH2CO2H); HRMS 




dimethoxyphenyl)acetic acid (92 mg, 0.232 mmol) was dissolved 
in CHCl3 (2.3 mL), where DIPEA (73 µL, 0.418 mmol) and T3P (50% 
solution in ethyl acetate, 208 µL, 0.348 mmol) were added 
sequentially and stirred at room temperature for 30 min. Upon completion the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, ethyl acetate) afforded 
the title compound as a pink oil (86 mg, 98%); RF 0.25 (ethyl acetate); νmax/cm–1 (thin film) 3286, 
2937, 1642, 1488; δH (400 MHz, CDCl3) 9.41 (1H, s, CHN), 7.64 (1H, s, CHN), 7.36–7.31 (2H, m, 2 
× CH), 7.27 (1H, s, CHCOH), 7.24–7.18 (2H, m, 2 × CH), 7.15–7.10 (1H, m, CH), 6.75 (1H, s, 
CHCOCH3), 6.57 (1H, s, CHCOCH3), 6.11 (1H, br s, OH), 5.10–5.01 (1H, m, OCHPh), 3.98 (1H, dd, J 
= 13.7, 9.2 Hz, CHH′CHO), 3.89 (3H, s, OCH3), 3.88 (3H, s, OCH3), 3.77 (1H, dd, J = 13.7, 3.8 Hz, 
CHH′CHO); δC (100 MHz, CDCl3) 158.6 (COH), 154.8 (CH3OC), 149.0 (CH3OC), 146.3 (CHN), 144.6 
(C), 138.0 (CHN), 137.9 (C), 135.2 (CN), 132.0 (CN), 128.4 (CH), 127.4 (CH), 125.7 (CH), 112.0 (C), 
108.7 (CHCOCH3), 102.1 (CHCOCH3), 99.8 (CHCOH), 74.5 (CH2O), 56.3 (OCH3), 56.1 (OCH3), 42.2 
(CH2CH); HRMS (ESI): calcd. for C22H21N2O4, 377.1496. Found: [MH]+, 377.1501 (−1.3 ppm error). 
2,6-Dibromo-4-dimethylaminopyridine (651) 
2,6-Dibromo-4-aminopyridine (1.8 g, 7.15 mmol) was dissolved in THF (35 mL) 
and DMF (35 mL) and cooled to 0 °C. Sodium Hydride (60% in mineral oil, 630 
mg, 15.7 mmol) was added and stirred for 10 min. Methyl iodide (980 µL, 15.7 
mmol) was then added and the solution was warmed to room temperature and stirred for 2 h. 
Upon completion, water (25 mL) was added and diluted with diethyl ether (100 mL). The 
aqueous phase was then extracted with diethyl ether (3 × 50 mL), dried over MgSO4, filtered and 
the solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 50% 
diethyl ether in hexanes) afforded the title compound as a colourless oil (1.94 g, 97%); RF 0.48 
(50% ethyl acetate in hexanes); δH (400 MHz, CDCl3) 6.57 (2H, s, 2 × CH), 2.96 (6H, s, 2 × NCH3). 
Data is consistent with those reported in the literature.136   
 
 
Chapter Seven: Experimental 
 
233 | P a g e  
 
2-Bromo-6-methyl-4-dimethylaminopyridine (652) 
2,6-Dibromo-4-dimethylaminopyridine (400 mg, 1.43 mmol) was dissolved in 
anhydrous THF (14.2 mL) and cooled to −78 °C. n-BuLi (1.6 m, 1.00 mL, 1.6 
mmol) was added dropwise and stirred for 1 h, before methyl iodide (134 µL, 
2.15 mmol) was added and stirred, at −78 °C for 4 h. The solution was then slowly warmed to 
room temperature and quenched with sat. NH4Cl(aq) solution (10 mL) and extracted with ethyl 
acetate (3 × 50 mL). The combined organic extracts were dried over MgSO4, filtered, and the 
solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 50% diethyl 
ether in hexanes) afforded the title compound as a colourless oil (211 mg, 69%); RF 0.43 (50% 
ethyl acetate in hexanes); δH (400 MHz, CDCl3) 6.48 (1H, d, J = 2.3 Hz, CH), 6.27 (1H, d, J = 2.3 Hz, 
CH), 2.95 (6H, s, 2 × NCH3), 2.38 (3H, s, CCH3); δC (100 MHz, CDCl3) 158.7 (CNMe2), 156.1 (CCH3), 
142.3 (CBr), 106.8 (CH), 105.1 (CH), 39.3 (N(CH3)2), 24.5 (CH3). Data is consistent with those 
reported in the literature.160 
1-(6-Bromo-4-(dimethylamino)pyridin-2-yl)propan-2-one (653) 
 N,N-Diisopropylamine (302 µL, 2.14 mmol) was dissolved in THF (10.7 mL) 
and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 1.34 mL, 2.14 
mmol) was added dropwise and stirred for 30 min. The LDA solution was 
then cooled to −78 °C, where a solution of 2-bromo-6-methyl-4-dimethylaminopyridine (230 mg, 
1.07 mmol) was added dropwise and stirred for 30 min. N-Methoxy-N-methylacetamide (228 
µL, 2.14 mmol) was added and stirred for a further 30 min at −78 °C before slowly warming to 
room temperature. The solution was then quenched with sat. NH4Cl(aq) (10 mL) and extracted 
with ethyl acetate (3 × 50 mL) and washed with brine (10 mL). The combined organic extracts 
were dried over MgSO4, filtered and removed in vacuo. Purification by flash column 
chromatography (SiO2, diethyl ether) afforded the title compound as a colourless oil (234 mg, 
85%); RF 0.56 (ethyl acetate); νmax/cm–1 (thin film) 2918, 1713, 1592, 1522; δH (400 MHz, CDCl3) 
6.52 (1H, d, J = 2.3 Hz, CH), 6.30 (1H, d, J = 2.3 Hz, CH), 3.71 (2H, s, CH2CO), 2.94 (6H, s, 2 × NCH3), 
2.19 (3H, s, COCH3); δC (100 MHz, CDCl3) 205.4 (CO), 156.1 (CN), 154.7 (CN), 142.4 (CBr), 107.8 
(CHCNMe2), 106.1 (CHCNMe2), 53.0 (CH2CO), 39.3 (N(CH3)2), 29.9 (CH3CO); HRMS (ESI): calcd. for 
C10H1479BrN2O, 257.0284. Found: [MH]+, 257.0282 (0.9 ppm error). 
1-(6-Bromo-4-(dimethylamino)pyridin-2-yl)propan-2-ol (654) 
1-(6-Bromo-4-(dimethylamino)pyridin-2-yl)propan-2-one (56.0 mg, 0.218 
mmol) was dissolved in methanol (2.2 mL) and cooled to 0 °C. Sodium 
borohydride (25.0 mg, 0.653 mmol) was added portionwise and stirred at 
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0 °C for 1 h, then allowed to warm to room temperature. Upon completion, the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% diethyl ether in 
hexanes→ethyl acetate) afforded the title compound as a colourless oil (54 mg, 96%); RF 0.42 
(ethyl acetate); νmax/cm–1 (thin film) 3368, 2966, 2926, 1596, 1524; δH (400 MHz, CDCl3) 6.50  (1H, 
d, J = 2.3 Hz, CHCNMe2), 6.25 (1H, d, J = 2.3 Hz, CHCNMe2), 4.30 (1H, br s, OH), 4.20–4.10 (1H, 
m, CHOH), 2.96 (6H, s, 2 × NCH3), 2.72 (1H, dd, J = 14.5, 3.0 Hz, CHH′CHOH), 2.64 (1H, dd, J = 
14.5, 8.4 Hz, CHH′CHOH), 1.22 (3H, d, J = 6.1 Hz, CHCH3); δC (100 MHz, CDCl3) 160.2 (CNMe2), 
156.1 (CN), 142.0 (CBr), 107.4 (CHC), 105.4 (CHC), 67.1 (CHOH), 45.5 (CH2CHOH), 39.3 (CH3N), 




1-(6-Bromo-4-(dimethylamino)pyridin-2-yl)propan-2-ol (215 mg, 
0.830 mmmol), methyl 2-(4-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetate (398 mg, 1.24 mmol), potassium 
phosphate (352 mg, 1.66 mmol) and PdCl2(dppf).CH2Cl2 (34 mg, 
41.5 µmmol) were dissolved in THF (8.3 mL) under a nitrogen 
atmosphere. H2O (75 µL, 4.15 mmol) was added and the solution heated, at reflux, to 80 °C for 
18 h. Upon completion, the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, ethyl acetate →10% methanol in ethyl acetate) afforded the title 
compound as an orange oil (86 mg, 29%); RF 0.10 (ethyl acetate); νmax/cm–1 (thin film) 3327, 2929, 
1734, 1597, 1541, 1503; δH (400 MHz, CDCl3) 7.21 (1H, d, J = 8.4 Hz, CH), 6.94 (1H, d, J = 3.1 Hz, 
CH), 6.86 (1H, dd, J = 8.4, 3.1 Hz, CH), 6.50 (1H, d, J = 2.3 Hz, CHCNMe2), 6.28 (1H, d, J = 2.3 Hz, 
CHCNMe2), 4.18 (1H, br s, CHOH), 3.78 (3H, s, COCH3), 3.71 (1H, d, J = 16.0 Hz, CHH′CO2Me), 3.64 
(1H, d, J = 16.0 Hz, CHH′CO2Me), 3.57 (3H, s, CO2CH3), 2.98 (6H, s, 2 × NCH3), 2.79 (1H, dd, J = 
14.5, 3.1 Hz, CHH′CHOH), 2.71 (1H, dd, J = 14.5, 9.2 Hz, CHH′CHOH), 1.23 (3H, d, J = 6.1 Hz. 
CHCH3); δC (100 MHz, CDCl3) 171.8 (CO2Me), 158.6 (MeOC), 157.4 (Me2NC), 157.2 (CN), 154.2 
(CN), 141.7 (CCN), 131.0 (CHCCH2CO2Me), 123.3 (CCH2CO2Me), 114.0 (CHCOMe), 112.8 
(CHCOMe), 104.2 (CHCN), 103.4 (CHCN), 66.2 (CHOH), 54.4 (COCH3), 50.9 (CO2CH3), 44.5 
(CH2CHOH), 38.2 (N(CH3)2), 37.3 (CH2CO2Me), 23.8 (CHCH3); HRMS (ESI): calcd. for C20H27N2O4, 
359.1965. Found: [MH]+, 359.1974 (2.5 ppm error). 
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2-(2-(4-(Dimethylamino)-6-(2-hydroxypropyl)pyridin-2-yl)-4-methoxyphenyl)acetic acid (657) 
 Methyl 2-(2-(4-(dimethylamino)-6-(2-hydroxypropyl)pyridin-2-yl)-
4-methoxyphenyl)acetate (82.0 mg, 0.220 mmol) was dissolved in 
THF (0.66 mL) and LiOH(aq) (0.5 m, 0.66 mL, 0.330 mmol) and stirred 
at room temperature for 3 h. Upon completion, the solvent was 
removed in vacuo. Purification by flash column chromatography 
(SiO2, ethyl acetate→50% methanol in ethyl acetate) afforded the title compound as a yellow oil 
(63 mg, 83%); RF 0.25 (50% methanol in ethyl acetate); νmax/cm–1 (thin film) 3279, 2967, 1624, 
1541, 1510; δH (400 MHz, CDCl3) 7.42 (1H, d, J = 8.4 Hz, CH), 6.99–6.92 (2H, m, 2 × CH), 6.58 (1H, 
d, J = 2.3 Hz, CHCNMe2), 6.55 (1H, d, J = 2.3 Hz, CHCNMe2), 4.22–4.13 (1H, m, CHOH), 3.81 (3H, 
s, OCH3), 3.49 (2H, s, CH2CO2H), 3.16 (6H, s, 2 × NCH3), 2.97 (1H, dd, J = 13.7, 4.6 Hz, CHH′CHOH), 
2.90 (1H, dd, J = 13.7, 7.6 Hz, CHH′CHOH), 1.26 (3H, d, J = 6.1 Hz, CHCH3); δC (100 MHz, CDCl3) 
175.9 (CO2H), 158.3 (COCH3), 156.8 (CNMe2), 154.1 (CN), 153.7 (CN), 136.1 (CCN), 132.6 
(CHCHCOCH3), 127.5 (CCH2CO2H), 116.2 (CHCOCH3), 115.0 (CHCOCH3), 106.1 (CHCNMe2), 105.0 
(CHCNMe2), 67.4 (CHOH), 55.5 (OCH3), 44.1 (CH2CHOH), 42.2 (CH2CO2H), 39.8 (N(CH3)2), 23.1 




methoxyphenyl)acetic acid (58.0 mg, 0.168 mmol) was dissolved in 
CHCl3 (1.7 mL) where DIPEA (53.0 µL, 0.303 mmol) and T3P (50% 
solution in ethyl acetate, 150 µL, 0.253 mmol) were added 
sequentially at room temperature and stirred for 30 min. Upon 
completion the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, diethyl ether→5% methanol in diethyl ether) afforded the title compound as a colourless 
oil (51 mg, 92%); RF 0.10 (ethyl acetate); νmax/cm–1 (thin film) 2928, 2244, 1721, 1597; δH (400 
MHz, CDCl3) 7.28 (1H, d, J = 3.0 Hz, CH), 7.24 (1H, d, J = 8.4 Hz, CH), 6.88 (1H, dd, J = 8.4, 3.0 Hz, 
CH), 6.68 (1H, d, J = 1.5 Hz, CHCNMe2), 6.27 (1H, d, J = 1.5 Hz, CHCNMe2), 5.50–5.39 (1H, m, 
CHOH), 3.85 (3H, s, OCH3), 3.59 (1H, d, J = 14.5 Hz, CHH′CO2), 3.43 (1H, d, J = 14.5 Hz, CHH′CO2), 
3.03 (6H, s, 2 × NCH3), 2.95 (1H, dd, J = 16.0, 3.8 Hz, CHH′CH), 2.87 (1H, dd, J = 14.5, 9.9 Hz, 
CHH′CH), 1.44 (3H, d, J = 6.1 Hz, CHCH3); δC (100 MHz, CDCl3) 171.8 (CO2CH), 158.7 (MeOC), 155.9 
(Me2NC), 155.8 (CN), 155.0 (CN), 138.7 (C), 134.0 (CH), 127.5 (C), 114.3 (CHCOMe), 113.0 
(CHCOMe), 104.1 (CHCNMe2), 102.1 (CHCNMe2), 70.4 (OCHCH3), 55.5 (OCH3), 42.2 (CH2CH), 41.0 
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(CH2CO2), 39.5 (N(CH3)2), 21.4 (CHCH3); HRMS (ESI): calcd. for C19H23N2O3, 327.1703. Found: 
[MH]+, 327.1705 (−0.6 ppm error). 
2-(6-Bromopyridin-2-yl)-N-methyl-1-phenylethan-1-amine (660) 
 N,N-Diisopropylamine (734 µL, 5.25 mmol) was dissolved in THF (12 mL) 
and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 3.28 mL, 
5.25 mmol) was added dropwise and stirred for 30 min. The LDA solution was then cooled to 
−78 °C, where 2-bromo-6-methylpyridine (296 µL, 2.63 mmol) was added dropwise and stirred 
for 30 min. N-Benzylidenemethylamine (656 µL, 5.25 mmol) was added and stirred for a further 
30 min at −78 °C before slowly warming to room temperature. The solution was then quenched 
with sat. NH4Cl(aq) (15 mL) and extracted with ethyl acetate (3 × 50 mL) and washed with brine 
(10 mL). The combined organic extracts were dried over MgSO4, filtered and removed in vacuo. 
Purification by flash column chromatography (SiO2, 50% ethyl acetate in hexane → ethyl acetate) 
afforded the title compound as a yellow oil (749 mg, 97%); RF 0.15 (ethyl acetate); νmax/cm–1 (thin 
film) 3027, 2791; 1582, 1552; δH (400 MHz, CDCl3) 7.36–7.17 (7H, m, ArH), 6.84 (1H, d, J = 7.9 
Hz, ArH), 3.96 (1H, dd, J = 8.4, 6.1 Hz, CHNHMe), 3.10 (1H, dd, J = 13.7, 8.4 Hz, CHH′CHPh), 2.98 
(1H, dd, J = 13.7, 6.1 Hz, CHH′CHPh), 2.23 (3H, s, NHCH3); δC (100 MHz, CDCl3) 160.7 (CCH2), 142.8 
(CBr), 141.5 (CCHNH), 138.4 (CH), 128.3 (CH), 127.3 (CH), 127.2 (CH), 125.7 (CH), 122.8 (CH), 65.0 
(CHNH), 46.4 (CH2CH), 34.5 (CH3NH); HRMS (ESI): calcd. for C14H1679BrN2, 291.0491. Found: 
[MH]+, 291.0491 (1.3 ppm error). 
t-Butyl (2-(6-bromopyridin-2-yl)-1-phenylethyl)(methyl)carbamate (661) 
2-(6-Bromopyridin-2-yl)-N-methyl-1-phenylethan-1-amine (670 mg, 
2.30 mmol) and DMAP (28 mg, 0.231 mmol) was dissolved in anhydrous 
CH2Cl2 (23 mL) and triethylamine (385 µL, 2.76 mmol) was added. The 
solution was cooled to 0 °C before Boc2O (603 mg, 2.76 mmol) was added portionwise, and the 
solution warmed to room temperature and stirred for 18 h. Upon completion, the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% ethyl acetate in 
hexanes) afforded the title compound (as a 2:1 mixture of rotamers) as a yellow oil (882 mg, 
98%); RF 0.67 (50% ethyl acetate in hexanes); νmax/cm–1 (thin film) 2981, 1784, 1722, 1583, 1555; 
δH (400 MHz, CDCl3) 7.48 (2H, t, J = 7.6 Hz, CH, both rotamers), 7.42–7.24 (14H, m, 7 × CH, both), 
5.78 (1H, dd, J = 9.9, 6.9 Hz, CHNHCH3, major rotamer), 5.66 (1H, dd, J = 10.7, 4.6 Hz, CHNCH3, 
minor rotamer),3.58–3.27 (4H, m, CH2CH, both), 2.71 (6H, s, NCH3, both), 1.61 (9H, s, 3 × CH3, 
minor), 1.49 (9H, s, 3 × CH3, major); δC (100 MHz, CDCl3) data for the major rotamer only: 159.2 
(CN), 150.5 (CO2tBu), 147.4 (CBr), 141.4 (C), 139.0 (CH), 128.7 (CH), 128.1 (CH), 127.6 (CH), 126.2 
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(CH), 122.0 (CH), 84.7 (CCH3), 58.9 (CHNCH3), 38.2 (CH2CHNCH3), 30.8 (NCH3), 27.5 (C(CH3)3); 
HRMS (ESI): calcd. for C19H2379BrN2NaO2, 413.0836. Found: [MNa]+, 413.0832 (0.7 ppm error). 
Methyl 2-(2-(6-(2-((tert-butoxycarbonyl)(methyl)amino)-2-phenylethyl)pyridin-2-
yl)phenyl)acetate (662) 
 t-Butyl (2-(6-bromopyridin-2-yl)-1-phenylethyl)(methyl)carbamate 
(410 mg, 1.18 mmol), methyl 2-(2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetate (487 mg, 1.76 mmol), potassium 
phosphate (500 mg, 2.36 mmol) and PdCl2(dppf).CH2Cl2 (48.0 mg, 
58.8 µmol) were dissolved in THF (11.7 mL) under a nitrogen atmosphere. H2O (106 µL, 5.88 
mmol) was added and the solution heated, at reflux, to 80 °C for 18 h. Upon completion, the 
solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 20% ethyl 
acetate in hexanes→33% ethyl acetate in hexanes) afforded the title compound (as a 4:5 mixture 
of rotamers) as a yellow oil (207 mg, 39%); RF 0.69 (ethyl acetate); νmax/cm–1 (thin film) 1736, 
1686, 1570, 1448; δH (400 MHz, CDCl3) 7.66 (2H, t, J = 7.6 Hz, CH, both rotamers), 7.52–7.04 
(22H, m, 11 × CH, both), 5.98 (1H, br s, CHNMe, minor rotamer), 5.71 (1H, br s, CHNMe, major 
rotamer), 3.95–3.67 (4H, m, CH2CO2Me, both), 3.61–3.31 (10H, m, CH2CHNMe and OCH3, both), 
2.74–2.54 (6H, m, NCH3, both), 1.45–1.15 (18H, m, C(CH3)3, both); δC Data for the major rotamer 
only (100 MHz, CDCl3) 172.4 (CO2Me), 158.9 (CN), 158.0 (CN), 155.7 (CO2tBu), 140.3 (C), 136.8 
(C), 132.4 (CH), 131.5 (C), 131.3 (CH), 129.9 (CH), 128.4 (CH), 127.5 (CH), 127.4 (CH), 127.3 (CH), 
127.1 (CH), 121.6 (CH), 121.3 (CH), 51.7 (CHNMe), 39.5 (OCH3), 38.9 (NCH3), 29.1 (CH2CHN), 28.3 
(CH2CO2Me), 22.6 (CCH3), 14.1 (C(CH3)3); HRMS (ESI): calcd. for C28H33N2O4, 461.2435. Found: 
[MH]+, 461.2433 (0.8 ppm error). 
2-(2-(6-(2-(Methylamino)-2-phenylethyl)pyridin-2-yl)phenyl)acetic acid (664) 
 Methyl 2-(2-(6-(2-((tert-butoxycarbonyl)(methyl)amino)-2-
phenylethyl)pyridin-2-yl)phenyl)acetate (187 mg, 0.406 mmol) was 
dissolved in 1,4-dioxane (1.6 mL) and methanol (1.6 mL) where HCl 
(4.0 m in dioxane, 1.52 mL, 6.08 mmol) was added and stirred at 
room temperature for 18 h. Upon completion the solution was diluted with ethyl acetate (50 
mL) and neutralised using 2 m NaOH(aq). The aqueous layer was extracted with ethyl acetate (3 
× 50 mL), and the combined organic extracts were dried over MgSO4, filtered and the solvent 
removed in vacuo. The crude material (140 mg, 0.388 mmol) was dissolved in THF (3.1 mL) and 
LiOH(aq) (0.5 m, 3.1 mL, 1.55 mmol) was added and the solution was stirred at room temperature 
for 18 h. Upon completion, the solvent was removed in vacuo. Purification by flash column 
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chromatography (SiO2, 50% methanol in ethyl acetate) afforded the title compound as a white 
foam (100 mg, 71% over both steps); RF 0.15 (50% methanol in ethyl acetate); νmax/cm–1 (thin 
film) 3349, 1563, 1415; δH (400 MHz, CDCl3) 7.73 (1H, t, J = 7.6 Hz, CH), 7.50–7.29 (10H, m, 10 × 
CH), 7.12 (1H, d, J = 7.6 Hz, CH), 4.74–4.66 (1H, m, CHNH), 3.64 (1H, dd, J = 15.3, 7.6 Hz, 
CHH′CHPh ), 3.61 (1H, d, J = 15.3 Hz, CHH′CO2H), 3.51 (1H, d, J = 15.3 Hz, CHH′CO2H), 3.38 (1H, 
dd, J = 15.3, 6.1 Hz, CHH′CHPh), 3.32–3.28 (1H, m, NH), 2.46 (3H, s, NHCH3); δC (100 MHz, CDCl3) 
179.0 (CO2H), 160.1 (CN), 155.9 (CN), 140.4 (C), 138.2 (CH), 136.3 (C), 135.3 (C), 131.9 (CH), 129.8 
(CH), 129.6 (CH), 129.5 (CH), 128.8 (CH), 128.6 (CH), 126.7 (CH), 123.3 (CH), 122.9 (CH), 63.5 
(CHNH), 43.3 (CH2CH), 41.2 (CH2CO2H), 31.0 (NCH3); HRMS (ESI): calcd. for C22H22N2O2, 347.1754. 
Found: [MH]+, 347.1758 (−1.0 ppm error). 
3-Methyl-4-phenyl-4,5-dihydro-1H-6,10-(azeno)benzo[d][1]azacyclododecin-2(3H)-one (665) 
 To a stirring solution of 2-(2-(6-(2-(methylamino)-2-
phenylethyl)pyridin-2-yl)phenyl)acetic acid (50.0 mg, 0.143 mmol) in 
chloroform (1.5 mL), was added diisopropylethylamine (45.0 µL, 0.260 
mmol) followed by the addition of T3P (50% solution in ethyl acetate, 
129 µL, 0.216 mmol). Upon the addition of T3P, the solution rapidly changed from a colourless 
to an orange solution. After stirring for 30 min at room temperature, the solution was taken 
directly to purification with no work-up. Purification by flash column chromatography (SiO2, 
ethyl acetate → 10% methanol in ethyl acetate) afforded the title compound (as a 8.7:1 mixture 
of rotamers) as a colourless oil (24 mg, 50%); RF 0.55 (ethyl acetate); δH (400 MHz, CDCl3) data 
for the major rotamer only: 7.95–7.89 (1H, m, CH), 7.75–7.69 (1H, m, CH), 7.67–7.62 (1H, m, 
CH), 7.46–7.39 (1H, m, CH), 7.37–7.32 (2H, m, 2 × CH), 7.29–7.19 (3H, m, 3 × CH), 7.03 (1H, d, J 
= 6.9 Hz, CH), 6.80–6.67 (2H, m, 2 × CH), 5.42–5.33 (1H, m, CHNMe), 5.29 (1H, d, J = 13.7 Hz, 
CHH′CO), 3.44 (1H, d, J = 13.7 Hz, CHH′CO), 2.97–2.91 (2H, m, CH2CHNMe) 2.31 (3H, s, NCH3); δC 
(100 MHz, CDCl3) data for the major rotamer only: 173.8 (CONMe), 155.8 (CN), 154.5 (CN), 137.2 
(C), 136.4 (CH), 136.3 (C), 134.7 (C), 129.4 (CH), 128.2 (CH), 128.1 (CH), 127.4 (CH), 126.2 (CH), 
126.0 (CH), 125.6 (CH), 119.1 (CH), 116.1 (CH), 52.3 (CHNMe), 42.4 (CO2NMe), 38.8 (CH2CHNMe), 
28.7 (NCH3); HRMS (ESI): calcd. for C22H20N2NaO, 351.1468. Found: [MNa]+, 351.1470 (–0.5 ppm 
error). 
High Dilution Method 
To a stirring solution of 2-(2-(6-(2-(methylamino)-2-phenylethyl)pyridin-2-yl)phenyl)acetic acid 
(50.0 mg, 0.143 mmol) in chloroform (143 mL), was added diisopropylethylamine (45.0 µL, 0.260 
mmol) followed by the addition of T3P (50% solution in ethyl acetate, 129 µL, 0.216 mmol). Upon 
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the addition of T3P, the solution rapidly changed from a colourless to an orange solution. After 
stirring for 3 h at room temperature, the solution was taken directly to purification with no work-
up. Purification by flash column chromatography (SiO2, diethyl ether → 10% methanol in ethyl 
acetate) afforded the title compound as a colourless oil (36 mg, 78%). 
1-(6-Bromopyridin-2-yl)propan-2-ol (666) 
Procedure for reduction with NaBH4 
1-(6-Bromopyridin-2-yl)propan-2-one (100 mg, 0.467 mmol) was dissolved 
in methanol (4.7 mL) and cooled to 0 °C. Sodium borohydride (53 mg, 1.40 mmol) was added 
portionwise and then allowed to warm to room temperature, and stirred for 1 h. Upon 
completion, the solvent was removed in vacuo. Purification by column chromatography (SiO2, 
diethyl ether) afforded the title compound as a yellow oil (88 mg, 87%); RF 0.50 (ethyl acetate); 
δH (400 MHz, CDCl3) 7.45 (1H, t, J = 7.6 Hz, CH), 7.31 (1H, d, J = 7.6 Hz, CH), 7.10 (1H, d, J = 7.6 
Hz, CH), 4.26–4.16 (1H, m, CHOH), 3.71 (1H, br s, OH), 2.86 (1H, dd, J = 14.5, 3.8 Hz, CHH′COH), 
2.80 (1H, dd, J = 14.5, 8.4 Hz, CHH′COH), 1.24 (3H, d, J = 6.1 Hz, CH3). Data is consistent with 
those available from commercial sources. 
Procedure for reduction with Jacobsen’s catalyst 
A solution of sodium borohydride (29 mg, 0.75 mmol) and furfuryl alcohol (727 µL, 7.5 mmol) 
dissolved in ethanol (44 µL, 0.75 mmol) and chloroform (1.5 mL) was prepared under inert 
conditions and cooled to −20 °C. The pre-made solution was then added dropwise, via cannula, 
to a solution of 1-(6-bromopyridin-2-yl)propan-2-one (137 mg, 0.50 mmol) with Jacobsen’s 
catalyst (13 mg, 4 mol%) in chloroform (4 mL) at −20 °C, under a nitrogen atmosphere. The 
solution was then stirred at −20 °C for 18 h. Upon completion, the solution was quenched with 
sat. NH4Cl(aq) solution (10 mL), extracted with CH2Cl2 (3 × 50 mL), washed with brine (10 mL), 
dried over MgSO4, filtered and the solvent removed in vacuo. Purification by column 
chromatography (SiO2, diethyl ether) afforded the title compound as a colourless oil (31 mg, 
19%). Data is consistent with those reported above. 
Procedure for reduction with LiAlH4 and menthol 
Lithium aluminium hydride (38 mg, 1 mmol) and L-(−)-menthol (782 mg, 5 mmol) was dissolved 
in anhydrous THF (5 mL) and ethanol (88 µL, 1 mmol), and stirred for 1 h at −20 °C. A solution of 
1-(6-bromopyridin-2-yl)propan-2-one (137 mg, 0.5 mmol) in THF (1 mL) was added slowly and 
the solution stirred, at −20 °C, for 2 h. Purification by column chromatography (SiO2, diethyl 
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ether) afforded the title compound as a yellow oil (88 mg, 82%). Data is consistent with those 
reported above.    
2-(6-Bromopyridin-2-yl)-1-phenylethan-1-ol (668) 
 N,N-Diisopropylamine (3.67 mL, 26.2 mmol) was dissolved in THF (60 
mL) and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 16.4 mL, 
26.2 mmol) was added dropwise and stirred for 30 min. The LDA solution was then cooled to 
−78 °C, where 2-bromo-6-methylpyridine (1.48 mL, 13.1 mmol) was added dropwise and stirred 
for 30 min. Benzaldehyde (2.67 mL, 26.2 mmol) was added and stirred for a further 30 min at 
−78 °C before slowly warming to room temperature. The solution was then quenched with sat. 
NH4Cl(aq) (20 mL) and extracted with ethyl acetate (3 × 50 mL) and washed with brine (10 mL). 
The combined organic extracts were dried over MgSO4, filtered and removed in vacuo. 
Purification by flash column chromatography (SiO2, 25% ethyl acetate in hexane → ethyl acetate) 
afforded the title compound as a yellow oil (3.02 g, 83%); RF 0.67 (50% ethyl acetate in hexanes); 
νmax/cm–1 (thin film) 3370, 3062, 3030, 2924, 1584,1553, 1437; δH (400 MHz, CDCl3) 7.44 (1H, t, 
J = 7.6 Hz, CH), 7.41–7.22 (6H, m, 6 × CH), 7.05 (1H, d, J = 7.6 Hz, CH), 5.19–5.10 (1H, m, CHOH), 
4.20–4.12 (1H, m, OH), 3.18–3.04 (2H, m, CH2CHOH); δC (100 MHz, CDCl3) 164.7 (CN), 147.4 (CBr), 
145.1 (C), 142.8 (CH), 132.3 (CH), 131.4 (CH), 129.9 (CH), 129.6 (CH), 126.6 (CH), 77.0 (CHOH), 
49.9 (CH2CHOH); HRMS (ESI): calcd. for C13H1279BrNNaO, 299.9994. Found: [MNa]+, 299.9994 (0.3 
ppm error). 
Methyl 2-(2-(6-(2-hydroxy-2-phenylethyl)pyridin-2-yl)phenyl)acetate (669) 
2-(6-Bromopyridin-2-yl)-1-phenylethan-1-ol (1.00 g, 3.61 mmol), 
methyl 2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) 
acetate (1.50 g, 5.41 mmol), potassium phosphate (1.53 g, 7.22 
mmol) and PdCl2(dppf).CH2Cl2 (16.0 mg, 0.181 mmol) were charged 
into an RBF purged with nitrogen. THF (36.1 mL) and de-ionised water (324 µL, 18.1 mmol) were 
added and heated to 80 °C, at reflux, for 18 h. Upon completion the solution was cooled to room 
temperature, diluted with water (15 mL), extracted with ethyl acetate (3 × 25 mL) and washed 
with brine (10 mL). The combined organic extracts were dried over MgSO4, filtered, and removed 
in vacuo. Purification by flash column chromatography (SiO2, CH2Cl2 → 1:1 ethyl acetate:hexane) 
afforded the title compound as a yellow oil (898 mg, 72%); RF 0.39 (1:1 ethyl acetate:hexane); 
νmax/cm–1 (thin film) 3409,3028, 2950, 1735, 1588, 1570; δH (400 MHz, CDCl3) 7.69 (1H, t, J = 7.6 
Hz, CH), 7.49–7.22 (10H, m, 10 × CH), 7.07 (1H, t, J = 8.4 Hz, CH), 5.23–5.13 (2H, m, CHOH and 
OH), 3.86 (1H, d, J = 16.0 Hz, CHH′CHOH), 3.78 (1H, d, J = 16.0 Hz, CHH′CHOH), 3.59 (3H, s, OCH3), 
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3.19–3.09 (2H, m, CH2CO2Me); δC (100 MHz, CDCl3) 176.2 (CO2Me), 162.8 (CN), 162.3 (CN), 148.0 
(C), 144.0 (C), 141.2 (CH), 136.1 (C), 135.3 (CH), 133.7 (CH), 132.5 (CH), 132.2 (CH), 132.1 (CH), 
131.3 (CH), 131.0 (CH), 129.6 (CH), 125.9 (CH), 77.0 (CHOH), 55.9 (OCH3), 50.1 (CH2CHOH), 43.2 
(CH2CO2Me); HRMS (ESI): calcd. for C22H22NO3, 348.1601. Found: [MH]+, 348.1601 (−1.9 ppm 
error). 
Methyl 2-(2-(6-(2-bromo-2-phenylethyl)pyridin-2-yl)phenyl)acetate (670) 
 Methyl 2-(2-(6-(2-hydroxy-2-phenylethyl)pyridin-2-
yl)phenyl)acetate (800 mg, 2.31 mmol) and tetrabromomethane 
(841 mg, 2.54 mmol) were dissolved in CH2Cl2 (5 mL) and cooled to 0 
°C. Triphenylphosphine (665 mg, 2.54 mmol) was added portionwise 
and the solution allowed to warm to room temperature over 30 min where the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% ethyl acetate in 
hexane) afforded the title compound as a yellow oil (896 mg, 95%); RF 0.58 (50% ethyl acetate in 
hexane); νmax/cm–1 (thin film) 3062, 3030, 2949, 1735, 1584; δH (400 MHz, CDCl3) 7.71–7.00 (12H, 
m, 12 × CH), 5.56 (1H, dd, J = 9.2, 6.9 Hz, CHBr), 3.83 (2H, s, CH2CO2Me), 3.78–3.60 (2H, m, 
CH2CHBr), 3.59 (3H, s, OCH3); δC (100 MHz, CDCl3) 172.4 (CO2Me), 159.3 (CN), 157.0 (CN), 141.7 
(CH), 138.6 (C), 136.9 (C), 132.4 (C), 131.6 (CH), 129.6 (CH), 128.71 (CH), 128.65 (CH), 128.4 (CH), 
127.5 (CH), 126.4 (CH), 123.0 (CH), 122.2 (CH), 53.8 (OCH3), 51.9 (CHBr), 47.6 (CH2CHBr), 39.2 
(CH2CO2Me); HRMS (ESI): calcd. for C22H2179BrNO2, 410.0750. Found: [MH]+, 410.0744 (1.6 ppm 
error). 
Methyl 2-(2-(6-(2-azido-2-phenylethyl)pyridin-2-yl)phenyl)acetate (671) 
 Methyl 2-(2-(6-(2-bromo-2-phenylethyl)pyridin-2-
yl)phenyl)acetate (350 mg, 0.856 mmol) was dissolved in anhydrous 
DMF (2.8 mL) and NaN3 (278 mg, 4.28 mmol) added, under a 
nitrogen atmosphere, and heater to 100 °C for 1 h. The solution was 
cooled, diluted with ethyl acetate (50 mL), washed with water (3 × 10 mL) and brine (10 mL). 
The combined organics were dried over MgSO4, filtered and removed in vacuo. Purification by 
flash column chromatography (SiO2, 50% ethyl acetate in hexanes) afforded the title compound 
as a yellow oil (225 mg, 71%); RF 0.60 (50% ethyl acetate in hexane); νmax/cm–1 (thin film) 3029, 
2949, 2097, 1737, 1583; δH (400 MHz, CDCl3) 7.92–6.94 (12H, m, 12 × CH), 5.08 (1H, dd, J = 8.7, 
5.5 Hz, CHN3), 3.83 (2H, s, CH2CO2Me), 3.58 (3H, s, OCH3), 3.32–3.08 (2H, m, CH2CHN3); δC (100 
MHz, CDCl3) 172.3 (CO2Me), 159.2 (CN), 156.8 (CN), 140.3 (C), 139.4 (C), 138.7 (C), 136.9 (CH), 
131.6 (CH), 129.9 (CH), 128.8 (CH), 128.6 (CH), 128.3 (CH), 127.5 (CH), 126.9 (CH), 122.3 (CH), 
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122.1 (CH), 65.7 (CN3), 51.9 (OCH3), 45.0 (CH2CHN3), 39.3 (CH2CO2Me); HRMS (ESI): calcd. for 
C22H21N4O2, 373.1659. Found: [MH]+, 373.1656 (0.7 ppm error). 
Methyl 2-(2-(6-(2-amino-2-phenylethyl)pyridin-2-yl)phenyl)acetate (672) 
 Methyl 2-(2-(6-(2-azido-2-phenylethyl)pyridin-2-yl)phenyl)acetate 
(175 mg, 0.470 mmol) was dissolved in methanol (5 mL) and placed 
under a nitrogen atmosphere. Palladium on carbon (47.0 mg, Pd 10% 
on carbon), was then added and the vessel backfilled with hydrogen 
(via balloon) several times, then stirred at room temperature under a slight positive pressure of 
hydrogen (balloon) for 4 h. The reaction was then purged with argon, filtered through Celite, 
washed with methanol where the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 50% diethyl ether in hexanes → 20% methanol in ethyl acetate) afforded 
the title compound as a yellow oil (89 mg, 55%); RF 0.25 (20% methanol in ethyl acetate); 
νmax/cm–1 (thin film) 3027, 2923, 1733, 1570, 1553; δH (400 MHz, CDCl3) 7.63 (1H, t, J = 8.4 Hz, 
CH), 7.47–7.21 (10H, m, 10 × CH), 7.02 (1H, d, J = 7.6 Hz, CH), 4.50 (1H, dd, J = 5.3, 9.2 Hz, CHNH2), 
3.89 (1H, d, J = 16.8 Hz, CHH′CO2CH3), 3.83 (1H, d, J = 16.8 Hz, CHH′CO2CH3), 3.57 (3H, s, CO2CH3), 
3.18 (1H, dd, J = 5.3, 13.7 Hz, CHH′CHNH2), 3.10 (1H, dd, J = 9.2, 13.7 Hz, CHH′CHNH2), 2.21 (2H, 
br s, NH2); δC (100 MHz, CDCl3) 172.3 (CO2CH3), 159.0 (CN), 158.5 (CN), 145.3 (C), 140.4 (C), 136.8 
(CH), 132.4 (C), 131.5 (CH), 129.9 (CH), 128.5 (CH), 128.4 (2 × CH), 127.4 (CH), 127.1 (CH), 126.5 
(2 × CH), 122.1 (CH), 121.7 (CH), 56.0 (CHNH2), 51.9 (CO2CH3), 47.9 (CH2CO2CH3), 39.3 
(CH2CHNH2); HRMS (ESI): calcd. for C22H23N2O2, 347.1754. Found: [MH]+, 347.1754 (0.1 ppm 
error). 
Alternative method via reduction: Methyl 2-(2-(6-(2-azido-2-phenylethyl)pyridin-2-
yl)phenyl)acetate S54 (210 mg, 0.564 mmol) was dissolved in THF/H2O (40:1 v/v, 5.6 mL) and 
PPh3 (192 mg, 0.733 mmol) was added, and heated, at reflux, to 70 °C for 2 h. Once cooled, 
NaOH(aq) (1.0 m, 10 mL) was added, extracted with ethyl acetate (3 × 25 mL) and washed with 
brine (5 mL). The combined organics were dried over MgSO4, filtered, and the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% ethyl acetate in 
hexanes→20% methanol in ethyl acetate) afforded the title compound (as a 3:2 ratio of 
diastereomers) as a yellow oil (182 mg, 93%). 
The same compound (presumed to be 72% ee) was prepared from a diastereomeric mixture 
(72% de) of 677 via the following procedure: methyl 2-(2-(6-(2-(((S)-tert-butylsulfinyl)amino)-2-
phenylethyl)pyridin-2-yl)phenyl)acetate (112 mg, 0.249 mmol) was dissolved in 1,4-dioxane (1 
mL) and methanol (1 mL) where HCl in dioxane (4.0 m, 0.93 mL, 3.72 mmol) was added and 
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stirred at room temperature for 18 h. Upon completion, the solution was diluted with ethyl 
acetate (50 mL) and neutralised with 2 m NaOH(aq). The aqueous layer was extracted with ethyl 
acetate (3 × 50 mL), and the combined organic extracts were dried over MgSO4, filtered, and the 
solvent removed in vacuo. Purification by flash column chromatography (SiO2, diethyl 
ether→50% methanol in diethyl ether) afforded the title compound as a yellow oil (86 mg, 99%). 
All of the data obtained matched those of the racemic sample above and the optical rotation 
was also measured: [α]D298 −10.5 (c = 1.0, CHCl3). 
4-Phenyl-4,5-dihydro-1H-6,10-(azeno)benzo[d][1]azacyclododecin-2(3H)-one (674) 
 To a stirring solution of methyl 2-(2-(6-(2-amino-2-phenylethyl)pyridin-
2-yl)phenyl)acetate (55.0 mg, 0.159 mmol) in THF (0.95 mL) was added 
LiOH(aq) (0.5 m, 0.95 mL, 0.476 mmol). The resulting solution was stirred 
at room temperature for 18 h, where upon completion the solvent was 
removed in vacuo. The crude salt was passed through a silica plug and eluted with methanol to 
remove the excess lithium salts and the crude material was used without further purification. 
The crude material was dissolved in chloroform (159 mL), where diisopropylethylamine (50.0 
µL, 0.286 mmol) and T3P (50% solution in ethyl acetate, 142 µL, 0.238 mmol) was added 
sequentially. Upon the addition of T3P, the solution rapidly changed from a colourless to an 
orange solution. After stirring for 30 min at room temperature, the solution was taken directly 
to purification with no work-up. Purification by flash column chromatography (SiO2, ethyl 
acetate → 10% methanol in ethyl acetate → 20% methanol in ethyl acetate) afforded the title 
compound (as a 4:1 mixture of rotamers) as a yellow oil (36 mg, 52%); RF 0.58 (20% methanol in 
ethyl acetate); νmax/cm–1 (thin film) 3288, 2853, 2925, 1646, 1577, 1452; δH (400 MHz, CDCl3) 
7.99–6.95 (24H, 12 × CH, both rotamers), 5.60 (1H, td, J = 11.5, 2.8 Hz, CHNH, major rotamer), 
5.55–5.41 (1H, m, NH, major), 5.33–5.25 (1H, m, NH, minor rotamer), 4.92 (1H, d, J = 13.3 Hz, 
CHNH, minor), 3.86 (1H, d, J = 15.1 Hz, CHH′CONH, major), 3.72 (1H, d, J = 15.1 Hz, CHH′CONH, 
major), 3.69–2.94 (6H, m, CH2CONH, minor and CH2CH, both); δC (100 MHz, CDCl3) data for major 
rotamer only: 176.4 (CONH), 156.4 (CN), 155.3 (CN), 141.2 (C), 137.4 (CH), 136.2 (C), 135.5 (C), 
129.4 (CH), 128.9 (CH), 128.7 (CH), 127.5 (CH), 126.8 (CH), 126.4 (CH), 126.2 (CH), 120.5 (CH), 
117.4 (CH), 57.3 (CHNH), 42.4 (CH2CONH), 29.4 (CH2CHNH); HRMS (ESI): calcd. for C21H18N2NaO, 
337.1311. Found: [MNa]+, 337.1310 (0.3 ppm error). 
The same compound (71% ee) was prepared using the procedure above from an 
enantioenriched sample of methyl 2-(2-(6-(2-amino-2-phenylethyl)pyridin-2-yl)phenyl)acetate 
672 (itself made from 677 - see below). All of the data obtained matched those of the racemic 
sample above and the optical rotation was also measured: [α]D298 −28.8 (c = 0.5, CHCl3). The ee 
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was determined using chiral HPLC as follows. An Agilent HPLC was used alongside an AD-H 
Chiralpak® column to separate enantiomers. The column temperature was not controlled and a 
50 µL injection was completed manually. Diode Array was used to identify the compounds at 5 
different wavelengths. For each enantiomerically enriched sample, racemic runs were initially 
screened to obtain the best separation. As compound 674 exists in two rotameric forms, four 
peaks in total were obtained (a major and minor enantiomer for each rotameric form). The ee 
of each pair was consistent within experimental error (72% and 70%) and averaged to give an 
ee of 71%.  
 
ee = 71%  
Major enantiomer is drawn, based on the stereochemistry of precursors 672/677. 
HPLC Conditions: AD-H column 80:20 hexane:IPA @ 1.0 mL/min 
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The HPLC trace for a racemic sample of 672 (which had a rotameric ratio) is included below. 
While we were unable to obtain full separation of all four peaks in either, we believe that the 
results are sufficient to conform that the enantioenrichment that originates from the Elman’s 
auxiliary derivative 676 and 677 are maintained in the product. 
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 N,N-Diisopropylamine (145 µL, 1.03 mmol) was dissolved in THF (2 
mL) and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 645 
µL, 1.03 mmol) was added dropwise and stirred for 30 min. The LDA 
solution was then cooled to −78 °C, where 2-bromo-6-methylpyridine (59 µL, 0.515 mmol) was 
added dropwise and stirred for 30 min. Elman’s sulfinyl imine (215 mg, 1.03 mmol) was added 
and stirred for a further 30 min at −78 °C before slowly warming to room temperature. The 
solution was then quenched with sat. NH4Cl(aq) (5 mL) and extracted with ethyl acetate (3 × 20 
mL) and washed with brine (5 mL). The combined organic extracts were dried over MgSO4, 
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filtered and removed in vacuo. Purification by flash column chromatography (SiO2, 33% ethyl 
acetate in hexane → ethyl acetate) afforded the title compound (as a 6.1:1 mixture of 
diastereomers = 72% de) as a yellow oil (126 mg, 64%); RF 0.42 (ethyl acetate); νmax/cm–1 (thin 
film) 3217, 2957, 1583, 1552; δH (400 MHz, CDCl3) 7.44–7.19 (14H, m, 7 × CH, both 
diastereomers), 6.99 (1H, d, J = 7.6 Hz, CH, minor diastereomer), 6.92 (1H, d, J = 6.9 Hz, CH, major 
diastereomer), 5.56 (1H, br s, NH, minor), 4.84 (1H, app dt, J = 8.4, 5.3 Hz, CHNH, major), 4.72 
(1H, ddd, J = 9.2, 3.8, 2.3 Hz, CHNH, minor), 4.22 (1H, d, J = 5.3 Hz, NH, major), 3.34 (1H, dd, J = 
13.7, 8.4 Hz, CHH′CHPh, major), 3.19 (1H, dd, J = 13.7, 6.9 Hz, CHH′CHPh, major), 3.14 (1H, d, J = 
9.2 Hz, CHH′CHPh, minor), 3.08 (1H, dd, J = 13.7, 3.8 Hz, CHH′CHPh, minor), 1.24 (9H, s, 3 × CH3, 
minor), 1.10 (9H, s, 3 × CH3, major); δC (100 MHz, CDCl3) 159.8 (CCH2, minor diastereomer), 158.7 
(CCH2, major diastereomer), 141.6 (CBr, minor), 141.4 (CBr, major), 141.3 (CCHNH, major), 141.2 
(CCHNH, minor), 139.1 (CHCHCBr, minor), 138.5 (CHCHCBr, major), 128.5 (CH, major), 128.4 (CH, 
minor), 127.74 (CH, major), 127.69 (CH, minor), 127.3 (CH, minor), 127.0 (CH, major), 126.3 (CH, 
minor), 125.9 (CH, major), 122.9 (CH, major), 122.7 (CH, minor), 59.4 (CHNH, major), 57.8 (CHNH, 
minor), 56.1 (CSO, major), 55.6 (CSO, minor), 45.4 (CH2, minor), 45.0 (CH2, major), 22.8 (3 × CH3, 
minor), 22.4 (3 × CH3, major); HRMS (ESI): calcd. for C17H2179BrN2NaOS, 403.0450. Found: [MNa]+, 




2-sulfinamide (96.0 mg, 0.252 mmol), methyl 2-(2-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (104 mg, 
0.378 mmol), potassium phosphate (107 mg, 0.504 mmol) and 
PdCl2(dppf).CH2Cl2 (10.0 mg, 12.6 µmol) were dissolved in THF 
(2.5 mL) under a nitrogen atmosphere. H2O (23.0 µL, 1.26 mmol) was added and the solution 
was heated, at reflux, to 80 °C for 18 h. Once cooled, the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 50% ethyl acetate in hexanes) afforded the 
title compound (as a 6.1:1 mixture of diastereomers = 72% de) as a yellow oil (108 mg, 95%); RF 
0.44 (ethyl acetate); νmax/cm–1 (thin film) 1732, 1570, 1448; δH (400 MHz, CDCl3) 7.66 (1H, t, J = 
7.6 Hz, CH, minor diasteromer), 7.60 (1H, t, J = 7.6 Hz, CH, major rotamer), 7.46–7.19 (20H, m, 
10 × CH, both diasteromers), 7.06 (1H, d, J = 7.6 Hz, CH, minor), 7.00 (1H, d, J = 7.6 Hz, CH, major), 
5.78 (1H, br s, NH, minor), 4.91–4.82 (1H, m, CHNH, major), 4.77–4.71 (1H, m, CHNH, minor), 
4.45 (1H, d, J = 5.3 Hz, NH, major), 3.83 (2H, d, J = 16.8 Hz, CH2CO2Me, minor), 3.73 (2H, s, 
CH2CO2Me, major), 3.60 (3H, s, OCH3, minor), 3.59 (3H, s, OCH3, major), 3.38 (2H, dd, J = 13.7, 
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8.4 Hz, CHH′CHNH, both), 3.24 (2H, dd, J = 13.7, 6.1 Hz, CHH′CHNH, both), 1.19 (9H, s, 3 × CH3, 
minor), 0.99 (9H, s, 3 × CH3, major); δC (100 MHz, CDCl3) data for the major diasteromer only: 
171.3 (CO2Me), 157.8 (CN), 156.6 (CN), 141.0 (C), 139.3 (C), 135.9 (CH), 131.3 (C), 130.4 (CH), 
128.9 (CH), 127.5 (CH), 126.6 (CH), 126.4 (CH), 126.2 (CH), 121.2 (CH), 120.8 (CH), 58.7 (CHNH), 
55.0 (CSO), 50.9 (OCH3), 44.7 (CH2CHNH), 38.4 (CH2CO2Me), 21.4 (3 × CH3); HRMS (ESI): calcd. for 
C26H31N2O3S, 451.2050. Found: [MH]+, 451.2044 (1.3 ppm error). 
Methyl 5-(benzyl(propan-3-ol)amino)pentanoate (691) 
3-(Benzylamino)propan-1-ol (957 µL, 6 mmol), potassium 
carbonate (415 mg, 3 mmol) and methyl 5-bromovalerate 
(430 µL, 3 mmol) was dissolved in acetonitrile (6 mL) and heated to 85 °C, at reflux, for 3 h. Upon 
completion, the reaction was quenched with water (10 mL), and extracted with ethyl acetate (3 
× 50 mL). The combined organic extracts were dried over MgSO4, filtered, and the solvent was 
removed in vacuo. Purification by flash column chromatography (SiO2, 50% ethyl acetate in 
hexanes → ethyl acetate) afforded the title compound as a yellow oil (785 mg, 94%); RF 0.30 
(ethyl acetate); δH (400 MHz, CDCl3) 7.33–7.21 (5H, m, 5 × CH), 3.71 (2H, t, J = 5.5 Hz, CH2OH), 
3.64 (3H, s, CO2CH3), 3.55 (2H, s, CH2Ph), 2.63 (2H, t, J = 5.5 Hz, NCH2), 2.42 (2H, t, J = 7.3 Hz, 
NCH2), 2.27 (2H, t, J = 6.9 Hz, CH2CO2Me), 1.74–1.66 (2H, m, CH2), 1.61–1.49 (4H, m, 2 × CH2). 
Data is consistent with those previously reported in the literature.140 
Methyl 5-(benzyl(3-bromopropyl)amino)pentanoate (692) 
 Methyl 5-(benzyl(propan-3-ol)amino)pentanoate (9.80 g, 
35.1 mmol) and carbon tetrabromide (12.8 g, 38.6 mmol) was dissolved in CH2Cl2 (70 mL) and 
cooled to 0 °C. Triphenylphosphine (10.1 g, 38.6 mmol) was added portionwise, and then the 
reaction was stirred for 1 h at 0 °C. Upon completion, the solvent was removed in vacuo. 
Purification by flash column chromatography (SiO2, 50% diethyl ether in hexanes) afforded the 
title compound as a colourless oil (10.4 g, 86%); RF 0.53 (50% ethyl acetate in hexanes); νmax/cm–
1 (thin film) 2951, 2807, 1734, 1452; δH (400 MHz, CDCl3) 7.29–7.05 (5H, m, 5 × CH), 3.57 (3H, s, 
CO2CH3), 3.50 (2H, t, J = 6.6 Hz, CH2Br), 3.47 (2H, s, CH2Ph), 2.50 (2H, t, J = 6.5 Hz, CH2N), 2.40–
2.34 (2H, m, CH2N), 2.26 (2H, t, J = 7.3 Hz, CH2CO2Me), 1.88–1.79 (2H, m, CH2), 1.77–1.68 (4H, 
m, 2 × CH2); δC (100 MHz, CDCl3) 174.1 (CO), 139.3 (C), 128.7 (CH), 128.2 (CH), 126.9 (CH), 58.6 
(CH2Ph), 52.8 (CH2N), 51.5 (CO2CH3), 50.6 (CH2N), 43.1 (CH2Br), 31.5 (CH2CO2Me), 22.3 (CH2), 20.4 
(CH2), 19.5 (CH2); HRMS (ESI): calcd. for C16H2579BrNO2, 342.1063. Found: [MH]+, 342.1065 (0.5 
ppm error).      
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Methyl 5-(benzyl(3-(benzyl(3-hydroxypropyl)amino)propyl)amino)pentanoate (693) 
 Methyl 5-(benzyl(3-bromopropyl)amino)pentanoate (798 mg, 
2.34 mmol), 3-(benzylamino)propan-1-ol (743 µL, 4.68 mmol) and 
potassium carbonate (323 mg, 2.34 mmol) was dissolved in 
acetonitrile (23 mL) and stirred at 85 °C, under reflux, for 4 h. Upon 
completion, the solvent was removed in vacuo. Purification by flash column chromatography 
(SiO2, ethyl acetate → 33% methanol in ethyl acetate) afforded the title compound as a 
colourless oil (713 mg, 72%); RF 0.55 (33% methanol in ethyl acetate); νmax/cm–1 (thin film) 3416, 
2948, 2804, 1736, 1452; δH (400 MHz, CDCl3) 7.37–7.14 (10H, m, 2 × Ph), 3.74–3.66 (2H, m, 
CH2OH), 3.63 (3H, s, CO2CH3), 3.53 (2H, s, NCH2Ph), 3.49 (2H, s, NCH2Ph), 2.67–2.58 (2H, m, 
CH2N), 2.46–2.33 (4H, m, 2 × CH2N), 2.30–2.21 (4H, m, CH2N and CH2CO2Me), 1.75–1.62 (4H, m, 
2 × CH2), 1.62–1.52 (2H, m, CH2), 1.48–1.40 (2H, m, CH2); δC (100 MHz, CDCl3) 174.2 (CO), 139.6 
(C), 138.2 (C), 129.1 (CH), 128.7 (CH), 128.4 (CH), 128.1 (CH), 127.2 (CH), 126.7 (CH), 64.3 
(CH2OH), 58.9 (CH2Ph), 58.5 (CH2Ph), 54.2 (CH2N), 52.7 (CH2N), 51.9 (CH2N), 51.7 (CH2N), 51.4 
(CO2CH3), 31.7 (CH2CO2Me), 27.8 (CH2), 24.3 (CH2), 22.3 (CH2), 20.1 (CH2); HRMS (ESI): calcd. for 
C26H39N2O3, 427.2955. Found [MH]+, 427.2960 (1.2 ppm error). 
5-(Benzyl(3-(benzyl(3-hydroxypropyl)amino)propyl)amino)pentanoic acid (694) 
Methyl 5-(benzyl(3-(benzyl(3-hydroxypropyl)amino)propyl)amino)-
pentanoate (703 mg, 1.65 mmol) was dissolved in aqueous lithium 
hydroxide solution (0.5 m, 4.1 mL, 1.98 mmol) and THF (4.1 mL). The 
resulting bi-phasic solution was vigorously stirred for 18 h. Upon 
completion, the solvent was removed in vacuo. The crude material was then passed through a 
silica plug and eluted with 50% methanol in ethyl acetate. The resulting mixture was then re-
dissolved in boiling chloroform and filtered (to remove silica) to obtain the title compound as a 
crude colourless oil (576 mg, 85%); RF 0.14 (50% methanol in ethyl acetate). The crude mixture 
was then used without further purification. 
2-(Tributylstannyl)-6-methylpyridine (696) 
2-bromo-6-methylpyridine (1.13 mL, 10.0 mmol) was dissolved in THF (10 
mL) and cooled to −78 °C before nBuLi (1.6 m in hexanes, 6.25 mL, 10.0 
mmol) was added dropwise. The solution undergoes an instant colour change from colourless 
to deep red upon addition of nBuLi solution. The solution was stirred at −78 °C for 1 h, where 
Bu3SnCl (2.18 mL, 8 mmol) was added slowly. The solution was then allowed to slowly warm to 
room temperature over 2 h. Upon completion, the reaction was quenched with sat. NH4Cl(aq) 
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solution (20 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organics were 
dried over MgSO4, filtered and the solvent was removed in vacuo. Purification by flash column 
chromatography (SiO2, 25% ethyl acetate in hexanes) afforded the title compound as a colourless 
oil (3.53 g, 92%); RF 0.65 (50% ethyl acetate in hexanes); δH (400 MHz, CDCl3) 7.34 (1H, t, J = 7.6 
Hz, CH), 7.16 (1H, d, J = 7.6 Hz, CH), 6.93 (1H, d, J = 7.6 Hz, CH), 2.52 (3H, s, CCH3), 1.59–1.49 (6H, 
m, 3 × CH2), 1.36–1.25 (6H, m, 3 × CH2), 1.07 (6H, t, J = 7.6 Hz, 3 × CH2Sn), 0.86 (9H, t, J = 6.9 Hz, 
3 × CH2CH3). Data is consistent with those reported in the literature.161 
6-Bromo-6'-methyl-2,2'-bipyridine (698) 
2,6-Dibromopyridine (1.19 g, 5 mmol), lithium chloride (390 mg, 9.3 mmol) 
and Pd(PPh3)4 (90 mg, 0.08 mmol) were charged into a RBF and purged 
with argon. 2-(Tributylstannyl)-6-methylpyridine (1.91 g, 5 mmol) and 
toluene (20 mL) were added under inert conditions and the solution was 
stirred at 110 °C, under reflux, for 18 h under an argon atmosphere. Upon completion, the 
reaction was quenched with sat. NH4Cl(aq) solution (20 mL) and extracted with ethyl acetate (3 × 
100 mL). The combined organics were dried over MgSO4, filtered and the solvent was removed 
in vacuo. Purification by flash column chromatography (SiO2, CH2Cl2 → ethyl acetate) afforded 
the title compound as a white solid (1.07 g, 86%); RF 0.62 (50% ethyl acetate in hexanes); δH (400 
MHz, CDCl3) 8.39 (1H, d, J = 7.6 Hz, CH), 8.18 (1H, d, J = 7.6 Hz, CH), 7.68 (1H, t, J = 7.6 Hz, CH), 
7.63 (1H, t, J = 7.6 Hz, CH), 7.45 (1H, d, J = 7.6 Hz, CH), 7.17 (1H, d, J = 7.6 Hz, CH), 2.60 (3H, s, 
CH3); δC (100 MHz, CDCl3) 158.0 (C), 157.7 (C), 153.8 (C), 141.5 (CBr), 139.1 (CH), 137.1 (CH), 
127.7 (CH), 123.8 (CH), 119.7 (CH), 118.5 (CH), 24.6 (CH3). Data is consistent with those 
previously reported in the literature.162       
1-(6'-Bromo-[2,2'-bipyridin]-6-yl)propan-2-one (699) 
 N,N-Diisopropylamine (564 µL, 4.0 mmol) was dissolved in THF (10 mL) 
and cooled to 0 ⁰C before n-BuLi (1.6 m solution in hexanes, 2.5 µL, 4.0 
mmol) was added dropwise and stirred for 30 min. The LDA solution was 
then cooled to −78 °C, where 6-bromo-6'-methyl-2,2'-bipyridine (490 mg, 
1.97 mmol) was added dropwise and stirred for 30 min. N-Methoxy-N-
methylacetamide (426 µL, 4.0 mmol) was added and stirred for a further 30 min at −78 °C before 
slowly warming to room temperature. The solution was then quenched with sat. NH4Cl(aq) (10 
mL) and extracted with ethyl acetate (3 × 100 mL) and washed with brine (5 mL). The combined 
organic extracts were dried over MgSO4, filtered and removed in vacuo. Purification by flash 
column chromatography (SiO2, 33% → 50% diethyl ether in hexanes) afforded the title 
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compound as a yellow oil (190 mg, 63%); RF 0.55 (50% ethyl acetate in hexanes); νmax/cm–1 (thin 
film) 1716, 1574, 1549, 1420; δH (400 MHz, CDCl3) 8.39 (1H, d, J = 7.6 Hz, CH), 8.31 (1H, d, J = 7.6 
Hz, CH), 7.80 (1H, t, J = 7.6 Hz, CH), 7.66 (1H, t, J = 7.6 Hz, CH), 7.51–7.47 (1H, m, CH), 7.28–7.24 
(1H, m, CH), 3.99 (2H, s, CH2CO), 2.27 (3H, s, CH3CO); δC (100 MHz, CDCl3) 205.5 (CO), 157.1 (CN), 
154.3 (CN), 154.2 (CN), 141.5 (BrCN), 139.2 (CH), 137.7 (CH), 128.0 (CH), 124.6 (CH), 119.8 (CH), 
119.7 (CH), 53.2 (CH2CO), 30.0 (CH3CO); HRMS (ESI): calcd. for C13H1279BrN2O, 291.0128. Found: 
[MH]+, 291.0125 (0.8 ppm error). 
1-(6'-bromo-[2,2'-bipyridin]-6-yl)propan-2-ol (700) 
1-(6'-bromo-[2,2'-bipyridin]-6-yl)propan-2-one (90 mg, 0.310 mmol) was 
dissolved in methanol (3.1 mL) and sodium borohydride (35 mg, 0.931 
mmol) was added portionwise. The solution was stirred at room 
temperature for 1 h and upon completion the solvent was removed in 
vacuo. Purification by flash column chromatography (SiO2, 50% diethyl 
ether in hexanes) afforded the title compound as a yellow oil (73 mg, 81%); Rf 0.22 (50% ethyl 
acetate in hexanes); νmax/cm–1 (thin film) 3391, 2966, 1572, 1549, 1418; δH (400 MHz, CDCl3) 8.29 
(1H, d, J = 8.3 Hz, CH), 8.25 (1H, d, J = 7.6 Hz, CH), 7.77 (1H, t, J = 7.6 Hz, CH), 7.66 (1H, t, J = 8.3 
Hz, CH), 7.49 (1H, d, J = 8.3 Hz, CH), 7.19 (1H, d, J = 7.6 Hz, CH), 5.18 (1H, br s, OH), 4.39–4.28 
(1H, m, CHOH), 2.99 (1H, dd, J = 15.3, 3.1 Hz, CHH′CHOH), 2.92 (1H, dd, J = 15.3, 8.4 Hz, 
CHH′CHOH), 1.32 (3H, d, J = 6.1 Hz, CH3); δC (100 MHz, CDCl3) 159.7 (CN), 156.8 (CN), 153.5 (CN), 
141.6 (BrCN), 139.3 (CH), 137.9 (CH), 128.1 (CH), 124.4 (CH), 119.5 (2 × CH), 67.1 (CHOH), 44.7 
(CH2), 22.9 (CH3); HRMS (ESI): calcd. for C13H1479BrN2O, 293.0284. Found: [MH]+, 293.0280 (1.5 
ppm error). 
Methyl 2-(2-(6'-(2-hydroxypropyl)-[2,2'-bipyridin]-6-yl)phenyl)acetate (701) 
1-(6'-bromo-[2,2'-bipyridin]-6-yl)propan-2-ol (50 mg, 0.171 mmol), 
K3PO4 (73 mg, 0.342 mmol), PdCl2dppf.CH2Cl2 (7.0 mg, 8.56 µmmol) 
and methyl 2-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetate (71 mg, 0.257 mmol) was charged into a vial and 
purged with argon. THF (1.7 mL) and water (15 µL, 0.856 mmol) 
were added under inert conditions and the reaction stirred, at 80 °C for 18 h. Upon completion, 
the solvent was removed in vacuo. Purification by flash column chromatography (SiO2, 50% 
diethyl ether → diethyl ether) afforded the title compound as a yellow oil (60 mg, 97%); RF 0.19 
(50% ethyl acetate in hexanes); νmax/cm–1 (thin film) 3421, 3064, 2924, 1711, 1449; δH (400 MHz, 
CDCl3) 8.29–8.22 (2H, m, 2 × CH), 7.86 (1H, t, J = 7.6 Hz, CH), 7.72 (1H, t, J = 7.6 Hz, CH), 7.52–
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7.45 (2H, m, 2 × CH), 7.42–7.34 (3H, m, 3 × CH), 7.14 (1H, d, J = 7.6 Hz, CH), 5.50 (1H, br s, OH), 
4.39–4.29 (1H, m, CHOH), 3.93 (2H, s, CH2CO2Me), 3.50 (3H, s, CO2CH3), 2.98 (1H, dd, J = 15.3, 
3.1 Hz, CHH′CH), 2.91 (1H, dd, J = 15.3, 8.4 Hz, CHH′CH), 1.32 (3H, d, J = 6.1 Hz, CHCH3); δC (100 
MHz, CDCl3) 172.2 (CO2Me), 159.5 (C), 159.0 (C), 155.0 (C), 154.7 (C), 140.4 (C), 137.7 (CH), 137.6 
(CH), 132.4 (C), 131.4 (CH), 130.1 (CH), 128.6 (CH), 127.5 (CH), 124.2 (CH), 123.7 (CH), 119.3 (CH), 
118.9 (CH), 67.1 (CHOH), 51.7 (CO2CH3), 44.6 (CH2CO2Me), 38.9 (CH2CHOH), 22.9 (CHCH3); HRMS 
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